CA3173857A1 - Gucy2c t cell-antigen couplers and uses thereof - Google Patents

Gucy2c t cell-antigen couplers and uses thereof Download PDF

Info

Publication number
CA3173857A1
CA3173857A1 CA3173857A CA3173857A CA3173857A1 CA 3173857 A1 CA3173857 A1 CA 3173857A1 CA 3173857 A CA3173857 A CA 3173857A CA 3173857 A CA3173857 A CA 3173857A CA 3173857 A1 CA3173857 A1 CA 3173857A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
gucy2c
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173857A
Other languages
French (fr)
Inventor
Andreas Bader
Christopher W. HELSEN
Philbert IP
Tania BENATAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Triumvira Immunologics Usa Inc
Original Assignee
Triumvira Immunologics Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Triumvira Immunologics Usa Inc filed Critical Triumvira Immunologics Usa Inc
Priority claimed from PCT/US2022/035871 external-priority patent/WO2023283111A2/en
Publication of CA3173857A1 publication Critical patent/CA3173857A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01002—Guanylate cyclase (4.6.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

GUCY2C T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds GUCY2C, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of and priority to U.S. Provisional Patent Application No.
63/203,106, filed j uly 8, 2021; and U.S. Provisional Patent Application No.
63/261,930, filed September 30, 2021, the disclosures of each of which are hereby incorporated by reference in their entireties for all purposes.
SEQUENCE LISTING
[0001] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on xxxx xx, 2022, is named xxxxxxxxx.txt and is xxx,xxx bytes in size.
SUMMARY
[0002] Disclosed herein, in certain embodiments, are polynucleotides encoding a GUCY2C
(Guanylate Cyclase 2C) T cell-antigen coupler (GUCY2C-TAC) polypeptide.
[0003] Disclosed herein, in certain embodiments, are Guanylate Cyclase 2C
(GUCY2C) T cell-antigen coupler (GUCY2C-TAC) proteins, comprising: (a) a first polypeptide encoding an antigen-binding domain that binds GUCY2C; (b) a second polypeptide encoding an antigen-binding domain that binds a protein associated with a TCR complex; and (c) a third polypeptide encoding a TCR co-receptor cytosolic domain and transmembrane domain; wherein components encoded by (a), components encoded by (b), and components encoded by (c) are fused directly to each other, or joined by at least one linker. In some embodiments, the first polynucleotide, the second polynucleotide, and the third polynucleotide are in order. In some embodiments, the antigen-binding domain that binds GUCY2C is a designed ankyrin repeat (DARPin) polypeptide, single chain variable fragment (scFv), single domain antibody, diabody, affibody, adnectin, affilin, phylomer; fynomer, affimer, peptide aptamer, knottin, centyrin, anticalin, or nanobody. In some embodiments, the antigen-binding domain that binds GUCY2C is a designed ankyrin repeat (DARPin) polypeptide, a single chain variable fragment (scFv), or a nanobody. In some embodiments, the antigen-binding domain that binds GUCY2C is a nanobody.
In some embodiments, the protein associated with the TCR complex is a CD3 protein. In some embodiments, the CD3 protein is a CD3y protein, CD36 protein and/or CDR
protein. In some embodiments, the CD3 protein is a CDR protein. In some embodiments, the CD3 protein is a CDR protein. In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex is a designed ankyrin repeat (DARPin) polypeptide, single CA 03173857 2022-9- ik63309 chain variable fragment (scFv), single domain antibody, diabody, affibody, adnectin, affilin, phylomer; fynomer, affimer, peptide aptamer, knottin, centyrin, anticalin, or nanobody. In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex is derived from an antibody selected from UCHT1 OKT3, F6A, and L2K. In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex is a UCHT1 antigen-binding domain. In some embodiments, the UCHT1 antigen-binding domain is an scFv of UCHT1. In some embodiments, the UCHT1 antigen-binding domain comprises a Y to T mutation at a position corresponding to amino acid 182 of SEQ ID
NO: 32 (Y182T). In some embodiments, the UCHT1 antigen-binding domain comprises a humanized variant of UCHT1 (huUCHT1). In some embodiments, the UCHT1 antigen-binding domain comprises a humanized variant of UCHT1 comprising a Y to T mutation at a position corresponding to amino acid 177 of SEQ ID NO: 40 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%
sequence identity with SEQ ID NO: 32 (UCHT1), SEQ ID NO: 44 (UCHT1 (Y182T)), SEQ ID NO: 40 (huUCHT1), or SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1), SEQ
ID NO: 44 (UCHT1 (Y182T)), SEQ ID NO: 40 (huUCHT1), or SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR
sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1), SEQ ID NO: 44 (UCHT1 (Y182T)), SEQ ID
NO: 40 (huUCHT1), or SEQ ID NO: 42 (huUCHT1 (Y177T)), and the non-CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the non-CDR sequences of the amino acid sequence of SEQ ID NO:
32 (UCHT1), SEQ ID NO: 44 (UCHT1 (Y182T)), SEQ ID NO: 40 (huUCHT1), or SEQ ID
NO:
42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex is an OKT3 antigen-binding domain. In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%
sequence identity with SEQ ID NO: 34 (OKT3). In some embodiments, the CDR sequences of the antigen-binding CA 03173857 2022-9- i63309 domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ
ID NO: 34 (OKT3), and the non-CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the non-CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex is a F6A
antigen-binding domain. In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO: 36 (F6A). In some embodiments, the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 36 (F6A). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 36 (F6A), and the non-CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the non-CDR sequences of the amino acid sequence of SEQ ID NO:
36 (F6A). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex is a L2K antigen-binding domain. In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO: 38 (L2K). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K), and the non-CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the non-CDR
sequences of the amino CA 03173857 2022-9- ik63309 acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the transmembrane domain is a CD4 transmembrane domain and the cytosolic domain is a CD4 cytosolic domain.
In some embodiments, the transmembrane and cytosolic domain comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 46 (CD4 transmembrane and cytosolic domain). In some embodiments, the transmembrane domain is a CD8 transmembrane domain and the cytosolic domain is a CD8 cytosolic domain. In some embodiments, the component encoded by (a) and the component encoded by (c) are fused to the component encoded by (b). In some embodiments, the component encoded by (b) and the component encoded by (c) are fused to the component encoded by (a). In some embodiments, the at least one linker joins the component encoded by (a) to the component encoded by (b). In some embodiments, the at least one linker is a glycine and/or serine-rich linker, a large protein domain, a long helix structure, or a short helix structure. In some embodiments, at least one linker comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26 ((G4S)4-based linker), SEQ ID NO: 28 (G4S-based linker), SEQ ID NO: 14 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID
NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ
ID NO: 24 ((G45)3 flexible linker). In some embodiments, the GUYC2C antigen binding domain is selected from an amino acid sequence according to any one of SEQ ID NOs: 53-127 or 514-521.
In some embodiments, the GUCY2C antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203. In some embodiments, the GUYC2C
antigen binding domain comprises a heavy chain variable region having an amino acid sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143,
- 4 -CA 03173857 2022-9- i63309 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203. In some embodiments, the GUCY2C
antigen-binding domain comprises a heavy chain variable region comprising (a) a CDR1 having an amino acid selected from the group consisting of SEQ ID NO: 204, 210, 216, 222, 228, 234, 240, 246, 252, 258, 264, 270, 276, 282, 288, 294, 300, 306, 312, 318, 324, 330, 336, 342, 348, 354, 393, 399, 405, 411, 417, 423, 429, 435, 441, 447, 453, 459, 522, 525, 528, 531, 534, 537, 540, and 543, (b) a CDR2 having an amino acid selected from the group consisting of SEQ ID
NO: 205, 211, 217, 223, 229, 235, 241, 247, 253, 259, 265, 271, 277, 283, 289, 295, 301, 307, 313, 319, 325, 331, 337, 343, 349, 355, 394, 400, 406, 412, 418, 424, 430, 436, 442, 448, 454 460, 523, 526, 529, 532, 535, 538, 541, and 544, and (c) a CDR3 having an amino acid selected from the group consisting of SEQ ID NO: 206, 212, 218, 224, 230, 236, 242, 248, 254, 260, 266, 272, 278, 284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 395, 401, 407, 413, 419, 425, 431, 437, 443, 449, 455, 461, 524, 527, 530, 533, 536, 539, 542, and 545; and a light chain variable region comprising (a) a CDR1 having an amino acid selected from the group consisting of SEQ ID NO: 207, 213, 219, 225, 231, 237, 243, 249, 255, 261, 267, 273, 279, 285, 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 396, 402, 408, 414, 420, 426, 432, 438, 444, 450, 456 and 462, (b) a CDR2 having an amino acid selected from the group consisting of SEQ ID NO: 208, 214, 220, 226, 232, 238, 244, 250, 256, 262, 268, 274, 280, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 397, 403, 409, 415, 421, 427, 433, 439, 445, 451, 457 and 463, and (c) a CDR3 having an amino acid selected from the group consisting of SEQ ID NO: 209, 215, 221, 227, 233, 239, 245, 251, 257, 263, 269, 275, 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341, 347, 353, 359, 398, 404, 410, 416, 422, 428, 434, 440, 446, 452, 458 and 464. In some embodiments, the GUCY2C antigen-binding domain is a nanobody and comprises (a) a VHH CDR1 having an amino acid selected from the group consisting of SEQ ID NO: 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, and 390; (b) a VHH
CDR2 having an amino acid selected from the group consisting of SEQ ID NO:
361, 364, 367, 370, 373, 376, 379, 382, 385, 388, and 391; and (c) a VHH CDR3 having an amino acid selected from the group consisting of SEQ ID NO: 362, 365, 368, 371, 374, 377, 380, 383, 386, 389, and 392. In some embodiments, the GUCY2C-TAC protein does not comprise a co-stimulatory domain. In some embodiments, the GUCY2C-TAC protein does not comprise an activation domain. In some embodiments, the GUCY2C-TAC protein further comprises a leader sequence.
In some embodiments, the leader sequence comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 2 (mulgG
- 5 -CA 03173857 2022-9- i63309 leader), SEQ ID NO: 18 (hulgG leader), SEQ ID NO: 20 (huCD8a -1 leader) or SEQ
ID NO: 30 (huCD8a -2 leader).
[0004] Disclosed herein, in certain embodiments, are GUCY2C TAC proteins comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686.
[0005] Disclosed herein, in certain embodiments, are GUCY2C TAC protein comprising an amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686.
[0006] Disclosed herein, in certain embodiments, are nucleic acid sequences encoding a GUCY2C-TAC protein described herein. In some embodiments, the nucleic acid sequence has at least 80% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 591-685. In some embodiments, the nucleic acid sequence comprises the nucleic acid sequence of any one of SEQ ID NOs: 591-685.
[0007] Disclosed herein, in certain embodiments, are T cells expressing a protein described herein. Disclosed herein, in certain embodiments, are T
cells comprising a nucleic acid described herein.
[0008] Disclosed herein, in certain embodiments, are pharmaceutical compositions comprising a T cell described herein, and a pharmaceutically acceptable excipient.
[0009] Disclosed herein, in certain embodiments, are method of treating a GUCY2C-expressing cancer in an individual in need thereof, comprising administering to the individual a pharmaceutical composition described herein. In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is a primary colorectal cancer, a primary gastric cancer, a primary gastroesophageal junction cancer, a primary esophageal cancer, or a primary pancreatic cancer. In some embodiments, the cancer is a metastatic colorectal cancer, a metastatic gastric cancer, a metastatic gastroesophageal junction cancer, a metastatic esphageal cancer, or a metastatic pancreatic cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] The invention can be more completely understood with reference to the following drawings.
[0011] FIG. 1 depicts a graph showing surface expression level of indicated GUCY2C-TACs as measured by flow cytometry.

CA 03173857 2022-9- ik63309
[0012] FIGs. 2A-2B depict graphs showing activation of T cells expressing the indicated TACs as measured by up-regulation of CD69 following co-culture with NALM6GUCY2C
(FIG. 2A) or N87Gucy2c (FIG. 2B) target cells.
[0013] FIGs. 3A-3B depict a cell trace assay. FIG. 3A depicts the normalized division indices of T cells expressing the indicated TACs following co-culture with NALM6GUCY2C
target cells.
FIG. 3B depicts representative graphs of cell trace violet (CTV) staining of T
cells expressing indicated TACs from FIG. 3A.
[0014] FIG. 4 depicts a graph showing cytotoxicity of NALM6GUCY2C -GFP target cells following co-culture with T cells expressing indicated TACs.
[0015] FIG. 5 depicts a graph showing activation of T cells expressing the indicated TACs as measured by up-regulation of CD69 following co-culture with indicated target cells.
[0016] FIG. 6 depicts a graph showing the normalized division indices of T
cells expressing the indicated TACs following co-culture with indicated target cells.
[0017] FIG. 7 depicts the relative cell counts of target NALM6 GUCY2C-GFPeLuc cells as measured by detection of fluorescence signal from target cells following co-culture with T cells expressing indicated TACs at indicated effector:target (E:T) ratios.
[0018] FIGs. 8A-8B depict results of an assay measuring activation of GUCY2C-TAC T cells against cell lines with varying expression of GUCY2C. FIG. 8A depicts graphs showing relative GUCY2C expression (horizonal axes) with cell counts shown on the vertical axes. FIG. 8B
depicts a graph showing activation of T cells expressing the indicated TACs as measured by up-regulation of CD69 following co-culture with indicated target cells.
DETAILED DESCRIPTION
[0019] Cancer is a major health challenge. According to the American Cancer Society, more than one million people in the United States are diagnosed with cancer each year. While patients with early stage disease are sometimes treated effectively by conventional therapies (surgery, radiation, chemotherapy), few options are available to patients with advanced disease, and those options are typically palliative in nature.
[0020] Active immunotherapy seeks to employ the patient's immune system to clear tumors and offers an option to patients who have failed conventional therapies.
Generally, this treatment involves infusing patients with large numbers of tumor-specific T cells. To this point, most engineered T cell therapies involving genetic modification of the T cells yield: (i) forced expression of T cell receptor (TCR); or (ii) a chimeric antigen receptor (CAR) specific for CA 03173857 2022-9- ik63309 antigen targets on the tumor. To date, the chimeric antigen receptors used for engineering T cells consist of: (i) a targeting domain, usually a single-chain fragment variable (scFv); (ii) a transmembrane domain; and (iii) a cytosolic domain that contains signaling elements from the T
cell receptor and associated proteins. Such chimeric antigen receptors have also been referred to as "T-body" or "Chimeric Immune Receptor" (CI R), but currently, most researchers use the term "CAR". One advantage of the CAR approach is that it allows any patient's immune cells to be targeted against any desirable target in a major histocompatibility complex (MHC) independent manner. This is appealing as MHC presentation is often defective in tumor cells.
[0021] CARs are considered in modular terms and scientists have spent considerable time investigating the influence of different cytoplasmic signaling domains on CAR
function.
Conventional CARs generally share two main components: (i) the CD3 zeta cytoplasmic domain, which contains immunotyrosine activation motifs (ITAMs) critical for T
cell activation;
and (ii) components of costimulatory receptors that trigger important survival pathways such as the Akt pathway.
[0022] The first-generation CARs employed a single signaling domain from either CD3 or FcERIy. Second-generation CARs combined the signaling domain of CD3 with the cytoplasmic domain of costimulatory receptors from either the CD28 or TNFR family of receptors. Most CAR-engineered T cells that are currently being tested in the clinic employ second-generation CARs where CD3 is coupled to the cytoplasmic domain of either CD28 or CD137.
These second generation CARs have demonstrated anti-tumor activity in CD19-positive tumors. Third-generation CARs combined multiple costimulatory domains, but there is concern that third-generation CARs may lose antigen-specificity.
[0023] While CAR-engineered T cells have shown considerable promise in clinical application, they rely on a synthetic method for replacing the native activation signal that is provided by the T cell receptor (TCR). Since this synthetic receptor does not deliver all of the signaling components associated with the TCR (ex. ITAMs on CD3y, CD3o, CDR), it remains unclear whether the T cells are optimally activated by the CAR or how the CAR
activation affects T cell differentiation (ex. progression to memory). Furthermore, since the CAR
signaling domains are disconnected from their natural regulatory partners by the very nature of the CAR structure, there is an inherent risk that CARs may lead to a low-level of constitutive activation, which could result in off-target toxicities. Therefore, the synthetic nature of the prototypic CAR may disrupt canonical mechanisms that limit TCR activation, and may underpin the severe toxicity often associated with therapeutic doses of conventional CART cells.

CA 03173857 2022-9- ik63309
[0024] Given these limitations, it is preferable to re-direct T cells to attack tumors via their natural TCR. An alternate chimeric receptor, termed a T cell Antigen Coupler (TAC or TAC) receptor, has been developed which employs a distinct biology to direct the T
cell to attack tumors. While the CAR is a fully synthetic receptor that stitches together components of T cell receptor (TCR) signaling complex, the TAC receptor re-directs the TCR towards tumor targets and recapitulates the native TCR signaling structure. For example, in some embodiments, the TACs disclosed herein activate natural Major Histocompatibility complex (MHC) signaling through the T cell receptor (TCR), while retaining MHC-unrestricted targeting.
Further, the TACs disclosed herein recruit the T Cell Receptor (TCR) in combination with co-receptor stimulation. Moreover, in some embodiments, TACs disclosed herein show enhanced activity and safety.
Certain terminology
[0025] The term "antigen-binding domain," refers to any substance or molecule that binds, directly or indirectly, to a target (e.g., GUCY2C). Antigen-binding domains include antibodies or fragments thereof, peptides, peptidomimetics, proteins, glycoproteins, proteoglycans, carbohydrates, lipids, nucleic acids, or small molecules that bind to a target.
[0026] As used herein, unless otherwise indicated, the term "antibody" is understood to mean an intact antibody (e.g., an intact monoclonal antibody), or a fragment thereof, such as a Fc fragment of an antibody (e.g., an Fc fragment of a monoclonal antibody), or an antigen-binding fragment of an antibody (e.g., an antigen-binding fragment of a monoclonal antibody), including an intact antibody, antigen-binding fragment, or Fc fragment that has been modified, engineered, or chemically conjugated. In general, antibodies are multimeric proteins that contain four polypeptide chains. Two of the polypeptide chains are called immunoglobulin heavy chains (H
chains), and two of the polypeptide chains are called immunoglobulin light chains (L chains).
The immunoglobulin heavy and light chains are connected by an interchain disulfide bond. The immunoglobulin heavy chains are connected by interchain disulfide bonds. A
light chain consists of one variable region (VL) and one constant region (CO. The heavy chain consists of one variable region (VH) and at least three constant regions (CHi, CH2 and CH3). The variable regions determine the binding specificity of the antibody. Each variable region contains three hypervariable regions known as complementarity determining regions (CDRs) flanked by four relatively conserved regions known as framework regions (FRs). The extent of the FRs and CDRs has been defined (Kabat, E.A., etal. (1991) SEQUENCES OF PROTEINS OF
IMMUNOLOGICAL
INTEREST, FIFTH EDITION, U.S. Department of Health and Human Services, NIH
Publication No.
91-3242; and Chothia, C. etal. (1987) J. Mu_ MI_ 196:901-917). CDRs can also be identified CA 03173857 2022-9- ik63309 by alignment of the amino acid sequences. FRs contain conserved amino acid sequences, thus CDR sequences can be identified by identification of non-conserved amino acid residues between variable regions with conserved FRs. The three CDRs, referred to as CDR', CDR2, and CDR3, contribute to the antibody binding specificity. Naturally occurring antibodies have been used as starting material for engineered antibodies, such as chimeric antibodies and humanized antibodies. Examples of antibody-based antigen-binding fragments include Fab, Fab', (Fab12, Fv, single chain antibodies (e.g., scFv), minibodies, and diabodies. Examples of antibodies that have been modified or engineered include chimeric antibodies, humanized antibodies, and multispecific antibodies (e.g., bispecific antibodies). An example of a chemically conjugated antibody is an antibody conjugated to a toxin moiety.
[0027] The term "T cell" as used herein refers to a type of lymphocyte that plays a central role in cell-mediated immunity. T cells, also referred to as T lymphocytes, are distinguished from other lymphocytes, such as B cells and natural killer cells, by the presence of a T-cell receptor (TCR) on the cell surface. There are several subsets of T cells with distinct functions, including but not limited to, T helper cells, cytotoxic T cells, memory T cells, regulatory T cells and natural killer T cells.
[0028] The term "y6 T cell" or "gamma delta T cell" or "gd T cell "as used herein refers to any lymphocyte having a y6 T cell receptor (TCR) on its surface, including one y-chain and one 6-chain.
[0029] The term "T cell antigen coupler" or TAC is used interchangeably with "trifunctional T
cell antigen coupler" or Tri-TAC and refers to an engineered nucleic acid construct or polypeptide comprising (a) an antigen-binding domain that binds a target, (b) an antigen-binding domain that binds a protein associated with a T cell receptor (TCR) complex, and (c) a T cell receptor signaling domain.
[0030] The term "polynucleotide" and/or "nucleic acid sequence" and/or "nucleic acid" as used herein refers to a sequence of nucleoside or nucleotide monomers consisting of bases, sugars and intersugar (backbone) linkages. The term also includes modified or substituted sequences comprising non-naturally occurring monomers or portions thereof. The nucleic acid sequences of the present application may be deoxyribonucleic acid sequences (DNA) or ribonucleic acid sequences (RNA) and may include naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil. The sequences may also contain modified bases.
Examples of such modified bases include aza and deaza adenine, guanine, cytosine, thymidine and uracil; and xanthine and hypoxanthine. The nucleic acids of the present disclosure may be isolated from CA 03173857 2022-9- ik63309 biological organisms, formed by laboratory methods of genetic recombination or obtained by chemical synthesis or other known protocols for creating nucleic acids.
[0031] The term "isolated polynucleotide" or "isolated nucleic acid sequence"
as used herein refers to a nucleic acid substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors, or other chemicals when chemically synthesized. An isolated nucleic acid is also substantially free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) from which the nucleic acid is derived. The term "nucleic acid" is intended to include DNA and RNA
and is either double stranded or single stranded, and represents the sense or antisense strand.
Further, the term "nucleic acid" includes the complementary nucleic acid sequences.
[0032] The term "recombinant nucleic acid" or "engineered nucleic acid" as used herein refers to a nucleic acid or polynucleotide that is not found in a biological organism. For example, recombinant nucleic acids may be formed by laboratory methods of genetic recombination (such as molecular cloning) to create sequences that would not otherwise be found in nature.
Recombinant nucleic acids may also be created by chemical synthesis or other known protocols for creating nucleic acids.
[0033] The terms "peptide", "polypeptide," and "protein" as used herein mean a chain of amino acids. The term protein as used herein further means a large molecule comprising one or more chains of amino acids and, in some embodiments, is a fragment or domain of a protein or a full length protein. Furthermore, as used herein, the term protein either refers to a linear chain of amino acids or to a chain of amino acids that has been processed and folded into a functional protein. The protein structure is divided into four distinct levels: (1) primary structure - referring to the sequence of amino acids in the polypeptide chain, (2) secondary structure - referring to the regular local sub-structures on the polypeptide backbone chain, such as a-helix and 13-sheets, (3) tertiary structure - referring to the three-dimensional structure if monomeric and multimeric protein molecules, and (4) quaternary structure - referring to the three-dimensional structure comprising the aggregation of two or more individual polypeptide chains that operate as a single functional unit. The use of peptide or polypeptide herein does not mean that the chain of amino acids is not also a protein (i.e., a chain of amino acids having a secondary, tertiary or quaternary structure).
[0034] The term "isolated polypeptide" refers to a polypeptide substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.

CA 03173857 2022-9- ik63309
[0035] The term "vector" as used herein refers to a polynucleotide that is used to deliver a nucleic acid to the inside of a cell. In some embodiments, a vector is an expression vector comprising expression control sequences (for example, a promoter) operatively linked to a nucleic acid to be expressed in a cell. Vectors known in the art include, but are not limited to, plasmids, phages, cosmids and viruses.
[0036] The term "tumor antigen" or "tumor associated antigen" as used herein refers to an antigenic substance produced in tumor cells that triggers an immune response in a host (e.g., which is presented by MHC complexes). In some embodiments, a tumor antigen is on the surface of a tumor cell.
[0037] As used herein, the term "transmembrane and cytosolic domain" refers to a polypeptide that comprises a transmembrane domain and a cytosolic domain of a protein associated with the T cell receptor (TCR) complex. In some embodiments, such transmembrane and cytosolic domain may include, but is not limited to, protein domains that (a) associate with the lipid raft and/or (b) bind Lck.
[0038] A "TCR co-receptor" as used herein, refers to a molecule that assists the T cell receptor (TCR) in communicating with an antigen-presenting cell and may be considered part of the first signal that leads to the activation of the TCR. Examples of TCR co-receptors include, but are not limited to, CD4, LAG3, and CD8.
[0039] A "TCR co-stimulator" or "co-stimulatory domain" as used herein, refers to a molecule that enhances the response of a T cell to an antigen and may be considered as the second signal that leads to the activation of the TCR. Examples of TCR co-stimulators include, but are not limited to, ICOS, CD27, CD28, 4-1BB (CD 137), 0X40 (CD134), CD30, CD40, lymphocyte fiction-associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds CD83.
[0040] The terms "recipient", "individual", "subject", "host", and "patient", are used interchangeably herein and in some embodiments, refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans. "Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and laboratory, zoo, sports, or pet animals, such as dogs, horses, cats, cows, sheep, goats, pigs, mice, rats, rabbits, guinea pigs, monkeys etc. In some embodiments, the mammal is human. None of these terms require the supervision of medical personnel.
[0041] As used herein, the terms "treatment," "treating," and the like, in some embodiments, refer to administering an agent, or carrying out a procedure, for the purposes of obtaining an CA 03173857 2022-9- ik63309 effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of affecting a partial or complete cure for a disease and/or symptoms of the disease. "Treatment," as used herein, may include treatment of a disease or disorder (e.g., cancer) in a mammal, particularly in a human, and includes: (a) preventing the disease or a symptom of a disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it (e.g., including diseases that may be associated with or caused by a primary disease; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.
Treating may refer to any indicia of success in the treatment or amelioration or prevention of a cancer, including any objective or subjective parameter such as abatement;
remission;
diminishing of symptoms; or making the disease condition more tolerable to the patient; slowing in the rate of degeneration or decline; or making the final point of degeneration less debilitating.
The treatment or amelioration of symptoms is based on one or more objective or subjective parameters; including the results of an examination by a physician.
Accordingly, the term "treating" includes the administration of the compounds or agents of the present invention to prevent, delay, alleviate, arrest or inhibit development of the symptoms or conditions associated with diseases (e.g., cancer). The term "therapeutic effect" refers to the reduction, elimination, or prevention of the disease, symptoms of the disease, or side effects of the disease in the subject.
[0042] As used herein, singular forms "a", "and," and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "an antibody" includes a plurality of antibodies and reference to "an antibody" in some embodiments includes multiple antibodies, and so forth.
[0043] As used herein, all numerical values or numerical ranges include whole integers within or encompassing such ranges and fractions of the values or the integers within or encompassing ranges unless the context clearly indicates otherwise. Thus, for example, reference to a range of 90-100%, includes 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc., and so forth. In another example, reference to a range of 1-5,000 fold includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, fold, etc., as well as 1.1, 1.2, 1.3, 1.4, 1.5, fold, etc., 2.1, 2.2, 2.3, 2.4, 2.5, fold, etc., and so forth.
[0044] "About" a number, as used herein, refers to range including the number and ranging from 10% below that number to 10% above that number. "About" a range refers to 10% below the lower limit of the range, spanning to 10% above the upper limit of the range.

CA 03173857 2022-9- ik63309
[0045] "Percent (%) identity" refers to the extent to which two sequences (nucleotide or amino acid) have the same residue at the same positions in an alignment. For example, "an amino acid sequence is X% identical to SEQ ID NO: Y" refers to % identity of the amino acid sequence to SEQ ID NO: Y and is elaborated as X% of residues in the amino acid sequence are identical to the residues of sequence disclosed in SEQ ID NO: Y. Generally, computer programs are employed for such calculations. Exemplary programs that compare and align pairs of sequences, include ALIGN (Myers and Miller, 1988), FASTA (Pearson and Lipman, 1988;
Pearson, 1990) and gapped BLAST (Altschul et al., 1997), BLASTP, BLASTN, or GCG (Devereux et al., 1984).
[0046] As used herein, the term "selective binding" refers to the higher affinity with which a molecule (e.g., protein such as an antigen-binding domain of TAC) binds its target molecule (e.g., target antigen such as GUCY2C) over other molecules. Unless indicated otherwise, the terms "selective binding" and "specific binding" are used interchangeably herein.
[0047] As used herein, the term GUCY2C means the enzyme Guanylate Cyclase 2C.

is a transmembrane protein that functions as a receptor for endogenous peptides guanylin and uroguanylin, and the heat-stable E. coli enterotoxin. The encoded protein activates the cystic fibrosis transmembrane conductance regulator. GUCY2C produces the cGMP
following activation by the binding of guanylin or uroguanylin, regulating intestinal homeostasis, tumorigenesis, and obesity. Cell surface expression of GUCY2C is found on luminal surfaces of the intestinal epithelium and certain hypothalamic neurons. Over-expression of GUCY2C is found in tumors that evolve from intestinal metaplasia, including colorectal, esophageal, gastric, and pancreatic cancers. Over-expression is maintained in >95% of colorectal cancer metastases.
T cell antigen couplers (TA Cs)
[0048] Disclosed herein, in certain embodiments, are nucleic acids encoding GUCY2C T cell-antigen coupler (TAC) polypeptides. In some embodiments, the nucleic acids encoding the GUCY2C TAC comprise: (a) a first polynucleotide encoding an antigen-binding domain that binds GUCY2C; (b) a second polynucleotide encoding an antigen-binding domain that binds the TCR complex; and (c) a third polynucleotide encoding a transmembrane domain and cytosolic domain. In some embodiments, the nucleic acids comprise, in order (e.g., from 5' to 3'): (a) the first polynucleotide; (b) the second polynucleotide; and (c) the third polynucleotide encoding a TCR co-receptor cytosolic domain and transmembrane domain. In some embodiments, the nucleic acids encoding the GUCY2C TAC do not encode a co-stimulatory domain.
In some CA 03173857 2022-9- ik63309 embodiments, the nucleic acids encoding the GUCY2C TAC do not encode a co-activation domain.
[0049] Further disclosed herein, in certain embodiments, are GUCY2C T cell-antigen coupler (TAC) polypeptides. In some embodiments, the GUCY2C TAC polypeptides comprise:
(a) an antigen-binding domain that binds GUCY2C; (b) an antigen-binding domain that binds the TCR
complex; and (c) a transmembrane domain and cytosolic domain. In some embodiments, the GUCY2C TAC polypeptides comprise, in order (e.g., from N-terminus to C-terminus) (a) the antigen-binding domain that binds GUCY2C; (b) the antigen-binding domain that binds the TCR complex; and (c) the transmembrane domain and cytosolic domain. In some embodiments, the GUCY2C TAC polypeptides do not include a co-stimulatory domain. In some embodiments, the GUCY2C TAC polypeptides do not include a co-activation domain.
[0050] Further disclosed herein, in certain embodiments, are expression vectors comprising a nucleic acid encoding a GUCY2C TAC polypeptide as described herein.
[0051] Further disclosed herein, in certain embodiments, are T cells comprising a nucleic acid encoding a GUCY2C TAC polypeptide as described herein, T cells comprising an expression vector encoding a GUCY2C TAC polypeptide as described herein, or T cells comprising a GUCY2C TAC polypeptide as described herein.
[0052] Further disclosed herein, in certain embodiments, are methods of treating a cancer in an individual in need thereof, comprising administering to the individual a T
cell comprising a GUCY2C T cell-antigen coupler (TAC) polypeptide as described herein.
TCR Complex Protein Antigen-Binding Domain
[0053] In certain embodiments, the GUCY2C TAC comprises an antigen-binding domain that binds a protein associated with the TCR complex. A "TCR complex protein antigen-binding domain," also referred to as a "TCR complex antigen-binding domain," "antigen-binding domain that binds the TCR complex," or "antigen-binding domain that binds a protein associated with the TCR complex," refers to any substance or molecule that binds, directly or indirectly, toa protein associated with a TCR complex. In some embodiments, the antigen-binding domain that binds a protein associated with a TCR complex selectively binds to a protein of the TCR. In some embodiments, the antigen-binding domain that binds a protein associated with a TCR complex comprises a substance that specifically binds to a protein of the TCR.
[0054] In some embodiments, the TCR complex protein antigen-binding domain is selected from antibodies or fragments thereof, for example, single chain antibodies (e.g., single-chain CA 03173857 2022-9- ik63309 fragment variable antibodies (scFvs)), single domain antibodies (e.g., heavy-chain-only antibodies (VHH), shark heavy-chain-only antibodies (VNAR)), nanobodies, diabodies, minibodies, Fab fragments, Fab' fragments, F(ab')2fragments, or Fv fragments that bind to a protein of the TCR. In some embodiments, the TCR complex protein antigen-binding domain is selected from ankyrin repeat proteins (DARPins), affibodies, adnectins, affilins, phylomers;
fynomers, affimers, peptide aptamers, lectins, knottins, centyrins, anticalins, peptides, peptidomimetics, proteins, glycoproteins, or proteoglycans that bind to a protein of the TCR, or naturally occurring ligands for a protein of the TCR. In some embodiments, the TCR complex protein antigen-binding domain is a non-protein compound that binds to a protein of the TCR, including but not limited to carbohydrates, lipids, nucleic acids, or small molecules. In some embodiments, the TCR complex protein antigen-binding domain is a designed ankyrin repeat (DARPin) targeted to a protein of the TCR. In some embodiments, the TCR
complex protein antigen-binding domain is a single-chain variable fragment (scFv) targeted to a protein of the TCR. In some embodiments, the TCR complex protein antigen-binding domain is a nanobody targeted to a protein of the TCR.
[0055] Proteins associated with the TCR include, but are not limited, to the TCR alpha (a) chain, TCR beta (13) chain, TCR gamma (y) chain, TCR delta (6) chain, CD3y chain, CD36 chain and CDR chains. In some embodiments, an antigen-binding domain that binds a protein associated with the TCR complex is an antibody to the TCR alpha (a) chain, TCR
beta (13) chain, TCR gamma (y) chain, TCR delta (6) chain, CD3y chain, CD36 chain and/or CDR
chain. In some embodiments, the protein associated with a TCR complex is CD3. In some embodiments, the protein associated with a TCR complex is CDR. In some embodiments, the antigen-binding domain that binds CD3 is an antibody, for example, a single chain antibody, for example a single-chain variable fragment (scFv). Examples of CD3 antibodies, include, but are not limited to, UCHT1, OKT3, F6A, L2K, muromonab, otelixizumab, teplizumab, visilizumab, CD3-12, MEM-57, 4D10A6, CD3D, or TR66.
[0056] In some embodiments, the antigen-binding domain that binds the TCR
complex is UCHT1, or a variant thereof. In some embodiments, the UCHT1 antigen-binding domain is encoded by SEQ ID NO: 31. In some embodiments, the UCHT1 antigen-binding domain comprises SEQ ID NO: 32. In some embodiments, the UCHT1 antigen-binding domain is mutated. In some embodiments, the UCHT1 antigen-binding domain comprises a Y
to T
mutation at a position corresponding to amino acid 182 of SEQ ID NO: 32 (Y182T). In some embodiments, the UCHT1 (Y182T) antigen-binding domain is encoded by SEQ ID NO:
43. In some embodiments, the UCHT1 (Y182T) antigen-binding domain comprises SEQ ID
NO: 44.

CA 03173857 2022-9- ik63309 In some embodiments, the antigen-binding domain that binds the TCR complex is a humanized UCHT1 (huUCHT1). In some embodiments, the huUCHT1 antigen-binding domain is encoded by SEQ ID NO: 39. In some embodiments, the huUCHT1 antigen-binding domain comprises SEQ ID NO: 40. In some embodiments, the huUCHT1 has a Y to T mutation at a position corresponding to amino acid 177 of SEQ ID NO: 40 (Y177T). In some embodiments, the huUCHT1 (Y177T) antigen-binding domain is encoded by SEQ ID NO: 41. In some embodiments, the huUCHT1 antigen-binding domain comprises SEQ ID NO: 42.
[0057] In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 31 (UCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 75%
sequence identity with the nucleotide sequence of SEQ ID NO: 31 (UCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 80%
sequence identity with the nucleotide sequence of SEQ ID NO: 31 (UCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 85%
sequence identity with the nucleotide sequence of SEQ ID NO: 31 (UCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 90%
sequence identity with the nucleotide sequence of SEQ ID NO: 31 (UCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 95%
sequence identity with the nucleotide sequence of SEQ ID NO: 31 (UCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 96%
sequence identity with the nucleotide sequence of SEQ ID NO: 31 (UCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 97%
sequence identity with the nucleotide sequence of SEQ ID NO: 31 (UCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 98%
sequence identity with the nucleotide sequence of SEQ ID NO: 31 (UCHT1). In some CA 03173857 2022-9- ik63309 embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 99%
sequence identity with the nucleotide sequence of SEQ ID NO: 31 (UCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises the nucleotide sequence of SEQ ID
NO: 31 (UCHT1).
[0058] In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 75% sequence identity with the amino acid sequence of SEQ ID
NO: 32 (UCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%
sequence identity with the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:
32 (UCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 95%
sequence identity with the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID NO:
32 (UCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 98%
sequence identity with the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises the amino acid CA 03173857 2022-9- ik63309 sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1) (i.e., the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence comprising a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, each having 100% identity to the corresponding CDR in the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1), and the non-CDR
(e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 32 (UCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 85%
sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID
NO: 32 (UCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR
sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 90% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the CDR

sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 32 (UCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 95%
sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID
NO: 32 (UCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR
sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 96% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the CDR

CA 03173857 2022-9- ik63309 sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 32 (UCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 97%
sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID
NO: 32 (UCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR
sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 98% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1). In some embodiments, the CDR

sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 32 (UCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 99%
sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID
NO: 32 (UCHT1).
[0059] In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 43 (UCHT1 (Y182T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 75% sequence identity with the nucleotide sequence of SEQ ID NO: 43 (UCHT1 (Y182T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 80% sequence identity with the nucleotide sequence of SEQ ID NO: 43 (UCHT1 (Y182T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 85% sequence identity with the nucleotide sequence of SEQ ID NO: 43 (UCHT1 (Y182T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence of SEQ ID NO: 43 (UCHT1 (Y182T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at CA 03173857 2022-9- ik63309 least 95% sequence identity with the nucleotide sequence of SEQ ID NO: 43 (UCHT1 (Y182T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 96% sequence identity with the nucleotide sequence of SEQ ID NO: 43 (UCHT1 (Y182T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 97% sequence identity with the nucleotide sequence of SEQ ID NO: 43 (UCHT1 (Y182T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 98% sequence identity with the nucleotide sequence of SEQ ID NO: 43 (UCHT1 (Y182T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 99% sequence identity with the nucleotide sequence of SEQ ID NO: 43 (UCHT1 (Y182T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises the nucleotide sequence of SEQ
ID NO: 43 (UCHT1 (Y182T)).
[0060] In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 75% sequence identity with the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 85%
sequence identity with the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 96%
sequence identity CA 03173857 2022-9- ik63309 with the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 99%
sequence identity with the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 44 (UCHT1 (Y182T)) (i.e., the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence comprising a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, each having 100% identity to the corresponding CDR
in the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 44 (UCHT1 (Y182T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80%
sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 85% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 90% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the CDR

CA 03173857 2022-9- ik63309 sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 44 (UCHT1 (Y182T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 95%
sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 96% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 97% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 44 (UCHT1 (Y182T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 98%
sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 99% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 44 (UCHT1 (Y182T)).
[0061] In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 39 (huUCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 75%
sequence identity with the nucleotide sequence of SEQ ID NO: 39 (huUCHT1). In some CA 03173857 2022-9- ik63309 embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 80%
sequence identity with the nucleotide sequence of SEQ ID NO: 39 (huUCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 85%
sequence identity with the nucleotide sequence of SEQ ID NO: 39 (huUCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 90%
sequence identity with the nucleotide sequence of SEQ ID NO: 39 (huUCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 95%
sequence identity with the nucleotide sequence of SEQ ID NO: 39 (huUCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 96%
sequence identity with the nucleotide sequence of SEQ ID NO: 39 (huUCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 97%
sequence identity with the nucleotide sequence of SEQ ID NO: 39 (huUCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 98%
sequence identity with the nucleotide sequence of SEQ ID NO: 39 (huUCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 99%
sequence identity with the nucleotide sequence of SEQ ID NO: 39 (huUCHT1). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises the nucleotide sequence of SEQ ID
NO: 39 (huUCHT1).
[0062] In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 75% sequence identity with the amino acid sequence of SEQ ID
NO: 40 (huUCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%

CA 03173857 2022-9- ik63309 sequence identity with the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID
NO: 40 (huUCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 95%
sequence identity with the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID
NO: 40 (huUCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 98%
sequence identity with the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1) (i.e., the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence comprising a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, each having 100% identity to the corresponding CDR in the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein CA 03173857 2022-9- ik63309 associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 85% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 90% sequence identity with the non-CDR
(e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 95% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 96% sequence identity with the non-CDR
(e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 97% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 98% sequence identity with the non-CDR
(e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino CA 03173857 2022-9- ik63309 acid sequence of SEQ ID NO: 40 (huUCHT1), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 99% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 40 (huUCHT1).
[0063] In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 41 (huUCHT1 (Y177T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 75% sequence identity with the nucleotide sequence of SEQ ID NO: 41 (huUCHT1 (Y177T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 80% sequence identity with the nucleotide sequence of SEQ ID NO: 41 (huUCHT1 (Y177T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 85% sequence identity with the nucleotide sequence of SEQ ID NO: 41 (huUCHT1 (Y177T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence of SEQ ID NO: 41 (huUCHT1 (Y177T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 95% sequence identity with the nucleotide sequence of SEQ ID NO: 41 (huUCHT1 (Y177T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 96% sequence identity with the nucleotide sequence of SEQ ID NO: 41 (huUCHT1 (Y177T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 97% sequence identity with the nucleotide sequence of SEQ ID NO: 41 (huUCHT1 (Y177T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 98% sequence identity with the nucleotide sequence of SEQ ID NO: 41 (huUCHT1 (Y177T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 99% sequence identity with the nucleotide sequence of SEQ ID NO: 41 (huUCHT1 CA 03173857 2022-9- ik63309 (Y177T)). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises the nucleotide sequence of SEQ
ID NO: 41 (huUCHT1 (Y177T)).
[0064] In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 75% sequence identity with the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 85%
sequence identity with the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 96%
sequence identity with the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 99%
sequence identity with the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID

CA 03173857 2022-9- ik63309 NO: 42 (huUCHT1 (Y177T)) (i.e., the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence comprising a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, each having 100% identity to the corresponding CDR
in the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 42 (huUCHT1 (Y177T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80%
sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 85% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO:

(huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR
sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 90% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 95% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID
NO: 42 (huUCHT1 (Y177T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 96%
sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%

CA 03173857 2022-9- ik63309 identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 97% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO:

(huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR
sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 98% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have at least 99% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 42 (huUCHT1 (Y177T)).
[0065] In some embodiments, the antigen-binding domain that binds to the protein associated with the TCR complex is OKT3. In some embodiments, the murine OKT3 antigen-binding domain is encoded by SEQ ID NO: 33. In some embodiments, the OKT3 antigen-binding domain comprises SEQ ID NO: 34.
[0066] In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO:
33(OKT3). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 75%
sequence identity with the nucleotide sequence of SEQ ID NO: 33(OKT3). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 80%
sequence identity with the nucleotide sequence of SEQ ID NO: 33(OKT3). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 85%
sequence identity with the nucleotide sequence of SEQ ID NO: 33(OKT3). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 90%

CA 03173857 2022-9- ik63309 sequence identity with the nucleotide sequence of SEQ ID NO: 33(OKT3). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 95%
sequence identity with the nucleotide sequence of SEQ ID NO: 33(OKT3). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 96%
sequence identity with the nucleotide sequence of SEQ ID NO: 33(OKT3). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 97%
sequence identity with the nucleotide sequence of SEQ ID NO: 33(OKT3). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 98%
sequence identity with the nucleotide sequence of SEQ ID NO: 33(OKT3). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 99%
sequence identity with the nucleotide sequence of SEQ ID NO: 33(OKT3). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises the nucleotide sequence of SEQ ID
NO: 33 (OKT3).
[0067] In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 75% sequence identity with the amino acid sequence of SEQ ID NO:
34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%
sequence identity with the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID
NO: 34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 90%
sequence identity with the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 95% sequence identity with the CA 03173857 2022-9- ik63309 amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO:
34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 97%
sequence identity with the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID
NO: 34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 99%
sequence identity with the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ
ID NO: 34 (OKT3) (i.e., the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence comprising a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, each having 100% identity to the corresponding CDR in the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 85% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 90% sequence identity with the non-CDR (e.g., CA 03173857 2022-9- ik63309 framework) sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 95% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 96% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 97% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 98% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 99% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3).
[0068] In some embodiments, the antigen-binding domain that binds to the protein associated with the TCR complex is F6A. In some embodiments, the murine F6A antigen-binding domain is encoded by SEQ ID NO: 35. In some embodiments, the F6A antigen-binding domain comprises SEQ ID NO: 36.

CA 03173857 2022-9- ik63309
[0069] In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO:
35(F6A). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 75%
sequence identity with the nucleotide sequence of SEQ ID NO: 35(F6A). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 80% sequence identity with the nucleotide sequence of SEQ ID NO: 35(F6A). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 85% sequence identity with the nucleotide sequence of SEQ ID NO: 35(F6A). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence of SEQ
ID NO: 35(F6A). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 95% sequence identity with the nucleotide sequence of SEQ ID
NO: 35(F6A). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 96%
sequence identity with the nucleotide sequence of SEQ ID NO: 35(F6A). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 97% sequence identity with the nucleotide sequence of SEQ ID NO: 35 (F6A). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 98% sequence identity with the nucleotide sequence of SEQ ID NO: 35(F6A). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 99% sequence identity with the nucleotide sequence of SEQ
ID NO: 35(F6A). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises the nucleotide sequence of SEQ ID NO: 35(F6A).
[0070] In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the antigen-binding CA 03173857 2022-9- ik63309 domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 75% sequence identity with the amino acid sequence of SEQ ID NO:
36 (F6A). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%
sequence identity with the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID
NO: 36 (F6A). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 90%
sequence identity with the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO:
36 (F6A). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 97%
sequence identity with the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID
NO: 36 (F6A). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 99%
sequence identity with the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ
ID NO: 36 (F6A) (i.e., the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence comprising a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, each having 100% identity to the corresponding CDR in the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 36 (F6A), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein CA 03173857 2022-9- ik63309 associated with the TCR complex have at least 80% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 36 (F6A), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 85% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 36 (F6A), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 90% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 36 (F6A), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 95% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 36 (F6A), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 96% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 36 (F6A), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 97% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 36 (F6A), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 98% sequence identity with the non-CDR (e.g., CA 03173857 2022-9- ik63309 framework) sequences of the amino acid sequence of SEQ ID NO: 36 (F6A). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 36 (F6A), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 99% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 36 (F6A).
[0071] In some embodiments, the antigen-binding domain that binds to the protein associated with the TCR complex is L2K. In some embodiments, the murine L2K antigen-binding domain is encoded by SEQ ID NO: 37. In some embodiments, the L2K antigen-binding domain comprises SEQ ID NO: 38.
[0072] In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 37 (L2K). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 75%
sequence identity with the nucleotide sequence of SEQ ID NO: 37 (L2K). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 80%
sequence identity with the nucleotide sequence of SEQ ID NO: 37 (L2K). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 85%
sequence identity with the nucleotide sequence of SEQ ID NO: 37 (L2K). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 90%
sequence identity with the nucleotide sequence of SEQ ID NO: 37 (L2K). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 95%
sequence identity with the nucleotide sequence of SEQ ID NO: 37 (L2K). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 96%
sequence identity with the nucleotide sequence of SEQ ID NO: 37 (L2K). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 97%

CA 03173857 2022-9- ik63309 sequence identity with the nucleotide sequence of SEQ ID NO: 37 (L2K). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 98%
sequence identity with the nucleotide sequence of SEQ ID NO: 37 (L2K). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises a nucleotide sequence having at least 99%
sequence identity with the nucleotide sequence of SEQ ID NO: 37 (L2K). In some embodiments, the polynucleotide encoding the antigen-binding domain that binds the protein associated with the TCR complex comprises the nucleotide sequence of SEQ ID
NO: 37 (L2K).
[0073] In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 75% sequence identity with the amino acid sequence of SEQ ID NO:
38 (L2K). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%
sequence identity with the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID
NO: 38 (L2K). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 90%
sequence identity with the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO:
38 (L2K). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 97%
sequence identity with the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID
NO: 38 (L2K). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 99%

CA 03173857 2022-9- ik63309 sequence identity with the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the antigen-binding domain that binds the protein associated with the TCR
complex comprises the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ
ID NO: 38 (L2K) (i.e., the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence comprising a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, each having 100% identity to the corresponding CDR in the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 85% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 90% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 95% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein CA 03173857 2022-9- ik63309 associated with the TCR complex have at least 96% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 97% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 98% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 38 (L2K). In some embodiments, the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K), and the non-CDR (e.g., framework) sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 99% sequence identity with the non-CDR (e.g., framework) sequences of the amino acid sequence of SEQ ID NO: 38 (L2K).
[0074] Amino acid and nucleotide sequences of exemplary antigen-binding domains that bind a protein associated with the TCR complex are provided in Table 1.
Table 1. Table of Sequences SEQ ID NO Description Nucleotide/Amino Acid SEQ ID NO: 31 UCHT1' Nucleotide SEQ ID NO: 32 UCHT12 Amino Acid SEQ ID NO: 33 OKT3 Nucleotide SEQ ID NO: 34 OKT3 Amino Acid SEQ ID NO: 35 F6A Nucleotide SEQ ID NO: 36 F6A Amino Acid SEQ ID NO: 37 L2K Nucleotide SEQ ID NO: 38 L2K Amino Acid SEQ ID NO: 39 huUCHT1 Nucleotide SEQ ID NO: 40 huUCHT1 Amino Acid SEQ ID NO: 41 huUCHT1 (Y177T) Nucleotide SEQ ID NO: 42 huUCHT1 (Y177T) Amino Acid SEQ ID NO: 43 UCHT1 (Y182T) Nucleotide SEQ ID NO: 44 UCHT1 (Y182T) Amino Acid 1 Light chain, nucleotides 1-324; Linker, nucleotides 325-387; Heavy chain, nucleotides 388-CA 03173857 2022-9- ik63309 2 Light chain, amino acids 1-108; Linker, amino acids 109-128; Heavy chain, amino acids 129-Transmembrane domain and Cytosolic domain
[0075] In some embodiments, a GUCY2C T cell antigen coupler polypeptide comprises a T cell receptor signaling domain polypeptide. In some embodiments, a GUCY2C T cell antigen coupler polypeptide comprises a transmembrane domain of a TCR signaling domain. In some embodiments, a GUCY2C T cell antigen coupler polypeptide comprises a cytosolic domain of a TCR signaling domain polypeptide. In some embodiments, a GUCY2C T cell antigen coupler polypeptide comprises a transmembrane domain and a cytosolic domain of a TCR
signaling domain polypeptide.
[0076] In some embodiments, the T cell receptor signaling domain polypeptide comprises a TCR co-receptor domain. In some embodiments, the TCR signaling domain polypeptide comprises a transmembrane domain and/or a cytosolic domain of a TCR co-receptor. In some embodiments, the TCR co-receptor is CD4, CD8, LAG3, or a chimeric variation thereof.
[0077] In some embodiments, the TCR co-receptor is CD4. In some embodiments, the GUCY2C TAC comprises a transmembrane domain and a cytosolic domain of a CD4 co-receptor. In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 45 (CD4 transmembrane and cytosolic domain).
In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 75% sequence identity with the nucleotide sequence of SEQ ID NO: 45 (CD4 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 80% sequence identity with the nucleotide sequence of SEQ ID NO: 45 (CD4 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 85% sequence identity with the nucleotide sequence of SEQ ID NO: 45 (CD4 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 90%
sequence identity with the nucleotide sequence of SEQ ID NO: 45 (CD4 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 95%
sequence identity with the nucleotide sequence of SEQ ID NO: 45 (CD4 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain CA 03173857 2022-9- ik63309 comprises a nucleotide sequence having at least 96% sequence identity with the nucleotide sequence of SEQ ID NO: 45 (CD4 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 97% sequence identity with the nucleotide sequence of SEQ ID NO: 45 (CD4 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 98% sequence identity with the nucleotide sequence of SEQ ID NO: 45 (CD4 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 99% sequence identity with the nucleotide sequence of SEQ ID NO: 45 (CD4 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises the nucleotide sequence of SEQ ID
NO: 45 (CD4 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 70%
sequence identity with the amino acid sequence of SEQ ID NO: 46 (CD4 transmembrane and cytosolic domain).
In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 75% sequence identity with the amino acid sequence of SEQ ID NO:
46 (CD4 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 80%
sequence identity with the amino acid sequence of SEQ ID NO: 46 (CD4 transmembrane and cytosolic domain).
In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO:
46 (CD4 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 90%
sequence identity with the amino acid sequence of SEQ ID NO: 46 (CD4 transmembrane and cytosolic domain).
In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:
46 (CD4 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 96%
sequence identity with the amino acid sequence of SEQ ID NO: 46 (CD4 transmembrane and cytosolic domain).
In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID NO:
46 (CD4 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 98%
sequence identity CA 03173857 2022-9- ik63309 with the amino acid sequence of SEQ ID NO: 46 (CD4 transmembrane and cytosolic domain).
In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 99% sequence identity with the amino acid sequence of SEQ ID NO:
46 (CD4 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise the amino acid sequence of SEQ ID NO: 46 (CD4 transmembrane and cytosolic domain).
[0078] In some embodiments, the TCR co-receptor is CD8. In some embodiments, the TCR co-receptor is CD8a. In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 70%
sequence identity with the nucleotide sequence of SEQ ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 75% sequence identity with the nucleotide sequence of SEQ ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 80% sequence identity with the nucleotide sequence of SEQ ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 85% sequence identity with the nucleotide sequence of SEQ ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence of SEQ ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 95%
sequence identity with the nucleotide sequence of SEQ ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 96%
sequence identity with the nucleotide sequence of SEQ ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 97% sequence identity with the nucleotide sequence of SEQ ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 98% sequence identity with the nucleotide sequence of SEQ ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide CA 03173857 2022-9- ik63309 sequence having at least 99% sequence identity with the nucleotide sequence of SEQ ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises the nucleotide sequence of SEQ
ID NO: 47 (CD8 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 70%
sequence identity with the amino acid sequence of SEQ ID NO: 48 (CD8 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 75% sequence identity with the amino acid sequence of SEQ ID
NO: 48 (CD8 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 80%
sequence identity with the amino acid sequence of SEQ ID NO: 48 (CD8 transmembrane and cytosolic domain).
In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO:
48 (CD8 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 90%
sequence identity with the amino acid sequence of SEQ ID NO: 48 (CD8 transmembrane and cytosolic domain).
In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO:
48 (CD8 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 96%
sequence identity with the amino acid sequence of SEQ ID NO: 48 (CD8 transmembrane and cytosolic domain).
In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID NO:
48 (CD8 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 98%
sequence identity with the amino acid sequence of SEQ ID NO: 48 (CD8 transmembrane and cytosolic domain).
In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 99% sequence identity with the amino acid sequence of SEQ ID NO:
48 (CD8 transmembrane and cytosolic domain). In some embodiments, the cytosolic and transmembrane domain comprise the amino acid sequence of SEQ ID NO: 48 (CD8 transmembrane and cytosolic domain).
[0079] In some embodiments, the TCR signaling domain polypeptide comprises a chimera of sequences or domains from co-receptors. In some embodiments, the TCR signaling domain polypeptide comprises a chimera of CD8a and CD813, wherein the CD8a arginine rich region is CA 03173857 2022-9- ik63309 replaced with the CD813 arginine rich region (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 75%
sequence identity with the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 80% sequence identity with the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 85%
sequence identity with the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 95%
sequence identity with the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 96% sequence identity with the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 97%
sequence identity with the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 98% sequence identity with the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 99%
sequence identity with the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises the nucleotide sequence of SEQ ID NO: 49 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 70%
sequence identity with the amino acid sequence of SEQ ID NO: 50 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 75%
sequence identity with the amino acid sequence of SEQ ID NO: 50 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID
NO: 50 CA 03173857 2022-9- ik63309 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 50 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 90%
sequence identity with the amino acid sequence of SEQ ID NO: 50 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 95%
sequence identity with the amino acid sequence of SEQ ID NO: 50 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID
NO: 50 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID NO: 50 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 98%
sequence identity with the amino acid sequence of SEQ ID NO: 50 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 99%
sequence identity with the amino acid sequence of SEQ ID NO: 50 (CD8a+R(13) chimera). In some embodiments, the cytosolic and transmembrane domain comprise the amino acid sequence of SEQ ID NO: 50 (CD8a+R(13) chimera).
[0080] In some embodiments, the TCR signaling domain polypeptide comprises a chimera of CD8a and CD813, where the CD8a CXCP domain, which contains an Lck binding motif, is appended to the C-terminus of the CD813 cytosolic domain (CD813+Lck chimera).
In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 75%
sequence identity with the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 80% sequence identity with the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 85% sequence identity with the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the CA 03173857 2022-9- ik63309 polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 95% sequence identity with the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 96%
sequence identity with the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 97% sequence identity with the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 98%
sequence identity with the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises a nucleotide sequence having at least 99% sequence identity with the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the polynucleotide encoding the cytosolic and transmembrane domain comprises the nucleotide sequence of SEQ ID NO: 51 (CD813+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID
NO: 52 (CD813+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 75% sequence identity with the amino acid sequence of SEQ ID NO: 52 (CD813+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 80%
sequence identity with the amino acid sequence of SEQ ID NO: 52 (CD813+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 85%
sequence identity with the amino acid sequence of SEQ ID NO: 52 (CD813+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID
NO: 52 (CD813+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 52 (CD813+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 96%
sequence identity with the amino acid sequence of SEQ ID NO: 52 (CD813+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 97%
sequence identity with the amino acid sequence of SEQ ID NO: 52 (CD813+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID
NO: 52 CA 03173857 2022-9- ik63309 (CD8J3+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise an amino acid sequence having at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 52 (CD8J3+Lck chimera). In some embodiments, the cytosolic and transmembrane domain comprise the amino acid sequence of SEQ ID NO: 52 (CD8J3+Lck chimera).
[0081] In some embodiments, the TCR signaling domain polypeptide includes both a cytosolic domain and a transmembrane domain of a TCR co-receptor protein. In some embodiments, the cytosolic domain and transmembrane domain are from the same co-receptor or from different co-receptors.
[0082] Amino acid and nucleotide sequences of exemplary transmembrane and cytosolic domains are provided in Table 2.
Table 2. Table of Sequences SEQ ID NO Description Nucleotide/Amino Acid SEQ ID NO: 45 CD4 Domain' Nucleotide SEQ ID NO: 46 CD4 Domain2 Amino Acid SEQ ID NO: 47 CD8a Domain Nucleotide SEQ ID NO: 48 CD8a Domain Amino Acid SEQ ID NO: 49 CD8a+R(13) Domain Nucleotide SEQ ID NO: 50 CD8a+R(J3) Domain Amino Acid SEQ ID NO: 51 CD8 a +Lck Domain Nucleotide SEQ ID NO: 52 CD8 a +Lck Domain Amino Acid 1 Extracellular linker, nucleotides 1-66; Transmembrane domain, nucleotides 67-132; Cytosolic domain, nucleotides 133-254 2 Extracellular linker, amino acids 1-22; Transmembrane domain, amino acids 23-44; Cytosolic domain, amino acids 45-84 Configurations, Linkers, and Connectors
[0083] In some embodiments, a nucleic acid disclosed herein is in an order of (1) a first polynucleotide encoding an antigen-binding domain that binds GUCY2C; (2) a second polynucleotide encoding an antigen-binding domain that binds a TCR complex;
(3) a third polynucleotide encoding a transmembrane domain and a cytosolic domain. In some embodiments, a nucleic acid disclosed herein is in an order of (1) a first polynucleotide encoding an antigen-binding domain that binds GUCY2C; (2) a second polynucleotide encoding an antigen-binding domain that binds a TCR complex; (3) a third polynucleotide encoding a transmembrane domain and a cytosolic domain, wherein the order is 5' end to 3' end. In some embodiments, a nucleic acid disclosed herein is in an order of (1) a first polynucleotide encoding an antigen-binding domain that binds GUCY2C; (2) a second polynucleotide encoding an antigen-binding domain that binds a TCR complex; (3) a third polynucleotide encoding a CA 03173857 2022-9- ik63309 transmembrane domain and a cytosolic domain, wherein the order is 3' end to 5' end. In some embodiments, a nucleic acid described herein is in an order of (1) a first polynucleotide encoding an antigen-binding domain that binds a TCR complex; (2) a second polynucleotide encoding an antigen-binding domain that binds GUCY2C; (3) a third polynucleotide encoding a transmembrane domain and a cytosolic domain. In some embodiments, a nucleic acid described herein is in an order of (1) a first polynucleotide encoding an antigen-binding domain that binds a TCR complex; (2) a second polynucleotide encoding an antigen-binding domain that binds GUCY2C; (3) a third polynucleotide encoding a transmembrane domain and a cytosolic domain, wherein the order is 5' end to 3' end. In some embodiments, a nucleic acid described herein is in an order of (1) a first polynucleotide encoding an antigen-binding domain that binds a TCR
complex; (2) a second polynucleotide encoding an antigen-binding domain that binds GUCY2C;
(3) a third polynucleotide encoding a transmembrane domain and a cytosolic domain, wherein the order is 3' end to 5' end.
[0084] In some embodiments, a GUCY2C TAC polypeptide disclosed herein is in an order of (1) an antigen-binding domain that binds GUCY2C; (2) an antigen-binding domain that binds a TCR complex; (3) a transmembrane domain and a cytosolic domain, wherein the order is N-terminus to C-terminus. In some embodiments, a GUCY2C TAC polypeptide disclosed herein is in an order of (1) an antigen-binding domain that binds GUCY2C; (2) an antigen-binding domain that binds a TCR complex; (3) a transmembrane domain and a cytosolic domain, wherein the order is C-terminus to N-terminus. In some embodiments, a GUCY2C
TAC
polypeptide described herein is in an order of (1) an antigen-binding domain that binds a TCR
complex; (2) an antigen-binding domain that binds GUCY2C; (3) a transmembrane domain and a cytosolic domain, wherein the order is N-terminus to C-terminus. In some embodiments, a GUCY2C TAC polypeptide described herein is in an order of (1) an antigen-binding domain that binds a TCR complex; (2) an antigen-binding domain that binds GUCY2C; (3) a transmembrane domain and a cytosolic domain, wherein the order is C-terminus to N-terminus.
[0085] In some embodiments, the antigen-binding domain that binds GUCY2C, the antigen-binding domain that binds the TCR complex, and/or the transmembrane domain and cytosolic domain are directly fused. For example, the antigen-binding domain that binds GUCY2C and the transmembrane domain and cytosolic domain are both fused to the antigen-binding domain that binds the TCR complex. In some embodiments, the antigen-binding domain that binds GUCY2C, the antigen-binding domain that binds the TCR complex, and/or the transmembrane domain and cytosolic domain are joined by at least one linker. In some embodiments, the antigen-binding domain that binds GUCY2C and the antigen-binding domain that binds the CA 03173857 2022-9- i63309 TCR complex are directly fused, and joined to the transmembrane domain and cytosolic domain by a linker. In some embodiments, the antigen-binding domain that binds the TCR complex and the transmembrane domain and cytosolic domain are directly fused, and joined to the antigen-binding domain that binds GUCY2C by a linker.
[0086] In some embodiments, the linker is a peptide linker. In some embodiments, the peptide linker comprises 1 to 40 amino acids. In some embodiments, the peptide linker comprises 1 to 30 amino acids. In some embodiments, the peptide linker comprises 1 to 15 amino acids. In some embodiments, the peptide linker comprises 1 to 10 amino acids. In some embodiments, the peptide linker comprises 1 to 6 amino acids. In some embodiments, the peptide linker comprises 30 to 40 amino acids. In some embodiments, the peptide linker comprises 32 to 36 amino acids.
In some embodiments, the peptide linker comprises 5 to 30 amino acids. In some embodiments, the peptide linker comprises 5 amino acids. In some embodiments, the peptide linker comprises amino acids. In some embodiments, the peptide linker comprises 15 amino acids.
In some embodiments, the peptide linker comprises 20 amino acids. In some embodiments, the peptide linker comprises 25 amino acids. In some embodiments, the peptide linker comprises 30 amino acids. In some embodiments, the peptide linker comprises a glycine and/or serine-rich linker.
[0087] In some embodiments, the at least one linker comprises an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 26 ((G45)4-based linker), SEQ ID NO: 28 (G45-based linker), SEQ ID NO: 6 (linker 1), SEQ ID NO: 8 (linker 2), SEQ
ID NO: 10 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID
NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ ID NO: 24 (G453 linker).
In some embodiments, the at least one linker comprises an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 26 ((G45)4-based linker), SEQ ID
NO: 28 (G45-based linker), SEQ ID NO: 6 (linker 1), SEQ ID NO: 8 (linker 2), SEQ ID NO: 10 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ ID NO: 24 (G453 linker). In some embodiments, the at least one linker comprises an amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 26 ((G45)4-based linker), SEQ ID
NO: 28 (G45-based linker), SEQ ID NO: 6 (linker 1), SEQ ID NO: 8 (linker 2), SEQ ID NO: 10 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ ID NO: 24 (G453 linker). In some embodiments, the at least one linker comprises an amino acid sequence having at least 95% identity with the amino acid sequence of SEQ ID NO: 26 ((G45)4-based linker), SEQ ID
NO: 28 (G45-based linker), SEQ ID NO: 6 (linker 1), SEQ ID NO: 8 (linker 2), SEQ ID NO: 10 CA 03173857 2022-9- i63309 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ ID NO: 24 (G453 linker). In some embodiments, the at least one linker comprises an amino acid sequence having at least 96% identity with the amino acid sequence of SEQ ID NO: 26 ((G45)4-based linker), SEQ ID
NO: 28 (G45-based linker), SEQ ID NO: 6 (linker 1), SEQ ID NO: 8 (linker 2), SEQ ID NO: 10 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ ID NO: 24 (G453 linker). In some embodiments, the at least one linker comprises an amino acid sequence having at least 97% identity with the amino acid sequence of SEQ ID NO: 26 ((G45)4-based linker), SEQ ID
NO: 28 (G45-based linker), SEQ ID NO: 6 (linker 1), SEQ ID NO: 8 (linker 2), SEQ ID NO: 10 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ ID NO: 24 (G453 linker). In some embodiments, the at least one linker comprises an amino acid sequence having at least 98% identity with the amino acid sequence of SEQ ID NO: 26 ((G45)4-based linker), SEQ ID
NO: 28 (G45-based linker), SEQ ID NO: 6 (linker 1), SEQ ID NO: 8 (linker 2), SEQ ID NO: 10 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ ID NO: 24 (G453 linker). In some embodiments, the at least one linker comprises an amino acid sequence having at least 99% identity with the amino acid sequence of SEQ ID NO: 26 ((G45)4-based linker), SEQ ID
NO: 28 (G45-based linker), SEQ ID NO: 6 (linker 1), SEQ ID NO: 8 (linker 2), SEQ ID NO: 10 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ ID NO: 24 (G453 linker). In some embodiments, the at least one linker comprises the amino acid sequence of SEQ ID NO:
26 ((G45)4-based linker), SEQ ID NO: 28 (G45-based linker), SEQ ID NO: 6 (linker 1), SEQ
ID NO: 8 (linker 2), SEQ ID NO: 10 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ ID NO: 24 (G453 linker).
[0088] In some embodiments, the peptide linker that joins the antigen-binding domain that binds GUCY2C to the antigen-binding domain that binds a TCR complex (e.g., UCHT1) is known as the connector to distinguish this protein domain from other linkers in the TAC. The connector may be of any size. In some embodiments, the connector between the antigen-binding domain that binds a TCR complex and the antigen-binding domain that binds GUCY2C is a short helix comprising SEQ ID NO: 12. In some embodiments, the connector between the antigen-binding domain that binds a TCR complex and the antigen-binding domain that binds GUCY2C is a CA 03173857 2022-9- i63309 short helix encoded by SEQ ID NO: 11. In some embodiments, the connector between the antigen-binding domain that binds a TCR complex and the antigen-binding domain that binds GUCY2C is a long helix comprising SEQ ID NO: 14. In some embodiments, the connector between the antigen-binding domain that binds a TCR complex and the antigen-binding domain that binds GUCY2C is a long helix encoded by SEQ ID NO: 13. In some embodiments, the connector between the antigen-binding domain that binds a TCR complex and the antigen-binding domain that binds GUCY2C is a large domain comprising SEQ ID NO: 16.
In some embodiments, the connector between the antigen-binding domain that binds a TCR
complex and the antigen-binding domain that binds GUCY2C is a large domain encoded by SEQ
ID NO: 15.
[0089] In some embodiments, a nucleic acid or TAC disclosed herein comprises a leader sequence. In some embodiments, the leader sequence is encoded by a nucleotide sequence having at least 80% sequence identity with the nucleotide sequence of SEQ ID
NO: 1 (mulgG
leader), SEQ ID NO: 17 (hulgG leader), SEQ ID NO: 19 (huCD8a leader), or SEQ
ID NO: 29 (huCD8a leader). In some embodiments, the leader sequence is encoded by a nucleotide sequence having at least 85% sequence identity with the nucleotide sequence of SEQ ID NO: 1 (mulgG leader), SEQ ID NO: 17 (hulgG leader), SEQ ID NO: 19 (huCD8a leader), or SEQ ID
NO: 29 (huCD8a leader). In some embodiments, the leader sequence is encoded by a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence of SEQ ID NO: 1 (mulgG leader), SEQ ID NO: 17 (hulgG leader), SEQ ID NO: 19 (huCD8a leader), or SEQ ID
NO: 29 (huCD8a leader). In some embodiments, the leader sequence is encoded by a nucleotide sequence having at least 95% sequence identity with the nucleotide sequence of SEQ ID NO: 1 (mulgG leader), SEQ ID NO: 17 (hulgG leader), SEQ ID NO: 19 (huCD8a leader), or SEQ ID
NO: 29 (huCD8a leader). In some embodiments, the leader sequence is encoded by a nucleotide sequence having at least 96% sequence identity with the nucleotide sequence of SEQ ID NO: 1 (mulgG leader), SEQ ID NO: 17 (hulgG leader), SEQ ID NO: 19 (huCD8a leader), or SEQ ID
NO: 29 (huCD8a leader). In some embodiments, the leader sequence is encoded by a nucleotide sequence having at least 97% sequence identity with the nucleotide sequence of SEQ ID NO: 1 (mulgG leader), SEQ ID NO: 17 (hulgG leader), SEQ ID NO: 19 (huCD8a leader), or SEQ ID
NO: 29 (huCD8a leader). In some embodiments, the leader sequence is encoded by a nucleotide sequence having at least 98% sequence identity with the nucleotide sequence of SEQ ID NO: 1 (mulgG leader), SEQ ID NO: 17 (hulgG leader), SEQ ID NO: 19 (huCD8a leader), or SEQ ID
NO: 29 (huCD8a leader). In some embodiments, the leader sequence is encoded by a nucleotide sequence having at least 99% sequence identity with the nucleotide sequence of SEQ ID NO: 1 (mulgG leader), SEQ ID NO: 17 (hulgG leader), SEQ ID NO: 19 (huCD8a leader), or SEQ ID

CA 03173857 2022-9- i63309 NO: 29 (huCD8a leader). In some embodiments, the leader sequence comprises the nucleotide sequence of SEQ ID NO: 1 (mulgG leader), SEQ ID NO: 17 (hulgG leader), SEQ ID
NO: 19 (huCD8a leader), or SEQ ID NO: 29 (huCD8a leader).
[0090] In some embodiments, a nucleic acid or TAC disclosed herein comprises a leader sequence. In some embodiments, the leader sequence comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2 (mulgG leader), SEQ ID NO: 18 (hulgG leader), or SEQ ID NO: 20 (huCD8a leader). In some embodiments, the leader sequence comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 2 (mulgG leader), SEQ ID NO: 18 (hulgG
leader), or SEQ ID NO: 20 (huCD8a leader). In some embodiments, the leader sequence comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 2 (mulgG leader), SEQ ID NO: 18 (hulgG leader), or SEQ ID NO: 20 (huCD8a leader). In some embodiments, the leader sequence comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 2 (mulgG leader), SEQ ID NO: 18 (hulgG leader), or SEQ ID NO: 20 (huCD8a leader). In some embodiments, the leader sequence comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO: 2 (mulgG leader), SEQ ID NO: 18 (hulgG
leader), or SEQ ID NO: 20 (huCD8a leader). In some embodiments, the leader sequence comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID NO: 2 (mulgG leader), SEQ ID NO: 18 (hulgG leader), or SEQ ID NO: 20 (huCD8a leader). In some embodiments, the leader sequence comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 2 (mulgG leader), SEQ ID NO: 18 (hulgG leader), or SEQ ID NO: 20 (huCD8a leader). In some embodiments, the leader sequence comprises an amino acid sequence having at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 2 (mulgG leader), SEQ ID NO: 18 (hulgG
leader), or SEQ ID NO: 20 (huCD8a leader). In some embodiments, the leader sequence comprises the amino acid sequence of SEQ ID NO: 2 (mulgG leader), SEQ ID NO: 18 (hulgG
leader), or SEQ
ID NO: 20 (huCD8a leader).
[0091] In some embodiments, a GUCY2C T cell antigen coupler polypeptide comprises a tag, e.g., a Myc tag. In some embodiments, the tag comprises an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 4 (Myc Tag). In some embodiments, the tag comprises an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 4 (Myc Tag). In some embodiments, the tag comprises an amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID
NO: 4 (Myc CA 03173857 2022-9- i63309 Tag). In some embodiments, the tag comprises an amino acid sequence having at least 95%
identity with the amino acid sequence of SEQ ID NO: 4 (Myc Tag). In some embodiments, the tag comprises an amino acid sequence having at least 96% identity with the amino acid sequence of SEQ ID NO: 4 (Myc Tag). In some embodiments, the tag comprises an amino acid sequence having at least 97% identity with the amino acid sequence of SEQ ID NO: 4 (Myc Tag). In some embodiments, the tag comprises an amino acid sequence having at least 98%
identity with the amino acid sequence of SEQ ID NO: 4 (Myc Tag). In some embodiments, the tag comprises an amino acid sequence having at least 99% identity with the amino acid sequence of SEQ ID NO:
4 (Myc Tag). In some embodiments, the tag comprises the amino acid sequence of SEQ ID NO:
4 (Myc Tag).
[0092] Amino acid and nucleotide sequences of exemplary linkers, connectors, tags, and leader sequences are provided in Table 3.
Table 3. Table of Sequences SEQ ID NO Description Nucleotide/Amino Acid SEQ ID NO: 1 mulgG leader (secretion signal) Nucleotide SEQ ID NO: 2 mulgG leader (secretion signal) Amino Acid SEQ ID NO: 3 Myc Tag Nucleotide SEQ ID NO: 4 Myc Tag Amino Acid SEQ ID NO: 5 Linker 1 Nucleotide SEQ ID NO: 6 Linker 1 Amino Acid SEQ ID NO: 7 Linker 2 Nucleotide SEQ ID NO: 8 Linker 2 Amino Acid SEQ ID NO: 9 CD4 linker Nucleotide SEQ ID NO: 10 CD4 linker Amino Acid SEQ ID NO: 11 Short Helix connector Nucleotide SEQ ID NO: 12 Short Helix connector Amino Acid SEQ ID NO: 13 Long Helix connector Nucleotide SEQ ID NO: 14 Long Helix connector Amino Acid SEQ ID NO: 15 Large domain connector Nucleotide SEQ ID NO: 16 Large domain connector Amino Acid SEQ ID NO: 17 hulgG Nucleotide SEQ ID NO: 18 hulgG Amino Acid SEQ ID NO: 19 huCD8a -1 Nucleotide SEQ ID NO: 20 huCD8a -1 Amino Acid SEQ ID NO: 21 Whitlow Linker Nucleotide SEQ ID NO: 22 Whitlow Linker Amino Acid SEQ ID NO: 23 (G45)3 linker Nucleotide SEQ ID NO: 24 (G45)3 linker Amino Acid SEQ ID NO: 25 (G45)4 linker Nucleotide SEQ ID NO: 26 (G45)4 linker Amino Acid SEQ ID NO: 27 G45 linker Nucleotide SEQ ID NO: 28 G45 linker Amino Acid SEQ ID NO: 29 huCD8a -2 Nucleotide CA 03173857 2022-9- i63309 SEQ ID NO: 30 huCD8a -2 Amino Acid GUCY2C Antigen-Binding Domain
[0093] In certain embodiments, the GUCY2C TAC polypeptide comprises a GUCY2C
antigen-binding domain. In some embodiments, the GUCY2C antigen-binding domain selectively binds GUCY2C. In some embodiments, the GUCY2C antigen-binding domain binds to GUCY2C
on a target cell. In some embodiments, a target cell is a cell associated with a disease state, including, but not limited to, cancer. In some embodiments, a target cell is a tumor cell.
[0094] In some embodiments, the GUCY2C antigen-binding domain is an antibody or a fragment thereof. In some embodiments, the GUCY2C antigen-binding domain is selected from single chain antibodies (e.g., single-chain fragment variable antibodies (scFvs)), single domain antibodies (e.g., heavy-chain-only antibodies (VHH), shark heavy-chain-only antibodies (VNAR)), nanobodies, diabodies, minibodies, Fab fragments, Fab' fragments, F(ablzfragments, or Fv fragments that bind to GUCY2C.
[0095] In some embodiments, the GUCY2C antigen-binding domain is selected from ankyrin repeat proteins (DARPins), affibodies, adnectins, affilins, phylomers, fynomers, affimers, peptide aptamers, lectins, knottins, centyrins, anticalins, peptides, peptidomimetics, proteins, glycoproteins, or proteoglycans that bind to GUCY2C, or naturally occurring ligands for GUCY2C. In some embodiments, the GUCY2C antigen-binding domain is a non-protein compound that binds to GUCY2C, including but not limited to carbohydrates, lipids, nucleic acids, or small molecules.
[0096] In some embodiments, the GUCY2C antigen-binding domain is a designed ankyrin repeat (DARPin) targeted to GUCY2C. In some embodiments, the GUCY2C antigen-binding domain is a single-chain variable fragment (scFv) targeted to GUCY2C. In some embodiments, the GUCY2C antigen-binding domain is a nanobody targeted to GUCY2C.
[0097] In some embodiments, the GUCY2C antigen-binding domain is selected from an amino acid sequence according to any one of SEQ ID NOs: 53-127 or 514-521.
[0098] In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 53-127 or 514-521. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 53-127 or 514-521. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence having at least 90%
sequence identity an amino acid sequence according to any one of SEQ ID NOs:
53-127 or 514-CA 03173857 2022-9- ik63309 521. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 53-127 or 514-521. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence having at least 96% sequence identity an amino acid sequence according to any one of SEQ ID NOs: 53-127 or 514-521. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence having at least 97%
sequence identity with an amino acid sequence according to any one of SEQ ID
NOs: 53-127 or 514-521. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 53-127 or 514-521. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 53-127 or 514-521.
[0099] In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence at least 80% identical to an amino acid sequence according to any one of SEQ ID NOs:
53-127 or 514-521, wherein the CDR sequences of the GUCY2C antigen-binding domain sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID
NO. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence at least 85% identical to an amino acid sequence according to any one of SEQ ID NOs:
53-127 or 514-521, wherein the CDR sequences of the GUCY2C antigen-binding domain sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID
NO. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence at least 90% identical to an amino acid sequence according to any one of SEQ ID NOs:
53-127 or 514-521, wherein the CDR sequences of the GUCY2C antigen-binding domain sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID
NO. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence at least 95% identical to an amino acid sequence according to any one of SEQ ID NOs:
53-127 or 514-521, wherein the CDR sequences of the GUCY2C antigen-binding domain sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID
NO. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence at least 96% identical to an amino acid sequence according to any one of SEQ ID NOs:
53-127 or 514-521, wherein the CDR sequences of the GUCY2C antigen-binding domain sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID
NO. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence at least 97% identical to an amino acid sequence according to any one of SEQ ID NOs:

CA 03173857 2022-9- ik63309 53-127 or 514-521, wherein the CDR sequences of the GUCY2C antigen-binding domain sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID
NO. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence at least 98% identical to an amino acid sequence according to any one of SEQ ID NOs:
53-127 or 514-521, wherein the CDR sequences of the GUCY2C antigen-binding domain sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID
NO. In some embodiments, the GUCY2C antigen-binding domain comprises an amino acid sequence at least 99% identical to an amino acid sequence according to any one of SEQ ID NOs:
53-127 or 514-521, wherein the CDR sequences of the GUCY2C antigen-binding domain sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID
NO.
[0100] Amino acid sequences of exemplary GUCY2C antigen-binding domains are provided in Table 4.
Table 4. Table of Sequences SEQ ID NO. Description Amino Acid/Nucleic Acid SEQ ID NO: 53 Y U652-1306 Amino Acid SEQ ID NO: 54 YU652-001 Amino Acid SEQ ID NO: 55 YU652-F02 Amino Acid SEQ ID NO: 56 YU652-H02 Amino Acid SEQ ID NO: 57 YU653-612 Amino Acid SEQ ID NO: 58 YU653-D11 Amino Acid SEQ ID NO: 59 YU653-F12 Amino Acid SEQ ID NO: 60 YU654-E01 Amino Acid SEQ ID NO: 61 YU667-A01 Amino Acid SEQ ID NO: 62 YU667-A02 Amino Acid SEQ ID NO: 63 YU667-A04 Amino Acid SEQ ID NO: 64 Y U667-601 Amino Acid SEQ ID NO: 65 Y U667-1302 Amino Acid SEQ ID NO: 66 Y U667-1303 Amino Acid SEQ ID NO: 67 YU667-004 Amino Acid SEQ ID NO: 68 YU667-006 Amino Acid SEQ ID NO: 69 YU667-D05 Amino Acid SEQ ID NO: 70 YU667-D06 Amino Acid SEQ ID NO: 71 YU667-E01 Amino Acid SEQ ID NO: 72 YU667-E05 Amino Acid SEQ ID NO: 73 YU667-F02 Amino Acid SEQ ID NO: 74 YU667-F06 Amino Acid SEQ ID NO: 75 YU667-G02 Amino Acid SEQ ID NO: 76 YU667-G04 Amino Acid SEQ ID NO: 77 YU667-G06 Amino Acid SEQ ID NO: 78 YU667-H06 Amino Acid SEQ ID NO: 79 YU652-1306-Whitlow Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO. Description Amino Acid/Nucleic Acid SEQ ID NO: 80 Y U652-001-Whitlow Amino Acid SEQ ID NO: 81 Y U652-F02-Whitlow Amino Acid SEQ ID NO: 82 Y U652-H02-Whitlow Amino Acid SEQ ID NO: 83 Y U653-612-Whitlow Amino Acid SEQ ID NO: 84 Y U653-D11-Whitlow Amino Acid SEQ ID NO: 85 Y U653-F12-Whitlow Amino Acid SEQ ID NO: 86 Y U654-E01-Whitlow Amino Acid SEQ ID NO: 87 Y U667-A01-Whitlow Amino Acid SEQ ID NO: 88 Y U667-A02-Whitlow Amino Acid SEQ ID NO: 89 Y U667-A04-Whitlow Amino Acid SEQ ID NO: 90 Y U667-601-Whitlow Amino Acid SEQ ID NO: 91 Y U667-1302-Whitlow Amino Acid SEQ ID NO: 92 Y U667-1303 -Whitlow Amino Acid SEQ ID NO: 93 Y U667-004-Whitlow Amino Acid SEQ ID NO: 94 YU667-006 -Whitlow Amino Acid SEQ ID NO: 95 Y U667-D05-Whitlow Amino Acid SEQ ID NO: 96 Y U667-D06-Whitlow Amino Acid SEQ ID NO: 97 Y U667-E01-Whitlow Amino Acid SEQ ID NO: 98 Y U667-E05-Whitlow Amino Acid SEQ ID NO: 99 Y U667-F02-Whitlow Amino Acid SEQ ID NO: 100 YU667-F06-Whitlow Amino Acid SEQ ID NO: 101 Y U667-G02-Whitlow Amino Acid SEQ ID NO: 102 Y U667-G04-Whitlow Amino Acid SEQ ID NO: 103 Y U667-G06-Whitlow Amino Acid SEQ ID NO: 104 Y U667-H06-Whitlow Amino Acid SEQ ID NO: 105 6293-R4A-C2 Amino Acid SEQ ID NO: 106 6293-R4A-E3 Amino Acid SEQ ID NO: 107 6293-R4A-G4 Amino Acid SEQ ID NO: 108 6293-RSA-A5 Amino Acid SEQ ID NO: 109 6293-RSA-B6 Amino Acid SEQ ID NO: 110 6293-RSA-E7 Amino Acid SEQ ID NO: 111 6293-RSA-F6 Amino Acid SEQ ID NO: 112 6293-R6A-A10 Amino Acid SEQ ID NO: 113 6293-R6A-B11 Amino Acid SEQ ID NO: 114 6293-R6A-C9 Amino Acid SEQ ID NO: 115 6293-R6A-G9 Amino Acid SEQ ID NO: 116 6293-R6A-H11 Amino Acid SEQ ID NO: 117 T1001-A23 Amino Acid SEQ ID NO: 118 T1001-A25 Amino Acid SEQ ID NO: 119 T1001-A28 Amino Acid SEQ ID NO: 120 T1001-A30 Amino Acid SEQ ID NO: 121 T1001-A48 Amino Acid SEQ ID NO: 122 T1001-V20 Amino Acid SEQ ID NO: 123 T1001-V30 Amino Acid SEQ ID NO: 124 T1001-V54 Amino Acid SEQ ID NO: 125 T1001-V65 Amino Acid SEQ ID NO: 126 T1001-V67 Amino Acid SEQ ID NO: 127 T1001-V68 Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO. Description Amino Acid/Nucleic Acid SEQ ID NO: 514 T1001-E8 Amino Acid SEQ ID NO: 515 T1001-E16 Amino Acid SEQ ID NO: 516 T1001-E6 Amino Acid SEQ ID NO: 517 T1001-E64 Amino Acid SEQ ID NO: 518 T1001-E55 Amino Acid SEQ ID NO: 519 T1001-E17 Amino Acid SEQ ID NO: 520 T1001-E24 Amino Acid SEQ ID NO: 521 T1001-E25 Amino Acid
[0101] In some embodiments, the GUCY2C antigen-binding domain comprises a heavy chain variable region having an amino acid sequence according to any one of SEQ ID
NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence according to any one of SEQ ID NOs:
129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203.
[0102] In some embodiments, the GUCY2C antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203. In some embodiments, the antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to any one of SEQ
ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to any one of SEQ
ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203. In some embodiments, the GUCY2C antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, CA 03173857 2022-9- i63309 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203. In some embodiments, the GUCY2C
antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to any one of SEQ ID
NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 95%
sequence identity with an amino acid sequence according to any one of SEQ ID
NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203. In some embodiments, the GUCY2C antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203. In some embodiments, the GUCY2C
antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to any one of SEQ ID
NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 97%
sequence identity with an amino acid sequence according to any one of SEQ ID
NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203. In some embodiments, the GUCY2C antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, CA 03173857 2022-9- i63309 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203. In some embodiments, the GUCY2C
antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to any one of SEQ ID
NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 99%
sequence identity with an amino acid sequence according to any one of SEQ ID
NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203.
[0103] In some embodiments, the GUCY2C antigen-binding domain comprises (a) a heavy chain variable region having an amino acid sequence at least 80% identical to a sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202, wherein the CDR sequences of the heavy chain variable region sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID NO.; and (b) a light chain variable region having an amino acid sequence at least 80% identical to a sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203, wherein the CDR
sequences of the light chain variable region sequence have 100% sequence identity to the CDR
sequences of the sequence of the SEQ ID NO.
[0104] In some embodiments, the GUCY2C antigen-binding domain comprises (a) a heavy chain variable region having an amino acid sequence at least 85% identical to a sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202, wherein the CDR sequences of the heavy chain variable region sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID NO.; and (b) a light chain variable region having an amino acid sequence at least 85% identical to a sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, CA 03173857 2022-9- ik63309 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203, wherein the CDR
sequences of the light chain variable region sequence have 100% sequence identity to the CDR
sequences of the sequence of the SEQ ID NO.
[0105] In some embodiments, the GUCY2C antigen-binding domain comprises (a) a heavy chain variable region having an amino acid sequence at least 90% identical to a sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202, wherein the CDR sequences of the heavy chain variable region sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID NO.; and (b) a light chain variable region having an amino acid sequence at least 90% identical to a sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203, wherein the CDR
sequences of the light chain variable region sequence have 100% sequence identity to the CDR
sequences of the sequence of the SEQ ID NO.
[0106] In some embodiments, the GUCY2C antigen-binding domain comprises (a) a heavy chain variable region having an amino acid sequence at least 95% identical to a sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202, wherein the CDR sequences of the heavy chain variable region sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID NO.; and (b) a light chain variable region having an amino acid sequence at least 95% identical to a sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203, wherein the CDR
sequences of the light chain variable region sequence have 100% sequence identity to the CDR
sequences of the sequence of the SEQ ID NO.
[0107] In some embodiments, the GUCY2C antigen-binding domain comprises (a) a heavy chain variable region having an amino acid sequence at least 96% identical to a sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202, wherein the CDR sequences of the heavy chain CA 03173857 2022-9- ik63309 variable region sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID NO.; and (b) a light chain variable region having an amino acid sequence at least 96% identical to a sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203, wherein the CDR
sequences of the light chain variable region sequence have 100% sequence identity to the CDR
sequences of the sequence of the SEQ ID NO.
[0108] In some embodiments, the GUCY2C antigen-binding domain comprises (a) a heavy chain variable region having an amino acid sequence at least 97% identical to a sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202, wherein the CDR sequences of the heavy chain variable region sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID NO.; and (b) a light chain variable region having an amino acid sequence at least 97% identical to a sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203, wherein the CDR
sequences of the light chain variable region sequence have 100% sequence identity to the CDR
sequences of the sequence of the SEQ ID NO.
[0109] In some embodiments, the GUCY2C antigen-binding domain comprises (a) a heavy chain variable region having an amino acid sequence at least 98% identical to a sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202, wherein the CDR sequences of the heavy chain variable region sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID NO.; and (b) a light chain variable region having an amino acid sequence at least 98% identical to a sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203, wherein the CDR
sequences of the light chain variable region sequence have 100% sequence identity to the CDR
sequences of the sequence of the SEQ ID NO.
[0110] In some embodiments, the GUCY2C antigen-binding domain comprises (a) a heavy chain variable region having an amino acid sequence at least 99% identical to a sequence CA 03173857 2022-9- ik63309 according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202, wherein the CDR sequences of the heavy chain variable region sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID NO.; and (b) a light chain variable region having an amino acid sequence at least 99% identical to a sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203, wherein the CDR
sequences of the light chain variable region sequence have 100% sequence identity to the CDR
sequences of the sequence of the SEQ ID NO.
[0111] Amino acid sequences of exemplary GUCY2C antigen-binding domain heavy chain variable regions and light chain variable regions are provided in Table 5.
Table 5. Table of Sequences SEQ ID NO Description Amino Acid/Nucleic Acid SEQ ID NO: 128 6293-R4A-C2 VH Amino Acid SEQ ID NO: 129 6293-R4A-C2 VL Amino Acid SEQ ID NO: 130 6293-R4A-E3 VH Amino Acid SEQ ID NO: 131 6293-R4A-E3 VL Amino Acid SEQ ID NO: 132 6293-R4A-G4 VH Amino Acid SEQ ID NO: 133 6293-R4A-G4 VL Amino Acid SEQ ID NO: 134 6293-RSA-AS VH Amino Acid SEQ ID NO: 135 6293-RSA-AS VL Amino Acid SEQ ID NO: 136 6293-RSA-B6 VH Amino Acid SEQ ID NO: 137 6293-RSA-B6 VL Amino Acid SEQ ID NO: 138 6293-RSA-E7 VH Amino Acid SEQ ID NO: 139 6293-RSA-E7 VL Amino Acid SEQ ID NO: 140 6293-RSA-F6 VH Amino Acid SEQ ID NO: 141 6293-RSA-F6 VL Amino Acid SEQ ID NO: 142 6293-R6A-A10 VH Amino Acid SEQ ID NO: 143 6293-R6A-A10 VL Amino Acid SEQ ID NO: 144 6293-R6A-B11 VH Amino Acid SEQ ID NO: 145 6293-R6A-B11 VL Amino Acid SEQ ID NO: 146 6293-R6A-C9 VH Amino Acid SEQ ID NO: 147 6293-R6A-C9 VL Amino Acid SEQ ID NO: 148 6293-R6A-G9 VH Amino Acid SEQ ID NO: 149 6293-R6A-G9 VL Amino Acid SEQ ID NO: 150 6293-R6A-H11 VH Amino Acid SEQ ID NO: 151 6293-R6A-H11 VL Amino Acid SEQ ID NO: 152 Y U652-1306 VH Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO Description Amino Acid/Nucleic Acid SEQ ID NO: 153 Y U652-1306 VL Amino Acid SEQ ID NO: 154 YU652-001 VH Amino Acid SEQ ID NO: 155 YU652-001 VL Amino Acid SEQ ID NO: 156 YU652-F02 VH Amino Acid SEQ ID NO: 157 YU652-F02 VL Amino Acid SEQ ID NO: 158 YU652-H02 VH Amino Acid SEQ ID NO: 159 YU652-H02 VL Amino Acid SEQ ID NO: 160 YU653-612 VH Amino Acid SEQ ID NO: 161 YU653-612 VL Amino Acid SEQ ID NO: 162 YU653-D11 VH Amino Acid SEQ ID NO: 163 YU653-D11 VL Amino Acid SEQ ID NO: 164 YU653-F12 VH Amino Acid SEQ ID NO: 165 YU653-F12 VL Amino Acid SEQ ID NO: 166 YU654-E01 VH Amino Acid SEQ ID NO: 167 YU654-E01 VL Amino Acid SEQ ID NO: 168 YU667-A01 VH Amino Acid SEQ ID NO: 169 YU667-A01 VL Amino Acid SEQ ID NO: 170 YU667-A02 VH Amino Acid SEQ ID NO: 171 YU667-A02 VL Amino Acid SEQ ID NO: 172 YU667-A04 VH Amino Acid SEQ ID NO: 173 YU667-A04 VL Amino Acid SEQ ID NO: 174 YU667-601 VH Amino Acid SEQ ID NO: 175 YU667-601 VL Amino Acid SEQ ID NO: 176 Y U667-1302 VH Amino Acid SEQ ID NO: 177 Y U667-1302 VL Amino Acid SEQ ID NO: 178 Y U667-1303 VH Amino Acid SEQ ID NO: 179 Y U667-1303 VL Amino Acid SEQ ID NO: 180 YU667-004 VH Amino Acid SEQ ID NO: 181 YU667-004 VL Amino Acid SEQ ID NO: 182 YU667-006 VH Amino Acid SEQ ID NO: 183 YU667-006 VL Amino Acid SEQ ID NO: 184 YU667-D05 VH Amino Acid SEQ ID NO: 185 YU667-D05 VL Amino Acid SEQ ID NO: 186 YU667-D06 VH Amino Acid SEQ ID NO: 187 YU667-D06 VL Amino Acid SEQ ID NO: 188 YU667-E01 VH Amino Acid SEQ ID NO: 189 YU667-E01 VL Amino Acid SEQ ID NO: 190 YU667-E05 VH Amino Acid SEQ ID NO: 191 YU667-E05 VL Amino Acid SEQ ID NO: 192 YU667-F02 VH Amino Acid SEQ ID NO: 193 YU667-F02 VL Amino Acid SEQ ID NO: 194 YU667-F06 VH Amino Acid SEQ ID NO: 195 YU667-F06 VL Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO Description Amino Acid/Nucleic Acid SEQ ID NO: 196 Y U667-G02 VH Amino Acid SEQ ID NO: 197 Y U667-G02 VL Amino Acid SEQ ID NO: 198 Y U667-G04 VH Amino Acid SEQ ID NO: 199 Y U667-G04 VL Amino Acid SEQ ID NO: 200 Y U667-G06 VH Amino Acid SEQ ID NO: 201 Y U667-G06 VL Amino Acid SEQ ID NO: 202 YU667-H06 VH Amino Acid SEQ ID NO: 203 YU667-H06 VL Amino Acid
[0112] In some embodiments, the GUCY2C antigen-binding domain comprises a heavy chain variable region comprising (a) a CDR1 having an amino acid selected from the group consisting of SEQ ID NO: 204, 210, 216, 222, 228, 234, 240, 246, 252, 258, 264, 270, 276, 282, 288, 294, 300, 306, 312, 318, 324, 330, 336, 342, 348, 354, 393, 399, 405, 411, 417, 423, 429, 435, 441, 447, 453, 459, 522, 525, 528, 531, 534, 537, 540, and 543, (b) a CDR2 having an amino acid selected from the group consisting of SEQ ID NO: 205, 211, 217, 223, 229, 235, 241, 247, 253, 259, 265, 271, 277, 283, 289, 295, 301, 307, 313, 319, 325, 331, 337, 343, 349, 355, 394, 400, 406, 412, 418, 424, 430, 436, 442, 448, 454, 460, 523, 526, 529, 532, 535, 538, 541, and 544, and (c) a CDR3 having an amino acid selected from the group consisting of SEQ
ID NO: 206, 212, 218, 224, 230, 236, 242, 248, 254, 260, 266, 272, 278, 284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 395, 401, 407, 413, 419, 425, 431, 437, 443, 449, 455, 461, 524, 527, 530, 533, 536, 539, 542, and 545; and a light chain variable region comprising (a) a CDR1 having an amino acid selected from the group consisting of SEQ ID NO: 207, 213, 219, 225, 231, 237, 243, 249, 255, 261, 267, 273, 279, 285, 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 396, 402, 408, 414, 420, 426, 432, 438, 444, 450, 456 and 462, (b) a CDR2 having an amino acid selected from the group consisting of SEQ ID NO: 208, 214, 220, 226, 232, 238, 244, 250, 256, 262, 268, 274, 280, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 397, 403, 409, 415, 421, 427, 433, 439, 445, 451, 457 and 463, and (c) a CDR3 having an amino acid selected from the group consisting of SEQ ID NO: 209, 215, 221, 227, 233, 239, 245, 251, 257, 263, 269, 275, 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341, 347, 353, 359, 398, 404, 410, 416, 422, 428, 434, 440, 446, 452, 458 and 464.
[0113] In some embodiments, the GUCY2C antigen-binding domain is a nanobody and comprises (a) a VHH CDR1 having an amino acid selected from the group consisting of SEQ ID
NO: 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, and 390; (b) a VHH CDR2 having an amino acid selected from the group consisting of SEQ ID NO: 361, 364, 367, 370, 373, 376, 379, 382, 385, 388, and 391; and (c) a VHH CDR3 having an amino acid selected from the group consisting of SEQ ID NO: 362, 365, 368, 371, 374, 377, 380, 383, 386, 389, and 392.

CA 03173857 2022-9- i63309
[0114] Amino acid sequences of exemplary GUCY2C antigen-binding domain CDRs are provided in Table 6.
Table 6. Table of Sequences SEQ ID NO Description Amino Acid/Nucleic Acid SEQ ID NO: 204 YU653-F12 VH CDR1 Amino Acid SEQ ID NO: 205 YU653-F12 VH CDR2 Amino Acid SEQ ID NO: 206 YU653-F12 VH CDR3 Amino Acid SEQ ID NO: 207 YU653-F12 VL CDR1 Amino Acid SEQ ID NO: 208 YU653-F12 VL CDR2 Amino Acid SEQ ID NO: 209 YU653-F12 VL CDR3 Amino Acid SEQ ID NO: 210 YU652-1306 VH CDR1 Amino Acid SEQ ID NO: 211 YU652-1306 VH CDR2 Amino Acid SEQ ID NO: 212 YU652-1306 VH CDR3 Amino Acid SEQ ID NO: 213 YU652-1306 VL CDR1 Amino Acid SEQ ID NO: 214 YU652-1306 VL CDR2 Amino Acid SEQ ID NO: 215 YU652-1306 VL CDR3 Amino Acid SEQ ID NO: 216 YU653-D11 VH CDR1 Amino Acid SEQ ID NO: 217 YU653-D11 VH CDR2 Amino Acid SEQ ID NO: 218 YU653-D11 VH CDR3 Amino Acid SEQ ID NO: 219 YU653-D11 VL CDR1 Amino Acid SEQ ID NO: 220 YU653-D11 VL CDR2 Amino Acid SEQ ID NO: 221 YU653-D11 VL CDR3 Amino Acid SEQ ID NO: 222 YU652-001 VH CDR1 Amino Acid SEQ ID NO: 223 YU652-001 VH CDR2 Amino Acid SEQ ID NO: 224 YU652-001 VH CDR3 Amino Acid SEQ ID NO: 225 YU652-001 VL CDR1 Amino Acid SEQ ID NO: 226 YU652-001 VL CDR2 Amino Acid SEQ ID NO: 227 YU652-001 VL CDR3 Amino Acid SEQ ID NO: 228 YU652-H02 VH CDR1 Amino Acid SEQ ID NO: 229 YU652-H02 VH CDR2 Amino Acid SEQ ID NO: 230 YU652-H02 VH CDR3 Amino Acid SEQ ID NO: 231 YU652-H02 VL CDR1 Amino Acid SEQ ID NO: 232 YU652-H02 VL CDR2 Amino Acid SEQ ID NO: 233 YU652-H02 VL CDR3 Amino Acid SEQ ID NO: 234 YU654-E01 VH CDR1 Amino Acid SEQ ID NO: 235 YU654-E01 VH CDR2 Amino Acid SEQ ID NO: 236 YU654-E01 VH CDR3 Amino Acid SEQ ID NO: 237 YU654-E01 VL CDR1 Amino Acid SEQ ID NO: 238 YU654-E01 VL CDR2 Amino Acid SEQ ID NO: 239 YU654-E01 VL CDR3 Amino Acid SEQ ID NO: 240 YU653-612 VH CDR 1 Amino Acid SEQ ID NO: 241 YU653-612 VH CDR2 Amino Acid SEQ ID NO: 242 YU653-612 VH CDR3 Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO Description Amino Acid/Nucleic Acid SEQ ID NO: 243 YU653-612 VL CDR 1 Amino Acid SEQ ID NO: 244 YU653-612 VL CDR 2 Amino Acid SEQ ID NO: 245 YU653-612 VL CDR 3 Amino Acid SEQ ID NO: 246 YU652-F02 VH CDR 1 Amino Acid SEQ ID NO: 247 YU652-F02 VH CDR 2 Amino Acid SEQ ID NO: 248 YU652-F02 VH CDR 3 Amino Acid SEQ ID NO: 249 YU652-F02 VL CDR 1 Amino Acid SEQ ID NO: 250 YU652-F02 VL CDR 2 Amino Acid SEQ ID NO: 251 YU652-F02 VL CDR 3 Amino Acid SEQ ID NO: 252 YU667-006 VH CDR 1 Amino Acid SEQ ID NO: 253 YU667-006 VH CDR 2 Amino Acid SEQ ID NO: 254 YU667-006 VH CDR 3 Amino Acid SEQ ID NO: 255 YU667-006 VL CDR 1 Amino Acid SEQ ID NO: 256 YU667-006 VL CDR 2 Amino Acid SEQ ID NO: 257 YU667-006 VL CDR 3 Amino Acid SEQ ID NO: 258 YU667-E01 VH CDR 1 Amino Acid SEQ ID NO: 259 YU667-E01 VH CDR 2 Amino Acid SEQ ID NO: 260 YU667-E01 VH CDR 3 Amino Acid SEQ ID NO: 261 YU667-E01 VL CDR 1 Amino Acid SEQ ID NO: 262 YU667-E01 VL CDR 2 Amino Acid SEQ ID NO: 263 YU667-E01 VL CDR 3 Amino Acid SEQ ID NO: 264 YU667-1303 VH CDR 1 Amino Acid SEQ ID NO: 265 YU667-1303 VH CDR 2 Amino Acid SEQ ID NO: 266 YU667-1303 VH CDR 3 Amino Acid SEQ ID NO: 267 YU667-1303 VL CDR 1 Amino Acid SEQ ID NO: 268 YU667-1303 VL CDR 2 Amino Acid SEQ ID NO: 269 YU667-1303 VL CDR 3 Amino Acid SEQ ID NO: 270 YU667-F06 VH CDR 1 Amino Acid SEQ ID NO: 271 YU667-F06 VH CDR 2 Amino Acid SEQ ID NO: 272 YU667-F06 VH CDR 3 Amino Acid SEQ ID NO: 273 YU667-F06 VL CDR 1 Amino Acid SEQ ID NO: 274 YU667-F06 VL CDR 2 Amino Acid SEQ ID NO: 275 YU667-F06 VL CDR 3 Amino Acid SEQ ID NO: 276 YU667-004 VH CDR 1 Amino Acid SEQ ID NO: 277 YU667-004 VH CDR 2 Amino Acid SEQ ID NO: 278 YU667-004 VH CDR 3 Amino Acid SEQ ID NO: 279 YU667-004 VL CDR 1 Amino Acid SEQ ID NO: 280 YU667-004 VL CDR 2 Amino Acid SEQ ID NO: 281 YU667-004 VL CDR 3 Amino Acid SEQ ID NO: 282 YU667-G06 VH CDR 1 Amino Acid SEQ ID NO: 283 YU667-G06 VH CDR 2 Amino Acid SEQ ID NO: 284 YU667-G06 VH CDR 3 Amino Acid SEQ ID NO: 285 YU667-G06 VL CDR 1 Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO Description Amino Acid/Nucleic Acid SEQ ID NO: 286 YU667-G06 VL CDR 2 Amino Acid SEQ ID NO: 287 YU667-G06 VL CDR 3 Amino Acid SEQ ID NO: 288 YU667-D06 VH CDR 1 Amino Acid SEQ ID NO: 289 YU667-D06 VH CDR 2 Amino Acid SEQ ID NO: 290 YU667-D06 VH CDR 3 Amino Acid SEQ ID NO: 291 YU667-D06 VL CDR 1 Amino Acid SEQ ID NO: 292 YU667-D06 VL CDR 2 Amino Acid SEQ ID NO: 293 YU667-D06 VL CDR 3 Amino Acid SEQ ID NO: 294 YU667-G04 VH CDR 1 Amino Acid SEQ ID NO: 295 YU667-G04 VH CDR 2 Amino Acid SEQ ID NO: 296 YU667-G04 VH CDR 3 Amino Acid SEQ ID NO: 297 YU667-G04 VL CDR 1 Amino Acid SEQ ID NO: 298 YU667-G04 VL CDR 2 Amino Acid SEQ ID NO: 299 YU667-G04 VL CDR 3 Amino Acid SEQ ID NO: 300 YU667-H06 VH CDR 1 Amino Acid SEQ ID NO: 301 YU667-H06 VH CDR 2 Amino Acid SEQ ID NO: 302 YU667-H06 VH CDR 3 Amino Acid SEQ ID NO: 303 YU667-H06 VL CDR 1 Amino Acid SEQ ID NO: 304 YU667-H06 VL CDR 2 Amino Acid SEQ ID NO: 305 YU667-H06 VL CDR 3 Amino Acid SEQ ID NO: 306 YU667-E05 VH CDR 1 Amino Acid SEQ ID NO: 307 YU667-E05 VH CDR 2 Amino Acid SEQ ID NO: 308 YU667-E05 VH CDR 3 Amino Acid SEQ ID NO: 309 YU667-E05 VL CDR 1 Amino Acid SEQ ID NO: 310 YU667-E05 VL CDR 2 Amino Acid SEQ ID NO: 311 YU667-E05 VL CDR 3 Amino Acid SEQ ID NO: 312 YU667-A04 VH CDR 1 Amino Acid SEQ ID NO: 313 YU667-A04 VH CDR 2 Amino Acid SEQ ID NO: 314 YU667-A04 VH CDR 3 Amino Acid SEQ ID NO: 315 YU667-A04 VL CDR 1 Amino Acid SEQ ID NO: 316 YU667-A04 VL CDR 2 Amino Acid SEQ ID NO: 317 YU667-A04 VL CDR 3 Amino Acid SEQ ID NO: 318 YU667-G02 VH CDR 1 Amino Acid SEQ ID NO: 319 YU667-G02 VH CDR 2 Amino Acid SEQ ID NO: 320 YU667-G02 VH CDR 3 Amino Acid SEQ ID NO: 321 YU667-G02 VL CDR 1 Amino Acid SEQ ID NO: 322 YU667-G02 VL CDR 2 Amino Acid SEQ ID NO: 323 YU667-G02 VL CDR 3 Amino Acid SEQ ID NO: 324 YU667-A01 VH CDR 1 Amino Acid SEQ ID NO: 325 YU667-A01 VH CDR 2 Amino Acid SEQ ID NO: 326 YU667-A01 VH CDR 3 Amino Acid SEQ ID NO: 327 YU667-A01 VL CDR 1 Amino Acid SEQ ID NO: 328 YU667-A01 VL CDR 2 Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO Description Amino Acid/Nucleic Acid SEQ ID NO: 329 YU667-A01 VL CDR 3 Amino Acid SEQ ID NO: 330 YU667-F02 VH CDR 1 Amino Acid SEQ ID NO: 331 YU667-F02 VH CDR 2 Amino Acid SEQ ID NO: 332 YU667-F02 VH CDR 3 Amino Acid SEQ ID NO: 333 YU667-F02 VL CDR 1 Amino Acid SEQ ID NO: 334 YU667-F02 VL CDR 2 Amino Acid SEQ ID NO: 335 YU667-F02 VL CDR 3 Amino Acid SEQ ID NO: 336 YU667-1302 VH CDR 1 Amino Acid SEQ ID NO: 337 YU667-1302 VH CDR 2 Amino Acid SEQ ID NO: 338 YU667-1302 VH CDR 3 Amino Acid SEQ ID NO: 339 YU667-1302 VL CDR 1 Amino Acid SEQ ID NO: 340 YU667-1302 VL CDR 2 Amino Acid SEQ ID NO: 341 YU667-1302 VL CDR 3 Amino Acid SEQ ID NO: 342 YU667-601 VH CDR 1 Amino Acid SEQ ID NO: 343 YU667-601 VH CDR 2 Amino Acid SEQ ID NO: 344 YU667-601 VH CDR 3 Amino Acid SEQ ID NO: 345 YU667-601 VL CDR 1 Amino Acid SEQ ID NO: 346 YU667-601 VL CDR 2 Amino Acid SEQ ID NO: 347 YU667-601 VL CDR 3 Amino Acid SEQ ID NO: 348 YU667-A02 VH CDR 1 Amino Acid SEQ ID NO: 349 YU667-A02 VH CDR 2 Amino Acid SEQ ID NO: 350 YU667-A02 VH CDR 3 Amino Acid SEQ ID NO: 351 YU667-A02 VL CDR 1 Amino Acid SEQ ID NO: 352 YU667-A02 VL CDR 2 Amino Acid SEQ ID NO: 353 YU667-A02 VL CDR 3 Amino Acid SEQ ID NO: 354 YU667-D05 VH CDR 1 Amino Acid SEQ ID NO: 355 YU667-D05 VH CDR 2 Amino Acid SEQ ID NO: 356 YU667-D05 VH CDR 3 Amino Acid SEQ ID NO: 357 YU667-D05 VL CDR 1 Amino Acid SEQ ID NO: 358 YU667-D05 VL CDR 2 Amino Acid SEQ ID NO: 359 YU667-D05 VL CDR 3 Amino Acid SEQ ID NO: 360 T1001-V54 VHH CDR 1 Amino Acid SEQ ID NO: 361 T1001-V54 VHH CDR 2 Amino Acid SEQ ID NO: 362 T1001-V54 VHH CDR 3 Amino Acid SEQ ID NO: 363 T1001-V65 VHH CDR 1 Amino Acid SEQ ID NO: 364 T1001-V65 VHH CDR 2 Amino Acid SEQ ID NO: 365 T1001-V65 VHH CDR 3 Amino Acid SEQ ID NO: 366 T1001-V20 VHH CDR 1 Amino Acid SEQ ID NO: 367 T1001-V20 VHH CDR 2 Amino Acid SEQ ID NO: 368 T1001-V20 VHH CDR 3 Amino Acid SEQ ID NO: 369 T1001-A23 VHH CDR 1 Amino Acid SEQ ID NO: 370 T1001-A23 VHH CDR 2 Amino Acid SEQ ID NO: 371 T1001-A23 VHH CDR 3 Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO Description Amino Acid/Nucleic Acid SEQ ID NO: 372 T1001-A25 VHH CDR 1 Amino Acid SEQ ID NO: 373 T1001-A25 VHH CDR 2 Amino Acid SEQ ID NO: 374 T1001-A25 VHH CDR 3 Amino Acid SEQ ID NO: 375 T1001-A28 VHH CDR 1 Amino Acid SEQ ID NO: 376 T1001-A28 VHH CDR 2 Amino Acid SEQ ID NO: 377 T1001-A28 VHH CDR 3 Amino Acid SEQ ID NO: 378 T1001-A30 VHH CDR 1 Amino Acid SEQ ID NO: 379 T1001-A30 VHH CDR 2 Amino Acid SEQ ID NO: 380 T1001-A30 VHH CDR 3 Amino Acid SEQ ID NO: 381 T1001-A48 VHH CDR 1 Amino Acid SEQ ID NO: 382 T1001-A48 VHH CDR 2 Amino Acid SEQ ID NO: 383 T1001-A48 VHH CDR 3 Amino Acid SEQ ID NO: 384 T1001-V30 VHH CDR 1 Amino Acid SEQ ID NO: 385 T1001-V30 VHH CDR 2 Amino Acid SEQ ID NO: 386 T1001-V30 VHH CDR 3 Amino Acid SEQ ID NO: 387 T1001-V67 VHH CDR 1 Amino Acid SEQ ID NO: 388 T1001-V67 VHH CDR 2 Amino Acid SEQ ID NO: 389 T1001-V67 VHH CDR 3 Amino Acid SEQ ID NO: 390 T1001-V68 VHH CDR 1 Amino Acid SEQ ID NO: 391 T1001-V68 VHH CDR 2 Amino Acid SEQ ID NO: 392 T1001-V68 VHH CDR 3 Amino Acid SEQ ID NO: 393 6293-R4A-C2 VH CDR 1 Amino Acid SEQ ID NO: 394 6293-R4A-C2 VH CDR 2 Amino Acid SEQ ID NO: 395 6293-R4A-C2 VH CDR 3 Amino Acid SEQ ID NO: 396 6293-R4A-C2 VL CDR 1 Amino Acid SEQ ID NO: 397 6293-R4A-C2 VL CDR 2 Amino Acid SEQ ID NO: 398 6293-R4A-C2 VL CDR 3 Amino Acid SEQ ID NO: 399 6293-R4A-E3 VH CDR 1 Amino Acid SEQ ID NO: 400 6293-R4A-E3 VH CDR 2 Amino Acid SEQ ID NO: 401 6293-R4A-E3 VH CDR 3 Amino Acid SEQ ID NO: 402 6293-R4A-E3 VL CDR 1 Amino Acid SEQ ID NO: 403 6293-R4A-E3 VL CDR 2 Amino Acid SEQ ID NO: 404 6293-R4A-E3 VL CDR 3 Amino Acid SEQ ID NO: 405 6293-R4A-G4 VH CDR 1 Amino Acid SEQ ID NO: 406 6293-R4A-G4 VH CDR 2 Amino Acid SEQ ID NO: 407 6293-R4A-G4 VH CDR 3 Amino Acid SEQ ID NO: 408 6293-R4A-G4 VL CDR 1 Amino Acid SEQ ID NO: 409 6293-R4A-G4 VL CDR 2 Amino Acid SEQ ID NO: 410 6293-R4A-G4 VL CDR 3 Amino Acid SEQ ID NO: 411 6293-RSA-A5 VH CDR 1 Amino Acid SEQ ID NO: 412 6293-RSA-A5 VH CDR 2 Amino Acid SEQ ID NO: 413 6293-RSA-A5 VH CDR 3 Amino Acid SEQ ID NO: 414 6293-RSA-A5 VL CDR 1 Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO Description Amino Acid/Nucleic Acid SEQ ID NO: 415 6293-RSA-A5 VL CDR 2 Amino Acid SEQ ID NO: 416 6293-RSA-A5 VL CDR 3 Amino Acid SEQ ID NO: 417 6293-RSA-B6 VH CDR 1 Amino Acid SEQ ID NO: 418 6293-RSA-B6 VH CDR 2 Amino Acid SEQ ID NO: 419 6293-RSA-B6 VH CDR 3 Amino Acid SEQ ID NO: 420 6293-RSA-B6 VL CDR 1 Amino Acid SEQ ID NO: 421 6293-RSA-B6 VL CDR 2 Amino Acid SEQ ID NO: 422 6293-RSA-B6 VL CDR 3 Amino Acid SEQ ID NO: 423 6293-RSA-E7 VH CDR 1 Amino Acid SEQ ID NO: 424 6293-RSA-E7 VH CDR 2 Amino Acid SEQ ID NO: 425 6293-RSA-E7 VH CDR 3 Amino Acid SEQ ID NO: 426 6293-RSA-E7 VL CDR 1 Amino Acid SEQ ID NO: 427 6293-RSA-E7 VL CDR 2 Amino Acid SEQ ID NO: 428 6293-RSA-E7 VL CDR 3 Amino Acid SEQ ID NO: 429 6293-RSA-F6 VH CDR 1 Amino Acid SEQ ID NO: 430 6293-RSA-F6 VH CDR 2 Amino Acid SEQ ID NO: 431 6293-RSA-F6 VH CDR 3 Amino Acid SEQ ID NO: 432 6293-RSA-F6 VL CDR 1 Amino Acid SEQ ID NO: 433 6293-RSA-F6 VL CDR 2 Amino Acid SEQ ID NO: 434 6293-RSA-F6 VL CDR 3 Amino Acid SEQ ID NO: 435 6293-R6A-A10 VH CDR 1 Amino Acid SEQ ID NO: 436 6293-R6A-A10 VH CDR 2 Amino Acid SEQ ID NO: 437 6293-R6A-A10 VH CDR 3 Amino Acid SEQ ID NO: 438 6293-R6A-A10 VL CDR 1 Amino Acid SEQ ID NO: 439 6293-R6A-A10 VL CDR 2 Amino Acid SEQ ID NO: 440 6293-R6A-A10 VL CDR 3 Amino Acid SEQ ID NO: 441 6293-R6A-B11 VH CDR 1 Amino Acid SEQ ID NO: 442 6293-R6A-B11 VH CDR 2 Amino Acid SEQ ID NO: 443 6293-R6A-B11 VH CDR 3 Amino Acid SEQ ID NO: 444 6293-R6A-B11 VL CDR 1 Amino Acid SEQ ID NO: 445 6293-R6A-B11 VL CDR 2 Amino Acid SEQ ID NO: 446 6293-R6A-B11 VL CDR 3 Amino Acid SEQ ID NO: 447 6293-R6A-C9 VH CDR 1 Amino Acid SEQ ID NO: 448 6293-R6A-C9 VH CDR 2 Amino Acid SEQ ID NO: 449 6293-R6A-C9 VH CDR 3 Amino Acid SEQ ID NO: 450 6293-R6A-C9 VL CDR 1 Amino Acid SEQ ID NO: 451 6293-R6A-C9 VL CDR 2 Amino Acid SEQ ID NO: 452 6293-R6A-C9 VL CDR 3 Amino Acid SEQ ID NO: 453 6293-R6A-G9 VH CDR 1 Amino Acid SEQ ID NO: 454 6293-R6A-G9 VH CDR 2 Amino Acid SEQ ID NO: 455 6293-R6A-G9 VH CDR 3 Amino Acid SEQ ID NO: 456 6293-R6A-G9 VL CDR 1 Amino Acid SEQ ID NO: 457 6293-R6A-G9 VL CDR 2 Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO Description Amino Acid/Nucleic Acid SEQ ID NO: 458 6293-R6A-G9 VL CDR 3 Amino Acid SEQ ID NO: 459 6293-R6A-H11 VH CDR 1 Amino Acid SEQ ID NO: 460 6293-R6A-H11 VH CDR 2 Amino Acid SEQ ID NO: 461 6293-R6A-H11 VH CDR 3 Amino Acid SEQ ID NO: 462 6293-R6A-H11 VL CDR 1 Amino Acid SEQ ID NO: 463 6293-R6A-H11 VL CDR 2 Amino Acid SEQ ID NO: 464 6293-R6A-H11 VL CDR 3 Amino Acid SEQ ID NO: 522 T1001-E8 CDR1 Amino Acid SEQ ID NO: 523 T1001-E8 CDR2 Amino Acid SEQ ID NO: 524 T1001-E8 CDR3 Amino Acid SEQ ID NO: 525 T1001-E16 CDR1 Amino Acid SEQ ID NO: 526 T1001-E16 CDR2 Amino Acid SEQ ID NO: 527 T1001-E16 CDR3 Amino Acid SEQ ID NO: 528 T1001-E6 CDR1 Amino Acid SEQ ID NO: 529 T1001-E6 CDR2 Amino Acid SEQ ID NO: 530 T1001-E6 CDR3 Amino Acid SEQ ID NO: 531 T1001-E64 CDR1 Amino Acid SEQ ID NO: 532 T1001-E64 CDR2 Amino Acid SEQ ID NO: 533 T1001-E64 CDR3 Amino Acid SEQ ID NO: 534 T1001-E55 CDR1 Amino Acid SEQ ID NO: 535 T1001-E55 CDR2 Amino Acid SEQ ID NO: 536 T1001-E55 CDR3 Amino Acid SEQ ID NO: 537 T1001-E17 CDR1 Amino Acid SEQ ID NO: 538 T1001-E17 CDR2 Amino Acid SEQ ID NO: 539 T1001-E17 CDR3 Amino Acid SEQ ID NO: 540 T1001-E24 CDR1 Amino Acid SEQ ID NO: 541 T1001-E24 CDR2 Amino Acid SEQ ID NO: 542 T1001-E24 CDR3 Amino Acid SEQ ID NO: 543 T1001-E25 CDR1 Amino Acid SEQ ID NO: 544 T1001-E25 CDR2 Amino Acid SEQ ID NO: 545 T1001-E25 CDR3 Amino Acid Specific TACs
[0115] Disclosed herein, in certain embodiments, are GUYC2C TAC proteins comprising an amino acid sequence with the amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686.
[0116] In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
465-513, 546-590, or 686. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686. In some embodiments, the GUCY2C
TAC

CA 03173857 2022-9- i63309 protein comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 95%
sequence identity with the amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
465-513, 546-590, or 686. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence of any one of SEQ
ID NOs: 465-513, 546-590, or 686. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 99%
sequence identity with the amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence of any one of SEQ
ID NOs: 465-513, 546-590, or 686.
[0117] In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID
NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence of SEQ ID
NO:
569.

CA 03173857 2022-9- ik63309
[0118] In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID
NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence of SEQ ID
NO:
570.
[0119] In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID
NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 580. In some CA 03173857 2022-9- ik63309 embodiments, the GUCY2C TAC protein comprises an amino acid sequence of SEQ ID
NO:
580.
[0120] In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
465-513, 546-590, or 686, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of the SEQ ID
NO. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
465-513, 546-590, or 686, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of the SEQ ID NO. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
465-513, 546-590, or 686, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of the SEQ ID NO. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
465-513, 546-590, or 686, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of the SEQ ID NO. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
465-513, 546-590, or 686, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of the SEQ ID NO. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 97% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
465-513, 546-590, or 686, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of the SEQ ID NO. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
465-513, 546-590, or 686, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of the SEQ ID NO. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 99% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
465-513, 546-590, or 686, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of the SEQ ID NO.

CA 03173857 2022-9- ik63309
[0121] In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID
NO: 569, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 85%
sequence identity with the amino acid sequence of SEQ ID NO: 569, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:
569, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 95%
sequence identity with the amino acid sequence of SEQ ID NO: 569, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO:
569, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 97%
sequence identity with the amino acid sequence of SEQ ID NO: 569, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID NO:
569, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 569. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 99%
sequence identity with the amino acid sequence of SEQ ID NO: 569, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 569.
[0122] In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID
NO: 570, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 85%
sequence identity CA 03173857 2022-9- ik63309 with the amino acid sequence of SEQ ID NO: 570, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:
570, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 95%
sequence identity with the amino acid sequence of SEQ ID NO: 570, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO:
570, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 97%
sequence identity with the amino acid sequence of SEQ ID NO: 570, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID NO:
570, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 570. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 99%
sequence identity with the amino acid sequence of SEQ ID NO: 570, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 570.
[0123] In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID
NO: 580, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 85%
sequence identity with the amino acid sequence of SEQ ID NO: 580, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:
580, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence CA 03173857 2022-9- ik63309 identity to the CDR sequences of the sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 95%
sequence identity with the amino acid sequence of SEQ ID NO: 580, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 96% sequence identity with the amino acid sequence of SEQ ID NO:
580, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 97%
sequence identity with the amino acid sequence of SEQ ID NO: 580, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence of SEQ ID NO:
580, wherein the CDR sequences of the GUCY2C TAC protein sequence have 100%
sequence identity to the CDR sequences of the sequence of SEQ ID NO: 580. In some embodiments, the GUCY2C TAC protein comprises an amino acid sequence having at least 99%
sequence identity with the amino acid sequence of SEQ ID NO: 580, wherein the CDR sequences of the GUCY2C
TAC protein sequence have 100% sequence identity to the CDR sequences of the sequence of SEQ ID NO: 580.
[0124] In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 80% sequence identity with the nucleic acid sequence of any one of SEQ ID
NOs: 591-685. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 85% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 591-685. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 90% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 591-685. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 95% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 591-685. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 96% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 591-685. In some embodiments, the GUCY2C
TAC
protein is encoded by a nucleic acid sequence having at least 97% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 591-685. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 98%
sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 591-685. In some CA 03173857 2022-9- ik63309 embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 99% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs:
591-685. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence of any one of SEQ ID NOs: 591-685.
[0125] In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 80% sequence identity with the nucleic acid sequence of SEQ ID
NOs: 663. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 85% sequence identity with the nucleic acid sequence of SEQ ID NOs: 663.
In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 90% sequence identity with the nucleic acid sequence of SEQ ID NOs: 663. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 95% sequence identity with the nucleic acid sequence of SEQ ID NOs: 663. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 96% sequence identity with the nucleic acid sequence of SEQ ID NOs: 663. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 97% sequence identity with the nucleic acid sequence of SEQ ID NOs: 663. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 98% sequence identity with the nucleic acid sequence of SEQ ID NOs: 663. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 99% sequence identity with the nucleic acid sequence of SEQ ID NOs: 663. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence of SEQ ID
NOs: 663.
[0126] In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 80% sequence identity with the nucleic acid sequence of SEQ ID
NOs: 664. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 85% sequence identity with the nucleic acid sequence of SEQ ID NOs: 664.
In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 90% sequence identity with the nucleic acid sequence of SEQ ID NOs: 664. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 95% sequence identity with the nucleic acid sequence of SEQ ID NOs: 664. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 96% sequence identity with the nucleic acid sequence of SEQ ID NOs: 664. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 97% sequence identity with the nucleic acid sequence of SEQ ID NOs: 664. In some CA 03173857 2022-9- ik63309 embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 98% sequence identity with the nucleic acid sequence of SEQ ID NOs: 664. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 99% sequence identity with the nucleic acid sequence of SEQ ID NOs: 664. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence of SEQ ID
NOs: 664.
[0127] In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 80% sequence identity with the nucleic acid sequence of SEQ ID
NOs: 674. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 85% sequence identity with the nucleic acid sequence of SEQ ID NOs: 674.
In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 90% sequence identity with the nucleic acid sequence of SEQ ID NOs: 674. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 95% sequence identity with the nucleic acid sequence of SEQ ID NOs: 674. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 96% sequence identity with the nucleic acid sequence of SEQ ID NOs: 674. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 97% sequence identity with the nucleic acid sequence of SEQ ID NOs: 674. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 98% sequence identity with the nucleic acid sequence of SEQ ID NOs: 674. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence having at least 99% sequence identity with the nucleic acid sequence of SEQ ID NOs: 674. In some embodiments, the GUCY2C TAC protein is encoded by a nucleic acid sequence of SEQ ID
NOs: 674.
[0128] Amino acid sequences and nucleic acid sequences of exemplary GUCY2C
TACs are provided in Table 7.
Table 7. Table of Sequences SEQ ID NO. Description Amino Acid/Nucleic Acid SEQ ID NO: 591 YU652-606-Whitlow-TAC Nucleotide SEQ ID NO: 465 Y U652- B06-Whitlow-TAC Amino Acid SEQ ID NO: 592 Y U652-001-Whitlow-TAC Nucleotide SEQ ID NO: 466 Y U652-001-Whitlow-TAC Amino Acid SEQ ID NO: 593 Y U652-F02-Whitlow-TAC Nucleotide SEQ ID NO: 467 Y U652-F02-Whitlow-TAC Amino Acid SEQ ID NO: 594 Y U652-H02-Whitlow-TAC Nucleotide SEQ ID NO: 468 YU652-H02-Whitlow-TAC Amino Acid CA 03173857 2022-9- ik63309 SEQ ID NO: 595 Y U653- B12-Whitlow-TAC Nucleotide SEQ ID NO: 469 Y U653- B12-Whitlow-TAC Amino Acid SEQ ID NO: 596 Y U653-D11-Whitlow-TAC Nucleotide SEQ ID NO: 470 Y U653-D11-Whitlow-TAC Amino Acid SEQ ID NO: 597 Y U653-F12-Whitlow-TAC Nucleotide SEQ ID NO: 471 Y U653-F12-Whitlow-TAC Amino Acid SEQ ID NO: 598 Y U654-E01-Whitlow-TAC Nucleotide SEQ ID NO: 472 Y U654-E01-Whitlow-TAC Amino Acid SEQ ID NO: 599 Y U667-A01-Whitlow-TAC Nucleotide SEQ ID NO: 473 Y U667-A01-Whitlow-TAC Amino Acid SEQ ID NO: 600 Y U667-A02-Whitlow-TAC Nucleotide SEQ ID NO: 474 Y U667-A02-Whitlow-TAC Amino Acid SEQ ID NO: 601 Y U667-A04-Whitlow-TAC Nucleotide SEQ ID NO: 475 Y U667-A04-Whitlow-TAC Amino Acid SEQ ID NO: 602 Y U667- B01-Whitlow-TAC Nucleotide SEQ ID NO: 476 Y U667- B01-Whitlow-TAC Amino Acid SEQ ID NO: 603 Y U667-1302-Whitlow-TAC Nucleotide SEQ ID NO: 477 Y U667-1302-Whitlow-TAC Amino Acid SEQ ID NO: 604 Y U667-1303-Whitlow-TAC Nucleotide SEQ ID NO: 478 Y U667-1303-Whitlow-TAC Amino Acid SEQ ID NO: 605 Y U667-004-Whitlow-TAC Nucleotide SEQ ID NO: 479 Y U667-004-Whitlow-TAC Amino Acid SEQ ID NO: 606 Y U667-006 -Whitlow-TAC Nucleotide SEQ ID NO: 480 Y U667-006 -Whitlow-TAC Amino Acid SEQ ID NO: 607 Y U667-D05-Whitlow-TAC Nucleotide SEQ ID NO: 481 Y U667-D05-Whitlow-TAC Amino Acid SEQ ID NO: 608 Y U667-D06-Whitlow-TAC Nucleotide SEQ ID NO: 482 Y U667-D06-Whitlow-TAC Amino Acid SEQ ID NO: 609 Y U667-E01-Whitlow-TAC Nucleotide SEQ ID NO: 483 Y U667-E01-Whitlow-TAC Amino Acid SEQ ID NO: 610 Y U667-E05-Whitlow-TAC Nucleotide SEQ ID NO: 484 Y U667-E05-Whitlow-TAC Amino Acid SEQ ID NO: 611 Y U667-F02-Whitlow-TAC Nucleotide SEQ ID NO: 485 Y U667-F02-Whitlow-TAC Amino Acid SEQ ID NO: 612 Y U667-F06-Whitlow-TAC Nucleotide SEQ ID NO: 486 Y U667-F06-Whitlow-TAC Amino Acid SEQ ID NO: 613 Y U667-G02-Whitlow-TAC Nucleotide SEQ ID NO: 487 Y U667-G02-Whitlow-TAC Amino Acid SEQ ID NO: 614 Y U667-G04-Whitlow-TAC Nucleotide SEQ ID NO: 488 Y U667-G04-Whitlow-TAC Amino Acid SEQ ID NO: 615 Y U667-G06-Whitlow-TAC Nucleotide SEQ ID NO: 489 Y U667-G06-Whitlow-TAC Amino Acid SEQ ID NO: 616 Y U667-H06-Whitlow-TAC Nucleotide SEQ ID NO: 490 Y U667-H06-Whitlow-TAC Amino Acid SEQ ID NO: 617 6293-R4A-C2-TAC Nucleotide SEQ ID NO: 491 6293-R4A-C2-TAC Amino Acid SEQ ID NO: 618 6293-R4A-E3-TAC Nucleotide SEQ ID NO: 492 6293-R4A-E3-TAC Amino Acid SEQ ID NO: 619 6293-R4A-G4-TAC Nucleotide CA 03173857 2022-9- i63309 SEQ ID NO: 493 6293-R4A-G4-TAC Amino Acid SEQ ID NO: 620 6293-R5A-A5-TAC Nucleotide SEQ ID NO: 494 6293-R5A-A5-TAC Amino Acid SEQ ID NO: 621 6293-R5A-B6-TAC Nucleotide SEQ ID NO: 495 6293-R5A-B6-TAC Amino Acid SEQ ID NO: 622 6293-R5A-E7-TAC Nucleotide SEQ ID NO: 496 6293-R5A-E7-TAC Amino Acid SEQ ID NO: 623 6293-R5A-F6-TAC Nucleotide SEQ ID NO: 497 6293-R5A-F6-TAC Amino Acid SEQ ID NO: 624 6293-R6A-A10-TAC Nucleotide SEQ ID NO: 498 6293-R6A-A10-TAC Amino Acid SEQ ID NO: 625 6293-R6A-B11-TAC Nucleotide SEQ ID NO: 499 6293-R6A-B11-TAC Amino Acid SEQ ID NO: 626 6293-R6A-C9-TAC Nucleotide SEQ ID NO: 500 6293-R6A-C9-TAC Amino Acid SEQ ID NO: 627 6293-R6A-G9-TAC Nucleotide SEQ ID NO: 501 6293-R6A-G9-TAC Amino Acid SEQ ID NO: 628 6293-R6A-H11-TAC Nucleotide SEQ ID NO: 502 6293-R6A-H11-TAC Amino Acid SEQ ID NO: 629 T1001-A23-TAC Nucleotide SEQ ID NO: 503 T1001-A23-TAC Amino Acid SEQ ID NO: 630 T1001-A25-TAC Nucleotide SEQ ID NO: 504 T1001-A25-TAC Amino Acid SEQ ID NO: 631 T1001-A28-TAC Nucleotide SEQ ID NO: 505 T1001-A28-TAC Amino Acid SEQ ID NO: 632 T1001-A30-TAC Nucleotide SEQ ID NO: 506 T1001-A30-TAC Amino Acid SEQ ID NO: 633 T1001-A48-TAC Nucleotide SEQ ID NO: 507 T1001-A48-TAC Amino Acid SEQ ID NO: 634 T1001-V20-TAC Nucleotide SEQ ID NO: 508 T1001-V20-TAC Amino Acid SEQ ID NO: 635 T1001-V30-TAC Nucleotide SEQ ID NO: 509 T1001-V30-TAC Amino Acid SEQ ID NO: 636 T1001-V54-TAC Nucleotide SEQ ID NO: 510 T1001-V54-TAC Amino Acid SEQ ID NO: 637 T1001-V65-TAC Nucleotide SEQ ID NO: 511 T1001-V65-TAC Amino Acid SEQ ID NO: 638 T1001-V67-TAC Nucleotide SEQ ID NO: 512 T1001-V67-TAC Amino Acid SEQ ID NO: 639 T1001-V68-TAC Nucleotide SEQ ID NO: 513 T1001-V68-TAC Amino Acid SEQ ID NO: 640 T1001-E6_HC-TAC Nucleotide SEQ ID NO: 548 T1001-E6_HC-TAC Amino Acid SEQ ID NO: 641 T1001-E8_HC-TAC Nucleotide SEQ ID NO: 546 T1001-E8_HC-TAC Amino Acid SEQ ID NO: 642 T1001-E16_HC-TAC Nucleotide SEQ ID NO: 547 T1001-E16_HC-TAC Amino Acid SEQ ID NO: 643 T1001-E17_HC-TAC Nucleotide SEQ ID NO: 551 T1001-E17 HC-TAC Amino Acid CA 03173857 2022-9- i63309 SEQ ID NO: 644 T1001-E24_HC-TAC Nucleotide SEQ ID NO: 552 T1001-E24_HC-TAC Amino Acid SEQ ID NO: 645 T1001-E25_HC-TAC Nucleotide SEQ ID NO: 553 T1001-E25_HC-TAC Amino Acid SEQ ID NO: 646 T1001-E55_HC-TAC Nucleotide SEQ ID NO: 550 T1001-E55_HC-TAC Amino Acid SEQ ID NO: 647 T1001-E64_HC-TAC Nucleotide SEQ ID NO: 549 T1001-E64_HC-TAC Amino Acid SEQ ID NO: 648 GUCY2C-TAC G7 Nucleotide SEQ ID NO: 554 GUCY2C-TAC G7 Amino Acid SEQ ID NO: 649 GUCY2C-TAC G8 Nucleotide SEQ ID NO: 555 GUCY2C-TAC G8 Amino Acid SEQ ID NO: 650 GUCY2C-TAC G9 Nucleotide SEQ ID NO: 556 GUCY2C-TAC G9 Amino Acid SEQ ID NO: 651 GUCY2C-TAC G10 Nucleotide SEQ ID NO: 557 GUCY2C-TAC G10 Amino Acid SEQ ID NO: 652 GUCY2C-TAC G11 Nucleotide SEQ ID NO: 558 GUCY2C-TAC G11 Amino Acid SEQ ID NO: 653 GUCY2C-TAC G12 Nucleotide SEQ ID NO: 559 GUCY2C-TAC G12 Amino Acid SEQ ID NO: 654 GUCY2C-TAC G13 Nucleotide SEQ ID NO: 560 GUCY2C-TAC G13 Amino Acid SEQ ID NO: 655 GUCY2C-TAC G14 Nucleotide SEQ ID NO: 561 GUCY2C-TAC G14 Amino Acid SEQ ID NO: 656 GUCY2C-TAC G15 Nucleotide SEQ ID NO: 562 GUCY2C-TAC G15 Amino Acid SEQ ID NO: 657 GUCY2C-TAC G16 Nucleotide SEQ ID NO: 563 GUCY2C-TAC G16 Amino Acid SEQ ID NO: 658 GUCY2C-TAC G17 Nucleotide SEQ ID NO: 564 GUCY2C-TAC G17 Amino Acid SEQ ID NO: 659 GUCY2C-TAC G18 Nucleotide SEQ ID NO: 565 GUCY2C-TAC G18 Amino Acid SEQ ID NO: 660 GUCY2C-TAC G19 Nucleotide SEQ ID NO: 566 GUCY2C-TAC G19 Amino Acid SEQ ID NO: 661 GUCY2C-TAC G20 Nucleotide SEQ ID NO: 567 GUCY2C-TAC G20 Amino Acid SEQ ID NO: 662 GUCY2C-TAC G21 Nucleotide SEQ ID NO: 568 GUCY2C-TAC G21 Amino Acid SEQ ID NO: 663 GUCY2C-TAC G22 Nucleotide SEQ ID NO: 569 GUCY2C-TAC G22 Amino Acid SEQ ID NO: 664 GUCY2C-TAC G23 Nucleotide SEQ ID NO: 570 GUCY2C-TAC G23 Amino Acid SEQ ID NO: 665 GUCY2C-TAC G24 Nucleotide SEQ ID NO: 571 GUCY2C-TAC G24 Amino Acid SEQ ID NO: 666 GUCY2C-TAC G25 Nucleotide SEQ ID NO: 572 GUCY2C-TAC G25 Amino Acid SEQ ID NO: 667 GUCY2C-TAC G26 Nucleotide SEQ ID NO: 573 GUCY2C-TAC G26 Amino Acid SEQ ID NO: 668 GUCY2C-TAC G27 Nucleotide CA 03173857 2022-9- i63309 SEQ ID NO: 574 GUCY2C-TAC G27 Amino Acid SEQ ID NO: 669 GUCY2C-TAC G28 Nucleotide SEQ ID NO: 575 GUCY2C-TAC G28 Amino Acid SEQ ID NO: 670 GUCY2C-TAC G29 Nucleotide SEQ ID NO: 576 GUCY2C-TAC G29 Amino Acid SEQ ID NO: 671 GUCY2C-TAC G30 Nucleotide SEQ ID NO: 577 GUCY2C-TAC G30 Amino Acid SEQ ID NO: 672 GUCY2C-TAC G31 Nucleotide SEQ ID NO: 578 GUCY2C-TAC G31 Amino Acid SEQ ID NO: 673 GUCY2C-TAC G32 Nucleotide SEQ ID NO: 579 GUCY2C-TAC G32 Amino Acid SEQ ID NO: 674 GUCY2C-TAC G33 Nucleotide SEQ ID NO: 580 GUCY2C-TAC G33 Amino Acid SEQ ID NO: 675 GUCY2C-TAC G34 Nucleotide SEQ ID NO: 581 GUCY2C-TAC G34 Amino Acid SEQ ID NO: 676 GUCY2C-TAC G35 Nucleotide SEQ ID NO: 582 GUCY2C-TAC G35 Amino Acid SEQ ID NO: 677 GUCY2C-TAC G36 Nucleotide SEQ ID NO: 583 GUCY2C-TAC G36 Amino Acid SEQ ID NO: 678 GUCY2C-TAC G37 Nucleotide SEQ ID NO: 584 GUCY2C-TAC G37 Amino Acid SEQ ID NO: 679 GUCY2C-TAC G38 Nucleotide SEQ ID NO: 585 GUCY2C-TAC G38 Amino Acid SEQ ID NO: 680 GUCY2C-TAC G39 Nucleotide SEQ ID NO: 586 GUCY2C-TAC G39 Amino Acid SEQ ID NO: 681 GUCY2C-TAC G40 Nucleotide SEQ ID NO: 587 GUCY2C-TAC G40 Amino Acid SEQ ID NO: 682 GUCY2C-TAC G41 Nucleotide SEQ ID NO: 588 GUCY2C-TAC G41 Amino Acid SEQ ID NO: 683 GUCY2C-TAC G42 Nucleotide SEQ ID NO: 589 GUCY2C-TAC G42 Amino Acid SEQ ID NO: 684 GUCY2C-TAC G43 Nucleotide SEQ ID NO: 590 GUCY2C-TAC G43 Amino Acid SEQ ID NO: 685 GUCY2C-TAC G44 Nucleotide SEQ ID NO: 686 GUCY2C-TAC G44 Amino Acid Vector Constructs
[0129] Disclosed herein, in certain embodiments, are vectors comprising a nucleic acid sequence as disclosed herein. In some embodiments, the vectors further comprise a promoter. In some embodiments, the promoter is functional in a mammalian cell.
Promoters, regions of DNA that initiate transcription of a particular nucleic acid sequence, are well known in the art. A "promoter functional in a mammalian cell" refers to a promoter that drives expression of the associated nucleic acid sequence in a mammalian cell. A
promoter that drives expression of a nucleic acid sequence is referred to as being "operably connected" to the nucleic acid sequence.

CA 03173857 2022-9- i63309
[0130] A variety of delivery vectors and expression vehicles are employed to introduce nucleic acids described herein into a cell.
[0131] Disclosed herein, in certain embodiments, are vectors comprising:
(a) a first polynucleotide encoding an antigen-binding domain that binds GUCY2C;
(b) a second polynucleotide encoding an antigen-binding domain that binds a protein associated with a TCR complex;
(c) a third polynucleotide encoding a T cell receptor signaling domain polypeptide; and (d) a promoter that is functional in a mammalian cell.
[0132] In some embodiments, the first polynucleotide and third polynucleotide are fused to the second polynucleotide and the coding sequence is operably connected to the promoter. In some embodiments, the second polynucleotide and third polynucleotide are fused to the first polynucleotide and the coding sequence is operably connected to the promoter.
In some embodiments, the vector is designed for expression in mammalian cells. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a retroviral vector.
[0133] In some embodiments, vectors that are useful comprise vectors derived from retroviruses, lentiviruses, Murine Stem Cell Viruses (MSCV), pox viruses, adenoviruses, and adeno-associated viruses. Other delivery vectors that are useful comprise vectors derived from herpes simplex viruses, transposons, vaccinia viruses, human papilloma virus, Simian immunodeficiency viruses, HTLV, human foamy virus and variants thereof.
Further vectors that are useful comprise vectors derived from spumaviruses, mammalian type B
retroviruses, mammalian type C retroviruses, avian type C retroviruses, mammalian type D
retroviruses and HTLV/BLV type retroviruses. One example of a lentiviral vector useful in the disclosed compositions and methods is the pCCL4 vector.
Pharmaceutical Compositions
[0134] Disclosed herein, in certain embodiments, are pharmaceutical compositions comprising an engineered T cell disclosed herein (transduced with and/or expressing a polypeptide), and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include, but are not limited to, buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins;
polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); or preservatives. In some embodiments, the engineered T cells are formulated for intravenous administration.

CA 03173857 2022-9- ik63309
[0135] Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). The quantity and frequency of administration is determined by such factors as the condition of the patient, and the type and severity of the patient's disease, although appropriate dosages are determined by clinical trials. When "an immunologically effective amount," "an anti-tumor effective amount," "a tumor-inhibiting effective amount," or "therapeutic amount" is indicated, the precise amount of the compositions of the present invention to be administered is determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject).
[0136] In some embodiments, the engineered T cells and/or pharmaceutical compositions described herein are administered at a dosage of 101 to 1015 cells per kg body weight, 104 to 109 cells per kg body weight, optionally 105 to 108 cells per kg body weight, 106 to 107 cells per kg body weight or 105 to 106 cells per kg body weight, including all integer values within those ranges. In some embodiments, the modified T cells and/or pharmaceutical compositions described herein are administered at a dosage of greater than 101 cells per kg body weight. In some embodiments, the modified T cells and/or pharmaceutical compositions described herein are administered at a dosage of less than 1015 cells per kg body weight.
[0137] In some embodiments, the engineered T cells and/or pharmaceutical compositions described herein are administered at a dosage of 0.5x106 cells, 2x106 cells, 4x106 cells, 5x106 cells, 1.2x107 cells, 2x107 cells, 5x107 cells, 2x108 cells, 5x108 cells, 2x109 cells, 0.5-2000x106 cells, 0.5-2x106 cells, 0.5-2x107 cells, 0.5-2x108 cells, or 0.5-2x109 cells, including all integer values within those ranges.
[0138] Also disclosed herein are pharmaceutical compositions comprising engineered/modified and unmodified T cells, or comprising different populations of engineered/modified T cells with or without unmodified T cells. One of ordinary skill in the art would understand that a therapeutic quantity of engineered/modified T cells need not be homogenous in nature.
[0139] In some embodiments, T cell compositions are administered multiple times at these dosages. In some embodiments, the dosage is administered a single time or multiple times, for example daily, weekly, biweekly, or monthly, hourly, or is administered upon recurrence, relapse or progression of the cancer being treated. The cells, in some embodiments, are administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988).

CA 03173857 2022-9- ik63309
[0140] In some embodiments, the pharmaceutical composition is substantially free of, e.g., there are no detectable levels of a contaminant, e.g., selected from the group consisting of endotoxin, mycoplasma, replication competent lentivirus (RCL), p24, VSV-G nucleic acid, HIV gag, residual anti-CD3/anti-CD28 coated beads, mouse antibodies, pooled human serum, bovine serum albumin, bovine serum, culture media components, vector packaging cell or plasmid components, a bacterium a fungus, mycoplasma, IL-2, and IL-7.
[0141] In some embodiments, the modified/engineered T cells and/or pharmaceutical compositions are administered by methods including, but not limited to, aerosol inhalation, injection, infusion, ingestion, transfusion, implantation or transplantation.
The modified T cells and/or pharmaceutical compositions may be administered to a subject transarterially, subcutaneously, intradermally, intratumorally, intranodally, intrameduliary, intramuscularly, by intravenous (i.v.) injection, by intravenous (i.v.) infusion, or intraperitoneally. The modified/engineered T cells and/or pharmaceutical compositions thereof may be administered to a patient by intradermal or subcutaneous injection. The modified/engineered T
cells and/or pharmaceutical compositions thereof may be administered by i.v. injection. The modified/engineered T cells and/or pharmaceutical compositions thereof may be injected directly into a tumor, lymph node, or site of infection.
[0142] A pharmaceutical composition may be prepared by known methods for the preparation of pharmaceutically acceptable compositions that are administered to subjects, such that an effective quantity of the T cells is combined in a mixture with a pharmaceutically acceptable carrier. Suitable carriers are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, 20th ed., Mack Publishing Company, Easton, Pa., USA, 2000). On this basis, the compositions may include, albeit not exclusively, solutions of the substances in association with one or more pharmaceutically acceptable carriers or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.
[0143] Suitable pharmaceutically acceptable carriers include essentially chemically inert and nontoxic compositions that do not interfere with the effectiveness of the biological activity of the pharmaceutical composition. Examples of suitable pharmaceutical carriers include, but are not limited to, water, saline solutions, glycerol solutions, N-(1(2,3-dioleyloxy)propyl)N,N,N-trimethylammonium chloride (DOTMA), diolesylphosphotidyl-ethanolamine (DOPE), and liposomes. In some embodiments, such compositions contain a therapeutically effective amount of the compound, together with a suitable amount of carrier so as to provide the form for direct administration to the patient.

CA 03173857 2022-9- ik63309
[0144] Pharmaceutical compositions include, without limitation, lyophilized powders or aqueous or non-aqueous sterile injectable solutions or suspensions, which may further contain antioxidants, buffers, bacteriostats and solutes that render the compositions substantially compatible with the tissues or the blood of an intended recipient. Other components that may be present in such compositions include water, surfactants (such as Tween), alcohols, polyols, glycerin and vegetable oils, for example. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, tablets, or concentrated solutions or suspensions.
[0145] A pharmaceutical composition disclosed herein may be formulated into a variety of forms and administered by a number of different means. A pharmaceutical formulation may be administered orally, rectally, or parenterally, in formulations containing conventionally acceptable carriers, adjuvants, and vehicles as desired. The term "parenteral"
as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection and infusion techniques. Administration includes injection or infusion, including intra-arterial, intracardiac, intracerebroventricular, intradermal, intraduodenal, intramedullary, intramuscular, intraosseous, intraperitoneal, intrathecal, intravascular, intravenous, intravitreal, epidural and subcutaneous), inhalational, transdermal, transmucosal, sublingual, buccal and topical (including epicutaneous, dermal, enema, eye drops, ear drops, intranasal, vaginal) administration. In some exemplary embodiments, a route of administration is via an injection such as an intramuscular, intravenous, subcutaneous, or intraperitoneal injection.
[0146] Liquid formulations include an oral formulation, an intravenous formulation, an intranasal formulation, an ocular formulation, an otic formulation, an aerosol, and the like. In certain embodiments, a combination of various formulations is administered. In certain embodiments a composition is formulated for an extended release profile.
Methods of Treatment and Use
[0147] Disclosed herein, in certain embodiments, are methods of using engineered T cells disclosed herein in the treatment of a GUCY2C-expressing cancer in an individual in need thereof.
[0148] In some embodiments, an antigen-binding domain that binds GUCY2C of a TAC
polypeptide disclosed herein binds to GUCY2C on a tumor cell. In some embodiments, an antigen-binding domain that binds GUCY2C of a TAC polypeptide disclosed herein selectively binds to GUCY2C on a tumor cell.

CA 03173857 2022-9- ik63309
[0149] Disclosed herein, in certain embodiments, are methods of treating a cancer expressing GUCY2C in an individual in need thereof, comprising administering to the individual an engineered T cell disclosed herein or a pharmaceutical composition comprising an engineered T
cell disclosed herein.
[0150] Further disclosed herein is use of an engineered T cell disclosed herein in the preparation of a medicament to treat cancer expressing GUCY2C in an individual in need thereof.
Additionally disclosed herein in certain embodiments is the use of an engineered T cell disclosed herein or a pharmaceutical composition disclosed herein to treat a cancer expressing GUCY2C in an individual in need thereof.
[0151] In some embodiments, the engineered T cells disclosed herein are part of a combination therapy. In some embodiments, effectiveness of a therapy disclosed herein is assessed multiple times. In some embodiments, patients are stratified based on a response to a treatment disclosed herein. In some embodiments, an effectiveness of treatment determines entrance into a trial.
[0152] In some embodiments, the engineered T cells disclosed herein are administered in combination with a lymphodepleting therapy, or are administered to a subject who has received a lymphodepleting therapy. Examples of lymphodepleting therapies include nonmyeloablative lymphodepleting chemotherapy, myeloablative lymphodepleting chemotherapy, fludarabine, cyclophosphamide, corticosteroids, alemtuzumab, total body irradiation (TB!), and any combination thereof.
[0153] Cancers that may be treated with engineered T cells disclosed herein include any form of neoplastic disease. In some embodiments, the cancer is a primary colorectal cancer, a primary gastric cancer, a primary gastroesophageal junction cancer, a primary esophageal cancer, or a primary pancreatic cancer. In some embodiments, the cancer is a metastatic colorectal cancer, a metastatic gastric cancer, a metastatic gastroesophageal junction cancer, a metastatic esophageal cancer, or a metastatic pancreatic cancer.
[0154] In some embodiments, the cancer that is to be treated is a primary colorectal cancer.
Colorectal cancer affects both men and women, and is responsible for 9.2% of all cancer deaths.
The lack of response to targeted therapy, such as anti-EGFR antibodies, has been correlated with mutations in the KRAS and BRAF oncogenes. In addition, immunotherapies, such as immune checkpoint inhibitors, have failed to show significant survival benefit in most patients with colorectal cancer, owing to low tumor mutational burden and reduced density of immune infiltration. Guanylyl Cyclase C (GUCY2C) is overexpressed in more than 90% of colorectal cancers across all stages.

CA 03173857 2022-9- ik63309
[0155] In some embodiments, the cancer that is to be treated is a primary gastric cancer, for example a primary gastroesophageal junction cancer. Gastric cancers are the 6th most common cancer in the world, and the second-leading cause of cancer-related deaths worldwide. In most of the world, stomach cancers form in the main part of the stomach (stomach body). In the United States, stomach cancer is more likely to affect the area where the esophagus meets the stomach, i.e., gastroesophageal junction cancer. Many gastric cancers evolve from intestinal metaplasia resulting in over 50% of gastric cancers and gastroesophageal junction cancers being characterized by ectopic over-expression of GUCY2C.
[0156] In some embodiments, the cancer that is to be treated is a primary pancreatic cancer.
Pancreatic cancer has the highest mortality rate of all major cancers. For all stages combined, the 5-year relative survival rate is 10%. For people diagnosed with local disease, the 5-year survival is only 39%. Many pancreatic cancers evolve from intestinal metaplasia resulting in over 50% of pancreatic cancers being characterized by overexpression of GUCY2C.
EXAMPLES
[0157] The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.
The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention.
Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.
Example 1: Manufacturing of GUCY2C-TAC T cells
[0158] T cells were engineered with lentiviral vectors to express a variety of receptors listed in Table 8. Surface expression was analyzed via flow cytometry (FIG. 1).
Results show that T cells expressed the 34 GUCY2C-TACs of Table 8.
Table 8 TAC ID Binding Domain Sequence ID
G7 muScFv SEQ ID NO: 554 G9 muScFv SEQ ID NO: 556 G10 muScFv SEQ ID NO: 557 G11 muScFv SEQ ID NO: 558 G12 muScFv SEQ ID NO: 559 G13 muScFv SEQ ID NO: 560 G14 muScFv SEQ ID NO: 561 G16 Nanobody SEQ ID NO: 563 G17 Nanobody SEQ ID NO: 564 CA 03173857 2022-9- ik63309 G18 Nanobody SEQ ID NO: 565 G19 Nanobody SEQ ID NO: 566 G21 Nanobody SEQ ID NO: 568 G22 Nanobody SEQ ID NO: 569 G23 Nanobody SEQ ID NO: 570 G25 huScFv SEQ ID NO: 572 G26 huScFv SEQ ID NO: 573 G27 huScFv SEQ ID NO: 574 G28 huScFv SEQ ID NO: 575 G29 huScFv SEQ ID NO: 576 G30 huScFv SEQ ID NO: 577 G31 huScFv SEQ ID NO: 578 G32 huScFv SEQ ID NO: 579 G33 huScFv SEQ ID NO: 580 G34 huScFv SEQ ID NO: 581 G35 huScFv SEQ ID NO: 582 G36 huScFv SEQ ID NO: 583 G37 huScFv SEQ ID NO: 584 G38 huScFv SEQ ID NO: 585 G39 huScFv SEQ ID NO: 586 G40 huScFv SEQ ID NO: 587 G41 huScFv SEQ ID NO: 588 G42 huScFv SEQ ID NO: 589 G43 huScFv SEQ ID NO: 590 G44 Nanobody SEQ ID NO: 686 Example 2: In vitro activation of GUCY2C-TAC T cells
[0159] T cells were engineered to express the GUCY2C-TAC receptors listed in Table 8. T cell activation was measured as a function of the upregulation of the early T cell activation marker, CD69. GUCY2C-TAC T cells were co-cultured at a 1:1 E:T ratio with a variety of tumor cell lines expressing GUCY2C (N87GucY2c, NALM6GucY2c). Following a 4-hour co-culture, GUCY2C-TAC T cells were harvested and analyzed for CD69 surface expression by flow cytometry. As shown in FIGs. 2A-2B, GUCY2C-TAC T cells were activated when co-cultured with GUCY2C-positive target cells NALM6GucY2c (FIG. 2A) and N87GucY2C (FIG.
2B).
Activation was not observed with GUCY2C negative control cells. The observed activation varied across all tested GUCY2C-TAC T cells. When stimulated with GUCY2C-positive target cells, GUCY2C-TAC T cells were able to induce the activation of non-transduced T cells in that same T cell populations.
Example 3: In vitro expansion of GUCY2C-TAC T cells
[0160] T cells were engineered to express a variety of GUCY2C-TAC receptors (Table 8).
Proliferation of GUCY2C-TAC T cells co-cultured in a 1:3 E:T ratio for 4 days with CA 03173857 2022-9- i63309 NALm6Gucy2c was evaluated. NALM6GUCY2C is a leukemic cell line that was engineered to overexpress a truncated version of GUCY2C lacking the cytosolic domains. The parental NALM6 cell line lacking GUCY2C expression was used as negative control. GUCY2C-TAC T
cells were evaluated via the CTV (cell trace violet) proliferation assay.
Target cells were inactivated using mitomycin C, and T cells were loaded with CTV dye prior to co-culture with target cells at a 1: E:T ratio. After a 4-day co-culture, T cells were analyzed via flow cytometry.
Results of the CTV proliferation assay were quantified (FIG. 3A), and representative examples are shown (FIG. 3B). The division index (DI), a measure of proliferation from all GUCY2C-TAC T cells was normalized to the division index of cells grown in the absence of target cells (FIG. 3A). The observed proliferation varied across all tested GUCY2C-TAC T
cells. The majority of GUCY2C-TAC T cells showed proliferation, including several GUCY2C-TAC T
cell candidates with high proliferative activity. No proliferation was observed against GUCY2C-negative control cells. GUCY2C-TAC G23 (SEQ ID NO: 570) and GUCY2C-TAC G36 (SEQ
ID NO: 583) T cells showed various levels of proliferation relative to the positive control of CD19-TAC T cells. No proliferation was observed in the HER2-TAC negative control cells.
Example 4: In vitro cytotoxicity of GUCY2C-TAC T cells
[0161] T cells were engineered to express GUCY2C-TAC receptors listed in Table 8.
GUCY2C-TAC T cells were co-cultured at E:T ratios 1:10 and 1:20 with 1x104 NALm6 GUCY2C-GFPeLuc target cells/well in a cell imaging reader. Photos were captured every 8 hours for 5 days.
The area of GFP-expressing cells is calculated for each time point and E:T
ratio. From these values, the area under the curve (AUC) for each of the GUCY2C-TAC T cells was calculated and plotted, representing target cell killing at each E:T ratio. Data shows percentage target cell killing of the GUCY2C-TAC T cells at E:T ratio of 1:10 (FIG. 4). The tested cells showed varying levels of cytotoxicity. No cytotoxicity was observed against GUCY2C
negative control cells. The positive control, CD19-TAC, showed nearly 100%
killing of target cells at E:T of 1:10. NTD is shown as the negative control.
Example 5: Antigen-specific in vitro activation of GUCY2C-TAC T cells
[0162] T cells were engineered to express GUCY2C-TAC receptors G22 (SEQ ID NO:
569), G23 (SEQ ID NO: 570), G26 (SEQ ID NO: 573), G32 (SEQ ID NO: 579), or G33 (SEQ
ID NO:
580). T cell activation was measured as a function of the upregulation of the early T cell activation marker, CD69. T cells expressing the GUCY2C-TAC were co-cultured at a 1:1 E:T
ratio with a variety of tumor cell lines expressing GUCY2C (NCI-N87GUCY2C, NALm6GUCY2C).
Following a 4 hour co-culture, GUCY2C-TAC T cells were harvested and analyzed for CD69 CA 03173857 2022-9- ik63309 surface expression by flow cytometry. As shown in FIG. 5, T cells expressing were activated when co-cultured with both GUCY2C positive target cells, N87GucY2c and NALM6GUCY2C, but not with GUCY2C negative control cells, NALM6. All 5 tested TAC T cell variants were activated in response to GUCY2C-expressing tumor cells, comparable to the relevant positive controls (i.e., HER2-TAC for N87GucY2c; CD19-TAC T
for NALM6GucY2c target cells).
Example 6: Antigen-specific in vitro expansion of GUCY2C-TAC T cells
[0163] T cells were engineered to express GUCY2C-TAC receptors G22 (SEQ ID NO:
569), G23 (SEQ ID NO: 570), G26 (SEQ ID NO: 573), G32 (SEQ ID NO: 579), or G33 (SEQ
ID NO:
580). GUCY2C-TAC T cells were evaluated via the CTV proliferation assay.
Target cells (N87 GUCY2C, NALM6GucY2c) were inactivated using mitomycin, and T cells were loaded with cell tracing (CTV) dye prior to co-culture with target cells at a 1:3 E:T ratio.
After a 4 day co-culture T cells were analyzed via flow cytometry. Results of the CTV proliferation assay were quantified (FIG. 6).
[0164] The division index (DI) was normalized to the respective positive controls (HER2-TAC
for N87GucY2c and CD19-TAC for NALM6GucY2c). All 5 tested GUCY2C-TAC T cell products proliferated upon co-culture with GUCY2C-expressing target cells. No proliferation was observed against GUCY2C negative control cells.
Example 7: Antigen-specific in vitro cytotoxicity of GUCY2C-TAC T cells
[0165] T cells were engineered to express GUCY2C-TAC receptors G22 (SEQ ID NO:
569), G23 (SEQ ID NO: 570), G26 (SEQ ID NO: 573), G32 (SEQ ID NO: 579), or G33 (SEQ
ID NO:
580). GUCY2C-TAC T cells were co-cultured at E:T ratios 1:5, 1:10 and 1:20 with 1x104 NALM6 GUCY2C-GFPeL" target cells/well in a cell imaging reader. Photos were captured every 8 hours for 5 days. The area of GFP-expressing cells is calculated for each time point and E:T
ratio. From these values, the area under the curve (AUC) for each of the GUCY2C-TAC T cells was calculated, normalized to target cells alone and plotted, representing target cell killing at each E:T ratio. FIG. 7 shows exemplary results of GUCY2C-TAC Nanobody 7 (closed circles), GUCY2C-TAC Nanobody 8 (closed squares), GUCY2C-TAC huScFV 2 (closed triangles), GUCY2C-TAC huScFV 8 (closed inverted triangles), and GUCY2C-TAC huScFV 9 (closed diamonds). Data shown demonstrate the different levels of target cell killing dependent on the E:T ratios used. NTD negative controls cells show no cytotoxicity. The graph demonstrated that all tested GUCY2C-TAC T cells show cytotoxicity, with some variants being close to the cytotoxicity observed by the positive control CD19-TAC T cells.

CA 03173857 2022-9- ik63309 Example 8: In vitro activity of GUCY2C-TAC T cells against various tumor cell types endogenously expressing GUCY2C
[0166] The natural surface expression levels of GUCY2C on T84, LS174T (colon carcinoma), LS1034 (colorectal carcinoma) cell lines were measured and activation of cells against the cells was analyzed. Engineered cell lines N87GUCY2C and NALM6GUCY2C were used as positive control. Dotted lines represent secondary antibody only and were used as negative control. Natural cell lines showed surface expression levels that were above background, which indicates lower expression levels compared to the engineered positive controls (FIG. 8A).
[0167] T cells were engineered to express GUCY2C-TAC receptors G22 (SEQ ID NO:
569), G23 (SEQ ID NO: 570), or G33 (SEQ ID NO: 580). GUCY2C-TAC T cells were co-cultured at a 1:1 ratio with the GUCY2C-expressing cells (FIG. 8A), while GUCY2C-negative cells were used as negative control. Following a 4-hour co-culture, GUCY2C-TAC
T cells were harvested and analyzed for CD69 surface expression by flow cytometry. As shown in FIG. 8B, GUCY2C-TAC T cells were activated when co-cultured with the GUCY2C-positive target cells.
The level of activation varied across cell lines with T84 cells inducing the lowest level of activation, while L51034 cells induced the highest levels of T cell activation. With the exception of the L5174T cell line, GUCY2C-TAC T cell activation was comparable with the respective positive control TAC T cells. Neither NTD negative controls nor T cells alone showed activation.
Example 9: In vitro screening of GUCY2C-TACs
[0168] T cells are engineered to express GUCY2C-TAC receptors (e.g., any one of SEQ ID
NOs: 465-513, 546-590, or 686). T cell activation is measured as a function of the upregulation of the early T cell activation marker, CD69. Engineered T cells are co-cultured at a 1:1 E:T ratio with target cells expressing GUCY2C or negative control cells that do not express GUCY2C.
Following a 4-hour co-culture, GUCY2C-TAC T cells are harvested and analyzed for CD69 surface expression by flow cytometry. Expansion of GUCY2C-TAC T cells is evaluated via the CTV proliferation assay. GUCY2C-positive target cells or GUCY2C-negative control cells are inactivated using mitomycin C, and T cells are loaded with CTV dye prior to co-culture with target or control cells at a 3:1 E:T ratio. After a 4-day co-culture, T cells are analyzed via flow cytometry. GFP/Luc-expressing GUCY2C-positive target cells or GUCY2C-negative control cells are used to assess cytotoxicity induced by TAC T cells in a cell imaging reader. Photos are captured every 8 hours for 5 days. The area of GFP-expressing cells is calculated for each time CA 03173857 2022-9- ik63309 point and E:T ratio. From these values, the area under the curve (AUC) for each of the GUCY2C-TAC T cells is calculated and plotted, representing target cell killing at each E:T
ratio. Results are analyzed to compare the relative effects of the GUCY2C-TAC
T cells on GUCY2C-positive target cells or GUCY2C-negative control cells.
Example 10: In vivo activity of GUCY2C-TAC T cells in mammalian subjects
[0169] T cells are engineered to express GUCY2C-TAC receptors (e.g., any one of SEQ ID
NOs: 465-513, 546-590, or 686). Mice are inoculated with 5x105-1x107 GUCY2C-expressing tumor cells. Four days after engraftment, mice are treated with a single intravenous dose of GUCY2C-TAC T cells. Non-treated (NT) mice and mice treated with non-transduced T cells (NTD) are used as negative controls. Mice are dosed with 4x106TAC T cells or an equivalent number of NTD cells that matches the total T cell dose used for TAC T cells.
Total luminescence is measured weekly. The resulting total flux (photons/second) as the sum of the dorsal and ventral reads, overall survival, and relative change in body weight as a means to assess toxicity are measured. Results are analyzed to compare animals treated with GUCY2C-TAC T cells to NT and NTD animals.
Example 11: Treatment of human subjects with GUCY2C-TAC T cells
[0170] A human subject having a GUCY2C-expressing primary colorectal cancer presents..
Autologous T cells are engineered to express a GUCY2C-TAC receptor (e.g., any one of SEQ
ID NOs: 465-513, 546-590, or 686) and expression of the TAC is confirmed. The subject is administered lymphodepleting chemotherapy followed by administration of TAC-expressing T
cells at an appropriate dose. The subject is monitored for toxicity and disease progression.

CA 03173857 2022- 9- ik3309 Sequence Listing SEQ Nucleotide/ Sequence ID Amino Acid NO
1 Nucleotide ATG GATTTC CA G G TC CA G ATTTTCTC CTTC CTG CTG ATTTC C
G CAA G C GTCATT
2 Amino Acid M DFQVQI FSFL LISASVI
3 N ucleotide GAACAGAAACTGATTAGCGAAGAAGACCTG
4 Amino Acid EQKLISEEDL
N ucleotide ACTAGTGGCGGAGGAGGATCACTCGAG
6 Amino Acid TSGGGGSLE
7 Nucleotide AACCCCGGGGGAGGAGGAGGGAGCGGGGGAGGAGGCAGCGGCGGGGGAGGCTCTGGAG
GAGGAGGGAGCGGATCC
8 Amino Acid NPGGGGGSGGGGSGGGGSGGGGSGS
9 N ucleotide AGCGGACAGGTGCTGCTGGAATCCAATATCAAAGTCCTGCCCACTTGGTCTACCCCCGTGC
AGCCT
Amino Acid SGQVLLESNI KVLPTVVSTPVQP
11 Nucleotide GCCGAAG CAG CAG CAAAGGAGG CCG CAG CGAAGGAAG CAG CTG
CGAAGG CC
12 Amino Acid AEAAAKEAAAKEAAAKA
13 Nucleotide GCCGAGGCAGCTGCAAAGGAAGCTGCGGCGAAGGAGGCCGCAGCGAAAGAAGCAGCGGC
AAAAGAAGCAGCCGCCAAAGCC
14 Amino Acid A EAAA K EAAA K EAAA K EAAA K EAAA KA
N ucleotide ATCGTAGTGTTGGCATTTCAAAAAGCGTCTAGCATCGTCTATAAGAAGGAAGGTGAACAA
GTCGAGTTTTCTTTCCCCCTTGCATTTACGGTGGAAAAGCTTACGGGTAGCGGCGAGCTGT
GGTGGCAAGCTGAACGGGCTTCAAGCTCAAAATCTTGGATTACTTTTGACTTGAAGAACAA
AGAGGTGAGTGTCAAAAGAGTTACTCAGGACCCAAAGCTTCAAATGGGGAAGAAACTTCC
GCTGCACCTGACGTTGCCTCAGGCCCTGCCTCAATATGCCGGCTCAGGCAATCTGACCCTC
GCGCTGGAAGCTAAGACCGGAAAATTGCACCAGGAAGTCAATTTGGTTGTGATGCGCGCC
ACTCAGCTCCAAAAAAATCTCACTTGCGAGGTATGGGGGCCTACGAGCCCAAAACTTATGC
TGTCTTTGAAGCTTGAAAACAAGGAAGCGAAAGTTTCTAAGCGCGAGAAAGCGGTATGGG
TTTTGAATCCTGAGGCTGGAATGTGGCAATGCCTCCTGAGCGATAGCGGGCAGGTGCTGTT
GGAGAGCAACATCAAGGTTTTGCCAGCAGCC
16 Amino Acid IVVLAFQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVS
VKRVTQDPKLQMG KK LP L H LTLPQALPQYAGSG N LTLA L EAKTG KL HQ EVN LVVM RATQLQ
KN LTCEVWGPTSPKL M LSLKL EN KEAKVSKREKAVWVL N PEAG MWQCLLSDSGQVLL ESN I K
VLPAA
17 N ucleotide ATGGAGACCCCCGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGCTGCCCGACACCACCGGC
18 Amino Acid METPAQLLFLLLLWLPDTTG
19 N ucleotide ATGGCCCTGCCAGTGACCGCCCTGCTGCTGCCACTGGCCCTGCTGCTGCACGCCGCCAGAC
CC
Amino Acid MALPVTALLLPLALLLHAARP
21 Nucleotide GGATCTACCAGCGGATCCGGCAAGCCTGGCAGCGGAGAGGGATCCACAAAGGGA
22 Amino Acid GSTSGSGKPGSGEGSTKG
23 N ucleotide ggcggcggcggaagtggaggaggaggctcaggcggaggagggagc 24 Amino Acid GGGGSGGGGSGGGGS
N ucleotide ggaggaggagggagcgggggaggaggcagcggcgggggaggctctggaggaggagggagc 26 Amino Acid GGGGSGGGGSGGGGSGGGGS
27 Nucleotide GGAGGAGGAGGGAGC
28 Amino Acid GGGGS
29 N ucleotide ATGGCCCTGCCAGTGACCGCCCTGCTGCTGCCACTGGCCCTGCTGCTGCACGCCGCCCGGC
CT
Amino Acid MALPVTALLLPLALLLHAARP

CA 031738M62gib-99- 28 31 Nucleotide ATGGACATCCAGATGACTCAGACCACAAGCTCCCTGTCTGCAAGTCTGGGCGACCGGGTG
ACAATCTCCTGCAGAG CCTCTCAG GATATTAG GAACTACCTGAATTG GTATCAG CAGAAAC
CTGATGGCACAGTCAAGCTGCTGATCTACTATACCAGCCGGCTGCACTCAGGCGTGCCAAG
CAAATTCTCAGGAAGCGGCTCCGGGACTGACTACTCCCTGACCATCTCTAACCTGGAGCAG
G AA GATATTG CTA C CTATTTCTG C CA G CA G G G CAATA CA CTG CCCTG G A CTTTTG C C
G GA G
GCACCAAACTGGAGATCAAGGGGGGAGGCGGGAGTGGAGGCGGGGGATCAGGAGGAGGA
GGCAGCGGAGGAGGAGGGTCCGAGGTCCAGCTGCAGCAGAGCGGACCAGAACTGGTGAA
GCCCGGAGCAAGTATGAAAATCTCCTGTAAGGCCTCAGGATACAGCTTCACCGGCTATACA
ATGAACTGGGTGAAACAGTCCCATGGCAAGAACCTGGAATGGATGGGGCTGATTAATCCT
TACAAAGGCGTCAG CACCTATAATCAGAAGTTTAAAGACAAGGCCACACTGACTGTGGAT
AAGTCTAGTTCAACCGCTTACATGGAGCTGCTGTCCCTGACATCTGAAGACAGTGCCGTGT
ACTATTGTGCTCGGTCTGGCTACTATGGGGACAGTGATTGGTACTTCGATGTCTGGGGACA
GGGCACTACCCTGACCGTGTTTTCT
32 Amino Acid M DI QMTQTTSSLSASLG DRVTI SC RASQDI RNY LNWYQQKPDGTVKLL
IYYTSRLHSGVPSKFS
GSGSGTDYSLTI SN LEQEDIATY FCQQGNTLPWTFAGGTKL El KGGGGSGGGGSGGGGSGGGG
SEVQLQQSGPELVKPGASM KI SCKASGYSFTGYTM NWVKQSHGKN L EW MG LI N PY KGVSTY N
QKFKDKATLTVDKSSSTAY M EL LSLTSEDSAVYYCARSGYYG DSDWY FDVWGQGTTLTVFS
33 Nucleotide ATGGCCGACATCGTGCTGACACAGAGCCCCGCCATCATGTCTGCCAGCCCTGGCGAGAAA
GTGACCATGACCTGTAGCGCCAGCAGCAGCGTGTCCTACATGAACTGGTATCAGCAGAAG
TCCGGCACCAGCCCCAAGCGGTGGATCTACGACACAAGCAAGCTGGCCTCTGGCGTGCCC
GCCCACTTTAGAGGCTCTGGCAGCGGCACAAGCTACAGCCTGACCATCAGCGGCATGGAA
GCCGAGGATGCCGCCACCTACTACTGCCAGCAGTGGTCCAGCAACCCCTTCACCTTTGGCT
CCGGCACAAAGCTGGAAATCAACCGGGCCGACACCGCCCCTACAGGCGGCGGAGGATCTG
GCGGAGGCGGATCTGGGGGCGGAGGAAGTGGGGGGGGAGGATCTATGGCTCAGGTGCAG
CTGCAGCAGTCTGGCGCCGAACTGGCTAGACCTGGCGCCTCCGTGAAGATGAGCTGCAAG
GCCAGCGGCTACACCTTCACCCGGTACACCATGCACTGGGTCAAGCAGAGGCCTGGACAG
GGCCTGGAATGGATCGGCTACATCAACCCCAGCCGGGGCTACACCAACTACAACCAGAAG
TTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGCCTACATGCAGCTG
TCCTCCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCCGGTACTACGACGACCACT
ACTCCCTGGACTACTGGGGCCAGGGCACCACACTGACCGTGTCTAGTA
34 Amino Acid MADIVLTQSPAI MSASPGEKVTMTCSASSSVSY M NWYQQKSGTSPKRWIY
DTSK LASGVPAH F
RGSGSGTSYSLTI SG M EAEDAATYYCQQWSSN PFTFGSGTK L El N RADTAPTGGGGSGGGGSG
GGGSGGGGSMAQVQLQQSGAELARPGASVKMSCKASGYTFTRYTM HWVKQRPGQG LEWIG
YIN PSRGYTNY NQKFKDKATLTTDKSSSTAY MQLSSLTSEDSAVYYCARYYDDHYSLDYWGQ
GTTLTVSS
35 Nucleotide CAGACCGTGGTGACCCAGGAGCCCAGCCTGACCGTGAGCCCCGGCGGCACCGTGACCCTG
ACCTGCGGCAGCAGCACCGGCGCCGTGACCAGCGGCTACTACCCCAACTGGGTGCAGCAG
AAGCCCGGCCAGGCCCCCAGGGGCCTGATCGGCGGCACCAAGTTCCTGGCCCCCGGCACC
CCCGCCAGGTTCAGCGGCAGCCTGCTGGGCGGCAAGGCCGCCCTGACCCTGAGCGGCGTG
CAGCCCGAGGACGAGGCCGAGTACTACTGCGCCCTGTGGTACAGCAACAGGTGGGTGTTC
GGCGGCGGCACCAAGCTGACCGTGCTGGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGG
CGGCGGCGGCAGCGAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGG
CAGCCTGAAGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAACATCTACGCCATGAACTGG
GTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCAGGATCAGGAGCAAGTACAA
CAACTACGCCACCTACTACGCCGACAGCGTGAAGAGCAGGTTCACCATCAGCAGGGACGA
CAGCAAGAACACCGCCTACCTGCAGATGAACAACCTGAAGACCGAGGACACCGCCGTGTA
CTACTGCGTGAGGCACGGCAACTTCGGCAACAGCTACGTGAGCTTCTTCGCCTACTGGGGC
CAGGGCACCCTGGTGACCGTGAGCAGC
36 Amino Acid QTVVTQEPSLIVSPGGIVTLTCGSSTGAVTSGYY PN WVQQKPGQAPRG LI
GGTKFLAPGTPAR
FSGSLLGG KAALTLSGVQPEDEAEYYCALWYSN RWVEGGGTKLIVLGGGGSGGGGSGGGGS
EVQL LESGGGLVQPGGSLKLSCAASG FTFN IYAM NWVRQAPG KG LEWVARI RSKY N NYATYY
ADSVKSRFTI SRDDSKNTAY LQM N N LKTEDTAVYYCVRHG N FGNSYVSFFAYWGQGTLVIVS
S
37 Nucleotide GACATCCAGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACC
ATGACCTGCAGGGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGAAGAGCGGC
ACCAGCCCCAAGAGGTGGATCTACGACACCAGCAAGGTGGCCAGCGGCGTGCCCTACAGG
TTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGCATGGAGGCCGAG
GACGCCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCCTGACCTTCGGCGCCGGC
ACCAAGCTGGAGCTGAAGGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGG
CAGCGACATCAAGCTGCAGCAGAGCGGCGCCGAGCTGGCCAGGCCCGGCGCCAGCGTGAA
GATGAGCTGCAAGACCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAAGCA

CA 031738M62gib-99- 28 GAGGCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAA
CTACAACCAGAAGTTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGC
CTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGTA
CTACGACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAG
C
38 Amino Acid DI QLTQSPAI MSASPG EKVTMTCRASSSVSY M NWYQQKSGTSPKRWIY
DTSKVASGVPY RFSG
SGSGTSYSLTI SSM EA EDAATYY CQQWSSN PLTFGAGTK L EL KGGGGSGGGGSGGGGSDI KLQ
QSGAELARPGASVKM SCKTSGYTFTRYTM HWVKQRPGQGL EWI GY IN PSRGYTNY NQKFKD
KATLTTDKSSSTAY MQLSSLTSEDSAVYYCARYY DDHYCLDYWGQGTTLTVSS
39 Nucleotide ATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCA
CCATCA CCTG CCGTGCCA GTCAGGA CATCCGTAATTATCTGAA CTG GTATCAACAGAAA CC
AG GAAAAGCTCCGAAACTACTGATTTACTATACCTCCCG CCTGGAGTCTG GAGTCCCTTCT
CGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGG
AAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGG
CACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAG
GGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCC
GTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAG
GCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCT
ACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCT
ACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGG
ATACTACGG CGATAGTGACTGGTATTTTGACGTGTGGGGTCAAG GAACCCTG GTCACCGTC
TCCTCG
40 Amino Acid M DI QMTQSPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLL
IYYTSRLESGVPSRFS
GSGSGTDYTLTI SSLQPEDFATYYCQQG NTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQL
VESGGGLVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVAL I N PY KGVSTY NQKFK
DRFTI SVDKSKNTAY LQM NSL RA EDTAVYY CA RSGYY G DSDWY FDVWGQGTLVTVSS
41 Nucleotide ATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCA
CCATCA CCTG CCGTGCCA GTCAGGA CATCCGTAATTATCTGAA CTG GTATCAACAGAAA CC
AG GAAAAGCTCCGAAACTACTGATTTACTATACCTCCCG CCTGGAGTCTG GAGTCCCTTCT
CGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGG
AAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGG
CACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAG
GGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCC
GTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAG
GCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCT
ACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCT
ACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGG
ATACTACGG CGATAGTGACTGGTATTTTGACGTGTGGGGTCAAG GAACCCTG GTCACCGTC
TCCTCG
42 Amino Acid M DI QMTQSPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLL
IYYTSRLESGVPSRFS
GSGSGTDYTLTI SSLQPEDFATYYCQQG NTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQL
VESGGGLVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVAL I N PTKGVSTY NQKFKD
RFT! SVDKSK NTAY LQM N SL RA EDTAVYYCA RSGYY GDSDWY FDVWGQGTLVIVSS
43 Nucleotide ATGGACATCCAGATGACTCAGACCACAAGCTCCCTGTCTGCAAGTCTGGGCGACCGGGTG
ACAATCTCCTGCAGAGCCTCTCAGGATATTAGGAACTACCTGAATTGGTATCAGCAGAAAC
CTGATGGCACAGTCAAGCTGCTGATCTACTATACCAGCCGGCTGCACTCAGGCGTGCCAAG
CAAATTCTCAGGAAGCGGCTCCGGGACTGACTACTCCCTGACCATCTCTAACCTGGAGCAG
G AA GATATTG CTA C CTATTTCTG C CA G CA G G G CAATA CA CTG CCCTG G A CTTTTG C C
G GA G
GCACCAAACTGGAGATCAAGGGGGGAGGCGGGAGTGGAGGCGGGGGATCAGGAGGAGGA
GGCAGCGGAGGAGGAGGGTCCGAGGTCCAGCTGCAGCAGAGCGGACCAGAACTGGTGAA
GCCCGGAGCAAGTATGAAAATCTCCTGTAAGGCCTCAGGATACAGCTTCACCGGCTATACA
ATGAACTGGGTGAAACAGTCCCATGGCAAGAACCTGGAATGGATGGGGCTGATTAATCCT
ACCAAAGGCGTCAGCACCTATAATCAGAAGTTTAAAGACAAGGCCACACTGACTGTGGAT
AAGTCTAGTTCAACCGCTTACATGGAGCTGCTGTCCCTGACATCTGAAGACAGTGCCGTGT
ACTATTGTGCTCGGTCTGGCTACTATGGGGACAGTGATTGGTACTTCGATGTCTGGGGACA
GGGCACTACCCTGACCGTGTTTTCT
44 Amino Acid M DI Q MTQTTSSLSASLG DRVTI SC RASQDI RNY LNWYQQKPDGTVKLL
IYYTSRL HSGVPSK FS
GSGSGTDYSLTI SN LEQEDIATY FCQQGNTLPWTFAGGTKL El KGGGGSGGGGSGGGGSGGGG

CA 031738M62gib-99- 28 SEVQLQQSGPELVKPGASM KISCKASGYSFTGYTM NWVKQSHGKN L EWM G LI NPTKGVSTY N
QKFKDKATLTVDKSSSTAY M ELLSLTSEDSAVYYCARSGYYGDSDWY FDVWGQGTTLTVFS
45 Nucleotide AGCGGACAGGTGCTGCTGGAATCCAATATCAAAGTCCTGCCCACTTGGTCTACCCCCGTGC
AG CCTATGG CTCTGATTGTGCTGGGAG GAGTCGCAG GACTG CTG CTGTTTATCG G G CTG G G
AATTTTCTTTTGCGTGCGCTGCCGGCACCGGAGAAGGCAGGCCGAGCGCATGAGCCAGATC
AAGCGACTGCTGAGCGAGAAGAAAACCTGTCAGTGTCCCCATAGATTCCAGAAGACCTGT
TCA C C GATT
46 Amino Acid SGQVL LESN I KVLPTVVSTPVQPMALIVLGGVAGL LL Fl GLG I
FFCVRCRH RRRQAERMSQIKRLL
SEKKTCQCPH RFQKTCSPI
47 Nucleotide CTCGAGCTGAGGCCCGAGGCTTCTAGACCTGCTGCCGGCGGAGCCGTGCACACCAGAGGC
CTGGACTTCGCCAGCGACATCTACATCTGGGCCCCTCTGGCCGGCACCTGTGGCGTGCTGC
TGCTGAGCCTGGTCATCACCCTGTACTGCAACCACCGGAACCGGCGGAGAGTGTGCAAGT
GCCCCAGACCCGTGGTCAAGAGCGGCGACAAGCCCAGCCTGAGCGCCAGATACGTG
48 Amino Acid LELRPEASRPAAGGAVHTRGLDFASDIY I WAPLAGTCGVLL LSLVITLYCN H
RN RRRVCKCPRP
VVKSGDKPSLSARYV
49 Nucleotide CTCGAGCTGAGGCCCGAGGCTTCTAGACCTGCTGCCGGCGGAGCCGTGCACACCAGAGGC
CTGGACTTCGCCAGCGACATCTACATCTGGGCCCCTCTGGCCGGCACCTGTGGCGTGCTGC
TGCTGAGCCTGGTCATCACCCTGTACCTGTGCTGCAGACGGCGGAGAGTGTGCAAGTGCCC
CAGACCCGTGGTCAAGAGCGGCGACAAGCCCAGCCTGAGCGCCAGATACGTG
50 Amino Acid LELRPEASRPAAGGAVHTRGLDFASDIY I WAPLAGTCGVLL LSLVITLY
LCCRRRRVCKCPRPV
VKSGDKPSLSARYV
51 Nucleotide CTCGAGAAGAAGTCCACCCTGAAGAAACGGGTGTCCCGGCTGCCCAGACCCGAGACACAG
AAGGGCCCCCTGAGCAGCCCTATCACCCTGGGACTGCTGGTGGCCGGCGTGCTGGTGCTGC
TGGTGTCTCTGGGAGTGGCCATCCACCTGTGCTGCCGGCGGAGAAGGGCCTGCAAGTGCCC
CA GA CTG C G GTTCATG AA G CA G TTCTA CAA G
52 Amino Acid LEKKSTL KKRVSRL PRPETQKGPLSSPITLG LLVAGVLVLLVSLGVAI
HLCCRRRRACKCPRLRF
MKQFYK
53 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSSGGGS
EGGGSEGGGSEGGGQSVLTQPPSASGTPGQRVTI SCSGGSSN I GSNYVYWYQQ LPGTAPKL LIY
RN NQ RPSGVPDRFSGSKSGTSASLAI SGL RSEDEADYYCAAWDDSLSGHVVFGGGTKLTVL
54 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSSGGGS
EGGGSEGGGSEGGGQSVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVYWYQQ LPGTAPKL LIY
RN NQ RPSGVPDRLSGSKSGTSASLAI SGL RSEDEADYYCAAWDDSLSAVVFGGGTKLTVL
55 Amino Acid QVQLQESGGGVVQPGRSLRLSCAASGFTLSSYGM HWVRQAPG KG LEWVAVI
SY DGSNKYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKSGWRYYYYYGMDVWGQGTLVTVSS
GGGSEGGGSEGGGSEGGGQSVLTQPPSVSGAPGQRVTISCTGSSSN I GAGY DVHWYQQLPGTA
PKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLT
VL
56 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTMVTVSSGGGS
EGGGSEGGGSEGGGQSVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVYWYQQ LPGTAPKL LIY
RN NQ RPSGVPDRFSGSKSGTSASLAI SGL RSEDEADYYCAAWDDSLSGPSVVEGGGTKLIVL
57 Amino Acid QVQLVQSGAEVKKPGASV KVSCKASGYTFTSYG I SWVRQAPGQG L EWM
GWI GAY NGNTNYA
QKLQGRVTMTTDTSTSTAY M ELRSLRSDDTAVYYCARDLRRYSSSWDGPGYWGQGTLVTVS
SGGGSEGGGSEGGGSEGGGQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGK
APKLM IY DVSNRPSGVSN RFSGSKSG NTASLTI SG LQAEDEADYY CSSYTSSSTRVFGTGTKLT
VL
58 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSSGGGS
EGGGSEGGGSEGGGSYVLTQPPSASGTPGQ RVTI SCSGSSSN I GG NYVYWYQQ LPGTAPKL LIY
RN NQ RPSGVPDRFSGSKSGTSASLAI SGL RSEDEADYYCAAWDDSLSGWVFGGGTKLTVL
59 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADKSTSTAY M ELSSLRSEDTAVYYCARDGGRYSYGRSFDYWGQGTLVTVSSGGG
SEGGGSEGGGSEGGGQSV LTQPPSVSGAPGQRVTI SCTGSSSN I GAGY DVHWYQQ LPGTAPKL
LIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSY DSSLSGPVVFGGGTKLTVL
60 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M E LSSLRSEDTAVYYCA RPL RPL HYY G M DVWGQGTLVTVSSGGGSE

CA 031738M62gib-99- 28 GGGSEGGGSEGGGQSVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVY WYQQ LPGTAPKLL IY R
N N Q RPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYY CAAWDDSLTEGV FGGGTKLTVL
61 Amino Acid QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRRAPG KG LEWVAVI
SY DGSN KYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKDGGDSGSLDYWGQGTLVWSSGGGS
EGGGSEGGGSEGGGDIVMTQSPDSLAVSLGERATI NCKSSQSVLYSSNNKNY LAWYQQKPGQP
PKLL IYWASTRESGVPDRFSGSGSGTDFTLTI SSLQAEDVAVYY CQQYYSTPLTFGGGTKLEI K
62 Amino Acid EVQL L ESGGG LVQPGGSL RLSCAASG FTFSSYWM SWVRQAPG KG L
EWVAN I KQDGSEKYYV
DSVKGRFTISRDNAKNSLY LQMNSLRAEDTAVYYCARPAGQLLYGMDVWGQGTLVWSSGG
GSEGGGSEGGGSEGGGSYV LTQPPSVSVSPGQTA RITCSG DA LP KQYAYWY QQ KPGQAPVLVI
Y KDSERPSG I PERFSGSSSGTTVTLTI SGVQAEDEADYYCQSADSSGTVVV FGGGTK LTVL
63 Amino Acid EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRQAPG KG L EWVAVI
SY DGSN KYYAD
SVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKDAADMGAFDYWGQGTLVWSSGGGS
EGGGSEGGGSEGGGDIQMTQSPDSLAVSLGERATM NCKSSQSVLYSSNN KNY LAWYQQKPGQ
PPKLLIYWASARESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEI K
64 Amino Acid EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSM NWVRQAPG KG LEWVSAI
SGSGGSTYYADS
VKGRFTISRDNSKNTLY LQM NSL RAEDTAVYY CARA RGYSY GSDAFDI WGQGTMVTVSSGGG
SEGGGSEGGGSEGGGQSVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVYWYQQ LPGTAPKL LI
Y RN NQ RPSGVPDRFSGSKSGTSASLAI SG LRSEDEADYYCAAWDDSLSGVVFGGGTKLTVL
65 Amino Acid QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRQAPG KG L EWVAVI
SY DGSN KYYA
DSVKGRFTISRDNSKNTLY LQM NSL RAEDTAVYYCAKGVPRYYYYY G M DVWGQGTMVIVSS
GGGSEGGGSEGGGSEGGGQSVLTQPPSVSGAPGQRVTISCTGSSSN I GAGY DVHWYQQLPGTA
PKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLT
VL
66 Amino Acid EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDRGRRYCSGGSCPNAFDIWGQGTMVWS
SGGGSEGGGSEGGGSEGGGEIVLTQSPATLSVSPGERATLSCRASQSVSSN LAWYQQKPGQAP
RL LIYGASTRATG I PA RFSGSGSGTEFTLTI SSLQSEDFAVYYCQQY N NWPPALTFGGGTKVEI K
67 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARGGYVWGSY RQNSNWFDPWGQGTLVTVS
SGGGSEGGGSEGGGSEGGGSYVLTQPPSASGTPGQ RVTI SCSGSSSN I GSNYVYWYQQLPGTAP
KLLIY RN NQ RPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGWV FGGGTKLT
VL
68 Amino Acid QVQLV ESGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG
I I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVWSSGGGS
EGGGSEGGGSEGGGQSVLTQPPSASGTPG RRVTI SCSGSSSN I GSNYVYWYQQ LPGTAPKL LIY
RN NQ RPSGVPDRFSGSKSGTSASLAI SGL RSEDEADYYCAAWDDSLSGVVFGGGTKLTVL
69 Amino Acid QVQLVESGGGLVQPGGSL RLSCAASG FTFSSYWM SWVRQAPG KG LEWVAN
I KQDGSEKYYV
DSVKGRFTISRDNAKNSLY LQM NSLRAEDTAVYYCARWSHYY DSSGLDYWGQGTLVWSSG
GGSEGGGSEGGGSEGGGSYV LTQPPSVSVSPGQTA RITCSG DA L PKQYAYWY QQ KPG QAPVL
VIY KDSERPSG I PERFSGSSSGTIVTLTI SGVQAEDEADYYCQSADSSGTVVVFGGGTKLTVL
70 Amino Acid QVQLV ESGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG
I I PI FGTANYAQK
FQGRVTITADKSTSTAY M ELSSLRSEDTAVYY GARTH LPYSYG LGG FDYWGQGTLVWSSGGG
SEGGGSEGGGSEGGGQSV LTQPPSVSGAPGQRVTI SCTGSSSN I GAGY DVHWYQQ LPGTAPKL
LIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSY DSSLSGPVVFGGGTKVTVL
71 Amino Acid EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDPSRDYYGSGRFSWFDPWGQGTLVWSS
GGGSEGGGSEGGGSEGGGQSVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVYWYQQ LPGTAPK
LLIY RN NQRPSGVPDRFSGSKSGTSASLA I SGL RSEDEADYYCAAWDDSLSGRGVEGGGTKLTV
L
72 Amino Acid QVQLVQSGAEVKKPGASV KVSCKASGYTFTSYG I SWVRQAPGQG L EWM
GWI SAY NGNTNYA
QKLQGRVTMTTDTSTSTAY M ELRSLRSDDTAVYYCARDI I RYCSSTSCY RG I DYWGQGTLVTV
SSGGGSEGGGSEGGGSEGGGQSALTQPASVSGSPGQSITI SCTGTSSDVGGY NYVSWYQQHPG
KAPKLM IY DVSN RPSGVSN RFSGSKSG NTASLTI SG LQAEDEADYY CSSYTSSSPHVVSGGGTK
LW L
73 Amino Acid QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRQAPG KG L EWVAVI
SY DGSNKYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCARDGTDY RGAFDIWGQGTMVTVSSGGG
SEGGGSEGGGSEGGG DI Q LTQSPDSLAVPLGERATI NCKSSQSVLYSSN N KNY LAWYQQKPGQ
PPKLL IYWASTRESGVPDRFSGSGSGTDFTLTI SSLQAEDVAVYY CQQYYSTPLTFGQGTKLEI K
74 Amino Acid EVQLVQSGAEVKKPGSSVRVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG I
I PI FGTANYAQK
FQGRVTITADKSTSTAY M ELSSLRSEDTAVYYCARGGGRWLHSRLDVWGQGTTVWSSGGGS

CA 031738M62gib-99- 28 EGGGSEGGGSEGGGQSVLTQPPSVSGAPGQRVTI SCTGSSSN I GAGY DVHWY QQ FPGTAPKLL I
FGN NN RPSGVPDRFSGSKSGTSASLAITGLQAEDEANYYCQSYDRSLSGPVVFGGGTKLTVL
75 Amino Acid EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRQAPG KG LEWVAVI
SY DGSNKYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKDAGDLGAFDIWGQGTMVTVSSGGGS
EGGGSEGGGSEGGGDIVMTQSPDSLAVSLGERATI NCKSSQSVLYSSNNKNY LAWYQQKPGQP
PKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGPGTKVEI K
76 Amino Acid QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAM HWVRQAPG KG L EWVAVI
SY DGSN KYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCARGRVYYYDSSGYSYWGQGTLVTVSSG
GGSEGGGSEGGGSEGGGQSVLTQPPSVSGAPGQRVTI SCTGSSSN I GAGY DVHWYQQLPGTAP
KLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSY DSSLSGREVFGTGTKLT
VL
77 Amino Acid QVQLV ESGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG
I I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARPLYAPRFGYGM DVWGQGTLVIVSSGGG
SEGGGSEGGGSEGGGQSVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVYWYQQ LPGTAPKL LI
Y RN NQ RPSGVPDRFSGSKSGTSASLAI SGL RSEDEADYYCAAWDDSLSGWVFGGGTQLTVL
78 Amino Acid EVQL L ESGGG LVQPGGSL RLSCAASG FTFSSYAM SWVRQAPG KG
LEWVSAI SGSGGSTYYADS
VKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKDRGGQRGFDYWGQGTLVIVSSGGGSE
GGGSEGGGSEGGGQSVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVY WYQQ LPGTAPKLL IY R
N N Q RPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYY CAAWDDSLSG LVFGGGTKLTVL
79 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSSGSTSG
SG KPGSGEGSTKGQSVLTQPPSASGTPGQRVTI SCSGGSSN I GSNYVY WYQQ LPGTAPKLL IY R
N N Q RPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYY CAAWDDSLSG HVVFGGGTKLTV L
80 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSSGSTSG
SG KPGSGEGSTKGQSVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVY WYQQ LPGTAPKLL IY RN
N Q RPSGVPDRLSGSKSGTSASLAI SG L RSEDEADYYCAAWDDSLSAVV FGGGTKLTVL
81 Amino Acid QVQLQESGGGVVQPGRSLRLSCAASGFTLSSYGM HWVRQAPG KG LEWVAVI
SY DGSNKYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKSGWRYYYYYGMDVWGQGTLVTVSS
GSTSGSG KPGSG EGSTKGQSVLTQPPSVSGAPGQ RVTI SCTGSSSN I GAGY DVHWYQQLPGTAP
KLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSY DSSLSGSVFGGGTKLTV
L
82 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTMVTVSSGSTS
GSGKPGSGEGSTKGQSVLTQPPSASGTPGQRVTISCSGSSSN IGSNYVYWYQQLPGTAPKLLIY R
N N Q RPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYY CAAWDDSLSG PSVVEGGGTKLIVL
83 Amino Acid QVQLVQSGAEVKKPGASV KVSCKASGYTFTSYG I SWVRQAPGQG L EWM
GWI GAY NGNTNYA
QKLQGRVTMTTDTSTSTAY M ELRSLRSDDTAVYYCARDLRRYSSSWDGPGYWGQGTLVTVS
SGSTSGSG KPGSG EGSTKGQSALTQPASVSGSPGQSITI SCTGTSSDVGGY NYVSWYQQH PG KA
PKLM IY DVSN RPSGVSN RFSGSKSG NTASLTI SG LQAEDEADYYCSSYTSSSTRVFGTGTKLTVL
84 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSSGSTSG
SG KPGSG EGSTKGSYVLTQPPSASGTPGQRVTI SCSGSSSN I GG NYVY WYQQ LPGTAPKLL IY R
N N Q RPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYY CAAWDDSLSGWVFGGGTK LTVL
85 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADKSTSTAY M ELSSLRSEDTAVYYCARDGGRYSYGRSFDYWGQGTLVTVSSGSTS
GSGKPGSGEGSTKGQSVLTQPPSVSGAPGQRVTISCTGSSSN I GAGY DVHWYQQLPGTAPKLL I
YG N SN RPSGVPDRFSGSKSGTSASLAITG LQAEDEADYYCQSY DSSLSG PVVFGGGTKLTVL
86 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY ME LSSLRSEDTAVYYCA RPL RPL HYY GM DVWGQGTLVTVSSGSTSG
SG KPGSGEGSTKGQSVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVY WYQQ LPGTAPKLL IY RN
NQRPSGVPDRFSGSKSGTSASLAI SG LRSEDEADYYCAAWDDSLTEGVFGGGTKLTVL
87 Amino Acid QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRRAPG KG LEWVAVI
SY DGSN KYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKDGGDSGSLDYWGQGTLVTVSSGSTS
GSGKPGSGEGSTKGDIVMTQSPDSLAVSLGERATI NCKSSQSVLYSSNNKNY LAWYQQKPGQP
PKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGGGTKLEI K
88 Amino Acid EVQL L ESGGG LVQPGGSL RLSCAASG FTFSSYWM SWVRQAPG KG L
EWVAN I KQDGSEKYYV
DSVKGRFTISRDNAKNSLY LQMNSLRAEDTAVYYCARPAGQLLYGMDVWGQGTLVTVSSGS
TSGSG KPGSG EGSTKGSYVLTQPPSVSVSPGQTA RITCSG DAL PKQYAYWYQQ KPGQAPVLVI
Y KDSERPSG I PERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTWVEGGGTKLIVL

CA 031738M62gib-99- 28 89 Amino Acid EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRQAPG KG L EWVAVI
SY DGSN KYYAD
SVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKDAADMGAFDYWGQGTLVTVSSGSTS
GSG KPGSGEGSTKG DI QMTQSPDSLAVSLG ERATM NCKSSQSVLYSSNN KNY LAWYQQKPGQ
PPKLLIYWASARESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEI K
90 Amino Acid EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSM NWVRQAPG KG LEWVSAI
SGSGGSTYYADS
VKGRFTISRDNSKNTLY LQM NSL RAEDTAVYY CARA RGYSY GSDAFDI WGQGTMVTVSSGST
SGSGKPGSGEGSTKGQSVLTQPPSASGTPGQRVTISCSGSSSN I GSNYVYWYQQ LPGTAPKL LIY
RN NQ RPSGVPDRFSGSKSGTSASLAI SGL RSEDEADYYCAAWDDSLSGVVFGGGTKLTVL
91 Amino Acid QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRQAPG KG L EWVAVI
SY DGSN KYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKGVPRYYYYYGMDVWGQGTMVTVSS
GSTSGSG KPGSG EGSTKGQSVLTQPPSVSGAPGQ RVTI SCTGSSSN I GAGY DVHWYQQLPGTAP
KLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSY DSSLSGSVFGGGTKLTV
L
92 Amino Acid EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCA RDRGRRYCSGGSCPNAFDI WGQGTMVTVS
SGSTSGSG KPGSG EGSTKG EIVLTQSPATLSVSPG ERATLSCRASQSVSSN LAWYQQKPGQAPR
LL IYGASTRATG I PARFSGSGSGTEFTLTISSLQSEDFAVYYCQQY NNWPPALTFGGGTKVEI K
93 Amino Acid QVQLVQSGAEVKKPGSSV KVSCKASGGTFSSYAI SWVRQAPGQG LEWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARGGYVWGSY RQNSNWFDPWGQGTLVTVS
SGSTSGSG KPGSG EGSTKGSYVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVYWY QQLPGTAP
KLLIY RN NQ RPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGWV FGGGTKLT
VL
94 Amino Acid QVQLV ESGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG
I I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSSGSTSG
SG KPGSGEGSTKGQSVLTQPPSASGTPG RRVTI SCSGSSSN IGSNYVYWYQQLPGTAPKLLIY RN
NQRPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGVVEGGGTKLTVL
95 Amino Acid QVQLVESGGGLVQPGGSL RLSCAASG FTFSSYWM SWVRQAPG KG LEWVAN
I KQDGSEKYYV
DSVKGRFTISRDNAKNSLY LQM NSLRAEDTAVYYCARWSHYY DSSGLDYWGQGTLVTVSSGS
TSGSG KPGSG EGSTKGSYVLTQPPSVSVSPGQTA RITCSG DAL PKQYAYWYQQ KPGQAPVLVI
Y KDSERPSG I PERFSGSSSGTTVTLTI SGVQAEDEADYYCQSADSSGTWVFGGGTKLTVL
96 Amino Acid QVQLV ESGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG
I I PI FGTANYAQK
FQGRVTITADKSTSTAY M ELSSLRSEDTAVYY GARTH LPYSYG LGG FDYWGQGTLVTVSSGST
SGSG KPGSG EGSTKGQSVLTQPPSVSGAPGQRVTI SCTGSSSN I GAGY DVHWYQQ LPGTAPKL L
IYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPVVEGGGTKVIVL
97 Amino Acid EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG I
I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDPSRDYYGSGRFSWFDPWGQGTLVTVSS
GSTSGSG KPGSG EGSTKGQSVLTQPPSASGTPGQ RVTI SCSGSSSN I GSNYVY WYQQ LPGTAPK
LLIY RN NQRPSGVPDRFSGSKSGTSASLA I SGL RSEDEADYYCAAWDDSLSGRGVEGGGTKLTV
L
98 Amino Acid QVQLVQSGAEVKKPGASV KVSCKASGYTFTSYG I SWVRQAPGQG L EWM
GWI SAY NGNTNYA
QKLQGRVTMTTDTSTSTAY M ELRSLRSDDTAVYYCARDI I RYCSSTSCY RG I DYWGQGTLVTV
SSGSTSGSGKPGSGEGSTKGQSALTQPASVSGSPGQSITISCTGTSSDVGGY NYVSWYQQH PG K
APKLM IY DVSNRPSGVSN RFSGSKSG NTASLTI SG LQAEDEADYY CSSYTSSSPHVVSGGGTKL
TV L
99 Amino Acid QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRQAPG KG L EWVAVI
SY DGSNKYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCARDGTDY RGAFDIWGQGTMVTVSSGST
SGSGKPGSGEGSTKGDIQLTQSPDSLAVPLGERATI NCKSSQSVLYSSN N KNY LAWYQQKPGQP
PKLL IYWASTRESGVPDRFSGSGSGTDFTLTI SSLQAEDVAVYYCQQYY STPLTFGQGTKL El K
100 Amino Acid EVQLVQSGAEVKKPGSSVRVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG I
I PI FGTANYAQK
FQGRVTITADKSTSTAY M ELSSLRSEDTAVYY CARGGG RWL H SRLDVWGQGTIVIVSSGSTS
GSGKPGSGEGSTKGQSVLTQPPSVSGAPGQRVTISCTGSSSN I GAGY DVHWYQQFPGTAPKL LI
FGN NN RPSGVPDRFSGSKSGTSASLAITG LQAEDEANYYCQSY DRSLSG PVVFGGGTKLTVL
101 Amino Acid EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRQAPG KG LEWVAVI
SY DGSNKYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKDAGDLGAFDIWGQGTMVTVSSGSTS
GSGKPGSGEGSTKGDIVMTQSPDSLAVSLGERATI NCKSSQSVLYSSNNKNY LAWYQQKPGQP
PKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGPGTKVEI K
102 Amino Acid QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAM HWVRQAPG KG L EWVAVI
SY DGSN KYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCARGRVYYYDSSGYSYWGQGTLVTVSSG
STSGSG KPGSG EGSTKGQSVLTQPPSVSGAPGQ RVTI SCTGSSSN I GAGY DVHWYQQLPGTAPK
LLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSY DSSLSGREVFGTGTKLTVL

CA 031738M62gib-99- 28 103 Amino Acid QVQLV ESGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG
I I PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARPLYAPRFGYGM DVWGQGTLVTVSSGSTS
GSGKPGSGEGSTKGQSVLTQPPSASGTPGQRVTISCSGSSSN IGSNYVYWYQQLPGTAPKLLIYR
N N Q RPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYY CAAWDDSLSGWVFGGGTQLTVL
104 Amino Acid EVQL L ESGGG LVQPGGSL RLSCAASG FTFSSYAM SWVRQAPG KG
LEWVSAI SGSGGSTYYADS
VKGRFTISRDNSKNTLYLQM NSLRAEDTAVYYCAKDRGGQRGFDYWGQGTLVIVSSGSTSGS
G KPGSGEGSTKGQSVLTQPPSASGTPGQRVTI SCSGSSSN I GSNYVY WYQQLPGTAPKLL IY RN
NQRPSGVPDRFSGSKSGTSASLAI SG LRSEDEADYYCAAWDDSLSG LVEGGGTKLIVL
105 Amino Acid EVKLVESGGGLVQPGGSLKLSCTTSGFTFSSYGLSWI RQTPDKRLELVASI N
RNGDNTYYTDSV
KG RFTISRH DAKNTLNLQM NSLKSEDTAMYYCTRGGFSYWGQGTLVTVSAGSTSGSGKPGSG
EGSTKGDIVLTQSPAI MSSSPGEKVTMTCSASSSVSY MYWYQQRPGSSPRLLIYDTSKLASGVP
VRFSGSVSGTSYSLTISRM ESEDAATYYCQQWSG FPPITFGAGTKL EL K
106 Amino Acid EVKLVESGGGLVQPGGSLKLSCTTSGFTFSSYGLSWI RQTPDKRLELVASI N
RNGDNTYYTDSV
RG RFTISRDNAKNTL N LQ M SSLKSEDTAMYYCTRGG FSYWGQGTLVTVSAGSTSGSG KPGSG E
GSTKGDIVLTQSPATMSASPGEKVTLTCSASPGVTY MYWYQQKPGSSPRLLIYDTSNLASGVPL
RFSGSGSGTSYSLTI SRTEAEDAATYYCQQWSGY PPITFGAGTKLELR
107 Amino Acid EVKLVESGGGLVQPGGSLKLSCTTSGFTFSSYGLSWI RQTPDKRLELVASI N
RNGDNAYY I DSV
KG RFTISRDNAKNAL N LQ M SSL KSEDTAMYYCTRGG FSHWGQGTLVTVAAGSTSGSG KPGSG
EGSTKGQIVLTQSPAI MSASPGEKVTMTCSASSSVSY MYWYQQKPGSSPRLLIYDTSNLASGVP
VRFSGSGSGTSYSL I I SRM EAEDAATYYCQQWSGY PPITFGAGTKL EL K
108 Amino Acid EVKLVESGGG LVQPGGSL KLSCAASG FTFSSY G LSWVRQTPDKG
LELVASI N RN GG NTYYTDS
VKGRFTISRDNAKNTLNLQMSSLKSEDTAMYYCARGGFTYWGQGTLVTVSAGSTSGSGKPGS
GEGSTKGQIVLTQSPAI MSAFPGEKVTMTCSASSSVGY MYWYQQKPGSSPRLLIYDTSNLASGV
PVRFSGSGSGTAYSLTISRM EAEDAATYY CQQWSGY PPITFGAGTKL EL K
109 Amino Acid QVQLKESGGGLVRPGGSLKLSCAASGFTFSNYGMSWI RQTPDKNLELVASI
NTSGGNTYYPDS
VKGRFTISRDNARATLNLQMSNLKSEDTAIYYCTRGGFTHWGQGTLVAVSAGSTSGSGKPGSG
EGSTKGQIVLTQSPAI MSASPGEKVTMTCSASSSVSY MYWYQQKPGSSPRLLIYDTSNLASGVP
VRFSGSGSGTSYFLTISRM EAEDAATYYCQQWTGYPPITFGAGTKLELR
110 Amino Acid QVQLKESGGGLVQPGGSL KLSCAASGFPFSSYGLSWVRQTPDKRLELVATI N
RNGDSAYY PDS
VKG RFTISRDDAKNTLY LQ M SSL KSEDTAMYYCTRGG FAY WGQGTLVTVSAGSTSGSG KPGS
GEGSTKGQIVLTQSPAI MSASPGEKVTMTCSGSSSVGY MYWYQQKPGFSPRLLIYDTSNLASGV
PVRFSGSGSGTSYSLTISRM EAEDAATYY CQQWSGY PPITFGAGTKL EL K
111 Amino Acid EVKLVESGGGLVRPGGSLKLSCAASGFTFSNYGMSWI RQTPDKN LELVASI
NTSGGNTYYPDS
VKGRFTISRDNARATLNLQMSNLKSEDTAIYYCTRGGFTHWGQGTLVTVSAGSTSGSGKPGSG
EGSTKGDIVLTQSPAI MSASPGEKVTMTCSASSSVAFMYWYQQKPGSSPRLLIY DTSKLASGVP
VRFSGSGSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGAGTKLELK
112 Amino Acid QVQLKESGGGLVQPGGSL KLSCTTSGFTFSSYGLSWI RQTPDKRLELVASI N
RNGDNTYYTDSV
RG RFTISRDNAKSTL N LQ M SSLKSEDTAMYYCTRGG FSYWGQGTLVTVSAGSTSGSG KPGSG E
GSTKGQIVLTQSPPLMSASPGEKVTMTCSASSSVGY MYWFQQRPGSSPRLLIYDTYNLASGVPV
RFSGSGSGTSYSLTI SRLEAEDAATYYCQQWSGY PPITFGAGTKLELR
113 Amino Acid EVKLVESGGG LVQPGGSL KLSCAASGFTFSSY G LSWVRQTPDKRL
ELVASVN RNGGNTYYTDS
VKGRFTISRDNAKNTLNLQMSSLKSEDTAMYYCARGGFTYWGQGTLVTVSAGSTSGSGKPGS
GEGSTKGQIVLTQSPAI MSASPGEKVTMTCSASSSVGY MYWYQQKPGSSPRLLIYDTSHLASGV
PVRFSGSGSGTSYSLTISRM EAEDAATYY CQQWSGY PPITFGAGTKL EL K
114 Amino Acid EVKLVESGGG LVQPGGSL KLSCAASGFPFSSYGLSWVRQTPDKRLELVATI N
RNGDSAYY PDS
VKG RFTISRDDAKNTLY LQ M SSL KSEDTAMYYCTRGG FAY WGQGTLVTVSAGSTSGSG KPGS
GEGSTKGQIVLTQSPVI MSASPGEKVTMTCSASSSVGY MYWYQQRPGSSPRLLIYDTSN LASGA
PVRFSGSGSGTSYSLTISRM EAEDAATYY CQQWSGY PPITFGAGTKL EL K
115 Amino Acid EVKLVESGGGLVQPGGSLKLSCTTSGFTFSSYGLSWI RQTPDKRLELVASI N
RNGDNTYYTDSV
KG RFTISRDNAKNTL N LQ M SSLKSEDTA MYYCTRGG FSYWGQGTLVTVSAGSTSGSG KPGSG
EGSTKGQIVLTQSPAI MSASPGEKVTMTCSASSSVSY MYWYQQKPGSSPRLLIYDTSNLASGVP
VRFSGSGSGTSYSLTISRM EAEDAATYYCQQWTGYPPITFGAGTKLELK
116 Amino Acid EVKLVESGGVLVQPGGSL KLSCAASGFTFSSY G MSWVRQTPDKRLELVASI N
KNGGSTYYPDS
VKGRFTISRDNAKTIVY LQ M SSLKSEDTAMYYCTRGG FAY WGQGTLVTVSAGSTSGSG KPGS
GEGSTKGQIVLTQSPAI MSASPGEKVTLTCSASSSVGY MYWYQQRPGSSPRLLIYDTSNLPSGV
PVRFSGSGSGTSYSLTISRM EAEDAATYY CQQWSGY PPITFGAGTKL EL K
117 Amino Acid QLQLQESGGGLVQAGGSLRLSCAASGRTGSSYAMGWFRQAPGKEREFVAAITVVSGGITAYAD
SVKGRFTISRDNAKNTVY LQM NSLKPEDTAVYCCAAGVTGSPSFDSWGQGTQVIVSS
118 Amino Acid QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISGSGGSIYYGDS
VKGRFTISRDNAKNTMYLQM NRLKPEDTAVYYCAAGPLGSPDFDSWGQGTQVTVSS

CA 031738M62gib-99- 28 119 Amino Acid EVQVVESGGGLVQPGGSLRLSCVASGRTFSSYAMGWFRQAPGKEREFVAAISGSGGSIYYGDS
VKGRFTISRDNAKNTMY LQM NRLKPEDTAVYYCAAGPLGSPDFDSWGQGTQVIVSS
120 Amino Acid KVQLVESGGGLVQAGGSLRLSCAASGRTGSSYAMGWFRQAPGKEREFVAAITVVSGGITAYAD
SVKGRFTISRDNAKNTVY LQM NSLKPEDTAVYCCAAGVTGSPSFDSWGQGTQVIVSS
121 Amino Acid EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISGSGGVTFYAHS
VKGRFTISRDNAKNIVY LQM NSLKPEDTAVYSCAGGAHGSPDFGSWGQGTQVIVSS
122 Amino Acid QVQLVESGGGLVQPGGSL RLSCAVSRNIASLY
RVDWYRQAPGKQRELVAGRTSGGTTTYLDA
VEGRFTISRDNVKDTVY LQM NSLTPEDTAVYYCHAHDHWRDSWGQGTQVIVSS
123 Amino Acid QVQLVESGGDLVQPGGSL
RLSCAASGSIGSIYAMGWYRQAPGRQRELVATTTSGGTTNYADS
VKG RFTIAG DNA KNTVFLQ M NSLRPEDTAVYYCKIQTHWYVYWGQGTQVTVSS
124 Amino Acid EVQLVESGGGLVQPGGSLRLSCAASRN I FSLY RVDWY
RQAPGKQRELVAGSTSGGTTTYADA
VKGRFTISTDNVKDTVY LQM NSLTPEDTAVYYCHAHDHWRDSWGQGTQVIVSS
125 Amino Acid QVQLVESGGGWVHPGGSLRLSCAASRN I FSMY RVDWY
RQAPGKQRELVAGITSGGTTSYADA
VKGRFTISTDNVKDTVY LQM NSVTPEDTAVYYCHAHDHWRDSWGQGTQVIVSS
126 Amino Acid EVQVQESGGDLVQPGGSLRLSCAASGSIGSIYRKGWYRQAPGSQRELVATITSAGTTNYADSV
KG RFTISRDNAKNIVY LQM NSLRPEDTAVYYCN FQTHWYVYWGQGTQVIVSS
127 Amino Acid EVRLVESGGGLVQPGGSLRLSCAVSKNI
FSIYRVDWYHQAPGKQRELVAGWTSGGSTSYADA
VKGRFTISTDNVKDTVY LQM NSLTPEDTAVYYCHAHDHWRDYWGQGTQVTVSS
128 Amino Acid EVKLVESGGGLVQPGGSLKLSCTTSGFTFSSYGLSWI RQTPDKRLELVASI N
RNGDNTYYTDSV
KG RFTISRH DAKNTLN LQM NSLKSEDTAMYYCTRGGFSYWGQGTLVTVSA
129 Amino Acid DIVLTQSPAI MSSSPGEKVTMTCSASSSVSYMYWYQQRPGSSPRLLIY
DTSKLASGVPVRFSGS
VSGTSYSLTISRM ESEDAATYYCQQWSGFPPITFGAGTKLELK
130 Amino Acid EVKLVESGGGLVQPGGSLKLSCTTSGFTFSSYGLSWI RQTPDKRLELVASI N
RNGDNTYYTDSV
RGRFTISRDNAKNTL N LQMSSLKSEDTAMYYCTRGG FSYWGQGTLVTVSA
131 Amino Acid DIVLTQSPATMSASPGEKVTLTCSASPGVTY MYWYQQKPGSSPRLLIY DTSN
LASGVPLRFSGS
GSGTSYSLTISRTEAEDAATYYCQQWSGYPPITFGAGTKLELR
132 Amino Acid EVKLVESGGGLVQPGGSLKLSCTTSGFTFSSYGLSWI RQTPDKRLELVASI N
RNGDNAYY I DSV
KG RFTISRDNAKNALN LQMSSLKSEDTAMYYCTRGG FSHWGQGTLVTVAA
133 Amino Acid QIVLTQSPAI MSASPGEKVTMTCSASSSVSY MY WYQQKPGSSPRL LIY
DTSN LASGVPVRFSGS
GSGTSYSLI I SRM EAEDAATYYCQQWSGYPPITFGAGTKLELK
134 Amino Acid EVKLVESGGG LVQPGGSL KLSCAASG FTFSSY G LSWVRQTPDKG
LELVASI N RN GG NTYYTDS
VKGRFTISRDNAKNTLNLQMSSLKSEDTAMYYCARGGFTYWGQGTLVTVSA
135 Amino Acid QIVLTQSPAI MSAFPGEKVTMTCSASSSVGY MY WYQQKPGSSPRL LIY
DTSN LASGVPVRFSGS
GSGTAYSLTISRM EAEDAATYYCQQWSGYPPITFGAGTKLELK
136 Amino Acid QVQLKESGGGLVRPGGSLKLSCAASGFTFSNYGMSWI RQTPDKNLELVASI
NTSGGNTYY PDS
VKGRFTISRDNARATLNLQMSNLKSEDTAIYYCTRGGFTHWGQGTLVAVSA
137 Amino Acid QIVLTQSPAI MSASPGEKVTMTCSASSSVSY MY WYQQKPGSSPRL LIY
DTSN LASGVPVRFSGS
GSGTSY FLTISRM EAEDAATYYCQQWTGYPPITFGAGTKLELR
138 Amino Acid QVQLKESGGGLVQPGGSL KLSCAASGFPFSSYGLSWVRQTPDKRLELVATI N
RNGDSAYY PDS
VKG RFTISRDDAKNTLY LQMSSL KSEDTAMYYCTRGGFAYWGQGTLVTVSA
139 Amino Acid QIVLTQSPAI MSASPGEKVTMTCSGSSSVGY MY WYQQKPG FSPRL LIY
DTSN LASGVPVRFSGS
GSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGAGTKLELK
140 Amino Acid EVKLVESGGGLVRPGGSLKLSCAASGFTFSNYGMSWI RQTPDKN LELVASI
NTSGG NTYY PDS
VKGRFTISRDNARATLNLQMSNLKSEDTAIYYCTRGGFTHWGQGTLVTVSA
141 Amino Acid DIVLTQSPAI MSASPGEKVTMTCSASSSVAFMYWYQQKPGSSPRLLIY
DTSKLASGVPVRFSGS
GSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGAGTKLELK
142 Amino Acid QVQLKESGGGLVQPGGSL KLSCTTSGFTFSSYGLSWI RQTPDKRLELVASI N
RNGDNTYYTDSV
RGRFTISRDNAKSTL N LQMSSLKSEDTAMYYCTRGG FSYWGQGTLVTVSA
143 Amino Acid QIVLTQSPPLMSASPGEKVTMTCSASSSVGY MYWFQQRPGSSPRLLIY DTY N
LASGVPVRFSGS
GSGTSY SLTI SRL EAEDAATYYCQQWSGYPPITFGAGTKLELR
144 Amino Acid EVKLVESGGG LVQPGGSL KLSCAASG FTFSSY G LSWVRQTPDKRL
ELVASVN RN GG NTYYTDS
VKGRFTISRDNAKNTLNLQMSSLKSEDTAMYYCARGGFTYWGQGTLVTVSA
145 Amino Acid QIVLTQSPAI MSASPGEKVTMTCSASSSVGY MY WYQQKPGSSPRL LIY
DTSH LASGVPVRFSGS
GSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGAGTKLELK
146 Amino Acid EVKLVESGGG LVQPGGSL KLSCAASGFPFSSYGLSWVRQTPDKRLELVATI N
RNGDSAYY PDS
VKG RFTISRDDAKNTLY LQMSSL KSEDTAMYYCTRGGFAYWGQGTLVTVSA
147 Amino Acid QIVLTQSPVI MSASPGEKVTMTCSASSSVGY
MYWYQQRPGSSPRLLIYDTSNLASGAPVRFSGS
GSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGAGTKLELK
148 Amino Acid EVKLVESGGGLVQPGGSLKLSCTTSGFTFSSYGLSWI RQTPDKRLELVASI N
RNGDNTYYTDSV
KG RFTISRDNAKNTLN LQMSSLKSEDTAMYYCTRGG FSYWGQGTLVTVSA

CA 031738M62gib-99- 28 149 Amino Acid QIVLTQSPAI MSASPGEKVTMTCSASSSVSY MY WYQQKPGSSPRL LIY
DTSN LASGVPVRFSGS
GSGTSYSLTISRM EAEDAATYYCQQWTGY PPITFGAGTKL ELK
150 Amino Acid EVKLVESGGV LVQPGGSL KLSCAASGFTFSSY G M SWVRQTPDKRLELVASI
N KN GGSTYY PDS
VKGRFTISRDNAKTIVY LQMSSLKSEDTAMYYCTRGGFAYWGQGTLVTVSA
151 Amino Acid QIVLTQSPAI MSASPGEKVTLTCSASSSVGY MYWYQQRPGSSPRLLIY DTSN
LPSGVPVRFSGSG
SGTSYSLTISRM EAEDAATYYCQQWSGY PPITFGAGTKL EL K
152 Amino Acid QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQG LEWM GG I I
PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSS
153 Amino Acid QSVLTQPPSASGTPGQRVTISCSGGSSN I GSNYVYWYQQLPGTAPKL LIY RN
NQ RPSGVPDRFS
GSKSGTSASLAI SG L RSEDEADYYCAAWDDSLSG HVVFGGGTKLTVL
154 Amino Acid QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQG LEWM GG I I
PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSS
155 Amino Acid QSVLTQPPSASGTPGQRVTISCSGSSSN I GSNYVYWYQQ LPGTAPKLL IY
RN NQRPSGVPDRLSG
SKSGTSASLAI SG L RSEDEADYYCAAWDDSLSAVVFGGGTKLTVL
156 Amino Acid QVQLQESGGGVVQPGRSLRLSCAASG FTLSSYG M HWVRQAPG KG L
EWVAVI SY DGSNKYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKSGWRYYYYYG M DVWGQGTLVTVSS
157 Amino Acid QSVLTQPPSVSGAPGQ RVTI SCTGSSSN I GAGY
DVHWYQQLPGTAPKLLIYG NSN RPSGVPDRF
SGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL
158 Amino Acid QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQG LEWM GG I I
PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTMVTVSS
159 Amino Acid QSVLTQPPSASGTPGQRVTISCSGSSSN I GSNYVYWYQQ LPGTAPKLL IY
RN NQRPSGVPDRFSG
SKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGPSVVFGGGTKLTVL
160 Amino Acid QVQLVQSGAEVKKPGASV KVSCKASGYTFTSYG I SWVRQAPGQG L EWM
GWI GAY NG NTNYA
QKLQGRVTMTTDTSTSTAY M ELRSLRSDDTAVYYCARDLRRYSSSWDGPGYWGQGTLVTVS
S
161 Amino Acid QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLM
IYDVSNRPSGVSNRF
SGSKSG NTASLTI SG LQAEDEADYYCSSYTSSSTRVEGTGTKLIVL
162 Amino Acid QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQG LEWM GG I I
PI FGTANYAQK
FQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSS
163 Amino Acid SYVLTQPPSASGTPGQRVTISCSGSSSN I GGNYVYWYQQLPGTAPKL LIY RN
NQ RPSGVPDRFS
GSKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGWV FGGGTKLTVL
164 Amino Acid QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQG LEWM GG I I
PI FGTANYAQK
FQGRVTITADKSTSTAY M ELSSLRSEDTAVYYCARDGGRYSYGRSFDYWGQGTLVTVSS
165 Amino Acid QSVLTQPPSVSGAPGQ RVTI SCTGSSSN I GAGY
DVHWYQQLPGTAPKLLIYG NSN RPSGVPDRF
SGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPVVFGGGTKLTVL
166 Amino Acid QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQG LEWM GG I I
PI FGTANYAQK
FQG RVTITADESTSTAY M ELSSLRSEDTAVYYCARPLRPLHYYG M DVWGQGTLVTVSS
167 Amino Acid QSVLTQPPSASGTPGQRVTISCSGSSSN I GSNYVYWYQQ LPGTAPKLL IY
RN NQRPSGVPDRFSG
SKSGTSASLAI SG L RSEDEADYYCAAWDDSLTEGVFGGGTKLTVL
168 Amino Acid QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRRAPG KG LEWVAVI
SY DGSN KYYA
DSVKG RFT! SRDNSKNTLY LQM NSLRAEDTAVYYCAKDGGDSGSLDYWGQGTLVTVSS
169 Amino Acid DIVMTQSPDSLAVSLGERATI NCKSSQSVLYSSN N KNY
LAWYQQKPGQPPKLLIYWASTRESG
VPDRFSGSGSGTDFTLTI SSLQAEDVAVYYCQQYYSTPLTFGGGTKLEI K
170 Amino Acid EVQL L ESGGG LVQPGGSL RLSCAASG FTFSSYWM SWVRQAPG KG L
EWVAN I KQDGSEKYYV
DSVKG RFT! SRDNAK NSLY LQM NSLRAEDTAVYYCARPAGQLLYG M DVWGQGTLVTVSS
171 Amino Acid SYVLTQPPSVSVSPGQTARITCSG DALPKQYAYWYQQ KPGQAPVLVIY
KDSERPSG I PERFSGSS
SGTIVTLTISGVQAEDEADYYCQSADSSGTVVVFGGGTKLIVL
172 Amino Acid EVQLLESGGGVVQPG RSLRLSCAASG FTFSSYGM HWVRQAPG KG L
EWVAVI SY DGSN KYYAD
SVKG RFT! SRDN SK NTLY LQM NSLRAEDTAVYYCAKDAADMGAFDYWGQGTLVTVSS
173 Amino Acid DIQMTQSPDSLAVSLGERATM
NCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASARES
GVPDRFSGSGSGTDFTLTI SSLQAEDVAVYY CQQYYSTPLTFGQGTKVEI K
174 Amino Acid EVQLLESGGGLVKPGGSLRLSCAASG FTFSSYSM NWVRQAPG KG
LEWVSAISGSGGSTYYADS
VKG RFT! SRDN SKNTLY LQM NSL RAEDTAVYY CARA RGYSY GSDAFDI WGQGTMVTVSS
175 Amino Acid QSVLTQPPSASGTPGQRVTISCSGSSSN I GSNYVYWYQQ LPGTAPKLL IY
RN NQRPSGVPDRFSG
SKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGVVFGGGTKLTVL
176 Amino Acid QVQLVQSGGGVVQPG RSLRLSCAASG FTFSSYGM HWVRQAPG KG L
EWVAVI SY DGSN KYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKGVPRYYYYYG M DVWGQGTMVTVSS
177 Amino Acid QSVLTQPPSVSGAPGQ RVTI SCTGSSSN I GAGY
DVHWYQQLPGTAPKLLIYG NSN RPSGVPDRF
SGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL

CA 031738M62gib-99- 28
178 Amino Acid EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG I
I PI FGTANYAQK
FQG RVTITADESTSTAY M E LSSLRSEDTAVYYCA RDRG RRYCSGGSCPNAFDI WGQGTMVTVS
S
179 Amino Acid EIVLTQSPATLSVSPG ERATLSCRASQSVSSN LAWYQQKPGQAPRL
LIYGASTRATG I PARFSGS
GSGTEFTLTISSLQSEDFAVYYCQQYN NWPPALTFGGGTKVEI K
180 Amino Acid QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQG LEWM GG I I
PI FGTANYAQK
FQG RVTITADESTSTAY M ELSSLRSEDTAVYYCARGGYVWGSY RQNSNWFDPWGQGTLVTVS
S
181 Amino Acid SYVLTQPPSASGTPGQRVTISCSGSSSN I GSNYVYWYQQ LPGTAPKLL IY
RN NQRPSGVPDRFSG
SKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGWVFGGGTKLTVL
182 Amino Acid QVQLV ESGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG
I I PI FGTANYAQK
FQG RVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSSGM DVWGQGTLVTVSS
183 Amino Acid QSVLTQPPSASGTPGRRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSG
SKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGVVFGGGTKLTVL
184 Amino Acid QVQLVESGGGLVQPGGSL RLSCAASG FTFSSYWM SWVRQAPG KG LEWVAN
I KQDGSEKYYV
DSVKG RFT! SRDNAK NSLY LQM NSLRAEDTAVYYCARWSHYY DSSGLDYWGQGTLVTVSS
185 Amino Acid SYVLTQPPSVSVSPGQTARITCSG DALPKQYAYWYQQ KPGQAPVLVIY
KDSERPSG I PERFSGSS
SGTIVTLTI SGVQAEDEADYYCQSADSSGTVVVFGGGTKLTVL
186 Amino Acid QVQLV ESGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG
I I PI FGTANYAQK
FQG RVTITADKSTSTAY M ELSSLRSEDTAVYY GARTH LPYSYG LGG FDYWGQGTLVTVSS
187 Amino Acid QSVLTQPPSVSGAPGQ RVTI SCTGSSSN I GAGY
DVHWYQQLPGTAPKLLIYG NSN RPSGVPDRF
SGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPVVFGGGTKVTVL
188 Amino Acid EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG I
I PI FGTANYAQK
FQG RVTITADESTSTAY M ELSSLRSEDTAVYYCARDPSRDYYGSGRFSWFDPWGQGTLVTVSS
189 Amino Acid QSVLTQPPSASGTPGQRVTISCSGSSSN I GSNYVYWYQQ LPGTAPKLL IY
RN NQRPSGVPDRFSG
SKSGTSASLAI SG L RSEDEADYYCAAWDDSLSG RGVEGGGTKLTVL
190 Amino Acid QVQLVQSGAEVKKPGASV KVSCKASGYTFTSYG I SWVRQAPGQG L EWM
GWI SAY NG NTNYA
QKLQGRVTMTTDTSTSTAY M ELRSLRSDDTAVYYCARDI I RYCSSTSCY RG I DYWGQGTLVTV
SS
191 Amino Acid QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLM
IYDVSNRPSGVSNRF
SGSKSG NTASLTI SG LQAEDEADYYCSSYTSSSPHVVSGGGTKLTVL
192 Amino Acid QVQLVESGGGVVQPGRSLRLSCAASG FTFSSYGM HWVRQAPG KG L EWVAVI
SY DGSNKYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCARDGTDY RGAFDIWGQGTMVTVSS
193 Amino Acid DIQLTQSPDSLAVPLGERATI
NCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGV
PDRFSGSGSGTDFTLTI SSLQAEDVAVYY CQQYYSTPLTFGQGTKLEI K
194 Amino Acid EVQLVQSGAEVKKPGSSVRVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG I
I PI FGTANYAQK
FQG RVTITADKSTSTAY M ELSSLRSEDTAVYY CARGGG RWL H SRLDVWGQGTIVIVSS
195 Amino Acid QSVLTQPPSVSGAPGQ RVTI SCTGSSSN I GAGY DVHWYQQFPGTAPKL LI
FGN N N RPSGVPDRF
SGSKSGTSASLAITGLQAEDEANYYCQSYDRSLSGPVVEGGGTKLTVL
196 Amino Acid EVQLVESGGGVVQPG RSLRLSCAASG FTFSSYG M HWVRQAPG KG L
EWVAVI SY DGSNKYYA
DSVKG RFT! SRDNSKNTLY LQM NSLRAEDTAVYYCAKDAGDLGAFDIWGQGTMVTVSS
197 Amino Acid DIVMTQSPDSLAVSLGERATI NCKSSQSVLYSSN N KNY
LAWYQQKPGQPPKLLIYWASTRESG
VPDRFSGSGSGTDFTLTI SSLQAEDVAVYYCQQYYSTPLTFGPGTKVEI K
198 Amino Acid QVQLVQSGGGVVQPG RSLRLSCAASG FTFSSYAM HWVRQAPG KG L
EWVAVI SY DGSN KYYA
DSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCARGRVYYYDSSGYSYWGQGTLVTVSS
199 Amino Acid QSVLTQPPSVSGAPGQ RVTI SCTGSSSN I GAGY
DVHWYQQLPGTAPKLLIYG NSN RPSGVPDRF
SGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSG REVFGTGTKLTVL
200 Amino Acid QVQLV ESGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG L EWM GG
I I PI FGTANYAQK
FQG RVTITADESTSTAY M ELSSLRSEDTAVYYCARPLYAPRFGYG M DVWGQGTLVTVSS
201 Amino Acid QSVLTQPPSASGTPGQRVTISCSGSSSN I GSNYVYWYQQ LPGTAPKLL IY
RN NQRPSGVPDRFSG
SKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGWV FGGGTQ LTVL
202 Amino Acid EVQLLESGGGLVQPGGSLRLSCAASG FTFSSYAM SWVRQAPG KG
LEWVSAISGSGGSTYYADS
VKG RFT! SRDN SKNTLY LQM NSLRAEDTAVYYCAKDRGGQRG FDYWGQGTLVTVSS
203 Amino Acid QSVLTQPPSASGTPGQRVTISCSGSSSN I GSNYVYWYQQ LPGTAPKLL IY
RN NQRPSGVPDRFSG
SKSGTSASLAI SG L RSEDEADYYCAAWDDSLSG LVFGGGTKLTVL
204 Amino Acid SYAIS
205 Amino Acid GI I PI FGTANYAQKFQG
206 Amino Acid DGGRYSYGRSFDY
207 Amino Acid TGSSSN I GAGY DVH

CA 031738M62gib-99- 28
208 Amino Acid GNSNRPS
209 Amino Acid QSYDSSLSGPVV
210 Amino Acid SYAIS
211 Amino Acid GI I PI FGTANYAQKFQG
212 Amino Acid DI LRLSVSSGM DV
213 Amino Acid SGGSSNIGSNYVY
214 Amino Acid RNNQRPS
215 Amino Acid AAWDDSLSGHVV
216 Amino Acid SYAIS
217 Amino Acid GI IPI FGTANYAQKFQG
218 Amino Acid DI LRLSVSSGM DV
219 Amino Acid SGSSSNIGGNYVY
220 Amino Acid RNNQRPS
221 Amino Acid AAWDDSLSGWV
222 Amino Acid SYAIS
223 Amino Acid GI I PI FGTANYAQKFQG
224 Amino Acid DI LRLSVSSGM DV
225 Amino Acid SGSSSNIGSNYVY
226 Amino Acid RNNQRPS
227 Amino Acid AAWDDSLSAVV
228 Amino Acid SYAIS
229 Amino Acid GI I PI FGTANYAQKFQG
230 Amino Acid DI LRLSVSSGM DV
231 Amino Acid SGSSSNIGSNYVY
232 Amino Acid RNNQRPS
233 Amino Acid AAWDDSLSGPSVV
234 Amino Acid SYAIS
235 Amino Acid GI I PI FGTANYAQKFQG
236 Amino Acid PLRPLHYYGM DV
237 Amino Acid SGSSSNIGSNYVY
238 Amino Acid RNNQRPS
239 Amino Acid AAWDDSLTEGV
240 Amino Acid SYGIS
241 Amino Acid WIGAYNGNTNYAQKLQG
242 Amino Acid DLRRYSSSWDGPGY
243 Amino Acid TGTSSDVGGYNYVS
244 Amino Acid DVSNRPS
245 Amino Acid SSYTSSSTRV
246 Amino Acid SYGMH
247 Amino Acid VISYDGSNKYYADSVKG
248 Amino Acid SGWRYYYYYGMDV
249 Amino Acid TGSSSNIGAGYDVH
250 Amino Acid GNSNRPS
251 Amino Acid QSYDSSLSGSV

CA 031738M62gib-99- 28
252 Amino Acid SYAIS
253 Amino Acid GI I PI FGTANYAQKFQG
254 Amino Acid DI LRLSVSSGM DV
255 Amino Acid SGSSSNIGSNYVY
256 Amino Acid RNNQRPS
257 Amino Acid AAWDDSLSGVV
258 Amino Acid SYAIS
259 Amino Acid GI I PI FGTANYAQKFQG
260 Amino Acid DPSRDYYGSGRFSWFDP
261 Amino Acid SGSSSNIGSNYVY
262 Amino Acid RNNQRPS
263 Amino Acid AAWDDSLSGRGV
264 Amino Acid SYAIS
265 Amino Acid GI I PI FGTANYAQKFQG
266 Amino Acid DRGRRYCSGGSCPNAFDI
267 Amino Acid RASQSVSSNLA
268 Amino Acid GASTRAT
269 Amino Acid QQYNNWPPALT
270 Amino Acid SYAIS
271 Amino Acid GI I PI FGTANYAQKFQG
272 Amino Acid GGGRWLHSRLDV
273 Amino Acid TGSSSNIGAGYDVH
274 Amino Acid GNNNRPS
275 Amino Acid QSYDRSLSGPVV
276 Amino Acid SYAIS
277 Amino Acid GI I PI FGTANYAQKFQG
278 Amino Acid GGYVWGSYRQNSNWFDP
279 Amino Acid SGSSSNIGSNYVY
280 Amino Acid RNNQRPS
281 Amino Acid AAWDDSLSGWV
282 Amino Acid SYAIS
283 Amino Acid GI I PI FGTANYAQKFQG
284 Amino Acid PLYAPRFGYGM DV
285 Amino Acid SGSSSNIGSNYVY
286 Amino Acid RNNQRPS
287 Amino Acid AAWDDSLSGWV
288 Amino Acid SYAIS
289 Amino Acid GI I PI FGTANYAQKFQG
290 Amino Acid THLPYSYGLGGFDY
291 Amino Acid TGSSSNIGAGYDVH
292 Amino Acid GNSNRPS
293 Amino Acid QSYDSSLSGPVV
294 Amino Acid SYAMH
295 Amino Acid VI SY DGSN KYYADSVKG

CA 031738M62gib-99- 28
296 Amino Acid GRVYYYDSSGYSY
297 Amino Acid TGSSSNIGAGYDVH
298 Amino Acid GNSNRPS
299 Amino Acid QSYDSSLSGREV
300 Amino Acid SYAMS
301 Amino Acid AISGSGGSTYYADSVKG
302 Amino Acid DRGGQRGFDY
303 Amino Acid SGSSSNIGSNYVY
304 Amino Acid RNNQRPS
305 Amino Acid AAWDDSLSGLV
306 Amino Acid SYGIS
307 Amino Acid WISAYNGNTNYAQKLQG
308 Amino Acid DI I RYCSSTSCYRGI DY
309 Amino Acid TGTSSDVGGYNYVS
310 Amino Acid DVSNRPS
311 Amino Acid SSYTSSSPHVV
312 Amino Acid SYGMH
313 Amino Acid VISYDGSNKYYADSVKG
314 Amino Acid DAADMGAFDY
315 Amino Acid KSSQSVLYSSNN KNY LA
316 Amino Acid WASARES
317 Amino Acid QQYYSTPLT
318 Amino Acid SYGMH
319 Amino Acid VISYDGSNKYYADSVKG
320 Amino Acid DAGDLGAFDI
321 Amino Acid KSSQSVLYSSNN KNY LA
322 Amino Acid WASTRES
323 Amino Acid QQYYSTPLT
324 Amino Acid SYGMH
325 Amino Acid VISYDGSNKYYADSVKG
326 Amino Acid DGGDSGSLDY
327 Amino Acid KSSQSVLYSSNN KNY LA
328 Amino Acid WASTRES
329 Amino Acid QQYYSTPLT
330 Amino Acid SYGMH
331 Amino Acid VISYDGSNKYYADSVKG
332 Amino Acid DGTDYRGAFDI
333 Amino Acid KSSQSVLYSSNN KNY LA
334 Amino Acid WASTRES
335 Amino Acid QQYYSTPLT
336 Amino Acid SYGMH
337 Amino Acid VISYDGSNKYYADSVKG
338 Amino Acid GVPRYYYYYGMDV
339 Amino Acid TGSSSNIGAGYDVH

CA 031738M62gib-99- 28
340 Amino Acid GNSNRPS
341 Amino Acid QSYDSSLSGSV
342 Amino Acid SYSMN
343 Amino Acid AISGSGGSTYYADSVKG
344 Amino Acid ARGYSYGSDAFDI
345 Amino Acid SGSSSNIGSNYVY
346 Amino Acid RNNQRPS
347 Amino Acid AAWDDSLSGVV
348 Amino Acid SYWMS
349 Amino Acid NI KQDGSEKYYVDSVKG
350 Amino Acid PAGQLLYGM DV
351 Amino Acid SGDALPKQYAY
352 Amino Acid KDSERPS
353 Amino Acid QSADSSGTWV
354 Amino Acid SYWMS
355 Amino Acid NI KQDGSEKYYVDSVKG
356 Amino Acid WSHYYDSSGLDY
357 Amino Acid SGDALPKQYAY
358 Amino Acid KDSERPS
359 Amino Acid QSADSSGTWV
360 Amino Acid RNIFSLYRVD
361 Amino Acid GSTSGGTTTYADA
362 Amino Acid HAHDHWRDS
363 Amino Acid RNIFSMYRVD
364 Amino Acid GITSGGTTSYADA
365 Amino Acid HAHDHWRDS
366 Amino Acid RNIASLYRVD
367 Amino Acid GRTSGGTTTYLDA
368 Amino Acid HAHDHWRDS
369 Amino Acid GRTGSSYAMG
370 Amino Acid AITVVSGGITAYADS
371 Amino Acid AAGVTGSPSFDS
372 Amino Acid GRTFSSYAMG
373 Amino Acid AISGSGGSIYYGDS
374 Amino Acid AAGPLGSPDFDS
375 Amino Acid GRTFSSYAMG
376 Amino Acid AISGSGGSIYYGDS
377 Amino Acid AAGPLGSPDFDS
378 Amino Acid GRTGSSYAMG
379 Amino Acid AITVVSGGITAYADS
380 Amino Acid AAGVTGSPSFDS
381 Amino Acid GRTFSSYAMG
382 Amino Acid AISGSGGVTFYAHS
383 Amino Acid AGGAHGSPDFGS

CA 031738M62gib-99- 28
384 Amino Acid GSIGSIYAMG
385 Amino Acid TTTSGGTTNYADS
386 Amino Acid KIQTHWYVY
387 Amino Acid GSIGSIYRKG
388 Amino Acid TITSAGTTNYADS
389 Amino Acid NFQTHWYVY
390 Amino Acid KNIFSIYRVD
391 Amino Acid GWTSGGSTSYADA
392 Amino Acid HAHDHWRDY
393 Amino Acid SGFTFSSYGLSWI
394 Amino Acid SI NRNGDNTYYT
395 Amino Acid TRGGFSY
396 Amino Acid SASSSVSY
397 Amino Acid DTSKLA
398 Amino Acid QQWSGFPPITF
399 Amino Acid SGFTFSSYGLSWI
400 Amino Acid SI NRNGDNTYYT
401 Amino Acid TRGGFSY
402 Amino Acid SASPGVTY
403 Amino Acid DTSNLA
404 Amino Acid QQWSGYPPITF
405 Amino Acid SGFTFSSYGLSWI
406 Amino Acid SI NRNGDNAYYI
407 Amino Acid TRGGFSH
408 Amino Acid SASSSVSY
409 Amino Acid DTSNLA
410 Amino Acid QQWSGYPPITF
411 Amino Acid SGFTFSSYGLSWV
412 Amino Acid SI NRNGGNTYYT
413 Amino Acid ARGGFTY
414 Amino Acid SASSSVGY
415 Amino Acid DTSNLA
416 Amino Acid QQWSGYPPITF
417 Amino Acid SGFTFSNYGMSWI
418 Amino Acid SI NTSGGNTYYP
419 Amino Acid TRGGFTH
420 Amino Acid SASSSVSY
421 Amino Acid DTSNLA
422 Amino Acid QQWTGYPPITF
423 Amino Acid SGFPFSSYGLSWV
424 Amino Acid TINRNGDSAYYP
425 Amino Acid TRGGFAY
426 Amino Acid SGSSSVGY
427 Amino Acid DTSNLA

CA 031738M62gib-99- 28
428 Amino Acid CQQWSGYPPITF
429 Amino Acid SGFTFSNYGMSWI
430 Amino Acid SI NTSGGNTYYP
431 Amino Acid TRGGFTH
432 Amino Acid SASSSVAF
433 Amino Acid DTSKLA
434 Amino Acid CQQWSGYPPITF
435 Amino Acid SGFTFSSYGLSWI
436 Amino Acid SI NRNGDNTYYT
437 Amino Acid TRGGFSY
438 Amino Acid SASSSVGY
439 Amino Acid DTYNLA
440 Amino Acid CQQWSGYPPITF
441 Amino Acid SGFTFSSYGLSWV
442 Amino Acid SVNRNGGNTYYT
443 Amino Acid ARGGFTY
444 Amino Acid SASSSVGY
445 Amino Acid DTSHLA
446 Amino Acid CQQWSGYPPITF
447 Amino Acid SGFPFSSYGLSWV
448 Amino Acid TINRNGDSAYYP
449 Amino Acid TRGGFAY
450 Amino Acid SASSSVGY
451 Amino Acid DTSNLA
452 Amino Acid CQQWSGYPPITF
453 Amino Acid SGFTFSSYGLSWI
454 Amino Acid SI NRNGDNTYYT
455 Amino Acid TRGGFSY
456 Amino Acid SASSSVSY
457 Amino Acid DTSNLA
458 Amino Acid CQQWTGYPPITF
459 Amino Acid SGFTFSSYGMSWV
460 Amino Acid SI NKNGGSTYYP
461 Amino Acid TRGGFAY
462 Amino Acid SASSSVGY
463 Amino Acid DTSNLP
464 Amino Acid CQQWSGYPPITF
465 Amino Acid MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
QGLEWMGGI I PI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSS
GM DVWGQGTLVTVSSGSTSGSGKPGSGEGSTKGQSVLTQPPSASGTPGQRVTISCSGGSSNIGS
NYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAI SGLRSEDEADYYCAAWDD
SLSGHVVEGGGTKLTVLEQKLISEEDLNPGGGGGSGGGGSGGGGSGGGGSGSMDIQMTQSPSS
LSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTI
SSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPG
GSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVA LI NPTKGVSTY NQKFKDRFTISVDKSKN
TAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLE

CA 031738M62gib-99- 28 CPH RFQKTCSPI
466 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSS
GM DVWGQGTLVTVSSGSTSGSGKPGSGEGSTKGQSVLTQPPSASGTPGQRVTISCSGSSSNIGS
NYVYWYQQLPGTAPKL LIY RN NQ RPSGVPDRLSGSKSGTSASLAI SG LRSEDEADYYCAAWDD
SLSAVVFGGGTKLTVLEQKL ISEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSL
SASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES

CPH RFQKTCSPI
467 Amino Acid MALPVTALLLPLALLLHAARPQVQLQESGGGVVQPGRSLRLSCAASGFTLSSYGM
HWVRQAP
G KG LEWVAVI SY DGSN KYYADSVKG RFT! SRDNSKNTLY LQ M NSLRAEDTAVYYCAKSGWR
YYYYYGM DVWGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSVLTQPPSVSGAPGQRVTI SCTGS
SSNIGAGYDVHWYQQLPGTAPKLLIYGNSN RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYY
CQSY DSSLSGSVFGGGTKLTVL EQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMT
QSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTD
YTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGL

KSKNTAY LQM NSLRAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLESGQ
VLL ESN I KVLPTVVSTPVQPMAL IVLGGVAG LLL Fl GLG I FFCVRCRH RRRQAERMSQIKRLLSEK
KTCQCPHRFQKTCSPI
468 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSS
GM DVWGQGTMVTVSSGSTSGSGKPGSGEGSTKGQSVLTQPPSASGTPGQRVTISCSGSSSNIGS
NYVYWYQQLPGTAPKL LIY RN NQ RPSGVPDRFSGSKSGTSASLAI SG LRSEDEADYYCAAWDD
SLSGPSVVFGGGTKLTVLEQKL I SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPS
SLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKL LIYYTSRLESGVPSRFSGSGSGTDYTL
TISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQP
GGSLRLSCAASGYSFTGYTM NWVRQAPGKG LEWVALI NPTKGVSTYNQKFKDRFTISVDKSK
NTAY LQM NSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLL
ESN! KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRHRRRQAERMSQIKRLLSEKKTC
QCPH RFQKTCSPI
469 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGASVKVSCKASGYTFTSYGISWV RQAP
GQG LEWMGWI GAY NGNTNYAQKLQG RVTMTTDTSTSTAY M ELRSLRSDDTAVYYCARDLR
RYSSSWDGPGYWGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSALTQPASVSGSPGQSITI SCTG
TSSDVGGYNYVSWYQQHPGKAPKLM IYDVSN RPSGVSN RFSGSKSGNTASLTI SG LQAEDEAD
YYCSSYTSSSTRVFGTGTK LTVLEQKLI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI Q M
TQSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGT
DYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGG
LVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG L EWVALI NPTKGVSTYNQKFKDRFTISV
DKSKNTAY LQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESG

KKTCQCPH RFQKTCSPI
470 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSS
GM DVWGQGTLVTVSSGSTSGSGKPGSGEGSTKGSYVLTQPPSASGTPGQRVTISCSGSSSNIGG
NYVYWYQQLPGTAPKL LIY RN NQ RPSGVPDRFSGSKSGTSASLAI SG LRSEDEADYYCAAWDD
SLSGWVFGGGTKLTVL EQKL I SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSL
SASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES

CPH RFQKTCSPI

CA 031738M62gib-99- 28
471 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADKSTSTAY M ELSSLRSEDTAVYY CA RDGG RYSY
G RSFDYWGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSVLTQPPSVSGAPGQ RVTI SCTGSSSNI
GAGYDVHWYQQLPGTAPKLLIYGNSN RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQS
Y DSSLSG PVVFGGGTK LTVL EQ KLI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQS
PSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYT
LTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQ
PGGSLRLSCAASGYSFTGYTM NWVRQAPGKG LEWVALI NPTKGVSTYNQKFKDRFTISVDKS
KNTAY LQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL

CQCPHRFQKTCSPI
472 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARPLRPLHYY
GM DVWGQGTLVTVSSGSTSGSGKPGSGEGSTKGQSVLTQPPSASGTPGQRVTISCSGSSSNIGS
NYVYWYQQLPGTAPKL LIY RN NQ RPSGVPDRFSGSKSGTSASLAI SG LRSEDEADYYCAAWDD
SLTEGVEGGGTKLIVLEQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSL
SASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES

CPH RFQKTCSPI
473 Amino Acid MALPVTALLLPLALLLHAARPQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
HWVRRAP
G KG LEWVAVI SY DGSN KYYADSVKG RFT! SRDNSKNTLY LQ M NSLRAEDTAVYYCAKDGGD
SGSLDYWGQGTLVTVSSGSTSGSG KPGSG EGSTKG DI VMTQSPDSLAVSLG E RATI NCKSSQSV
LYSSN N K NY LAWYQQKPGQPPKL LIYWASTRESGVPDRFSGSGSGTDFTLTI SSLQAEDVAVY
YCQQYYSTPLTFGGGTKL El KEQKL 1 SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQ
SPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDY
TLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLV
QPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALI NPTKGVSTY NQKFKDRFTISVDK
SKNTAY LQM NSL RAEDTAVYY CA RSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLESGQV
LL ESN I KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRH RRRQAERMSQIKRLLSEKK
TCQCPHRFQKTCSPI
474 Amino Acid MALPVTALL LPLALL L HAARPEVQL LESGGGLVQPGGSLRLSCAASG
FTFSSYWMSWVRQAP

LLYG M DVWGQGTLVTVSSGSTSGSG KPGSG EGSTKGSYVLTQPPSVSVSPGQTARITCSG DAL
PKQYAYWYQQ KPGQAPVLVIY KDSERPSGIPERFSGSSSGTIVTLTI SGVQAEDEADYYCQSAD
SSGTVVVFGGGTKLTVL EQKLI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSL
SASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES

CPH RFQKTCSPI
475 Amino Acid MALPVTALL LPLALL L HAARPEVQL LESGGGVVQPG RSLRLSCAASG
FTFSSYGM HWVRQAP
G KG LEWVAVI SY DGSN KYYADSVKG RFT! SRDNSKNTLY LQ M NSLRAEDTAVYYCAKDAAD
M GAFDYWGQGTLVTVSSGSTSGSG KPGSG EGSTKG DI QMTQSPDSLAVSLG ERATM NCKSSQ
SVLYSSN N KNYLAWYQQKPGQPPKLLIYWASARESGVPDRFSGSGSGTDFTLTISSLQAEDVA

MTQSPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGS
GTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESG
GGLVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KGL EWVAL I NPTKGVSTYNQKFKDRFTI
SVDKSKNTAY LQM N SLRA EDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLE
SGQVLL ESN 1 KVLPTWSTPVQPMA LIVLGGVAGL LL Fl GLG 1 FFCVRCRH RRRQAERMSQIKRLL
SEKKTCQCPH RFQKTCSPI
476 Amino Acid MALPVTALL LPLALL L HAARPEVQL LESGGGLVKPGGSLRLSCAASG
FTFSSYSM NWVRQAPG
KG LEWVSAI SGSGGSTYYADSVKG RFTISRDN SKNTLY LQM NSLRAEDTAVYYCARARGYSY
GSDAFDIWGQGTMVIVSSGSTSGSGKPGSGEGSTKGQSVLTQPPSASGTPGQRVTISCSGSSSNI
GSNYVYWYQQ LPGTAPKL LIY RN NQ RPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYYCAAW
DDSLSGVVFGGGTKLTVLEQKLI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPS
SLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKL LIYYTSRLESGVPSRFSGSGSGTDYTL

CA 031738M62gib-99- 28 TISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQP
GGSLRLSCAASGYSFTGYTM NWVRQAPGKG LEWVALI NPTKGVSTYNQKFKDRFTISVDKSK
NTAY LQM NSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLL
ESN! KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRHRRRQAERMSQIKRLLSEKKTC
QCPH RFQKTCSPI
477 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGGGVVQPGRSL RLSCAASG
FTFSSYG M HWVRQAP
G KG LEWVAVI SY DGSN KYYADSVKG RFT! SRDNSKNTLY LQ M NSLRAEDTAVYYCAKGVPRY
YYYYGM DVWGQGTMVIVSSGSTSGSG KPGSG EGSTKGQSVLTQPPSVSGAPGQ RVTI SCTGSS

CQSY DSSLSGSVFGGGTKLTVL EQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMT
QSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTD
YTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGL

KSKNTAY LQM NSLRAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLESGQ
VLL ESN I KVLPTVVSTPVQPMAL IVLGGVAG LLL Fl GLG I FFCVRCRH RRRQAERMSQIKRLLSEK
KTCQCPHRFQKTCSPI
478 Amino Acid MALPVTALL LPLALL L HAARPEVQLVQSGAEV
KKPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDRGRRYC
SGGSCPNAFDIWGQGTMVIVSSGSTSGSGKPGSGEGSTKGEIVLTQSPATLSVSPGERATLSCR
ASQSVSSN LAWYQQ KPGQAPRLL IYGASTRATGIPARFSGSGSGTEFTLTI SSLQSEDFAVYYCQ

SPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDY
TLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLV
QPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALI NPTKGVSTY NQKFKDRFTISVDK
SKNTAY LQM NSL RAEDTAVYY CA RSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLESGQV
LL ESN I KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRH RRRQAERMSQIKRLLSEKK
TCQCPHRFQKTCSPI
479 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARGGYVWGS
YRQNSNWFDPWGQGTLVTVSSGSTSGSGKPGSGEGSTKGSYVLTQPPSASGTPGQRVTISCSGS

AAWDDSLSGWVFGGGTKLTVL EQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI Q M
TQSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGT
DYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGG
LVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG L EWVALI NPTKGVSTYNQKFKDRFTISV
DKSKNTAY LQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESG

KKTCQCPH RFQKTCSPI
480 Amino Acid MALPVTALL LPLALL L HAARPQVQLVESGAEV
KKPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSS
GM DVWGQGTLVTVSSGSTSGSGKPGSGEGSTKGQSVLTQPPSASGTPGRRVTISCSGSSSNIGS
NYVYWYQQLPGTAPKL LIY RN NQ RPSGVPDRFSGSKSGTSASLAI SG LRSEDEADYYCAAWDD
SLSGVVFGGGTKLTVLEQKL ISEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSL
SASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES

CPH RFQKTCSPI
481 Amino Acid MALPVTALL LPLALL L HAARPQVQLVESGGGLVQPGGSLRLSCAASG
FTFSSYWMSWVRQAP

Y DSSG LDYWGQGTLVTVSSGSTSGSG KPGSG EGSTKGSYVLTQPPSVSVSPGQTARITCSG DAL
PKQYAYWYQQ KPGQAPVLVIY KDSERPSGIPERFSGSSSGTIVTLTI SGVQAEDEADYYCQSAD
SSGTVVVFGGGTKLTVL EQKLI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSL
SASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES

CPH RFQKTCSPI

CA 031738M62gib-99- 28
482 Amino Acid MALPVTALL LPLALL L HAARPQVQLVESGAEV
KKPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADKSTSTAY M ELSSLRSEDTAVYY CA RTH LPYSYG
LGGFDYWGQGTLVTVSSGSTSGSGKPGSGEGSTKGQSVLTQPPSVSGAPGQRVTISCTGSSSNI
GAGYDVHWYQQLPGTAPKLLIYGNSN RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQS
Y DSSLSGPVVEGGGTKVIVL EQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQS
PSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYT
LTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQ
PGGSLRLSCAASGYSFTGYTM NWVRQAPGKGLEWVALI NPTKGVSTYNQKFKDRFTISVDKS
KNTAYLQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL

CQCPHRFQKTCSPI
483 Amino Acid MALPVTALL LPLALL L HAARPEVQLVQSGAEV
KKPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDPSRDYY
GSG RFSWFDPWGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSVLTQPPSASGTPGQ RVTI SCSGS

AAWDDSLSGRGVEGGGTKLIVL EQKLI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QM
TQSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGT
DYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGG
LVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG L EWVALI NPTKGVSTYNQKFKDRFTISV
DKSKNTAYLQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESG

KKTCQCPH RFQKTCSPI
484 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGASVKVSCKASGYTFTSYGISWV RQAP
GQG LEWMGWI SAY NG NTNYAQKLQG RVTMTTDTSTSTAY M ELRSLRSDDTAVYYCARDIIR
YCSSTSCY RGIDYWGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSALTQPASVSGSPGQSITI SCT
GTSSDVGGY NYVSWYQQ H PG KAPKLM IYDVSN RPSGVSN RFSGSKSGNTASLTI SG LQAEDEA
DYYCSSYTSSSPHVVSGGGTKLTVL EQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI
QMTQSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSG
SGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVES

ISVDKSKNTAYLQM NSLRAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL
ESGQVL LESN I KVLPTWSTPVQPMA LIVLGGVAGL LL Fl GLG I FFCVRCRHRRRQAERMSQIKRL
LSEKKTCQCPHRFQKTCSPI
485 Amino Acid MALPVTALLLPLALLLHAARPQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
HWVRQAP
G KG LEWVAVI SY DGSN KYYADSVKG RFT! SRDNSKNTLY LQ M NSLRAEDTAVYYCARDGTD
Y RGAFDI WGQGTMVIVSSGSTSGSG KPGSG EGSTKG DI Q LTQSPDSLAVPLG ERATI NCKSSQS
VLYSSNN KNY LAWYQQKPGQPPKL LIYWASTRESGVPDRFSGSGSGTDFTLTI SSLQAEDVAV
YYCQQYYSTPLTFGQGTKL El KEQKLISEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMT
QSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTD
YTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGL

KSKNTAYLQM NSLRAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLESGQ
VLL ESN I KVLPTVVSTPVQPMAL IVLGGVAG LLL Fl GLG I FFCVRCRH RRRQAERMSQIKRLLSEK
KTCQCPHRFQKTCSPI
486 Amino Acid MALPVTALL LPLALL L HAARPEVQLVQSGAEV
KKPGSSVRVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADKSTSTAY M ELSSLRSEDTAVYY CA RGGG RWL H
SRLDVWGQGTTVIVSSGSTSGSG KPGSG EGSTKGQSVLTQPPSVSGAPGQ RVTI SCTGSSSNIG

DRSLSGPVVFGGGTKLTVLEQKLI SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSP
SSLSASVG DRVTITCRASQ DI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYT
LTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQ
PGGSLRLSCAASGYSFTGYTM NWVRQAPGKGLEWVALI NPTKGVSTYNQKFKDRFTISVDKS
KNTAYLQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL

CQCPHRFQKTCSPI
487 Amino Acid MALPVTALLLPLALLLHAARPEVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM
HWVRQAP
G KG LEWVAVI SY DGSN KYYADSVKG RFT! SRDNSKNTLY LQ M NSLRAEDTAVYYCAKDAGD
LGAFDIWGQGTMVIVSSGSTSGSGKPGSGEGSTKGDIVMTQSPDSLAVSLGERATI NCKSSQSV
LYSSN N K NY LAWYQQKPGQPPKL LIYWASTRESGVPDRFSGSGSGTDFTLTI SSLQAEDVAVY
YCQQYYSTPLTFGPGTKVEI KEQKL ISEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQ
SPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDY

CA 031738M62gib-99- 28 TLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLV
QPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALI NPTKGVSTY NQKFKDRFTISVDK
SKNTAY LQM NSL RAEDTAVYY CA RSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLESGQV
LL ESN I KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRH RRRQAERMSQI KRLLSEKK
TCQCPHRFQKTCSPI
488 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGGGVVQPGRSL RLSCAASG
FTFSSYA M HWVRQAP
G KG LEWVAVI SY DGSN KYYADSVKG RFT! SRDNSKNTLY LQ M NSLRAEDTAVYYCARGRVY
YY DSSGYSY WGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSVLTQPPSVSGAPGQ RVTI SCTGSS

CQSY DSSLSG REVEGTGTKLIVLEQKLI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI QM
TQSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGT
DYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGG
LVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG L EWVALI NPTKGVSTYNQKFKDRFTISV
DKSKNTAY LQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESG

KKTCQCPH RFQKTCSPI
489 Amino Acid MALPVTALL LPLALL L HAARPQVQLVESGAEV
KKPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAYM ELSSLRSEDTAVYYCARPLYAPRFG
YGM DVWGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSVLTQPPSASGTPGQRVTI SCSGSSSNIG
SNYVYWYQQLPGTAPKLL IYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWD
DSLSGWVFGGGTQLTVLEQKLISEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSS
LSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTI
SSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPG
GSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVA LI NPTKGVSTYNQKFKDRFTISVDKSKN
TAY LQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LE
SNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQ
CPH RFQKTCSPI
490 Amino Acid MALPVTALL LPLALL L HAARPEVQL LESGGGLVQPGGSLRLSCAASG
FTFSSYAMSWVRQAPG
KG LEWVSAI SGSGGSTYYADSVKG RFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKDRGGQR
G FDYWGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSV LTQPPSASGTPGQ RVTI SCSGSSSNIGSN
YVYWYQQLPGTAPKLL IY RN NQRPSGVPDRFSGSKSGTSASLAI SGL RSEDEADYYCAAWDDS
LSGLVFGGGTKLTVL EQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLS
ASVG DRVTITCRASQ DI RNY L NWYQQ KPG KAPKLL IYYTSRL ESGVPSRFSGSGSGTDYTLTI SS
LQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS
LRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY N QKFKDRFTI SVDKSKNTA
YLQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNI
KVLPTWSTPVQPMALIVLGGVAGLLLFI GLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCP
H RFQKTCSPI
491 Amino Acid MALPVTALL LPLALL L HAARPEVKLVESGGG LVQPGGSL
KLSCTTSGFTFSSYGLSWI RQTPDK
RLELVASI N RNGDNTYYTDSVKG RFT! SRH DAK NTL N LQM NSLKSEDTAMYYCTRGGFSYWG
QGTLVTVSAGSTSGSGKPGSGEGSTKGDIVLTQSPAI MSSSPGEKVTMTCSASSSVSYMYWYQ
QRPGSSPRLLIYDTSKLASGVPVRFSGSVSGTSYSLTI SRMESEDAATYYCQQWSGFPPITFGAG

CRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYY
CQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGY
SFTGYTM NWVRQAPGKGL EWVA LI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLRAE
DTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTWSTPV
QPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RFQKTCSPI
492 Amino Acid MALPVTALL LPLALL L HAARPEVKLVESGGG LVQPGGSL
KLSCTTSGFTFSSYGLSWI RQTPDK
RLELVASI N RNGDNTYYTDSVRGRFTISRDNAKNTLN LQMSSLKSEDTAMYYCTRGGFSYWG
QGTLVTVSAGSTSGSGKPGSGEGSTKGDIVLTQSPATMSASPGEKVTLTCSASPGVTYMYWYQ
QKPGSSPRLLIYDTSNLASGVPLRFSGSGSGTSYSLTISRTEAEDAATYYCQQWSGYPPITFGAG
TKL EL REQKLI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVGDRVTIT
CRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYY
CQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGY
SFTGYTM NWVRQAPGKGL EWVA LI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLRAE
DTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTWSTPV
QPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RFQKTCSPI
493 Amino Acid MALPVTALL LPLALL L HAARPEVKLVESGGG LVQPGGSL
KLSCTTSGFTFSSYGLSWI RQTPDK
RLELVASI N RNGDNAYY 1 DSVKG RFT! SRDNAKNAL N LQ MSSLKSEDTAMYYCTRGGFSHWG
QGTLVTVAAGSTSGSGKPGSGEGSTKGQIVLTQSPAI MSASPGEKVTMTCSASSSVSYMYWYQ

CA 031738M62gib-99- 28 QKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLIISRM EAEDAATYYCQQWSGYPPITFGAG

CRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYY
CQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGY
SFTGYTM NWVRQAPGKGL EWVA LI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLRAE
DTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTWSTPV
QPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RFQKTCSPI
494 Amino Acid MALPVTALL LPLALL L HAARPEVKLVESGGG LVQPGGSL KLSCAASG
FTFSSYG LSWVRQTPD
KG LELVASI N RNGG NTYYTDSVKG RFT! SRDNAKNTLNLQMSSLKSEDTAMYYCARGGFTYW
GQGTLVTVSAGSTSGSGKPGSGEGSTKGQIVLTQSPAIMSAFPGEKVTMTCSASSSVGYMYWY
QQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTAYSLTISRMEAEDAATYYCQQWSGYPPITFG

TITCRASQ DI RNY LNWYQQKPGKAPKLL IYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPEDFA
TYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAA
SGYSFTGYTM NWVRQAPG KG LEWVALI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSL
RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVLL ESNIKVLPTWS

SPI
495 Amino Acid MALPVTALL LPLALL L HAARPQVQL KESGGGLVRPGGSLKLSCAASG
FTFSNYG MSWI RQTPD
KN LELVASI NTSGGNTYYPDSVKGRFTISRDNARATLN LQMSNLKSEDTAIYYCTRGGFTHWG
QGTLVAVSAGSTSGSGKPGSGEGSTKGQIVLTQSPAI MSASPGEKVTMTCSASSSVSYMYWYQ
QKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYFLTISRM EAEDAATYYCQQWTGYPPITFGAG
TKL EL REQKLI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVGDRVTIT
CRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYY
CQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGY
SFTGYTM NWVRQAPGKGL EWVA LI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLRAE
DTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTWSTPV
QPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCPHRFQKTCSPI
496 Amino Acid MALPVTALL LPLALL L HAARPQVQL KESGGGLVQPGGSLKLSCAASG
FPFSSYGLSWVRQTPD
KRLELVATI N RNGDSAYY PDSVKG RFTISRDDAKNTLY LQ MSSLKSEDTAMYYCTRGGFAYW
GQGTLVTVSAGSTSGSGKPGSGEGSTKGQIVLTQSPAIMSASPGEKVTMTCSGSSSVGYMYWY
QQKPGFSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGA

ITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFAT
YYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAS
GYSFTGYTM NWVRQAPGKG LEWVA LI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLR
AEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTVVST
PVQPMALIVLGGVAGLLL FIGLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCPHRFQKTCS
PI
497 Amino Acid MALPVTALL LPLALL L HAARPEVKLVESGGG LVRPGGSL KLSCAASG
FTFSNYG MSWI RQTPD
KN LELVASI NTSGGNTYYPDSVKGRFTISRDNARATLN LQMSNLKSEDTAIYYCTRGGFTHWG
QGTLVTVSAGSTSGSGKPGSGEGSTKGDIVLTQSPAI MSASPGEKVTMTCSASSSVAFMYWYQ
QKPGSSPRLLIYDTSKLASGVPVRFSGSGSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGAG

CRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYY
CQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGY
SFTGYTM NWVRQAPGKGL EWVA LI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLRAE
DTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTWSTPV
QPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RFQKTCSPI
498 Amino Acid MALPVTALL LPLALL L HAARPQVQL KESGGGLVQPGGSLKLSCTTSG
FTFSSYG LSWI RQTPDK
RLELVASI N RNGDNTYYTDSVRGRFTISRDNAKSTLN LQMSSLKSEDTAMYYCTRGGFSYWGQ
GTLVTVSAGSTSGSGKPGSGEGSTKGQIVLTQSPPLMSASPGEKVTMTCSASSSVGYMYWFQQ
RPGSSPRLLIYDTYNLASGVPVRFSGSGSGTSYSLTISRLEAEDAATYYCQQWSGYPPITFGAGT

RASQDI RNY L NWYQQKPGKAPKL L IYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPEDFATYYC
QQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYS

TAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVLL ESNIKVLPTWSTPVQ
PMALIVLGGVAGL LL Fl G LG I FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RFQKTCSPI

CA 031738M62gib-99- 28
499 Amino Acid MALPVTALL LPLALL L HAARPEVKLVESGGG LVQPGGSL KLSCAASG
FTFSSYG LSWVRQTPD
KRL ELVASVN RNGGNTYYTDSVKG RFT! SRDNAKNTL N LQ MSSLKSEDTAMYYCARGG FTY
WGQGTLVTVSAGSTSGSGKPGSGEGSTKGQIVLTQSPAI MSASPGEKVTMTCSASSSVGY MYW
YQQKPGSSPRLLIYDTSHLASGVPVRFSGSGSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFG

TITCRASQ DI RNY LNWYQQKPGKAPKLL IYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPEDFA
TYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAA
SGYSFTGYTM NWVRQAPG KG LEWVALI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSL
RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVLL ESNIKVLPTWS

SPI
500 Amino Acid MALPVTALL LPLALL L HAARPEVKLVESGGG LVQPGGSL KLSCAASG
FPFSSYGLSWVRQTPD
KRLELVATI N RNGDSAYY PDSVKG RFTISRDDAKNTLY LQ MSSLKSEDTAMYYCTRGGFAYW
GQGTLVTVSAGSTSGSGKPGSGEGSTKGQIVLTQSPVIMSASPGEKVTMTCSASSSVGY MYWY
QQRPGSSPRLLIYDTSNLASGAPVRFSGSGSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGA

ITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFAT
YYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAS
GYSFTGYTM NWVRQAPGKG LEWVA LI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLR
AEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTVVST
PVQPMALIVLGGVAGLLL FIGLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCPHRFQKTCS
PI
501 Amino Acid MALPVTALL LPLALL L HAARPEVKLVESGGG LVQPGGSL
KLSCTTSGFTFSSYGLSWI RQTPDK
RLELVASI N RNGDNTYYTDSVKGRFTISRDNAKNTLN LQMSSLKSEDTAMYYCTRGGFSYWG
QGTLVTVSAGSTSGSGKPGSGEGSTKGQIVLTQSPAI MSASPGEKVTMTCSASSSVSY MYWYQ
QKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRM EAEDAATYYCQQWTGYPPITFGAG

CRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYY
CQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGY
SFTGYTM NWVRQAPGKGL EWVA LI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLRAE
DTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTWSTPV
QPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RFQKTCSPI
502 Amino Acid MALPVTALL LPLALL L HAARPEVKLVESGGVLVQPGGSL KLSCAASG
FTFSSYG MSWVRQTPD
KRLELVASI N KNGGSTYY PDSVKG RFT! SRDNAKTTVY LQMSSL KSEDTAMYY CTRGG FAYW
GQGTLVTVSAGSTSGSGKPGSGEGSTKGQIVLTQSPAIMSASPGEKVTLTCSASSSVGY MYWY
QQRPGSSPRLLIYDTSNLPSGVPVRFSGSGSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGA

ITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFAT
YYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAS
GYSFTGYTM NWVRQAPGKG LEWVA LI NPTKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLR
AEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTVVST
PVQPMALIVLGGVAGLLL FIGLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCPHRFQKTCS
PI
503 Amino Acid MALPVTALL LPLALL L HAARPQLQLQ ESGGG LVQAGGSL
RLSCAASGRTGSSYA MGWFRQAP
GKEREFVAAITVVSGGITAYADSVKGRFTISRDNAKNTVYLQM NSLKPEDTAVYCCAAGVTGSP
SFDSWGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLS
ASVG DRVTITCRASQ DI RNY L NWYQQ KPG KAPKLL IYYTSRL ESGVPSRFSGSGSGTDYTLTI SS
LQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS
LRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY N QKFKDRFTI SVDKSKNTA
YLQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNI
KVLPTWSTPVQPMALIVLGGVAGLLLFI GLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCP
H RFQKTCSPI
504 Amino Acid MALPVTALL LPLALL L HAARPQVQLQESGGGLVQAGGSLRLSCAASG
RTFSSYAMGWFRQAP
GKEREFVAAISGSGGSIYYGDSVKGRFTISRDNAKNTMYLQM N RLKPEDTAVYYCAAGPLGSP
DFDSWGQGTQVIVSSEQK LI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLS
ASVG DRVTITCRASQ DI RNY L NWYQQ KPG KAPKLL IYYTSRL ESGVPSRFSGSGSGTDYTLTI SS
LQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS
LRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY N QKFKDRFTI SVDKSKNTA
YLQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNI
KVLPTWSTPVQPMALIVLGGVAGLLLFI GLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCP
H RFQKTCSPI

CA 031738M62gib-99- 28
505 Amino Acid MALPVTALL LPLALL L HAARPEVQVVESGGG LVQPGGSLRLSCVASG
RTFSSYAMGWFRQAP
GKEREFVAAISGSGGSIYYGDSVKGRFTISRDNAKNTMYLQM N RLKPEDTAVYYCAAGPLGSP
DFDSWGQGTQVIVSSEQK LI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLS
ASVG DRVTITCRASQ DI RNY L NWYQQ KPG KAPKLL IYYTSRL ESGVPSRFSGSGSGTDYTLTI SS
LQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS
LRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY N QKFKDRFTI SVDKSKNTA
YLQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNI
KVLPTWSTPVQPMALIVLGGVAGLLLFI GLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCP
H RFQKTCSPI
506 Amino Acid MALPVTALL LPLALL L HAARPKVQLVESGGGLVQAGGSLRLSCAASG
RTGSSYAMGWFRQAP
GKEREFVAAITVVSGGITAYADSVKGRFTISRDNAKNTVYLQM NSLKPEDTAVYCCAAGVTGSP
SFDSWGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLS
ASVG DRVTITCRASQ DI RNY L NWYQQ KPG KAPKLL IYYTSRL ESGVPSRFSGSGSGTDYTLTI SS
LQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS
LRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY N QKFKDRFTI SVDKSKNTA
YLQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNI
KVLPTWSTPVQPMALIVLGGVAGLLLFI GLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCP
H RFQKTCSPI
507 Amino Acid MALPVTALL LPLALL L HAARPEVQLVESGGG LVQAGGSL
RLSCAASGRTFSSYA MGWFRQAP
GKEREFVAAISGSGGVTFYAHSVKGRFTISRDNAKNIVYLQM NSLKPEDTAVYSCAGGANGSP
DFGSWGQGTQVIVSSEQK LI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLS
ASVG DRVTITCRASQ DI RNY L NWYQQ KPG KAPKLL IYYTSRL ESGVPSRFSGSGSGTDYTLTI SS
LQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS
LRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY N QKFKDRFTI SVDKSKNTA
YLQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNI
KVLPTWSTPVQPMALIVLGGVAGLLLFI GLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCP
H RFQKTCSPI
508 Amino Acid MALPVTALL LPLALL L HAARPQVQLVESGGGLVQPGGSLRLSCAVSRN
IASLY RVDWY RQAP
GKQRELVAGRTSGGTTTY LDAVEG RFT! SRDNVKDTVY LQ M NSLTPEDTAVYYCHAHDHWR
DSWGQGTQVTVSSEQK LI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSLSAS
VGDRVTITCRASQDI RNYL NWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQ
PEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLR
LSCAASGYSFTGYTM NWVRQAPG KG L EWVALI NPTKGVSTYNQKFKDRFTISVDKSKNTAYL
QM NSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIK
VLPTWSTPVQPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH
RFQKTCSPI
509 Amino Acid MALPVTALLLPLALLLHAARPQVQLVESGGDLVQPGGSLRLSCAASGSIGSIYAMGWYRQAPG
RQRELVATTTSGGTTNYADSVKGRFTIAGDNAKNTVFLQM NSLRPEDTAVYYCKIQTHWYVY
WGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVG
DRVTITCRASQDI RNY L NWYQQKPG KAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPE
DFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLS
CAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY NQK FKDRFTI SVDKSKNTAY LQ
M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL

QKTCSPI
510 Amino Acid MALPVTALL LPLALL L HAARPEVQLVESGGG LVQPGGSL
RLSCAASRNIFSLY RVDWY RQAPG
KQRELVAGSTSGGTTTYADAVKGRFTISTDNVKDTVYLQM NSLTPEDTAVYYCHAHDHWRD
SWGQGTQVTVSSEQKL I SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSLSASV
GDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQP
EDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRL

M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL

QKTCSPI
511 Amino Acid MALPVTALL LPLALL L HAARPQVQLVESGGGWVHPGGSLRLSCAASRNIFSMY
RVDWY RQAP
G KQ RELVAG ITSGGTTSYADAVKG RFT! STDNVKDTVY LQM NSVTPEDTAVYY CHAN DHWR
DSWGQGTQVTVSSEQK LI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSLSAS
VGDRVTITCRASQDI RNYL NWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQ
PEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLR
LSCAASGYSFTGYTM NWVRQAPG KG L EWVALI NPTKGVSTYNQKFKDRFTISVDKSKNTAYL
QM NSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIK

CA 031738M62gib-99- 28 VLPTWSTPVQPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH
RFQKTCSPI
512 Amino Acid SQRELVATITSAGTTNYADSVKGRFTISRDNAKNTVY LQM NSLRPEDTAVYYCN FQTHWYVY
WGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVG
DRVTITCRASQDI RNY L NWYQQKPG KAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPE
DFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLS
CAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY NQK FKDRFTI SVDKSKNTAY LQ
M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL

QKTCSPI
513 Amino Acid MALPVTALL LPLALL L HAARPEVRLVESGGG LVQPGGSL RLSCAVSKN 1 FSIY RVDWYHQAPG
KQRELVAGWTSGGSTSYADAVKGRFTISTDNVKDTVYLQM NSLTPEDTAVYYCHAHDHWRD
YWGQGTQVTVSSEQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSLSASV
GDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQP
EDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRL

M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL

QKTCSPI
514 Amino Acid QVQLQESGGGLVQPGGSL RLSCAASGIIFSI NTMAWY RQGPG KQRDLVAL 1 SSGG NTSYADSV
NG RFT! SRDNAKNTVY LQ M NGLKPEDTAVYYCNSAGRSYSGSYGAYWGQGTQVTVSS
515 Amino Acid EVQLVESGGGLVQPGGSLRLSCAASRSI FVIAFM
DWYRQAPGKQREFVAGISSSGATSYASSVK
GRFTVSRDTAKNTMYLQM NN LLPEDSAVYYCKADTATTTDWGQGTQVTVSS
516 Amino Acid QVQLQESGGGLVQPGGSL RLSCAASRSI FGIAFM DWY RQAPG KQREFVAG

KG RFTVSRDNAKNTMY LQM NNLLPEDSAVYYCKADTATNTDWGQGTQVTVSS
517 Amino Acid QLQLVESGGG LVQAGGSL RLSCAVSG N IWVFTVMAWY RQVPG
KQRELVAASTNGGSTNYAD
SVKGRFTISRDNVKNTVY LQM NSLKPEDTAVYYCN RQRTVIGM NPLAPWGQGTQVTVSS
518 Amino Acid QVQLVESGGGLVQPGGSL RLSCATSGIIFHIYTMGWY
RGAPGKQRELVARITSGGDTNYADSV
KG RFTISRDNVKNTMY LQM NSLKPEDTAVYYCNRFPGATFSWGQGTQVTVSS
519 Amino Acid EVQLVESGGGLVQPGGSLRLSCAASGIIFSI NTMAWY RQGPGKERDLVAVI
KGDGSTSYADSV
NGRFTISRDNAKNTVYLRM NG L KPEDTAVYYCN SAG RSY SGVYGAYWGQGTQVTVSS
520 Amino Acid EVQLQESGGGLVQPGGSLKLSCAASGSI FSI GAM
RWYRQVPGNERELVAGITNGGNTNYADSV
KARFTISRDNAKNTVYLQM NSLKPEDTTVY FCNADVQNSGYVWGNYWGQGTQVTVSS
521 Amino Acid EVQLVESGGGLVQPGGSLRLSCAASRSI FVIAFM DWY RQAPG KQREFVAG I
SSSGATSYADSVK
GRFTVSRDTAKNTMYLQM NN LLPEDSAVYYCKADTATNTDWGQGTQVTVSS
522 Amino Acid GI I FSI NTMA
523 Amino Acid LI SSGG NTSYADS
524 Amino Acid NSAGRSYSGSYGAY
525 Amino Acid RSI FVIA FM D
526 Amino Acid GISSSGATSYASS
527 Amino Acid KA DTATTTD
528 Amino Acid RSI FGIA FM D
529 Amino Acid GI SHSGATSYADS
530 Amino Acid KADTATNTD
531 Amino Acid GNIWVFTVMA
532 Amino Acid ASTNGGSTNYADS
533 Amino Acid N RQRTVI GM NPLAP
534 Amino Acid GI I FHIYTMG
535 Amino Acid RITSGGDTNYADS
536 Amino Acid NRFPGATFS
537 Amino Acid GI I FSI NTMA
538 Amino Acid VI KGDGSTSYADS

CA 031738M62gib-99- 28
539 Amino Acid NSAGRSYSGVYGAY
540 Amino Acid GSI FSI GAM R
541 Amino Acid GITNGGNTNYADS
542 Amino Acid NADVQNSGYVWG NY
543 Amino Acid RSI FVIA FM D
544 Amino Acid GISSSGATSYA DS
545 Amino Acid KA DTATNTD
546 Amino Acid MALPVTALLLPLALLLHAARPQVQLQESGGGLVQPGGSLRLSCAASGIIFSI
NTMAWYRQGPG
KQRDLVALISSGGNTSYADSVNGRFTISRDNAKNTVYLQM NGLKPEDTAVYYCNSAGRSYSGS
YGAYWGQGTQVIVSSEQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSL
SASVG DRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES

CPH RFQKTCSPI
547 Amino Acid MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASRSI FVIAFM
DWYRQAPG
KQ REFVAG I SSSGATSYASSVKG RFTVSRDTAKNTMY LQM N N LLPEDSAVYYCKADTATTTD
WGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVG
DRVTITCRASQDI RNY L NWYQQKPG KAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPE
DFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLS
CAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY NQK FKDRFTI SVDKSKNTAY LQ
M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL

QKTCSPI
548 Amino Acid MALPVTALL LPLALL L HAARPQVQLQESGGGLVQPGGSLRLSCAASRSI
FGIAFM DWY RQAPG
KQ REFVAG I SHSGATSYADSVKG RFTVSRDNAKNTMY LQM N N LLPEDSAVYYCKADTATNTD
WGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVG
DRVTITCRASQDI RNY L NWYQQKPG KAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPE
DFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLS
CAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY NQK FKDRFTI SVDKSKNTAY LQ
M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL

QKTCSPI
549 Amino Acid MALPVTALLLPLALLLHAARPQLQLVESGGGLVQAGGSLRLSCAVSGNIWVFTVMAWYRQVP
G KQ RELVAASTNGGSTNYADSVKG RFT! SRDNVKNTVY LQ M NSLKPEDTAVYYCNRQRTVIG
M N PLAPWGQGTQVTVSSEQK LI SEEDLN PGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPS
SLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKL LIYYTSRLESGVPSRFSGSGSGTDYTL
TISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQP
GGSLRLSCAASGYSFTGYTM NWVRQAPGKG LEWVALI NPTKGVSTYNQKFKDRFTISVDKSK
NTAY LQM NSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLL
ESN! KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRHRRRQAERMSQIKRLLSEKKTC
QCPH RFQKTCSPI
550 Amino Acid MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCATSGIIFHIYTMGWYRGAPG
KQRELVARITSGGDTNYADSVKGRFTISRDNVKNTMYLQM NSLKPEDTAVYYCN RFPGATFS
WGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVG
DRVTITCRASQDI RNY L NWYQQKPG KAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPE
DFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLS
CAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY NQK FKDRFTI SVDKSKNTAY LQ
M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL

QKTCSPI
551 Amino Acid MALPVTALL LPLALL L HAARPEVQLVESGGG LVQPGGSL
RLSCAASGIIFSI NTMAWYRQGPGK
ERDLVAVI KGDGSTSYADSVNGRFTISRDNAKNTVY LRM NG LKPEDTAVYYCNSAGRSYSGV
YGAYWGQGTQVIVSSEQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSL
SASVG DRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVLL ES

CA 031738M62gib-99- 28 NIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQ
CPH RFQKTCSPI
552 Amino Acid MALPVTALLLPLALLLHAARPEVQLQESGGGLVQPGGSLKLSCAASGS1 FSI
GAM RWYRQVPG
N ERELVAG ITNGGNTNYADSVKA RFT! SRDNAKNTVY LQ M NSLKPEDTTVY FCNADVQNSGY
VWG NYWGQGTQVIVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSS
LSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTI
SSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPG
GSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALI NPTKGVSTYNQKFKDRFTISVDKSKN
TAY LQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LE
SNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQ
CPH RFQKTCSPI
553 Amino Acid MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASRSI FVIAFM
DWYRQAPG
KQ REFVAG I SSSGATSYADSVKG RFTVSRDTAKNTMY LQ M N N LLPEDSAVYYCKADTATNTD
WGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVG
DRVTITCRASQDI RNY L NWYQQKPG KAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPE
DFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLS
CAASGYSFTGYTM NWVRQAPG KG LEWVALIN PTKGVSTY NQK FKDRFTI SVDKSKNTAY LQ
M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL
PTVVSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RE
QKTCSPI
554 Amino Acid MALPVTALL LPLALL L HAARPEVKLVESGGG LVQPGGSL KLSCAASG
FTFSSYG LSWVRQTPD
KG LELVASI N RNGG NTYYTDSVKG RFT! SRDNAKNTLNLQMSSLKSEDTAMYYCARGGFTYW
GQGTLVTVSAGSTSGSGKPGSGEGSTKGQIVLTQSPAIMSAFPGEKVTMTCSASSSVGYMYWY
QQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTAYSLTISRMEAEDAATYYCQQWSGYPPITFG

TITCRASQDI RNY LNWYQQKPGKAPKLL IYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPEDFA
TYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAA
SGYSFTGYTM NWVRQAPG KG LEWVALI NPYKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSL
RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVLL ESNIKVLPTWS

SPI
555 Amino Acid MALPVTALLLPLALLLHAARPQIVLTQSPAI
MSAFPGEKVTMTCSASSSVGYMYWYQQKPGSS
PRLLIYDTSNLASGVPVRFSGSGSGTAYSLTISRM EAEDAATYYCQQWSGYPPITFGAGTKLEL
KGSTSGSG KPGSG EGSTKG EVKLVESGGG LVQPGGSLKLSCAASG FTFSSYG LSWVRQTPDKG
LELVASI NRNGGNTYYTDSVKGRFTISRDNAKNTLN LQMSSLKSEDTAMYYCARGGFTYWGQ
GTLVTVSAEQKLISEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVGDRV
TITCRASQDI RNY LNWYQQKPGKAPKLL IYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPEDFA
TYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAA
SGYSFTGYTM NWVRQAPG KG LEWVALI NPYKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSL
RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVLL ESNIKVLPTWS

SPI
556 Amino Acid MALPVTALL LPLALL L HAARPQVQL KESGGGLVQPGGSLKLSCTTSG
FTFSSYG LSWI RQTPDK
RLELVASI N RNGDNTYYTDSVRGRFTISRDNAKSTLN LQMSSLKSEDTAMYYCTRGGFSYWGQ
GTLVTVSAGSTSGSGKPGSGEGSTKGQIVLTQSPPLMSASPGEKVTMTCSASSSVGYMYWFQQ
RPGSSPRLLIYDTYNLASGVPVRFSGSGSGTSYSLTISRLEAEDAATYYCQQWSGYPPITFGAGT

RASQDI RNY L NWYQQKPGKAPKL L IYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPEDFATYYC
QQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYS

DTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTWSTPV
QPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RFQKTCSPI
557 Amino Acid MALPVTALL LPLALL L HAARPQIVLTQSPPL MSASPG
EKVTMTCSASSSVGY MYWFQQRPGSS
PRL LIY DTY N LASGVPVRFSGSGSGTSYSLTI SRL EAEDAATYYCQQWSGY PPITFGAGTKLELR
GSTSGSG KPGSG EGSTKGQVQL KESGGG LVQPGGSL KLSCTTSG FTFSSYG LSWI RQTPDKRLE
LVASI NRNGDNTYYTDSVRGRFTISRDNAKSTLN LQMSSLKSEDTAMYYCTRGGFSYWGQGT
LVTVSAEQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVGDRVTIT
CRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYY
CQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGY
SFTGYTM NWVRQAPGKGL EWVA LI NPYKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLRAE

CA 031738M62gib-99- 28 DTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTWSTPV
QPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RFQKTCSPI
558 Amino Acid MALPVTALL LPLALL L HAARPQVQL KESGGGLVRPGGSLKLSCAASG
FTFSNYG MSWI RQTPD
KN LELVASI NTSGGNTYYPDSVKGRFTISRDNARATLN LQMSNLKSEDTAIYYCTRGGFTHWG
QGTLVAVSAGSTSGSGKPGSGEGSTKGQIVLTQSPAI MSASPGEKVTMTCSASSSVSY MYWYQ
QKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYFLTISRM EAEDAATYYCQQWTGYPPITFGAG
TKL EL REQKLI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVGDRVTIT
CRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYY
CQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGY
SFTGYTM NWVRQAPGKGL EWVA LI NPYKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSLRAE
DTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTWSTPV
QPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RFQKTCSPI
559 Amino Acid MALPVTALLLPLALLLHAARPQIVLTQSPAI MSASPGEKVTMTCSASSSVSY
MYWYQQKPGSS
PRLLIYDTSNLASGVPVRFSGSGSGTSYFLTISRM EAEDAATYYCQQWTGYPPITFGAGTKLELR
GSTSGSG KPGSGEGSTKGQVQL KESGGGLVRPGGSL KLSCAASG FTFSNYG MSWI RQTPDKNL
ELVASI NTSGGNTYYPDSVKGRFTISRDNARATLN LQMSN LKSEDTAIYYCTRGGFTHWGQGT

TCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATY
YCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASG

AEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTVVST
PVQPMALIVLGGVAGLLL FIGLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCPHRFQKTCS
PI
560 Amino Acid MALPVTALL LPLALL L HAARPQVQL KESGGGLVQPGGSLKLSCAASG
FPFSSYGLSWVRQTPD
KRLELVATI N RNGDSAYY PDSVKG RFTISRDDAKNTLY LQ MSSLKSEDTAMYYCTRGGFAYW
GQGTLVTVSAGSTSGSGKPGSGEGSTKGQIVLTQSPAIMSASPGEKVTMTCSGSSSVGY MYWY
QQKPGFSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGA

ITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFAT
YYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAS
GYSFTGYTM NWVRQAPGKG LEWVA LI NPYKGVSTYNQKFKDRFTISVDKSKNTAYLQM NSL
RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVLL ESNIKVLPTWS

SPI
561 Amino Acid MALPVTALLLPLALLLHAARPQIVLTQSPAI MSASPGEKVTMTCSGSSSVGY
MYWYQQKPGFS
PRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRM EAEDAATYYCQQWSGYPPITFGAGTKLELK
GSTSGSG KPGSGEGSTKGQVQL KESGGGLVQPGGSL KLSCAASGFPFSSYGLSWVRQTPDKRL
ELVATI N RNGDSAYY PDSVKG RFTISRDDAKNTLY LQMSSL KSEDTAMYY CTRGG FAYWGQG
TLVTVSAEQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVGDRVTI
TCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATY
YCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASG

AEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVLPTVVST
PVQPMALIVLGGVAGLLL FIGLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCPHRFQKTCS
PI
562 Amino Acid MALPVTALL LPLALL L HAARPQVQLQESGGGLVQPGGSLRLSCAASRSI
FGIAFM DWY RQAPG
KQ REFVAG I SHSGATSYADSVKG RFTVSRDNAKNTMY LQ M N N LLPEDSAVYYCKADTATNTD
WGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVG
DRVTITCRASQDI RNY L NWYQQKPG KAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPE
DFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLS

M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL

QKTCSPI
563 Amino Acid MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASRSI FVIAFM
DWYRQAPG
KQ REFVAG I SSSGATSYASSVKG RFTVSRDTAKNTMY LQ M N N LLPEDSAVYYCKADTATTTD
WGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVG
DRVTITCRASQDI RNY L NWYQQKPG KAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPE
DFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLS

CA 031738M62gib-99- 28 M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL
PTVVSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RE
QKTCSPI
564 Amino Acid MALPVTALL LPLALL L HAARPEVQLVESGGG LVQPGGSL
RLSCAASGIIFSI NTMAWYRQGPGK
ERDLVAVI KGDGSTSYADSVNGRFTISRDNAKNTVY LRM NG LKPEDTAVYYCNSAGRSYSGV
YGAYWGQGTQVIVSSEQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSL
SASVG DRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES
NIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQ
CPH RFQKTCSPI
565 Amino Acid MALPVTALLLPLALLLHAARPEVQLQESGGGLVQPGGSLKLSCAASGS1 FSI
GAM RWYRQVPG
N ERELVAG ITNGGNTNYADSVKA RFT! SRDNAKNTVY LQM NSLKPEDTTVY FCNADVQNSGY
VWG NYWGQGTQVIVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSS
LSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTI
SSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPG
GSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVA LI NPYKGVSTYNQKFKDRFTISVDKSKN
TAY LQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LE
SNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQ
CPH RFQKTCSPI
566 Amino Acid MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASRSI FVIAFM
DWYRQAPG
KQ REFVAG I SSSGATSYADSVKG RFTVSRDTAKNTMY LQM N N LLPEDSAVYYCKADTATNTD
WGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVG
DRVTITCRASQDI RNY L NWYQQKPG KAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPE
DFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLS

M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL
PTVVSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RE
QKTCSPI
567 Amino Acid MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCATSGIIFHIYTMGWYRGAPG
KQRELVARITSGGDTNYADSVKGRFTISRDNVKNTMYLQM NSLKPEDTAVYYCN RFPGATFS
WGQGTQVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLSASVG
DRVTITCRASQDI RNY L NWYQQKPG KAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQPE
DFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLS

M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL
PTVVSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH RE
QKTCSPI
568 Amino Acid MALPVTALLLPLALLLHAARPQLQLVESGGGLVQAGGSLRLSCAVSGNIWVFTVMAWYRQVP
G KQRELVAASTNGGSTNYADSVKG RFT! SRDNVKNTVY LQ M NSLKPEDTAVYYCNRQRTVIG
M N PLAPWGQGTQVTVSSEQK LI SEEDLN PGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPS
SLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKL LIYYTSRLESGVPSRFSGSGSGTDYTL
TISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQP
GGSLRLSCAASGYSFTGYTM NWVRQAPGKGLEWVALI NPYKGVSTYNQKFKDRFTISVDKSK
NTAY LQM NSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLL
ESN! KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRHRRRQAERMSQIKRLLSEKKTC
QCPH RFQKTCSPI
569 Amino Acid MALPVTALL LPLALL L HAARPQVQLVESGGGLVQPGGSLRLSCAVSRN
IASLY RVDWY RQAP
GKQRELVAGRTSGGTTTY LDAVEG RFT! SRDNVKDTVY LQ M NSLTPEDTAVYYCHAHDHWR
DSWGQGTQVTVSSEQK LI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSLSAS
VGDRVTITCRASQDI RNYL NWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQ
PEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLR
LSCAASGYSFTGYTM NWVRQAPG KG L EWVALI NPY KGVSTYNQKFKDRFTISVDKSKNTAYL
QM NSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIK
VLPTWSTPVQPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQCPH
RFQKTCSPI
570 Amino Acid MALPVTALL LPLALL L HAARPEVQLVESGGG LVQPGGSL
RLSCAASRNIFSLY RVDWY RQAPG
KQRELVAGSTSGGTTTYADAVKGRFTISTDNVKDTVYLQM NSLTPEDTAVYYCHAHDHWRD
SWGQGTQVTVSSEQKL I SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSLSASV
GDRVTITCRASQDI RNY LNWYQQKPGKAPKL LIYYTSRLESGVPSRFSGSGSGTDYTLTI SSLQP

CA 031738M62gib-99- 28 EDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRL
SCAASGYSFTGYTM NWVRQAPG KG LEWVALIN PY KGVSTY N Q KFKDRFTI SVDKSKNTAY LQ
M NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNIKVL

QKTCSPI
571 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSVSS
GM DVWGQGTLVTVSSGSTSGSGKPGSGEGSTKGQSVLTQPPSASGTPGQRVTISCSGSSSNIGS
NYVYWYQQLPGTAPKL LIY RN NQ RPSGVPDRLSGSKSGTSASLAI SG LRSEDEADYYCAAWDD
SLSAVVFGGGTKLTVLEQKL ISEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSL
SASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES

CPH RFQKTCSPI
572 Amino Acid MALPVTALL LPLALL L HAARPQSVLTQPPSASGTPGQ RVTI SCSGSSSN 1 GSNYVYWYQQ LPGT
APKLL IY RN NQRPSGVPDRLSGSKSGTSASLAI SGL RSEDEADYYCAAWDDSLSAVVFGGGTK
LTVLGSTSGSG KPGSG EGSTKGQVQ LVQSGAEVKKPGSSVKVSC KASGGTFSSYAI SWVRQAP
GQGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDI LRLSV
SSG M DVWGQGTLVIVSSEQKLI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPS
SLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKL LIYYTSRLESGVPSRFSGSGSGTDYTL
TISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQP
GGSLRLSCAASGYSFTGYTM NWVRQAPGKG LEWVALI NPYKGVSTYNQKFKDRFTISVDKSK
NTAY LQM NSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLL
ESN! KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRHRRRQAERMSQIKRLLSEKKTC
QCPH RFQKTCSPI
573 Amino Acid MALPVTALLLPLALLLHAARPQVQLQESGGGVVQPGRSLRLSCAASGFTLSSYGM
HWVRQAP
G KG LEWVAVI SY DGSN KYYADSVKG RFT! SRDNSKNTLY LQ M NSLRAEDTAVYYCAKSGWR
YYYYYGM DVWGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSVLTQPPSVSGAPGQRVTI SCTGS
SSNIGAGYDVHWYQQLPGTAPKLLIYGNSN RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYY
CQSY DSSLSGSVFGGGTKLTVL EQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMT
QSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTD
YTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGL

KSKNTAY LQM NSLRAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLESGQ
VLL ESN I KVLPTVVSTPVQPMAL IVLGGVAG LLL Fl GLG I FFCVRCRH RRRQAERMSQIKRLLSEK
KTCQCPHRFQKTCSPI
574 Amino Acid MALPVTALL LPLALL L HAARPQSVLTQPPSVSGAPGQ RVTI SCTGSSSN 1 GAGY DVHWYQQLPG
TAPKLLIYGNSN RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSY DSSLSGSVFGGGTK
LTVLGSTSGSG KPGSG EGSTKGQVQ LQESGGGVVQPG RSL RLSCAASG FTLSSY GM HWVRQA
PG KGLEWVAVI SY DGSN KYYADSVKGRFTI SRDNSKNTLY LQM NSLRAEDTAVYYCAKSGW
RYYYYYGM DVWGQGTLVTVSSEQKL I SEEDLN PGGGGGSGGGGSGGGGSGGGGSGSM DI QM
TQSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGT
DYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGG
LVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG L EWVALI NPY KGVSTY NQKFKDRFTISV
DKSKNTAY LQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESG

KKTCQCPH RFQKTCSPI
575 Amino Acid MALPVTALL LPLALL L HAARPEVQL LESGGGLVQPGGSLRLSCAASG
FTFSSYWMSWVRQAP

LLYG M DVWGQGTLVTVSSGSTSGSG KPGSG EGSTKGSYVLTQPPSVSVSPGQTARITCSG DAL
PKQYAYWYQQ KPGQAPVLVIY KDSERPSGIPERFSGSSSGTIVTLTI SGVQAEDEADYYCQSAD
SSGTVVVFGGGTKLTVL EQKLI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSL
SASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES

CPH RFQKTCSPI

CA 031738M62gib-99- 28
576 Amino Acid MALPVTALL LPLALL L
HAARPSYVLTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQA
PVLVIYKDSERPSGIPERFSGSSSGTIVTLTISGVQAEDEADYYCQSADSSGTWVFGGGTKLIVL
GSTSGSG KPGSG EGSTKG EVQ LL ESGGG LVQPGGSL RLSCAASG FTFSSYWM SWVRQAPG KG L
EWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLY LQM NSLRAEDTAVYY CA RPAGQ LLYG
M DVWGQGTLVTVSSEQK LI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPSSLS
ASVG DRVTITCRASQ DI RNY L NWYQQ KPG KAPKLL IYYTSRL ESGVPSRFSGSGSGTDYTLTI SS
LQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS
LRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALIN PY KGVSTY NQKFKDRFTISVDKSKNTA
Y LQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLLESNI
KVLPTWSTPVQPMALIVLGGVAGLLLFI GLGI FFCVRCRH RRRQAERMSQIKRLLSEKKTCQCP
H RFQKTCSPI
577 Amino Acid MALPVTALL LPLALL L HAARPEVQL LESGGGVVQPG RSLRLSCAASG
FTFSSYGM HWVRQAP
G KG LEWVAVI SY DGSN KYYADSVKG RFT! SRDNSKNTLY LQM NSLRAEDTAVYYCAKDAAD
M GAFDYWGQGTLVTVSSGSTSGSG KPGSG EGSTKG DI QMTQSPDSLAVSLG ERATM NCKSSQ
SVLYSSN N KNY LAWYQQKPGQPPKLL IYWASA RESGVPDRFSGSGSGTDFTLTI SSLQAEDVA

MTQSPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGS
GTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESG
GGLVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KGL EWVAL I NPYKGVSTY NQKFKDRFTI
SVDKSKNTAY LQM N SLRA EDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLE
SGQVLL ESN 1 KVLPTWSTPVQPMA LIVLGGVAGL LL Fl GLG 1 FFCVRCRH RRRQAERMSQIKRLL
SEKKTCQCPH RFQKTCSPI
578 Amino Acid MALPVTALLLPLALLLHAARPDIQMTQSPDSLAVSLGERATM NCKSSQSVLYSSN
NKNY LAW
YQQ KPGQPPKL LIYWASARESGVPDRFSGSGSGTDFTLTI SSLQAEDVAVYYCQQYYSTPLTFG
QGTKVEI KGSTSGSGKPGSGEGSTKGEVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGM HWV
RQAPG KG LEWVAVI SY DGSN KYYADSVKGRFTISRDNSKNTLY LQM NSLRAEDTAVYYCAKD
AADMGAFDYWGQGTLVTVSSEQK LI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI Q MT
QSPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTD
YTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGL

KSKNTAY LQM NSLRAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLESGQ
VLL ESN I KVLPTVVSTPVQPMAL IVLGGVAG LLL Fl GLG I FFCVRCRH RRRQAERMSQIKRLLSEK
KTCQCPHRFQKTCSPI
579 Amino Acid MALPVTALL LPLALL L HAARPEVQL LESGGGLVKPGGSLRLSCAASG
FTFSSYSM NWVRQAPG
KG LEWVSAI SGSGGSTYYADSVKG RFTISRDN SKNTLY LQM NSLRAEDTAVYYCARARGYSY
GSDAFDIWGQGTMVIVSSGSTSGSGKPGSGEGSTKGQSVLTQPPSASGTPGQRVTISCSGSSSNI
GSNYVYWYQQ LPGTAPKL LIY RN NQ RPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYYCAAW
DDSLSGVVFGGGTKLTVLEQKLI SEEDL NPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSPS
SLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKL LIYYTSRLESGVPSRFSGSGSGTDYTL
TISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQP
GGSLRLSCAASGYSFTGYTM NWVRQAPGKGLEWVALI NPYKGVSTY NQKFKDRFTISVDKSK
NTAY LQM NSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSTSGGGGSLESGQVLL
ESN! KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRHRRRQAERMSQIKRLLSEKKTC
QCPH RFQKTCSPI
580 Amino Acid MALPVTALL LPLALL L HAARPQSVLTQPPSASGTPGQ RVTI SCSGSSSN 1 GSNYVYWYQQ LPGT
APKLL IY RN NQRPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGVVFGGGTKL
TVLGSTSGSG KPGSG EGSTKG EVQ LLESGGG LV KPGGSLRLSCAASG FTFSSYSM NWVRQAPG
KG LEWVSAI SGSGGSTYYADSVKG RFTISRDN SKNTLY LQM NSLRAEDTAVYYCARARGYSY
GSDAFDIWGQGTMVIVSSEQKLI SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQSP
SSLSASVG DRVTITCRASQ DI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYT
LTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQ
PGGSLRLSCAASGYSFTGYTM NWVRQAPGKGLEWVALI NPYKGVSTY NQKFKDRFTISVDKS
KNTAY LQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL

CQCPHRFQKTCSPI
581 Amino Acid MALPVTALL LPLALL L HAARPEVQLVQSGAEV
KKPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARDRGRRYC
SGGSCPNAFDIWGQGTMVIVSSGSTSGSGKPGSGEGSTKGEIVLTQSPATLSVSPGERATLSCR
ASQSVSSN LAWYQQ KPGQAPRLL IYGASTRATGIPARFSGSGSGTEFTLTI SSLQSEDFAVYYCQ

SPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDY

CA 031738M62gib-99- 28 TLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLV
QPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALI NPYKGVSTYNQKFKDRFTISVDK
SKNTAYLQM NSL RAEDTAVYY CA RSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLESGQV
LL ESN I KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRH RRRQAERMSQIKRLLSEKK
TCQCPHRFQKTCSPI
582 Amino Acid MALPVTALL LPLALL L HAARPEIVLTQSPATLSVSPGERATLSCRASQSVSSN
LAWYQQKPGQA
PRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPALTFGGGTKVEI
KGSTSGSG KPGSG EGSTKG EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAI SWVRQAPGQG
LEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYY CA RDRGRRYCSG
GSCPNAFDIWGQGTMVIVSSEQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQ
SPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDY
TLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLV
QPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG LEWVALI NPYKGVSTYNQKFKDRFTISVDK
SKNTAYLQM NSL RAEDTAVYY CA RSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSLESGQV
LL ESN I KVLPTVVSTPVQPMAL IVLGGVAG LL LEI GLG I FFCVRCRH RRRQAERMSQIKRLLSEKK
TCQCPHRFQKTCSPI
583 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARGGYVWGS
YRQNSNWFDPWGQGTLVTVSSGSTSGSGKPGSGEGSTKGSYVLTQPPSASGTPGQRVTISCSGS

AAWDDSLSGWVFGGGTKLTVL EQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI Q M
TQSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGT
DYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGG
LVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG L EWVALI NPY KGVSTY NQKFKDRFTISV
DKSKNTAYLQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESG

KKTCQCPH RFQKTCSPI
584 Amino Acid MALPVTALLLPLALLLHAARPSYVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGT
APKLL IY RN NQRPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGWVFGGGTK
LTVLGSTSGSG KPGSG EGSTKGQVQ LVQSGAEVKKPGSSVKVSC KASGGTFSSYAI SWVRQAP
GQGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARGGYVWG
SY RQNSNWFDPWGQGTLVIVSSEQKLI SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI QM
TQSPSSLSASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGT
DYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGG
LVQPGGSLRLSCAASGYSFTGYTM NWVRQAPG KG L EWVALI NPY KGVSTY NQKFKDRFTISV
DKSKNTAYLQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESG

KKTCQCPH RFQKTCSPI
585 Amino Acid MALPVTALL LPLALL L HAARPQVQLVESGAEV
KKPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADKSTSTAY M ELSSLRSEDTAVYY CA RTH LPYSYG
LGGFDYWGQGTLVTVSSGSTSGSGKPGSGEGSTKGQSVLTQPPSVSGAPGQRVTISCTGSSSNI
GAGYDVHWYQQLPGTAPKLLIYGNSN RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQS
Y DSSLSGPVVEGGGTKVIVL EQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQS
PSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYT
LTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQ
PGGSLRLSCAASGYSFTGYTM NWVRQAPGKG LEWVALI NPYKGVSTYNQKFKDRFTISVDKS
KNTAYLQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL

CQCPHRFQKTCSPI
586 Amino Acid MALPVTALL LPLALL L HAARPQSVLTQPPSVSGAPGQRVTI SCTGSSSN 1 GAGY DVHWYQQLPG
TAPKLLIYGNSN RPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSY DSSLSGPVVFGGGT
KVTVLGSTSGSGKPGSGEGSTKGQVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQA

YG LGGFDYWGQGTLVTVSSEQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI QMTQS
PSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYT
LTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQ
PGGSLRLSCAASGYSFTGYTM NWVRQAPGKG LEWVALI NPYKGVSTYNQKFKDRFTISVDKS
KNTAYLQM NSL RAEDTAVYYCARSGYYG DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL

CQCPHRFQKTCSPI

CA 031738M62gib-99- 28
587 Amino Acid MALPVTALL LPLALL L HAARPQVQLVQSGAEVK
KPGASVKVSCKASGYTFTSYGISWV RQAP
GQG LEWMGWI SAY NG NTNYAQKLQG RVTMTTDTSTSTAY M ELRSLRSDDTAVYYCARDIIR
YCSSTSCY RGIDYWGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSALTQPASVSGSPGQSITI SCT
GTSSDVGGY NYVSWYQQ H PG KAPKLM IYDVSN RPSGVSN RFSGSKSGNTASLTI SG LQAEDEA
DYYCSSYTSSSPHVVSGGGTKLTVL EQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI
QMTQSPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSG
SGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVES

TISVDKSKNTAY LQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGS

LLSEKKTCQCPH RFQKTCSPI
588 Amino Acid MALPVTALL LPLALL L HAARPQSALTQPASVSGSPGQSITI
SCTGTSSDVGGY NYVSWY QQ H PG
KAPKLM IY DVSN RPSGVSN RFSGSKSG NTASLTI SG LQAEDEADYY CSSYTSSSPHVVSGGGTK
LTVLGSTSGSG KPGSG EGSTKGQVQ LVQSGAEVKKPGASVKVSCKASGYTFTSY GISWVRQAP
GQG LEWMGWI SAY NG NTNYAQKLQG RVTMTTDTSTSTAY M ELRSLRSDDTAVYYCARDIIR
YCSSTSCY RGI DYWGQGTLVTVSSEQ KL I SEEDL N PGGGGGSGGGGSGGGGSGGGGSGSM DI Q
MTQSPSSLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGS
GTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESG
GGLVQPGGSLRLSCAASGYSFTGYTM NWV RQAPG KGL EWVAL I NPY KGVSTY NQKFKDRFTI
SVDKSKNTAY LQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLE
SGQVLL ESN 1 KVLPTWSTPVQPMA LIVLGGVAGL LL Fl GLG 1 FFCVRCRH RRRQAERMSQIKRLL
SEKKTCQCPH RFQKTCSPI
589 Amino Acid MALPVTALL LPLALL L HAARPQVQLVESGAEV
KKPGSSVKVSCKASGGTFSSYAI SWVRQAPG
QGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARPLYAPRFG
YGM DVWGQGTLVTVSSGSTSGSG KPGSG EGSTKGQSVLTQPPSASGTPGQRVTI SCSGSSSNIG
SNYVYWYQQLPGTAPKLL IY RN NQ RPSGVPDRFSGSKSGTSASLAI SGL RSEDEADYYCAAWD
DSLSGWVFGGGTQLTVLEQKLISEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSS
LSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTI
SSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPG
GSLRLSCAASGYSFTGYTM NWV RQAPG KG LEWVA LI NPY KGVSTY NQKFKDRFTISVDKSKN
TAY LQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LE

CPH RFQKTCSPI
590 Amino Acid MALPVTALL LPLALL L HAARPQSVLTQPPSASGTPGQ RVTI SCSGSSSN 1 GSNYVYWYQQ LPGT
APKLLIY RN N QRPSGVPDRFSGSKSGTSASLAI SG L RSEDEADYYCAAWDDSLSGWVFGGGTQ
LIVLGSTSGSGKPGSGEGSTKGQVQLVESGAEVKKPGSSVKVSCKASGGTESSYAISWVRQAP
GQGLEWMGGIIPI FGTANYAQKFQGRVTITADESTSTAY M ELSSLRSEDTAVYYCARPLYAPRF
GYGM DVWGQGTLVIVSSEQKLISEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPS
SLSASVGDRVTITCRASQDI RNY LNWYQQKPGKAPKL LIYYTSRLESGVPSRFSGSGSGTDYTL
TISSLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQP
GGSLRLSCAASGYSFTGYTM NWVRQAPGKGLEWVALI NPY KGVSTY NQKFKDRFTISVDKSK
NTAY LQM NSLRAEDTAVYYCARSGYYGDSDWY FDVWGQGTLVTVSSTSGGGGSLESGQVLL

QCPH RFQKTCSPI
591 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAG GGCTTGAGTGGATG G GAG GGATCATCCCTATCTTTG GTACAG CAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGACATAT
TACGATTGAGCGTGTCCTCGGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTC
CTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGTTGACGCAGCCGCCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCT
TGTTCTGGAGGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAG
GAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCG
ATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAG
G ATGA G G CTGATTATTA CTG TG CA G CATG G G ATGA CA G C CTGA G TG GTCATGTG
GTATTCG
GCGGAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATC
CTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCG
GATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGG
CGATAGGGTCACCATCACCTG CCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTAT

CA 031738M62gib-99- 28 CAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTG
GAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGT
CTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGT
TCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCA
GGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGG
GGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTG
GGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGG
TGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAA
AACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTG
CTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCT
GGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTG
GAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTG
TGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGG
TGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGA
GAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
592 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGACATAT
TACGATTGAGCGTGTCCTCGGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTC
CTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCT
TGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAG
GAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCG
ACTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAG
GATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGCTGTGGTATTCGGCG
GAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT
CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
593 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGCAGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCCTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCT
CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTAT
GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAGAGCGGCT
GGAGATATTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTC
CTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCC
TGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGTACCAGCAGCTTC
CAGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGCCCTCAGGGGTCCCTGA
CCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCT
GAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGTTCGGTATTCG
GCGGAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATC

CA 031738M62gib-99- 28 CTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCG
GATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGG
CGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTAT
CAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTG
GAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGT
CTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGT
TCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCA
GGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGG
GGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTG
GGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGG
TGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAA
AACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTG
CTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCT
GGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTG
GAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTG
TGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGG
TGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGA
GAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
594 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGACATAT
TACGATTGAGCGTGTCCTCGGGTATGGACGTCTGGGGCCAAGGGACAATGGTCACCGTGTC
TTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCT
TGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAG
GAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCG
ATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAG
GATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGCCCCTCCGTGGTAT
TCGGCGGAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGA
ATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTG
GCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGT
GGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGG
TATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGT
CTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGC
AGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGA
CGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGC
TCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCA
GGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAA
CTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAA
GGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCA
AAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTG
TGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAAC
CCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTG
CTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGA
TTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTG
CGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGC
GAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
595 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT
CTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGATGGATCGGCGCTTACAATGGTAACACAAACTAT
GCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTAC
ATGGAGCTGAGGAGCCTGAGGAGCGACGACACGGCCGTGTATTACTGTGCGAGGGACCTG
AGGCGGTATAGCAGCAGCTGGGACGGCCCCGGGTACTGGGGCCAGGGAACCCTGGTCACC
GTGTCCTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAG
GGTCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCAT
CTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAA
CACCCAGGCAAAGCCCCCAAACTCATGATTTATGATGTCAGTAATCGGCCCTCAGGGGTTT

CA 031738M62gib-99- 28 CTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAG
GCTGAGGACGAGGCTGATTATTACTGCAGCTCATATACAAGCAGCAGCACTCGGGTCTTCG
GAACTGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATC
CTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCG
GATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGG
CGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTAT
CAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTG
GAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGT
CTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGT
TCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCA
GGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGG
GGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTG
GGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGG
TGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAA
AACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTG
CTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCT
GGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTG
GAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTG
TGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGG
TGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGA
GAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
596 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGACATAT
TACGATTGAGCGTGTCCTCGGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTC
CTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTTCC
TATGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTT
GTTCTGGAAGCAGCTCCAACATCGGAGGTAATTATGTATACTGGTACCAGCAGCTCCCAGG
AACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCGA
TTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAGG
ATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGTTGGGTGTTCGGCGG
AGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGG
CGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATC
TGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGAT
AGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAAC
AGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGT
CCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGC
AACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGG
ACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCG
GAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCT
CACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTG
CGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTA
GTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACA
CAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAG
AAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTC
ACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAA
GCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTT
GGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAG
ACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGA
AAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC

CA 031738M62gib-99- 28
597 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTTCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGATGGGG
GTCGATACAGCTATGGGAGGTCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTGTC
CTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCC
TGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGTACCAGCAGCTTC
CAGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGCCCTCAGGGGTCCCTGA
CCGATTCTCCGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCT
GAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGTCCCGTGGTAT
TCGGCGGAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGA
ATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTG
GCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGT
GGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGG
TATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGT
CTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGC
AGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGA
CGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGC
TCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCA
GGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAA
CTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAA
GGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCA
AAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTG
TGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAAC
CCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTG
CTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGA
TTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTG
CGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGC
GAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
598 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTTCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGACCATTAC
GGCCCCTACACTACTACGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTCCTC
AGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCAGTC
TGTGCTGACGCAGCCGCCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTTGT
TCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAGGAA
CGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCGATT
CTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAGGAT
GAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGACCGAGGGGGTGTTCGGCGGA
GGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGC
GGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCT
GGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATA
GGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACA
GAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTC
CCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCA
ACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGA
CAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGG
AGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTC
ACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGC
GTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAG
TACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACAC
AGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGA
AGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCA
CCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAG
CAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTG
GCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGA

CA 031738M62gib-99- 28 CATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAA
AACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
599 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT
CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCGGGCT
CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTAT
GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGATGGGG
GCGACAGTGGGAGTCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGGGTC
AACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTGACATCGTGAT
GACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCAACTGCAAG
TCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGTACCAGCAGA
AACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCC
TGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAG
GCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATAGTACTCCGCTCACTTTCGGCG
GAGGGACCAAGCTGGAGATCAAAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCT
GGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGG
ATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGC
GATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATC
AACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGG
AGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTC
TGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTT
CGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAG
GCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGG
GCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGG
GTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGT
GTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAA
ACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGC
TAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCT
GGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTG
GAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTG
TGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGG
TGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGA
GAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
600 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTC
TCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGATGAGCTGGGTCCGCCAGGCTCC
AGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAATACTATG
TGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCT
GCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGACCGGCGGG
CCAGCTGCTCTACGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTCCTCAGGG
TCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTTCCTATGTGC
TGACTCAGCCACCCTCGGTGTCAGTGTCCCCAGGACAGACGGCCAGGATCACCTGCTCTGG
AGATGCATTGCCAAAGCAATATGCTTATTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGT
GCTGGTGATATATAAAGACAGTGAGAGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCC
AGCTCAGGGACAACAGTCACGTTGACCATCAGTGGAGTCCAGGCAGAAGACGAGGCTGAC
TATTACTGTCAATCAGCAGACAGCAGTGGTACTTGGGTGTTCGGCGGAGGCACCAAGCTGA
CCGTCCTCGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAA
GTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATA
TCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCAC
CTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAA
AGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCT

CA 031738M62gib-99- 28 CTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTT
CGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAG
GTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGA
GGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCC
TGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAG
GTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCA
GAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCA
AATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTAC
GGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGA
CATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGG
TGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCC
GGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGA
GACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGT
GCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
601 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCT
CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTAT
GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGATGCCG
CGGATATGGGGGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGGGTC
AACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTGACATCCAGAT
GACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATGAACTGCAAG
TCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGTACCAGCAGA
AACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTGCCCGGGAATCTGGGGTCCC
TGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAG
GCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATAGTACTCCTCTCACTTTTGGCCA
GGGGACCAAGGTGGAAATCAAAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT
CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
602 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCT
CCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTAC
GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGCACGTG
GATACAGCTATGGCTCTGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTGTC
TTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCT
TGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAG
GAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCG
ATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAG
GATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGCGTGGTATTCGGCG
GAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT

CA 031738M62gib-99- 28 CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
603 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTTCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC
TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTC
CAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTATG
CAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCT
GCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGGTGTCCC
CCGGTACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACAATGGTCACCGTGTCT
TCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCAG
TCTGTGTTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCCT
GCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGTACCAGCAGCTTCC
AGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGCCCTCAGGGGTCCCTGAC
CGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCTG
AGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGTTCGGTGTTCGG
CGGAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCC
TGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGG
ATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGC
GATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATC
AACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGG
AGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTC
TGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTT
CGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAG
GCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGG
GCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGG
GTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGT
GTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAA
ACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGC
TAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCT
GGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTG
GAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTG
TGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGG
TGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGA
GAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
604 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCCGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGATCGGG
GGAGAAGATATTGTAGTGGTGGTAGCTGCCCTAATGCTTTTGATATCTGGGGCCAAGGGAC
AATGGTCACCGTGTCTTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGC
TCCACAAAGGGTGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGG
AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCA
GCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGT
ATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCC

CA 031738M62gib-99- 28 TGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCCCCGGCCCTC
ACTTTCGGCGGAGGGACCAAGGTGGAAATCAAAGAGCAGAAACTGATCAGCGAGGAAGA
TCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGG
CGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCC
TCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGA
ACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCT
GGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCA
TCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCC
GTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAG
GAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGC
AGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACT
ATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTA
CCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAA
ATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTAT
TATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAG
GAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGT
GCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCT
CTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTG
CGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCT
GAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
605 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTTCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGGGGGTT
ACGTTTGGGGGAGTTATCGTCAGAACTCCAACTGGTTCGACCCCTGGGGCCAGGGAACCCT
GGTCACCGTGTCCTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCC
ACAAAGGGTTCCTATGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGG
GTCACCATCTCTTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACC
AGCAGCTCCCAGGAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAG
GGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGG
GCTCCGGTCCGAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGT
TGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAA
GATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCA
GGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCG
CCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCT
GAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGC
CTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGAC
CATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTG
CCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGG
AGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGT
GCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACA
CTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCC
TACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGAT
AAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTC
TATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTC
AAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACA
GGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATG
GCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTT
TTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCT
GCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCAT
C

CA 031738M62gib-99- 28
606 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCGGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGACATAT
TACGATTGAGCGTGTCCTCGGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTC
CTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCGGAGGGTCACCATCTCT
TGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAG
GAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCG
ATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAG
GATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGTGTGGTATTCGGCG
GAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT
CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
607 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGATGAGCTGGGTCCGCCAGGCTC
CAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAATACTAT
GTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATC
TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGATGGAGTC
ATTACTATGATAGTAGTGGTCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTGTCCTC
AGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTTCCTAT
GTGCTGACTCAGCCACCCTCGGTGTCAGTGTCCCCAGGACAGACGGCCAGGATCACCTGCT
CTGGAGATGCATTGCCAAAGCAATATGCTTATTGGTACCAGCAGAAGCCAGGCCAGGCCC
CTGTGCTGGTGATATATAAAGACAGTGAGAGGCCCTCAGGGATCCCTGAGCGATTCTCTGG
CTCCAGCTCAGGGACAACAGTCACGTTGACCATCAGTGGAGTCCAGGCAGAAGACGAGGC
TGACTATTACTGTCAATCAGCAGACAGCAGTGGTACTTGGGTGTTCGGCGGAGGGACCAA
GCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGG
AGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTAT
GGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACC
ATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAG
GAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCG
CTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAA
GACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCA
CCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGG
AGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTT
TGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCC
CCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACA
ACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACC
TGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATA
CTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCC
TCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATC
AAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAG
TTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGG

CA 031738M62gib-99- 28 CGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTG
TCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
608 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGGACCCATC
TACCATACAGCTATGGTTTAGGCGGGTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGT
GTCCTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGG
TCAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATC
TCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGTACCAGCAGC
TTCCAGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGCCCTCAGGGGTCCC
TGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAG
GCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGCCCGGTGG
TATTCGGCGGAGGGACCAAGGTCACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATC
TGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCG
GTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTC
TGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAAC
TGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGG
AGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATC
AGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGT
GGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGA
GGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAG
CCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTAT
GAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACC
AAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAAT
CCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTA
TTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGA
ACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGC
TGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCT
GATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCG
TGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGA
GCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
609 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGATCCAA
GTCGGGATTACTATGGTTCGGGGAGATTCTCATGGTTCGACCCCTGGGGCCAGGGAACCCT
GGTCACCGTGTCCTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCC
ACAAAGGGTCAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGG
GTCACCATCTCTTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACC
AGCAGCTCCCAGGAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAG
GGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGG
GCTCCGGTCCGAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGT
CGGGGGGTATTCGGCGGAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAG
GAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGA
TCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGT
CCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTA
TCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCC

CA 031738M62gib-99- 28 CGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCT
GACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACT
CTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGG
AGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCT
GGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCT
ACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTA
ATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGT
AGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGC
CGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGG
GGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTG
GACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCC
TATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCT
TCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGC
GGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCC
CCATC
610 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT
CTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAAACTAT
GCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTAC
ATGGAGCTGAGGAGCCTGAGGAGCGACGACACGGCCGTGTATTACTGTGCGAGAGATATA
ATACGATATTGTAGTAGTACCAGCTGCTATAGAGGGATTGACTACTGGGGCCAGGGAACC
CTGGTCACCGTGTCCTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCT
CCACAAAGGGTCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTC
GATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGG
TACCAACAGCACCCAGGCAAAGCCCCCAAACTCATGATTTATGATGTCAGTAATCGGCCCT
CAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCT
GGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCTCATATACAAGCAGCAGCCCC
CATGTGGTATCCGGCGGAGGGACCAAGCTGACGGTCCTAGAGCAGAAACTGATCAGCGAG
GAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGA
TCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGT
CCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTA
TCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCC
CGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCT
GACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACT
CTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGG
AGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCT
GGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCT
ACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTA
ATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGT
AGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGC
CGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGG
GGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTG
GACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCC
TATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCT
TCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGC
GGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCC
CCATC
611 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCT
CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTAT
GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGAA
CGGACTACCGAGGTGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTGTCTTCAGG
GTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTGACATCCA
GTTGACCCAGTCTCCAGACTCCCTGGCTGTGCCTCTGGGCGAGAGGGCCACCATCAACTGC
AAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGTACCAGC
AGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGT
CCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTG
CAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATAGTACTCCTCTGACGTTCG

CA 031738M62gib-99- 28 GCCAAGGGACCAAGCTGGAGATCAAAGAGCAGAAACTGATCAGCGAGGAAGATCTGAAT
CCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGC
GGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGG
GCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTA
TCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCT
GGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAG
TCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACG
TTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTC
AGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGG
GGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACT
GGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAG
GTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAA
AAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGT
GCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACC
CTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGC
TGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGAT
TGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGC
GGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGC
GAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
612 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAGGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGGGGGCG
GAAGGTGGCTACACTCCCGTCTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTGTCCTC
AGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCAGTC
TGTGTTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCCTGC
ACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGTATCAGCAGTTTCCAG
GAACAGCCCCCAAACTCCTCATCTTTGGTAACAACAATCGGCCCTCAGGGGTCCCTGACCG
ATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCTGAG
GATGAGGCTAATTATTACTGCCAGTCCTATGACAGGAGCCTGAGTGGTCCCGTGGTCTTCG
GCGGAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATC
CTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCG
GATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGG
CGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTAT
CAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTG
GAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGT
CTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGT
TCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCA
GGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGG
GGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTG
GGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGG
TGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAA
AACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTG
CTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCT
GGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTG
GAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTG
TGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGG
TGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGA
GAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC

CA 031738M62gib-99- 28
613 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCT
CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTAT
GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGATGCTG
GGGACCTGGGTGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTGTCTTCAGGGTC
AACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTGACATCGTGAT
GACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCAACTGCAAG
TCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGTACCAGCAGA
AACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCC
TGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAG
GCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATAGTACTCCTCTCACTTTCGGCCC
TGGGACCAAGGTGGAAATCAAAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGG
CGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATC
TGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGAT
AGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAAC
AGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGT
CCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGC
AACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGG
ACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCG
GAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCT
CACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTG
CGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTA
GTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACA
CAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAG
AAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTC
ACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAA
GCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTT
GGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAG
ACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGA
AAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
614 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTC
CAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTACG
CAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCT
GCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGGGCGGGT
GTATTACTATGATAGTAGTGGTTATAGCTACTGGGGCCAGGGAACCCTGGTCACCGTGTCC
TCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCAG
TCTGTGTTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCCT
GCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGTACCAGCAGCTTCC
AGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGCCCTCAGGGGTCCCTGAC
CGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCTG
AGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGCCGGGAGGTCTT
CGGAACTGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAA
TCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGG
CGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTG
GGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGT
ATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTC
TGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCA
GTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGAC
GTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCT
CAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAG
GGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAAC
TGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAA
GGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCA
AAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTG
TGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAAC
CCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTG
CTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGA
TTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTG

CA 031738M62gib-99- 28 CGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGC
GAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
615 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGCGCCCCCTGT
ATGCCCCTCGCTTCGGATACGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTC
CTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGTTGACGCAGCCGCCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCT
TGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAG
GAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCG
ATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAG
GATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGTTGGGTGTTCGGCG
GAGGCACCCAGCTGACCGTCCTCGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT
CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
616 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT
CCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTAC
GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGATCGAG
GGGGGCAGCGGGGTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGGGT
CAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCAGTCTGTGCT
GACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTTGTTCTGGA
AGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAGGAACGGCC
CCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCTG
GCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAGGATGAGGC
TGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGTCTGGTGTTCGGCGGAGGGACC
AAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGC
GGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCT
ATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCA
CCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACC
AGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCT

CA 031738M62gib-99- 28 CGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGG
AAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGG
CACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAG
GGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCC
GTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAG
GCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCT
ACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCT
ACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGG
ATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTC
TCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAAC
ATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCG
GAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACAT
CGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAAC
CTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
617 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCACCACCAGCGGCTTCACCTTCAGCAGCTACGGCCTGAGCTGGATCAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCAGCATCAACAGGAACGGCGACAACACCTACTA
CACCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGCACGACGCCAAGAACACCCTGAA
CCTGCAGATGAACAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCACCAGGGGCGG
CTTCAGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCGACATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCAGCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGAGCTACATGTACTGGTACCAGCAGAGGCCCGGCAGCAGCCCCAGGCTGCTGATCTA
CGACACCAGCAAGCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGTGAGCGGCAC
CAGCTACAGCCTGACCATCAGCAGGATGGAGAGCGAGGACGCCGCCACCTACTACTGCCA
GCAGTGGAGCGGCTTCCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
618 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCACCACCAGCGGCTTCACCTTCAGCAGCTACGGCCTGAGCTGGATCAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCAGCATCAACAGGAACGGCGACAACACCTACTA
CACCGACAGCGTGAGGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGAA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCACCAGGGGCGG
CTTCAGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCGACATCGTGCTGACCCAGAGCCC
CGCCACCATGAGCGCCAGCCCCGGCGAGAAGGTGACCCTGACCTGCAGCGCCAGCCCCGG
CGTGACCTACATGTACTGGTACCAGCAGAAGCCCGGCAGCAGCCCCAGGCTGCTGATCTAC
GACACCAGCAACCTGGCCAGCGGCGTGCCCCTGAGGTTCAGCGGCAGCGGCAGCGGCACC
AGCTACAGCCTGACCATCAGCAGGACCGAGGCCGAGGACGCCGCCACCTACTACTGCCAG
CAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAGGGAG
CAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGG
AGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACC

CA 031738M62gib-99- 28 CAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCA
GTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAAC
TACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTT
CTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTA
CTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAA
AGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGG
TGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTC
TGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTG
GAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGG
ACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCT
GCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGAC
TGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCG
GAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCT
GGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTC
TTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGA
GAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGT
TCCAGAAAACATGCAGCCCCATC
619 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCACCACCAGCGGCTTCACCTTCAGCAGCTACGGCCTGAGCTGGATCAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCAGCATCAACAGGAACGGCGACAACGCCTACTA
CATCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACGCCCTGAA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCACCAGGGGCGG
CTTCAGCCACTGGGGCCAGGGCACCCTGGTGACCGTGGCCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGAGCTACATGTACTGGTACCAGCAGAAGCCCGGCAGCAGCCCCAGGCTGCTGATCTA
CGACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCAC
CAGCTACAGCCTGATCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCA
GCAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
620 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCCTGAGCTGGGTGAGGCAGAC
CCCCGACAAGGGCCTGGAGCTGGTGGCCAGCATCAACAGGAACGGCGGCAACACCTACTA
CACCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGAA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCGCCAGGGGCGG
CTTCACCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCTTCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGGGCTACATGTACTGGTACCAGCAGAAGCCCGGCAGCAGCCCCAGGCTGCTGATCTA
CGACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCAC
CGCCTACAGCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCA

CA 031738M62gib-99- 28 GCAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
621 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGAAGGAGAGCGGCGGCGGCCTGGTGAGGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAACTACGGCATGAGCTGGATCAGGCAGAC
CCCCGACAAGAACCTGGAGCTGGTGGCCAGCATCAACACCAGCGGCGGCAACACCTACTA
CCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAGGGCCACCCTGAA
CCTGCAGATGAGCAACCTGAAGAGCGAGGACACCGCCATCTACTACTGCACCAGGGGCGG
CTTCACCCACTGGGGCCAGGGCACCCTGGTGGCCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGAGCTACATGTACTGGTACCAGCAGAAGCCCGGCAGCAGCCCCAGGCTGCTGATCTA
CGACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCAC
CAGCTACTTCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCA
GCAGTGGACCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAGGGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC

CA 031738M62gib-99- 28
622 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGAAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCTTCCCCTTCAGCAGCTACGGCCTGAGCTGGGTGAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCACCATCAACAGGAACGGCGACAGCGCCTACTA
CCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACGACGCCAAGAACACCCTGTA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCACCAGGGGCGG
CTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGGCAGCAGCAG
CGTGGGCTACATGTACTGGTACCAGCAGAAGCCCGGCTTCAGCCCCAGGCTGCTGATCTAC
GACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCACC
AGCTACAGCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCAG
CAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGAG
CAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGG
AGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACC
CAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCA
GTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAAC
TACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTT
CTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTA
CTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAA
AGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGG
TGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTC
TGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTG
GAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGG
ACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCT
GCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGAC
TGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCG
GAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCT
GGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTC
TTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGA
GAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGT
TCCAGAAAACATGCAGCCCCATC
623 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGAGGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAACTACGGCATGAGCTGGATCAGGCAGAC
CCCCGACAAGAACCTGGAGCTGGTGGCCAGCATCAACACCAGCGGCGGCAACACCTACTA
CCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAGGGCCACCCTGAA
CCTGCAGATGAGCAACCTGAAGAGCGAGGACACCGCCATCTACTACTGCACCAGGGGCGG
CTTCACCCACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCGACATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGGCCTTCATGTACTGGTACCAGCAGAAGCCCGGCAGCAGCCCCAGGCTGCTGATCTAC
GACACCAGCAAGCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCACC
AGCTACAGCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCAG
CAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGAG
CAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGG
AGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACC
CAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCA
GTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAAC
TACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTT
CTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTA
CTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAA
AGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGG
TGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTC
TGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTG
GAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGG
ACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCT
GCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGAC
TGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCG
GAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCT
GGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTC
TTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGA

CA 031738M62gib-99- 28 GAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGT
TCCAGAAAACATGCAGCCCCATC
624 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGAAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCACCACCAGCGGCTTCACCTTCAGCAGCTACGGCCTGAGCTGGATCAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCAGCATCAACAGGAACGGCGACAACACCTACTA
CACCGACAGCGTGAGGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAGCACCCTGAA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCACCAGGGGCGG
CTTCAGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CCCCCTGATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGGGCTACATGTACTGGTTCCAGCAGAGGCCCGGCAGCAGCCCCAGGCTGCTGATCTAC
GACACCTACAACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCACC
AGCTACAGCCTGACCATCAGCAGGCTGGAGGCCGAGGACGCCGCCACCTACTACTGCCAG
CAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAGGGAG
CAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGG
AGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACC
CAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCA
GTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAAC
TACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTT
CTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTA
CTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAA
AGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGG
TGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTC
TGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTG
GAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGG
ACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCT
GCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGAC
TGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCG
GAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCT
GGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTC
TTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGA
GAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGT
TCCAGAAAACATGCAGCCCCATC
625 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCCTGAGCTGGGTGAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCAGCGTGAACAGGAACGGCGGCAACACCTACTA
CACCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGAA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCGCCAGGGGCGG
CTTCACCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGGGCTACATGTACTGGTACCAGCAGAAGCCCGGCAGCAGCCCCAGGCTGCTGATCTA
CGACACCAGCCACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCAC
CAGCTACAGCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCA
GCAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG

CA 031738M62gib-99- 28 GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
626 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCTTCCCCTTCAGCAGCTACGGCCTGAGCTGGGTGAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCACCATCAACAGGAACGGCGACAGCGCCTACTA
CCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACGACGCCAAGAACACCCTGTA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCACCAGGGGCGG
CTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGTGATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGGGCTACATGTACTGGTACCAGCAGAGGCCCGGCAGCAGCCCCAGGCTGCTGATCTA
CGACACCAGCAACCTGGCCAGCGGCGCCCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCAC
CAGCTACAGCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCA
GCAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
627 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCACCACCAGCGGCTTCACCTTCAGCAGCTACGGCCTGAGCTGGATCAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCAGCATCAACAGGAACGGCGACAACACCTACTA
CACCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGAA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCACCAGGGGCGG
CTTCAGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGAGCTACATGTACTGGTACCAGCAGAAGCCCGGCAGCAGCCCCAGGCTGCTGATCTA
CGACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCAC
CAGCTACAGCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCA
GCAGTGGACCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA

CA 031738M62gib-99- 28 CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
628 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAAGCTGGTGGAGAGCGGCGGCGTGCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCATGAGCTGGGTGAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCAGCATCAACAAGAACGGCGGCAGCACCTACTA
CCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGACCACCGTGTA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCACCAGGGGCGG
CTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCCTGACCTGCAGCGCCAGCAGCAG
CGTGGGCTACATGTACTGGTACCAGCAGAGGCCCGGCAGCAGCCCCAGGCTGCTGATCTA
CGACACCAGCAACCTGCCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCAC
CAGCTACAGCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCA
GCAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
629 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGCTGCAGCTGCAGGAGAGCGGCGGCGGCCTGGTGCAGGCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCGGCAGGACCGGCAGCAGCTACGCCATGGGCTGGTTCAGGCAGGC
CCCCGGCAAGGAGAGGGAGTTCGTGGCCGCCATCACCTGGAGCGGCGGCATCACCGCCTA
CGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCGTGTA
CCTGCAGATGAACAGCCTGAAGCCCGAGGACACCGCCGTGTACTGCTGCGCCGCCGGCGT
GACCGGCAGCCCCAGCTTCGACAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG

CA 031738M62gib-99- 28 GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
630 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGCAGGAGAGCGGCGGCGGCCTGGTGCAGGCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCGGCAGGACCTTCAGCAGCTACGCCATGGGCTGGTTCAGGCAGGC
CCCCGGCAAGGAGAGGGAGTTCGTGGCCGCCATCAGCGGCAGCGGCGGCAGCATCTACTA
CGGCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCATGTA
CCTGCAGATGAACAGGCTGAAGCCCGAGGACACCGCCGTGTACTACTGCGCCGCCGGCCC
CCTGGGCAGCCCCGACTTCGACAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
631 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGGTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGTGGCCAGCGGCAGGACCTTCAGCAGCTACGCCATGGGCTGGTTCAGGCAGGC
CCCCGGCAAGGAGAGGGAGTTCGTGGCCGCCATCAGCGGCAGCGGCGGCAGCATCTACTA
CGGCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCATGTA
CCTGCAGATGAACAGGCTGAAGCCCGAGGACACCGCCGTGTACTACTGCGCCGCCGGCCC
CCTGGGCAGCCCCGACTTCGACAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC

CA 031738M62gib-99- 28 GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
632 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TAAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGGCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCGGCAGGACCGGCAGCAGCTACGCCATGGGCTGGTTCAGGCAGGC
CCCCGGCAAGGAGAGGGAGTTCGTGGCCGCCATCACCTGGAGCGGCGGCATCACCGCCTA
CGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCGTGTA
CCTGCAGATGAACAGCCTGAAGCCCGAGGACACCGCCGTGTACTGCTGCGCCGCCGGCGT
GACCGGCAGCCCCAGCTTCGACAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
633 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGGCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCGGCAGGACCTTCAGCAGCTACGCCATGGGCTGGTTCAGGCAGGC
CCCCGGCAAGGAGAGGGAGTTCGTGGCCGCCATCAGCGGCAGCGGCGGCGTGACCTTCTA
CGCCCACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCGTGTA
CCTGCAGATGAACAGCCTGAAGCCCGAGGACACCGCCGTGTACAGCTGCGCCGGCGGCGC
CCACGGCAGCCCCGACTTCGGCAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC

CA 031738M62gib-99- 28
634 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGTGAGCAGGAACATCGCCAGCCTGTACAGGGTGGACTGGTACAGGCAGGC
CCCCGGCAAGCAGAGGGAGCTGGTGGCCGGCAGGACCAGCGGCGGCACCACCACCTACCT
GGACGCCGTGGAGGGCAGGTTCACCATCAGCAGGGACAACGTGAAGGACACCGTGTACCT
GCAGATGAACAGCCTGACCCCCGAGGACACCGCCGTGTACTACTGCCACGCCCACGACCA
CTGGAGGGACAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGA
TCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTG
GCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGA
GCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACAT
CCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTAC
TATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGA
TTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAA
GGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGC
GGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGG
CGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCT
TTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGC
ACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACT
ATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAG
GACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTG
ACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCT
GGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCC
AGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCC
TGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCC
AGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAA
CATGCAGCCCCATC
635 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGAGCGGCGGCGACCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCGGCAGCATCGGCAGCATCTACGCCATGGGCTGGTACAGGCAGGC
CCCCGGCAGGCAGAGGGAGCTGGTGGCCACCACCACCAGCGGCGGCACCACCAACTACGC
CGACAGCGTGAAGGGCAGGTTCACCATCGCCGGCGACAACGCCAAGAACACCGTGTTCCT
GCAGATGAACAGCCTGAGGCCCGAGGACACCGCCGTGTACTACTGCAAGATCCAGACCCA
CTGGTACGTGTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGAT
CAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGG
CGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAG
CTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATC
CGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACT
ATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGAT
TACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAG
GTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCG
GAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGC
GGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTT
TACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGC
ACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACT
ATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAG
GACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTG
ACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCT
GGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCC
AGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCC
TGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCC
AGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAA
CATGCAGCCCCATC
636 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCAGGAACATCTTCAGCCTGTACAGGGTGGACTGGTACAGGCAGGC
CCCCGGCAAGCAGAGGGAGCTGGTGGCCGGCAGCACCAGCGGCGGCACCACCACCTACGC
CGACGCCGTGAAGGGCAGGTTCACCATCAGCACCGACAACGTGAAGGACACCGTGTACCT
GCAGATGAACAGCCTGACCCCCGAGGACACCGCCGTGTACTACTGCCACGCCCACGACCA
CTGGAGGGACAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGA
TCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTG
GCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGA

CA 031738M62gib-99- 28 GCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACAT
CCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTAC
TATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGA
TTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAA
GGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGC
GGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGG
CGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCT
TTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGC
ACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACT
ATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAG
GACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTG
ACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCT
GGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCC
AGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCC
TGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCC
AGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAA
CATGCAGCCCCATC
637 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGAGCGGCGGCGGCTGGGTGCACCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCAGGAACATCTTCAGCATGTACAGGGTGGACTGGTACAGGCAGGC
CCCCGGCAAGCAGAGGGAGCTGGTGGCCGGCATCACCAGCGGCGGCACCACCAGCTACGC
CGACGCCGTGAAGGGCAGGTTCACCATCAGCACCGACAACGTGAAGGACACCGTGTACCT
GCAGATGAACAGCGTGACCCCCGAGGACACCGCCGTGTACTACTGCCACGCCCACGACCA
CTGGAGGGACAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGA
TCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTG
GCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGA
GCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACAT
CCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTAC
TATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGA
TTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAA
GGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGC
GGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGG
CGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCT
TTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGC
ACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACT
ATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAG
GACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTG
ACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCT
GGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCC
AGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCC
TGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCC
AGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAA
CATGCAGCCCCATC
638 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGGTGCAGGAGAGCGGCGGCGACCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCGGCAGCATCGGCAGCATCTACAGGAAGGGCTGGTACAGGCAGGC
CCCCGGCAGCCAGAGGGAGCTGGTGGCCACCATCACCAGCGCCGGCACCACCAACTACGC
CGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCGTGTACCT
GCAGATGAACAGCCTGAGGCCCGAGGACACCGCCGTGTACTACTGCAACTTCCAGACCCA
CTGGTACGTGTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGAT
CAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGG
CGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAG
CTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATC
CGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACT
ATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGAT
TACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAG
GTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCG
GAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGC
GGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTT
TACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGC
ACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACT

CA 031738M62gib-99- 28 ATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAG
GACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTG
ACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCT
GGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCC
AGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCC
TGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCC
AGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAA
CATGCAGCCCCATC
639 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAGGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGTGAGCAAGAACATCTTCAGCATCTACAGGGTGGACTGGTACCACCAGGC
CCCCGGCAAGCAGAGGGAGCTGGTGGCCGGCTGGACCAGCGGCGGCAGCACCAGCTACGC
CGACGCCGTGAAGGGCAGGTTCACCATCAGCACCGACAACGTGAAGGACACCGTGTACCT
GCAGATGAACAGCCTGACCCCCGAGGACACCGCCGTGTACTACTGCCACGCCCACGACCA
CTGGAGGGACTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGAT
CAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGG
CGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAG
CTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATC
CGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACT
ATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGAT
TACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAG
GTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCG
GAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGC
GGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTT
TACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGC
ACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACT
ATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAG
GACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTG
ACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCT
GGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCC
AGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCC
TGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCC
AGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAA
CATGCAGCCCCATC
640 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGCAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCAGGAGCATCTTCGGCATCGCCTTCATGGACTGGTACAGGCAGGC
CCCCGGCAAGCAGAGGGAGTTCGTGGCCGGCATCAGCCACAGCGGCGCCACCAGCTACGC
CGACAGCGTGAAGGGCAGGTTCACCGTGAGCAGGGACAACGCCAAGAACACCATGTACCT
GCAGATGAACAACCTGCTGCCCGAGGACAGCGCCGTGTACTACTGCAAGGCCGACACCGC
CACCAACACCGACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGAT
CAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGG
CGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAG
CTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATC
CGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACT
ATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGAT
TACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAG
GTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCG
GAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGC
GGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTT
TACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGC
ACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACT
ATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAG
GACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTG
ACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCT
GGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCC
AGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCC
TGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCC
AGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAA
CATGCAGCCCCATC

CA 031738M62gib-99- 28
641 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGCAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCGGCATCATCTTCAGCATCAACACCATGGCCTGGTACAGGCAGGG
CCCCGGCAAGCAGAGGGACCTGGTGGCCCTGATCAGCAGCGGCGGCAACACCAGCTACGC
CGACAGCGTGAACGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCGTGTACCT
GCAGATGAACGGCCTGAAGCCCGAGGACACCGCCGTGTACTACTGCAACAGCGCCGGCAG
GAGCTACAGCGGCAGCTACGGCGCCTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAG
CGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTG
GCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGA
TGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCG
TGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCC
GAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTT
CTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAAC
TTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAG
ATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCA
GCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCA
GCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGG
GCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTT
CAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAA
CAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGAT
AGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTG
GCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGC
CCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTG
CTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGG
CTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTC
ACCGGTTCCAGAAAACATGCAGCCCCATC
642 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCAGGAGCATCTTCGTGATCGCCTTCATGGACTGGTACAGGCAGGCC
CCCGGCAAGCAGAGGGAGTTCGTGGCCGGCATCAGCAGCAGCGGCGCCACCAGCTACGCC
AGCAGCGTGAAGGGCAGGTTCACCGTGAGCAGGGACACCGCCAAGAACACCATGTACCTG
CAGATGAACAACCTGCTGCCCGAGGACAGCGCCGTGTACTACTGCAAGGCCGACACCGCC
ACCACCACCGACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGATC
AGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGC
GGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCT
CCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCG
TAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTAT
ACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTA
CACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGT
AATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGA
AGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGG
TGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTA
CCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCAC
TGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTAT
AAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGA
CACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGAC
GTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGG
AATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGT
TCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGG
GCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGA
TCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACAT
GCAGCCCCATC
643 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCGGCATCATCTTCAGCATCAACACCATGGCCTGGTACAGGCAGGG
CCCCGGCAAGGAGAGGGACCTGGTGGCCGTGATCAAGGGCGACGGCAGCACCAGCTACGC
CGACAGCGTGAACGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCGTGTACCT
GAGGATGAACGGCCTGAAGCCCGAGGACACCGCCGTGTACTACTGCAACAGCGCCGGCAG
GAGCTACAGCGGCGTGTACGGCGCCTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAG
CGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTG
GCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGA

CA 031738M62gib-99- 28 TGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCG
TGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCC
GAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTT
CTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAAC
TTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAG
ATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCA
GCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCA
GCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGG
GCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTT
CAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAA
CAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGAT
AGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTG
GCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGC
CCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTG
CTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGG
CTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTC
ACCGGTTCCAGAAAACATGCAGCCCCATC
644 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGCAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCAGCATCTTCAGCATCGGCGCCATGAGGTGGTACAGGCAGGT
GCCCGGCAACGAGAGGGAGCTGGTGGCCGGCATCACCAACGGCGGCAACACCAACTACGC
CGACAGCGTGAAGGCCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCGTGTACCT
GCAGATGAACAGCCTGAAGCCCGAGGACACCACCGTGTACTTCTGCAACGCCGACGTGCA
GAACAGCGGCTACGTGTGGGGCAACTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAG
CGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTG
GCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGA
TGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCG
TGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCC
GAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTT
CTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAAC
TTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAG
ATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCA
GCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCA
GCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGG
GCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTT
CAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAA
CAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGAT
AGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTG
GCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGC
CCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTG
CTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGG
CTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTC
ACCGGTTCCAGAAAACATGCAGCCCCATC
645 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCAGGAGCATCTTCGTGATCGCCTTCATGGACTGGTACAGGCAGGCC
CCCGGCAAGCAGAGGGAGTTCGTGGCCGGCATCAGCAGCAGCGGCGCCACCAGCTACGCC
GACAGCGTGAAGGGCAGGTTCACCGTGAGCAGGGACACCGCCAAGAACACCATGTACCTG
CAGATGAACAACCTGCTGCCCGAGGACAGCGCCGTGTACTACTGCAAGGCCGACACCGCC
ACCAACACCGACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGATC
AGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGC
GGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCT
CCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCG
TAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTAT
ACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTA
CACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGT
AATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGA
AGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGG
TGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTA
CCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCAC
TGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTAT

CA 031738M62gib-99- 28 AAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGA
CACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGAC
GTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGG
AATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGT
TCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGG
GCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGA
TCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACAT
GCAGCCCCATC
646 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCACCAGCGGCATCATCTTCCACATCTACACCATGGGCTGGTACAGGGGCGCC
CCCGGCAAGCAGAGGGAGCTGGTGGCCAGGATCACCAGCGGCGGCGACACCAACTACGCC
GACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGTGAAGAACACCATGTACCTG
CAGATGAACAGCCTGAAGCCCGAGGACACCGCCGTGTACTACTGCAACAGGTTCCCCGGC
GCCACCTTCAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGATC
AGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGC
GGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCT
CCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCG
TAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTAT
ACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTA
CACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGT
AATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGA
AGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGG
TGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTA
CCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCAC
TGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTAT
AAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGA
CACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGAC
GTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGG
AATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGT
TCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGG
GCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGA
TCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACAT
GCAGCCCCATC
647 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGCTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGGCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGTGAGCGGCAACATCTGGGTGTTCACCGTGATGGCCTGGTACAGGCAGGT
GCCCGGCAAGCAGAGGGAGCTGGTGGCCGCCAGCACCAACGGCGGCAGCACCAACTACGC
CGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGTGAAGAACACCGTGTACCT
GCAGATGAACAGCCTGAAGCCCGAGGACACCGCCGTGTACTACTGCAACAGGCAGAGGAC
CGTGATCGGCATGAACCCCCTGGCCCCCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAG
CGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTG
GCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGA
TGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCG
TGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCC
GAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTT
CTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAAC
TTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAG
ATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCA
GCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCA
GCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGG
GCCTGGAATGGGTTGCACTGATTAATCCTACCAAAGGTGTTAGTACCTACAACCAGAAGTT
CAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAA
CAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGAT
AGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTG
GCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGC
CCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTG
CTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGG
CTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTC
ACCGGTTCCAGAAAACATGCAGCCCCATC

CA 031738M62gib-99- 28
648 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCCTGAGCTGGGTGAGGCAGAC
CCCCGACAAGGGCCTGGAGCTGGTGGCCAGCATCAACAGGAACGGCGGCAACACCTACTA
CACCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGAA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCGCCAGGGGCGG
CTTCACCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCTTCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGGGCTACATGTACTGGTACCAGCAGAAGCCCGGCAGCAGCCCCAGGCTGCTGATCTA
CGACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCAC
CGCCTACAGCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCA
GCAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
649 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGATCGTGCTGACCCAGAGCCCCGCCATCATGAGCGCCTTCCCCGGCGAGAAGGTGACC
ATGACCTGCAGCGCCAGCAGCAGCGTGGGCTACATGTACTGGTACCAGCAGAAGCCCGGC
AGCAGCCCCAGGCTGCTGATCTACGACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGG
TTCAGCGGCAGCGGCAGCGGCACCGCCTACAGCCTGACCATCAGCAGGATGGAGGCCGAG
GACGCCGCCACCTACTACTGCCAGCAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCG
GCACCAAGCTGGAGCTGAAGGGCAGCACCAGCGGCAGCGGCAAGCCCGGCAGCGGCGAG
GGCAGCACCAAGGGCGAGGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGG
CGGCAGCCTGAAGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCCTGAGC
TGGGTGAGGCAGACCCCCGACAAGGGCCTGGAGCTGGTGGCCAGCATCAACAGGAACGGC
GGCAACACCTACTACACCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCC
AAGAACACCCTGAACCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTAC
TGCGCCAGGGGCGGCTTCACCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGAG
CAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGG
AGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACC
CAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCA
GTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAAC
TACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTT
CTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTA
CTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAA
AGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGG
TGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTC
TGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTG
GAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGG
ACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCT
GCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGAC
TGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCG
GAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCT
GGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTC
TTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGA

CA 031738M62gib-99- 28 GAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGT
TCCAGAAAACATGCAGCCCCATC
650 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGAAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCACCACCAGCGGCTTCACCTTCAGCAGCTACGGCCTGAGCTGGATCAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCAGCATCAACAGGAACGGCGACAACACCTACTA
CACCGACAGCGTGAGGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAGCACCCTGAA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCACCAGGGGCGG
CTTCAGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CCCCCTGATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGGGCTACATGTACTGGTTCCAGCAGAGGCCCGGCAGCAGCCCCAGGCTGCTGATCTAC
GACACCTACAACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCACC
AGCTACAGCCTGACCATCAGCAGGCTGGAGGCCGAGGACGCCGCCACCTACTACTGCCAG
CAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAGGGAG
CAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGG
AGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACC
CAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCA
GTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAAC
TACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTT
CTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTA
CTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAA
AGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGG
TGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTC
TGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTG
GAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGG
ACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCT
GCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGAC
TGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCG
GAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCT
GGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTC
TTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGA
GAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGT
TCCAGAAAACATGCAGCCCCATC
651 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGATCGTGCTGACCCAGAGCCCCCCCCTGATGAGCGCCAGCCCCGGCGAGAAGGTGAC
CATGACCTGCAGCGCCAGCAGCAGCGTGGGCTACATGTACTGGTTCCAGCAGAGGCCCGG
CAGCAGCCCCAGGCTGCTGATCTACGACACCTACAACCTGGCCAGCGGCGTGCCCGTGAG
GTTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGGCTGGAGGCCGA
GGACGCCGCCACCTACTACTGCCAGCAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCC
GGCACCAAGCTGGAGCTGAGGGGCAGCACCAGCGGCAGCGGCAAGCCCGGCAGCGGCGA
GGGCAGCACCAAGGGCCAGGTGCAGCTGAAGGAGAGCGGCGGCGGCCTGGTGCAGCCCG
GCGGCAGCCTGAAGCTGAGCTGCACCACCAGCGGCTTCACCTTCAGCAGCTACGGCCTGA
GCTGGATCAGGCAGACCCCCGACAAGAGGCTGGAGCTGGTGGCCAGCATCAACAGGAACG
GCGACAACACCTACTACACCGACAGCGTGAGGGGCAGGTTCACCATCAGCAGGGACAACG
CCAAGAGCACCCTGAACCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACT
ACTGCACCAGGGGCGGCTTCAGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCG
AGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGC
GGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATG
ACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTG
CCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGA
AACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCT

CA 031738M62gib-99- 28 GGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTT
ATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGA
TCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAG
CTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAG
CTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGG
CCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTC
AAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAAC
AGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATA
GTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGG
CGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCC
CACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGC
TGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGC
TGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCA
CCGGTTCCAGAAAACATGCAGCCCCATC
652 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGAAGGAGAGCGGCGGCGGCCTGGTGAGGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAACTACGGCATGAGCTGGATCAGGCAGAC
CCCCGACAAGAACCTGGAGCTGGTGGCCAGCATCAACACCAGCGGCGGCAACACCTACTA
CCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAGGGCCACCCTGAA
CCTGCAGATGAGCAACCTGAAGAGCGAGGACACCGCCATCTACTACTGCACCAGGGGCGG
CTTCACCCACTGGGGCCAGGGCACCCTGGTGGCCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGCCAGCAGCAG
CGTGAGCTACATGTACTGGTACCAGCAGAAGCCCGGCAGCAGCCCCAGGCTGCTGATCTA
CGACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCAC
CAGCTACTTCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCA
GCAGTGGACCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAGGGA
GCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCG
GAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGA
CCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGC
CAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAA
ACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTG
GTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTA
TTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGAT
CAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGC
TGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGC
TTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGC
CTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCA
AGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACA
GCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAG
TGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGC
GGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCC
ACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCT
GCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCT
GAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCAC
CGGTTCCAGAAAACATGCAGCCCCATC
653 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGATCGTGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGAC
CATGACCTGCAGCGCCAGCAGCAGCGTGAGCTACATGTACTGGTACCAGCAGAAGCCCGG
CAGCAGCCCCAGGCTGCTGATCTACGACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAG
GTTCAGCGGCAGCGGCAGCGGCACCAGCTACTTCCTGACCATCAGCAGGATGGAGGCCGA
GGACGCCGCCACCTACTACTGCCAGCAGTGGACCGGCTACCCCCCCATCACCTTCGGCGCC
GGCACCAAGCTGGAGCTGAGGGGCAGCACCAGCGGCAGCGGCAAGCCCGGCAGCGGCGA
GGGCAGCACCAAGGGCCAGGTGCAGCTGAAGGAGAGCGGCGGCGGCCTGGTGAGGCCCG
GCGGCAGCCTGAAGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAACTACGGCATGA
GCTGGATCAGGCAGACCCCCGACAAGAACCTGGAGCTGGTGGCCAGCATCAACACCAGCG
GCGGCAACACCTACTACCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACG
CCAGGGCCACCCTGAACCTGCAGATGAGCAACCTGAAGAGCGAGGACACCGCCATCTACT
ACTGCACCAGGGGCGGCTTCACCCACTGGGGCCAGGGCACCCTGGTGGCCGTGAGCGCCG
AGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGC
GGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATG

CA 031738M62gib-99- 28 ACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTG
CCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGA
AACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCT
GGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTT
ATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGA
TCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAG
CTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAG
CTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGG
CCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTC
AAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAAC
AGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATA
GTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGG
CGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCC
CACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGC
TGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGC
TGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCA
CCGGTTCCAGAAAACATGCAGCCCCATC
654 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGAAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCTTCCCCTTCAGCAGCTACGGCCTGAGCTGGGTGAGGCAGAC
CCCCGACAAGAGGCTGGAGCTGGTGGCCACCATCAACAGGAACGGCGACAGCGCCTACTA
CCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACGACGCCAAGAACACCCTGTA
CCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTACTGCACCAGGGGCGG
CTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGGCAGCACCAGCGGCAG
CGGCAAGCCCGGCAGCGGCGAGGGCAGCACCAAGGGCCAGATCGTGCTGACCCAGAGCCC
CGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGCGGCAGCAGCAG
CGTGGGCTACATGTACTGGTACCAGCAGAAGCCCGGCTTCAGCCCCAGGCTGCTGATCTAC
GACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGGTTCAGCGGCAGCGGCAGCGGCACC
AGCTACAGCCTGACCATCAGCAGGATGGAGGCCGAGGACGCCGCCACCTACTACTGCCAG
CAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGAG
CAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGG
AGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACC
CAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCA
GTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAAC
TACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTT
CTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTA
CTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAA
AGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGG
TGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTC
TGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTG
GAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGG
ACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCT
GCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGAC
TGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCG
GAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCT
GGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTC
TTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGA
GAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGT
TCCAGAAAACATGCAGCCCCATC
655 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGATCGTGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGAC
CATGACCTGCAGCGGCAGCAGCAGCGTGGGCTACATGTACTGGTACCAGCAGAAGCCCGG
CTTCAGCCCCAGGCTGCTGATCTACGACACCAGCAACCTGGCCAGCGGCGTGCCCGTGAGG
TTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGGATGGAGGCCGAG
GACGCCGCCACCTACTACTGCCAGCAGTGGAGCGGCTACCCCCCCATCACCTTCGGCGCCG
GCACCAAGCTGGAGCTGAAGGGCAGCACCAGCGGCAGCGGCAAGCCCGGCAGCGGCGAG
GGCAGCACCAAGGGCCAGGTGCAGCTGAAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGG
CGGCAGCCTGAAGCTGAGCTGCGCCGCCAGCGGCTTCCCCTTCAGCAGCTACGGCCTGAGC
TGGGTGAGGCAGACCCCCGACAAGAGGCTGGAGCTGGTGGCCACCATCAACAGGAACGGC
GACAGCGCCTACTACCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACGACGCC
AAGAACACCCTGTACCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCATGTACTAC

CA 031738M62gib-99- 28 TGCACCAGGGGCGGCTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCCGAG
CAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGG
AGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACC
CAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCA
GTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAAC
TACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTT
CTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTA
CTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAA
AGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGG
TGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTC
TGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTG
GAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGG
ACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCT
GCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGAC
TGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCG
GAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCT
GGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTC
TTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGA
GAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGT
TCCAGAAAACATGCAGCCCCATC
656 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGCAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCAGGAGCATCTTCGGCATCGCCTTCATGGACTGGTACAGGCAGGC
CCCCGGCAAGCAGAGGGAGTTCGTGGCCGGCATCAGCCACAGCGGCGCCACCAGCTACGC
CGACAGCGTGAAGGGCAGGTTCACCGTGAGCAGGGACAACGCCAAGAACACCATGTACCT
GCAGATGAACAACCTGCTGCCCGAGGACAGCGCCGTGTACTACTGCAAGGCCGACACCGC
CACCAACACCGACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGAT
CAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGG
CGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAG
CTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATC
CGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACT
ATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGAT
TACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAG
GTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCG
GAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGC
GGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTT
TACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGC
ACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACT
ATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAG
GACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTG
ACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCT
GGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCC
AGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCC
TGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCC
AGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAA
CATGCAGCCCCATC
657 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCAGGAGCATCTTCGTGATCGCCTTCATGGACTGGTACAGGCAGGCC
CCCGGCAAGCAGAGGGAGTTCGTGGCCGGCATCAGCAGCAGCGGCGCCACCAGCTACGCC
AGCAGCGTGAAGGGCAGGTTCACCGTGAGCAGGGACACCGCCAAGAACACCATGTACCTG
CAGATGAACAACCTGCTGCCCGAGGACAGCGCCGTGTACTACTGCAAGGCCGACACCGCC
ACCACCACCGACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGATC
AGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGC
GGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCT
CCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCG
TAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTAT
ACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTA
CACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGT
AATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGA
AGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGG

CA 031738M62gib-99- 28 TGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTA
CCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCAC
TGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTAT
AAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGA
CACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGAC
GTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGG
AATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGT
TCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGG
GCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGA
TCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACAT
GCAGCCCCATC
658 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCGGCATCATCTTCAGCATCAACACCATGGCCTGGTACAGGCAGGG
CCCCGGCAAGGAGAGGGACCTGGTGGCCGTGATCAAGGGCGACGGCAGCACCAGCTACGC
CGACAGCGTGAACGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCGTGTACCT
GAGGATGAACGGCCTGAAGCCCGAGGACACCGCCGTGTACTACTGCAACAGCGCCGGCAG
GAGCTACAGCGGCGTGTACGGCGCCTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAG
CGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTG
GCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGA
TGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCG
TGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCC
GAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTT
CTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAAC
TTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAG
ATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCA
GCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCA
GCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGG
GCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTT
CAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAA
CAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGAT
AGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTG
GCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGC
CCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTG
CTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGG
CTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTC
ACCGGTTCCAGAAAACATGCAGCCCCATC
659 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGCAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGCT
GAGCTGCGCCGCCAGCGGCAGCATCTTCAGCATCGGCGCCATGAGGTGGTACAGGCAGGT
GCCCGGCAACGAGAGGGAGCTGGTGGCCGGCATCACCAACGGCGGCAACACCAACTACGC
CGACAGCGTGAAGGCCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCGTGTACCT
GCAGATGAACAGCCTGAAGCCCGAGGACACCACCGTGTACTTCTGCAACGCCGACGTGCA
GAACAGCGGCTACGTGTGGGGCAACTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAG
CGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTG
GCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGA
TGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCG
TGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCC
GAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTT
CTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAAC
TTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAG
ATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCA
GCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCA
GCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGG
GCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTT
CAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAA
CAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGAT
AGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTG
GCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGC
CCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTG
CTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGG

CA 031738M62gib-99- 28 CTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTC
ACCGGTTCCAGAAAACATGCAGCCCCATC
660 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCAGGAGCATCTTCGTGATCGCCTTCATGGACTGGTACAGGCAGGCC
CCCGGCAAGCAGAGGGAGTTCGTGGCCGGCATCAGCAGCAGCGGCGCCACCAGCTACGCC
GACAGCGTGAAGGGCAGGTTCACCGTGAGCAGGGACACCGCCAAGAACACCATGTACCTG
CAGATGAACAACCTGCTGCCCGAGGACAGCGCCGTGTACTACTGCAAGGCCGACACCGCC
ACCAACACCGACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGATC
AGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGC
GGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCT
CCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCG
TAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTAT
ACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTA
CACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGT
AATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGA
AGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGG
TGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTA
CCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCAC
TGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTAT
AAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGA
CACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGAC
GTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGG
AATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGT
TCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGG
GCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGA
TCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACAT
GCAGCCCCATC
661 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCACCAGCGGCATCATCTTCCACATCTACACCATGGGCTGGTACAGGGGCGCC
CCCGGCAAGCAGAGGGAGCTGGTGGCCAGGATCACCAGCGGCGGCGACACCAACTACGCC
GACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGTGAAGAACACCATGTACCTG
CAGATGAACAGCCTGAAGCCCGAGGACACCGCCGTGTACTACTGCAACAGGTTCCCCGGC
GCCACCTTCAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGATC
AGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGC
GGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCT
CCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCG
TAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTAT
ACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTA
CACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGT
AATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGA
AGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGG
TGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTA
CCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCAC
TGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTAT
AAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGA
CACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGAC
GTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGG
AATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGT
TCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGG
GCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGA
TCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACAT
GCAGCCCCATC

CA 031738M62gib-99- 28
662 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGCTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGGCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGTGAGCGGCAACATCTGGGTGTTCACCGTGATGGCCTGGTACAGGCAGGT
GCCCGGCAAGCAGAGGGAGCTGGTGGCCGCCAGCACCAACGGCGGCAGCACCAACTACGC
CGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGTGAAGAACACCGTGTACCT
GCAGATGAACAGCCTGAAGCCCGAGGACACCGCCGTGTACTACTGCAACAGGCAGAGGAC
CGTGATCGGCATGAACCCCCTGGCCCCCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAG
CGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTG
GCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGA
TGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCG
TGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCC
GAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTT
CTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAAC
TTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAG
ATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCA
GCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCA
GCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGG
GCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTT
CAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAA
CAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGAT
AGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTG
GCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGC
CCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTG
CTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGG
CTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTC
ACCGGTTCCAGAAAACATGCAGCCCCATC
663 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGTGAGCAGGAACATCGCCAGCCTGTACAGGGTGGACTGGTACAGGCAGGC
CCCCGGCAAGCAGAGGGAGCTGGTGGCCGGCAGGACCAGCGGCGGCACCACCACCTACCT
GGACGCCGTGGAGGGCAGGTTCACCATCAGCAGGGACAACGTGAAGGACACCGTGTACCT
GCAGATGAACAGCCTGACCCCCGAGGACACCGCCGTGTACTACTGCCACGCCCACGACCA
CTGGAGGGACAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGA
TCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTG
GCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGA
GCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACAT
CCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTAC
TATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGA
TTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAA
GGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGC
GGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGG
CGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCT
TTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGC
ACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACT
ATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAG
GACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTG
ACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCT
GGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCC
AGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCC
TGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCC
AGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAA
CATGCAGCCCCATC
664 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCAGGAACATCTTCAGCCTGTACAGGGTGGACTGGTACAGGCAGGC
CCCCGGCAAGCAGAGGGAGCTGGTGGCCGGCAGCACCAGCGGCGGCACCACCACCTACGC
CGACGCCGTGAAGGGCAGGTTCACCATCAGCACCGACAACGTGAAGGACACCGTGTACCT
GCAGATGAACAGCCTGACCCCCGAGGACACCGCCGTGTACTACTGCCACGCCCACGACCA
CTGGAGGGACAGCTGGGGCCAGGGCACCCAGGTGACCGTGAGCAGCGAGCAGAAACTGA
TCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTG
GCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGA

CA 031738M62gib-99- 28 GCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACAT
CCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTAC
TATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGA
TTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAA
GGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGC
GGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGG
CGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCT
TTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGC
ACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACT
ATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAG
GACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTG
ACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCT
GGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCC
AGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCC
TGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCC
AGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAA
CATGCAGCCCCATC
665 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGACATAT
TACGATTGAGCGTGTCCTCGGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTC
CTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCT
TGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAG
GAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCG
ACTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAG
GATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGCTGTGGTATTCGGCG
GAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT
CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
666 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATC
TCTTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCC
CAGGAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGA
CCGACTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCC
GAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGCTGTGGTATTCG
GCGGAGGGACCAAGCTGACCGTCCTAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCG
GCGAAGGCTCCACAAAGGGTCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGC
CTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTAT
CAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTAT
CTTTGGTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGA
ATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTA

CA 031738M62gib-99- 28 TTACTGTGCGAGAGACATATTACGATTGAGCGTGTCCTCGGGTATGGACGTCTGGGGCCAA
GGGACCCTGGTCACCGTGTCCTCAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCT
GGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGG
ATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGC
GATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATC
AACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGG
AGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTC
TGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTT
CGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAG
GCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGG
GCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGG
GTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTG
TTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAA
CACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCT
AGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTG
GTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGG
AAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGT
GCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGT
GCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAG
AAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
667 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGCAGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCCTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCT
CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTAT
GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAGAGCGGCT
GGAGATATTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTC
CTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCC
TGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGTACCAGCAGCTTC
CAGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGCCCTCAGGGGTCCCTGA
CCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCT
GAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGTTCGGTATTCG
GCGGAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATC
CTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCG
GATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGG
CGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTAT
CAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTG
GAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGT
CTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGT
TCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCA
GGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGG
GGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTG
GGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGT
GTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAA
ACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGC
TAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCT
GGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTG
GAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTG
TGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGG
TGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGA
GAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC

CA 031738M62gib-99- 28
668 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATC
TCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGTACCAGCAGC
TTCCAGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGCCCTCAGGGGTCCC
TGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAG
GCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGTTCGGTAT
TCGGCGGAGGGACCAAGCTGACCGTCCTAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCT
CCGGCGAAGGCTCCACAAAGGGTCAGGTGCAGCTGCAGGAGTCGGGGGGAGGCGTGGTCC
AGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCCTCAGTAGCTATGG
CATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATA
TGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGA
CAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGT
GTATTACTGTGCGAAGAGCGGCTGGAGATATTACTACTACTACGGTATGGACGTCTGGGGC
CAAGGGACCCTGGTCACCGTGTCCTCAGAGCAGAAACTGATCAGCGAGGAAGATCTGAAT
CCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGC
GGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGG
GCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTA
TCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCT
GGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAG
TCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACG
TTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTC
AGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGG
GGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACT
GGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAG
GTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAA
AAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGT
GCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACC
CTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGC
TGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGAT
TGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGC
GGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGC
GAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
669 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTC
TCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGATGAGCTGGGTCCGCCAGGCTCC
AGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAATACTATG
TGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCT
GCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGACCGGCGGG
CCAGCTGCTCTACGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTCCTCAGGG
TCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTTCCTATGTGC
TGACTCAGCCACCCTCGGTGTCAGTGTCCCCAGGACAGACGGCCAGGATCACCTGCTCTGG
AGATGCATTGCCAAAGCAATATGCTTATTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGT
GCTGGTGATATATAAAGACAGTGAGAGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCC
AGCTCAGGGACAACAGTCACGTTGACCATCAGTGGAGTCCAGGCAGAAGACGAGGCTGAC
TATTACTGTCAATCAGCAGACAGCAGTGGTACTTGGGTGTTCGGCGGAGGCACCAAGCTGA
CCGTCCTCGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAA
GTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATA
TCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCAC
CTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAA
AGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCT
CTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTT
CGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAG
GTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGA
GGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCC
TGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAG
GTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCA
GAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCA
AATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTAC
GGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGA
CATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGG
TGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCC
GGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGA

CA 031738M62gib-99- 28 GACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGT
GCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
670 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TTCCTATGTGCTGACTCAGCCACCCTCGGTGTCAGTGTCCCCAGGACAGACGGCCAGGATC
ACCTGCTCTGGAGATGCATTGCCAAAGCAATATGCTTATTGGTACCAGCAGAAGCCAGGCC
AGGCCCCTGTGCTGGTGATATATAAAGACAGTGAGAGGCCCTCAGGGATCCCTGAGCGAT
TCTCTGGCTCCAGCTCAGGGACAACAGTCACGTTGACCATCAGTGGAGTCCAGGCAGAAG
ACGAGGCTGACTATTACTGTCAATCAGCAGACAGCAGTGGTACTTGGGTGTTCGGCGGAG
GCACCAAGCTGACCGTCCTCGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAG
GCTCCACAAAGGGTGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGG
GGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGATGAGCTGG
GTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAAGT
GAGAAATACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAG
AACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTG
CGAGACCGGCGGGCCAGCTGCTCTACGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCA
CCGTGTCCTCAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAG
GAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGG
ATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCAT
CACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGA
AAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTT
CTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGAC
TTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCA
AGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGC
GAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGT
CCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCC
AGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAAC
CAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTG
CAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACT
ACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTC
GACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAA
GGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTG
CCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGG
AGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCA
GTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
671 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCT
CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTAT
GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGATGCCG
CGGATATGGGGGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGGGTC
AACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTGACATCCAGAT
GACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATGAACTGCAAG
TCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGTACCAGCAGA
AACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTGCCCGGGAATCTGGGGTCCC
TGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAG
GCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATAGTACTCCTCTCACTTTTGGCCA
GGGGACCAAGGTGGAAATCAAAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT
CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG

CA 031738M62gib-99- 28 TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
672 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGACATCCAGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACC
ATGAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTT
GGTACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTGCCCGGGA
ATCTGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATC
AGCAGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATAGTACTCCTC
TCACTTTTGGCCAGGGGACCAAGGTGGAAATCAAAGGGTCAACCTCTGGTAGCGGTAAGC
CTGGCTCCGGCGAAGGCTCCACAAAGGGTGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCG
TGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAG
CTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTAT
ATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCC
AGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACG
GCTGTGTATTACTGTGCGAAAGATGCCGCGGATATGGGGGCCTTTGACTACTGGGGCCAGG
GAACCCTGGTCACCGTGTCCTCAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT
CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
673 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACT
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCT
CCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTAC
GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC
TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGCACGTG
GATACAGCTATGGCTCTGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTGTC
TTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCT
TGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAG
GAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCG
ATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAG
GATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGCGTGGTATTCGGCG
GAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT

CA 031738M62gib-99- 28 CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
674 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATC
TCTTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCC
CAGGAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGA
CCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCC
GAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGCGTGGTATTCG
GCGGAGGGACCAAGCTGACCGTCCTAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCG
GCGAAGGCTCCACAAAGGGTGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTCAAGC
CTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCAT
GAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAG
TGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAAT
TCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTAT
TACTGTGCGAGAGCACGTGGATACAGCTATGGCTCTGATGCTTTTGATATCTGGGGCCAAG
GGACAATGGTCACCGTGTCTTCAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT
CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
675 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCCGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGATCGGG
GGAGAAGATATTGTAGTGGTGGTAGCTGCCCTAATGCTTTTGATATCTGGGGCCAAGGGAC
AATGGTCACCGTGTCTTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGC
TCCACAAAGGGTGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGG
AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCA
GCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGT
ATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCC

CA 031738M62gib-99- 28 TGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCCCCGGCCCTC
ACTTTCGGCGGAGGGACCAAGGTGGAAATCAAAGAGCAGAAACTGATCAGCGAGGAAGA
TCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGG
CGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCC
TCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGA
ACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCT
GGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCA
TCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCC
GTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAG
GAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGC
AGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACT
ATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTT
ATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAA
ATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTAT
TATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAG
GAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGT
GCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCT
CTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTG
CGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCT
GAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
676 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACC
CTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTG
GCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAG
GTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAA
GATTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCCCCGGCCCTCACTTTCGGCGG
AGGGACCAAGGTGGAAATCAAAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGA
AGGCTCCACAAAGGGTGAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGG
GTCCTCGGTGAAGGTCTCCTGCAAGGCTTCCGGAGGCACCTTCAGCAGCTATGCTATCAGC
TGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTG
GTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCA
CGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACT
GTGCGAGAGATCGGGGGAGAAGATATTGTAGTGGTGGTAGCTGCCCTAATGCTTTTGATAT
CTGGGGCCAAGGGACAATGGTCACCGTGTCTTCAGAGCAGAAACTGATCAGCGAGGAAGA
TCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGG
CGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCC
TCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGA
ACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCT
GGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCA
TCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCC
GTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAG
GAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGC
AGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACT
ATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTT
ATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAA
ATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTAT
TATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAG
GAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGT
GCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCT
CTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTG
CGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCT
GAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC

CA 031738M62gib-99- 28
677 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTTCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGAGGGGGTT
ACGTTTGGGGGAGTTATCGTCAGAACTCCAACTGGTTCGACCCCTGGGGCCAGGGAACCCT
GGTCACCGTGTCCTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCC
ACAAAGGGTTCCTATGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGG
GTCACCATCTCTTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACC
AGCAGCTCCCAGGAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAG
GGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGG
GCTCCGGTCCGAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGT
TGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAGAGCAGAAACTGATCAGCGAGGAA
GATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCA
GGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCG
CCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCT
GAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGC
CTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGAC
CATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTG
CCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGG
AGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGT
GCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACA
CTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCC
TTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGAT
AAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTC
TATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTC
AAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACA
GGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATG
GCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTT
TTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCT
GCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCAT
C
678 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TTCCTATGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATC
TCTTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCC
CAGGAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGA
CCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCC
GAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGTTGGGTGTTCG
GCGGAGGGACCAAGCTGACCGTCCTAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCG
GCGAAGGCTCCACAAAGGGTCAGGTTCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGC
CTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTAT
CAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTAT
CTTTGGTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGA
ATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTA
TTACTGTGCGAGAGGGGGTTACGTTTGGGGGAGTTATCGTCAGAACTCCAACTGGTTCGAC
CCCTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGAGCAGAAACTGATCAGCGAGGAA
GATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCA
GGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCG
CCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCT
GAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGC
CTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGAC
CATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTG
CCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGG
AGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGT
GCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACA
CTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCC
TTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGAT
AAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTC
TATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTC
AAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACA
GGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATG

CA 031738M62gib-99- 28 GCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTT
TTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCT
GCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCAT
C
679 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGAGGACCCATC
TACCATACAGCTATGGTTTAGGCGGGTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGT
GTCCTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGG
TCAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATC
TCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGTACCAGCAGC
TTCCAGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGCCCTCAGGGGTCCC
TGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAG
GCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGCCCGGTGG
TATTCGGCGGAGGGACCAAGGTCACCGTCCTAGAGCAGAAACTGATCAGCGAGGAAGATC
TGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCG
GTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTC
TGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAAC
TGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGG
AGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATC
AGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGT
GGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGA
GGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAG
CCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTAT
GAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTAT
AAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAAT
CCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTA
TTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGA
ACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGC
TGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCT
GATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCG
TGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGA
GCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
680 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATC
TCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTACACTGGTACCAGCAGC
TTCCAGGAACAGCCCCCAAACTCCTCATCTATGGTAACAGCAATCGGCCCTCAGGGGTCCC
TGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAG
GCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGCCCGGTGG
TATTCGGCGGAGGGACCAAGGTCACCGTCCTAGGGTCAACCTCTGGTAGCGGTAAGCCTG
GCTCCGGCGAAGGCTCCACAAAGGGTCAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGA
AGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTA
TGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCAT
CCCTATCTTTGGTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCG
GACAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCC
GTGTATTACTGTGCGAGGACCCATCTACCATACAGCTATGGTTTAGGCGGGTTTGACTACT
GGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGAGCAGAAACTGATCAGCGAGGAAGATC
TGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCG
GTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTC
TGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAAC
TGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGG

CA 031738M62gib-99- 28 AGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATC
AGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGT
GGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGA
GGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAG
CCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTAT
GAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTAT
AAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAAT
CCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTA
TTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGA
ACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGC
TGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCT
GATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCG
TGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGA
GCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
681 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT
CTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAAACTAT
GCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTAC
ATGGAGCTGAGGAGCCTGAGGAGCGACGACACGGCCGTGTATTACTGTGCGAGAGATATA
ATACGATATTGTAGTAGTACCAGCTGCTATAGAGGGATTGACTACTGGGGCCAGGGAACC
CTGGTCACCGTGTCCTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCT
CCACAAAGGGTCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTC
GATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGG
TACCAACAGCACCCAGGCAAAGCCCCCAAACTCATGATTTATGATGTCAGTAATCGGCCCT
CAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCT
GGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCTCATATACAAGCAGCAGCCCC
CATGTGGTATCCGGCGGAGGGACCAAGCTGACGGTCCTAGAGCAGAAACTGATCAGCGAG
GAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGA
TCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGT
CCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTA
TCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCC
CGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCT
GACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACT
CTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGG
AGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCT
GGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCT
ACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTA
ATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGT
AGATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGC
CGTCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGG
GGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTG
GACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCC
TATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCT
TCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGC
GGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCC
CCATC
682 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCT
CCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAGCA
CCCAGGCAAAGCCCCCAAACTCATGATTTATGATGTCAGTAATCGGCCCTCAGGGGTTTCT
AATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGG
CTGAGGACGAGGCTGATTATTACTGCAGCTCATATACAAGCAGCAGCCCCCATGTGGTATC
CGGCGGAGGGACCAAGCTGACGGTCCTAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTC
CGGCGAAGGCTCCACAAAGGGTCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAA
GCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGT
ATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCT
TACAATGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGAC
ACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGGAGCGACGACACGGCCGTG
TATTACTGTGCGAGAGATATAATACGATATTGTAGTAGTACCAGCTGCTATAGAGGGATTG
ACTACTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGAGCAGAAACTGATCAGCGAGG

CA 031738M62gib-99- 28 AAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGAT
CAGGCGGTGGCGGATCTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTC
CGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTAT
CTGAACTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCC
GCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTG
ACCATCAGCAGTCTGCAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTC
TGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGA
GGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTG
GTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTA
CACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAAT
CCTTATAAAGGTGTTAGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAG
ATAAATCCAAAAACACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCG
TCTATTATTGTGCTAGAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGG
TCAAGGAACCCTGGTCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGA
CAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTA
TGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTC
TTTTGCGTGCGGTGCAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGG
CTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCC
ATC
683 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC
CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACG
CACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACA
TGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTATTACTGTGCGCGCCCCCTGT
ATGCCCCTCGCTTCGGATACGGTATGGACGTCTGGGGCCAAGGGACCCTGGTCACCGTGTC
CTCAGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGGCGAAGGCTCCACAAAGGGTCA
GTCTGTGTTGACGCAGCCGCCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCT
TGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCCCAG
GAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGACCG
ATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAG
GATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGTTGGGTGTTCGGCG
GAGGCACCCAGCTGACCGTCCTCGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT
CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC

CA 031738M62gib-99- 28
684 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGTCTGTGTTGACGCAGCCGCCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATC
TCTTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTATGTATACTGGTACCAGCAGCTCC
CAGGAACGGCCCCCAAACTCCTCATCTATAGGAATAATCAGCGGCCCTCAGGGGTCCCTGA
CCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCC
GAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAGTGGTTGGGTGTTCG
GCGGAGGCACCCAGCTGACCGTCCTCGGGTCAACCTCTGGTAGCGGTAAGCCTGGCTCCGG
CGAAGGCTCCACAAAGGGTCAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCC
TGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATC
AGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATC
TTTGGTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAA
TCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACGGCCGTGTAT
TACTGTGCGCGCCCCCTGTATGCCCCTCGCTTCGGATACGGTATGGACGTCTGGGGCCAAG
GGACCCTGGTCACCGTGTCCTCAGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTG
GCGGAGGCGGAGGAAGTGGTGGCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGAT
CTGGATCTATGGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGA
TAGGGTCACCATCACCTGCCGTGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAA
CAGAAACCAGGAAAAGCTCCGAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAG
TCCCTTCTCGCTTCTCTGGTTCTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTG
CAACCGGAAGACTTCGCAACTTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCG
GACAGGGCACCAAGGTGGAGATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGC
GGAGGAGGGAGCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGC
TCACTCCGTTTGTCCTGTGCAGCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGT
GCGTCAGGCCCCAGGTAAGGGCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTT
AGTACCTACAACCAGAAGTTCAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAAC
ACAGCCTACCTGCAAATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTA
GAAGCGGATACTACGGCGATAGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGG
TCACCGTCTCCTCGACATCTGGCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGA
AAGCAACATCAAGGTGCTGCCCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTG
CTTGGCGGAGTTGCCGGCCTGCTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTG
CAGACATCGGCGGAGACAGGCTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGA
AGAAAACCTGTCAGTGCCCTCACCGGTTCCAGAAAACATGCAGCCCCATC
685 Nucleotide ATGGCTCTGCCTGTGACAGCTCTGTTGCTGCCTCTGGCTCTGCTGCTGCATGCTGCTAGACC
TCAGGTGCAGCTGCAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCT
GAGCTGCGCCGCCAGCGGCATCATCTTCAGCATCAACACCATGGCCTGGTACAGGCAGGG
CCCCGGCAAGCAGAGGGACCTGGTGGCCCTGATCAGCAGCGGCGGCAACACCAGCTACGC
CGACAGCGTGAACGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCGTGTACCT
GCAGATGAACGGCCTGAAGCCCGAGGACACCGCCGTGTACTACTGCAACAGCGCCGGCAG
GAGCTACAGCGGCAGCTACGGCGCCTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCAG
CGAGCAGAAACTGATCAGCGAGGAAGATCTGAATCCTGGCGGAGGCGGAGGAAGTGGTG
GCGGAGGTTCTGGTGGCGGTGGATCAGGCGGTGGCGGATCTGGATCTATGGATATCCAGA
TGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCG
TGCCAGTCAGGACATCCGTAATTATCTGAACTGGTATCAACAGAAACCAGGAAAAGCTCC
GAAACTACTGATTTACTATACCTCCCGCCTGGAGTCTGGAGTCCCTTCTCGCTTCTCTGGTT
CTGGTTCTGGGACGGATTACACTCTGACCATCAGCAGTCTGCAACCGGAAGACTTCGCAAC
TTATTACTGTCAGCAAGGTAATACTCTGCCGTGGACGTTCGGACAGGGCACCAAGGTGGAG
ATCAAAGGCGGCGGCGGAAGTGGAGGAGGAGGCTCAGGCGGAGGAGGGAGCGAGGTTCA
GCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGGCTCACTCCGTTTGTCCTGTGCA
GCTTCTGGCTACTCCTTTACCGGCTACACTATGAACTGGGTGCGTCAGGCCCCAGGTAAGG
GCCTGGAATGGGTTGCACTGATTAATCCTTATAAAGGTGTTAGTACCTACAACCAGAAGTT
CAAGGACCGTTTCACTATAAGCGTAGATAAATCCAAAAACACAGCCTACCTGCAAATGAA
CAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTGCTAGAAGCGGATACTACGGCGAT
AGTGACTGGTATTTTGACGTGTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGACATCTG
GCGGCGGAGGATCTCTGGAATCTGGACAGGTGCTGCTGGAAAGCAACATCAAGGTGCTGC
CCACCTGGTCTACCCCAGTTCAGCCTATGGCTCTGATTGTGCTTGGCGGAGTTGCCGGCCTG
CTGCTCTTTATCGGCCTGGGCATCTTCTTTTGCGTGCGGTGCAGACATCGGCGGAGACAGG
CTGAGAGAATGAGCCAGATCAAGCGGCTGCTGAGCGAGAAGAAAACCTGTCAGTGCCCTC
ACCGGTTCCAGAAAACATGCAGCCCCATC

CA 031738M62gib-99- 28
686 Amino Acid MALPVTALLLPLALLLHAARPQVQLQESGGGLVQPGGSLRLSCAASGIIFSI
NTMAWYRQGPG
KQRDLVALISSGGNTSYADSVNGRFTISRDNAKNTVYLQM NGLKPEDTAVYYCNSAGRSYSGS
YGAYWGQGTQVTVSSEQKL I SEEDLNPGGGGGSGGGGSGGGGSGGGGSGSM DI Q MTQSPSSL
SASVGDRVTITCRASQDI RNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTIS
SLQPEDFATYYCQQGNTLPWTFGQGTKVEI KGGGGSGGGGSGGGGSEVQLVESGGGLVQPGG

AY LQM NSLRAEDTAVYY CARSGYY G DSDWY FDVWGQGTLVTVSSTSGGGGSL ESGQVL LES
NIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGI FFCVRCRH RRRQAERMSQI KRLLSEKKTCQ
CPH RFQKTCSPI

CA 031738M62gib-99- 28

Claims (59)

WHAT IS CLAIMED IS:
1. A Guanylate Cyclase 2C (GUCY2C) T cell-antigen coupler (GUCY2C-TAC) protein, comprising:
(a) a first polypeptide encoding an antigen-binding domain that binds GUCY2C;
(b) a second polypeptide encoding an antigen-binding domain that binds a protein associated with a TCR complex; and (c) a third polypeptide encoding a TCR co-receptor cytosolic domain and transmembrane domain;
wherein components encoded by (a), components encoded by (b), and components encoded by (c) are fused directly to each other, or joined by at least one linker.
2. The GUCY2C-TAC protein of claim 1, wherein the first polynucleotide, the second polynucleotide, and the third polynucleotide are in order.
3. The GUCY2C-TAC protein of claim 1 or 2, wherein the antigen-binding domain that binds GUCY2C is a designed ankyrin repeat (DARPin) polypeptide, single chain variable fragment (scFv), single domain antibody, diabody, affibody, adnectin, affilin, phylomer;
fynomer, affimer, peptide aptamer, knottin, centyrin, anticalin, or nanobody.
4. The GUCY2C-TAC protein of any one of claims 1-3, wherein the antigen-binding domain that binds GUCY2C is a designed ankyrin repeat (DARPin) polypeptide, a single chain variable fragment (scFv), or a nanobody.
5. The GUCY2C-TAC protein of any one of claims 1-4, wherein the antigen-binding domain that binds GUCY2C is a nanobody.
6. The GUCY2C-TAC protein of any one of claims 1-5, wherein the protein associated with the TCR complex is a CD3 protein.
7. The GUCY2C-TAC protein of claim 6, wherein the CD3 protein is a CD3y protein, CD38 protein and/or CDR protein. In some embodiments, the CD3 protein is a protein.
8. The GUCY2C-TAC protein of claim 7, wherein the CD3 protein is a CDR
protein.
9. The GUCY2C-TAC protein of any one of claims 1-8, wherein the antigen-binding domain that binds the protein associated with the TCR complex is a designed ankyrin repeat (DARPin) polypeptide, single chain variable fragment (scFv), single domain antibody, diabody, affibody, adnectin, affilin, phylomer; fynomer, affimer, peptide aptamer, knottin, centyrin, anticalin, or nanobody.

CA 03173857 2022- 9- ik63309
10. The GUCY2C-TAC protein of any one of claims 1-9, wherein the antigen-binding domain that binds the protein associated with the TCR complex is derived from an antibody selected from UCHT1 OKT3, F6A, and L2K.
11. The GUCY2C-TAC protein of claim 10, wherein the antigen-binding domain that binds the protein associated with the TCR complex is a UCHT1 antigen-binding domain.
12. The GUCY2C-TAC protein of claim 11, wherein the UCHT1 antigen-binding domain is an scFv of UCHT1.
13. The GUCY2C-TAC protein of claim 11 or 12, wherein the UCHT1 antigen-binding domain comprises a Y to T mutation at a position corresponding to amino acid 182 of SEQ
ID NO: 32 (Y182T).
14. The GUCY2C-TAC protein of any one of claims 10-12, wherein the UCHT1 antigen-binding domain comprises a humanized variant of UCHT1 (huUCHT1).
15. The GUCY2C-TAC protein of claim 14, wherein the UCHT1 antigen-binding domain comprises a humanized variant of UCHT1 comprising a Y to T mutation at a position corresponding to amino acid 177 of SEQ ID NO: 40 (huUCHT1 (Y177T)).
16. The GUCY2C-TAC protein of any one of claims 10-12, wherein antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO: 32 (UCHT1), SEQ ID NO: 44 (UCHT1 (Y182T)), SEQ ID NO: 40 (huUCHT1), or SEQ ID NO: 42 (huUCHT1 (Y177T)).
17. The GUCY2C-TAC protein of any one of claims 10-12, wherein the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO:

(UCHT1), SEQ ID NO: 44 (UCHT1 (Y182T)), SEQ ID NO: 40 (huUCHT1), or SEQ ID NO:

42 (huUCHT1 (Y177T)).
18. The GUCY2C-TAC protein of any one of claims 10-12, wherein the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO:

(UCHT1), SEQ ID NO: 44 (UCHT1 (Y182T)), SEQ ID NO: 40 (huUCHT1), or SEQ ID NO:

42 (huUCHT1 (Y177T)), and the non-CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%
sequence identity with the non-CDR sequences of the amino acid sequence of SEQ ID NO: 32 (UCHT1), SEQ

CA 03173857 2022- 9- i63309 ID NO: 44 (UCHT1 (Y182T)), SEQ ID NO: 40 (huUCHT1), or SEQ ID NO: 42 (huUCHT1 (Y177T)).
19. The GUCY2C-TAC protein of claim 10, wherein the antigen-binding domain that binds the protein associated with the TCR complex is an OKT3 antigen-binding domain.
20. The GUCY2C-TAC protein of claim 19, wherein the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO: 34 (OKT3).
21. The GUCY2C-TAC protein of claim 19 or 20, wherein the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3).
22. The GUCY2C-TAC protein of claim 19 or claim 20, wherein the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO:

(OKT3), and the non-CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the non-CDR
sequences of the amino acid sequence of SEQ ID NO: 34 (OKT3).
23. The GUCY2C-TAC protein of claim 10, wherein the antigen-binding domain that binds the protein associated with the TCR complex is a F6A antigen-binding domain.
24. The GUCY2C-TAC protein of claim 23, wherein the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO: 36 (F6A).
25. The GUCY2C-TAC protein of claim 23 or 24, wherein the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 36 (F6A).
26. The GUCY2C-TAC protein of claim 23 or claim 24, wherein the CDR
sequences of the antigen-binding domain that binds the protein associated with the TCR
complex have 100% identity with the CDR sequences of the amino acid sequence of SEQ ID NO:
36 (F6A), and the non-CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the non-CDR
sequences of the amino acid sequence of SEQ ID NO: 36 (F6A).

CA 03173857 2022- 9- i63309
27. The GUCY2C-TAC protein of claim 10, wherein the antigen-binding domain that binds the protein associated with the TCR complex is a L2K antigen-binding domain.
28. The GUCY2C-TAC protein of claim 27, wherein the antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO: 38 (L2K).
29. The GUCY2C-TAC protein of claim 27 or 28, wherein the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K).
30. The GUCY2C-TAC protein of claim 27 or 28, wherein the CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have 100%
identity with the CDR sequences of the amino acid sequence of SEQ ID NO: 38 (L2K), and the non-CDR sequences of the antigen-binding domain that binds the protein associated with the TCR complex have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the non-CDR
sequences of the amino acid sequence of SEQ ID NO: 38 (L2K).
31. The GUCY2C-TAC protein of any one of claims 1-30, wherein the transmembrane domain is a CD4 transmembrane domain and the cytosolic domain is a CD4 cytosolic domain.
32. The GUCY2C-TAC protein of claim 31, wherein the transmembrane and cytosolic domain comprise an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%
sequence identity with the amino acid sequence of SEQ ID NO: 46 (CD4 transmembrane and cytosolic domain).
33. The GUCY2C-TAC protein of any one of claims 1-32, wherein the transmembrane domain is a CD8 transmembrane domain and the cytosolic domain is a CD8 cytosolic domain.
34. The GUCY2C-TAC protein of any one of claims 1-33, wherein the component encoded by (a) and the component encoded by (c) are fused to the component encoded by (b).
35. The GUCY2C-TAC protein of any one of claims 1-33, wherein the component encoded by (b) and the component encoded by (c) are fused to the component encoded by (a).
36. The GUCY2C-TAC protein of any one of claims 1-35, wherein at least one linker joins the component encoded by (a) to the component encoded by (b).

CA 03173857 2022- 9- ik63309
37. The GUCY2C-TAC protein of claim 36, wherein the at least one linker is a glycine and/or serine-rich linker, a large protein domain, a long helix structure, or a short helix structure.
38. The GUCY2C-TAC protein of claim 36 or 37, wherein the at least one linker comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 26 ((G4S)4-based linker), SEQ ID NO: 28 (G45-based linker), SEQ ID NO: 14 (CD4 based linker), SEQ ID NO: 12 (short helix connector), SEQ ID NO: 14 (long helix connector), SEQ ID NO: 16 (large domain connector), or SEQ ID
NO: 24 ((G45)3 flexible linker).
39. The GUCY2C-TAC protein of any one of claims 1-38, wherein the GUYC2C
antigen binding domain is selected from an amino acid sequence according to any one of SEQ ID
NOs: 53-127 or 514-521.
40. The GUCY2C-TAC protein of any one of claims 1-38, wherein the GUCY2C
antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203.
41. The GUCY2C-TAC protein of any one of claims 1-38, wherein the GUYC2C
antigen binding domain comprises a heavy chain variable region having an amino acid sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203.
42. The GUCY2C-TAC protein of any one of claims 1-38, wherein the GUCY2C
antigen-binding domain comprises a heavy chain variable region comprising (a) a CDR1 having an amino acid selected from the group consisting of SEQ ID NO: 204, 210, 216, 222, CA 03173857 2022- 9- i63309 228, 234, 240, 246, 252, 258, 264, 270, 276, 282, 288, 294, 300, 306, 312, 318, 324, 330, 336, 342, 348, 354, 393, 399, 405, 411, 417, 423, 429, 435, 441, 447, 453, 459, 522, 525, 528, 531, 534, 537, 540, and 543, (b) a CDR2 having an amino acid selected from the group consisting of SEQ ID NO: 205, 211, 217, 223, 229, 235, 241, 247, 253, 259, 265, 271, 277, 283, 289, 295, 301, 307, 313, 319, 325, 331, 337, 343, 349, 355, 394, 400, 406, 412, 418, 424, 430, 436, 442, 448, 454, 460, 523, 526, 529, 532, 535, 538, 541, and 544, and (c) a CDR3 having an amino acid selected from the group consisting of SEQ ID NO:
206, 212, 218, 224, 230, 236, 242, 248, 254, 260, 266, 272, 278, 284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 395, 401, 407, 413, 419, 425, 431, 437, 443, 449, 455, 461, 524, 527, 530, 533, 536, 539, 542, and 545; and a light chain variable region comprising (a) a CDR1 having an amino acid selected from the group consisting of SEQ ID NO:
207, 213, 219, 225, 231, 237, 243, 249, 255, 261, 267, 273, 279, 285, 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 396, 402, 408, 414, 420, 426, 432, 438, 444, 450, 456 and 462, (b) a CDR2 having an amino acid selected from the group consisting of SEQ ID
NO: 208, 214, 220, 226, 232, 238, 244, 250, 256, 262, 268, 274, 280, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 397, 403, 409, 415, 421, 427, 433, 439, 445, 451, 457 and 463, and (c) a CDR3 having an amino acid selected from the group consisting of SEQ ID
NO: 209, 215, 221, 227, 233, 239, 245, 251, 257, 263, 269, 275, 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341, 347, 353, 359, 398, 404, 410, 416, 422, 428, 434, 440, 446, 452, 458 and 464.
43. The GUCY2C-TAC protein of any one of claims 1-38, wherein the GUCY2C
antigen-binding domain is a nanobody and comprises (a) a VHH CDR1 having an amino acid selected from the group consisting of SEQ ID NO: 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, and 390; (b) a VHH CDR2 having an amino acid selected from the group consisting of SEQ ID NO: 361, 364, 367, 370, 373, 376, 379, 382, 385, 388, and 391; and (c) a VHH CDR3 having an amino acid selected from the group consisting of SEQ ID
NO: 362, 365, 368, 371, 374, 377, 380, 383, 386, 389, and 392.
44. The GUCY2C-TAC protein of any one of claims 1-43, wherein the GUCY2C-TAC
protein does not comprise a co-stimulatory domain.
45. The GUCY2C-TAC protein of any one of claims 1-44, wherein the GUCY2C-TAC
protein does not comprise an activation domain.
46. The GUCY2C-TAC protein of any one of claims 1-45, wherein the GUCY2C-TAC
protein further comprises a leader sequence.

CA 03173857 2022- 9- i63309
47. The GUCY2C-TAC protein of claim 46, wherein the leader sequence comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 2 (mulgG leader), SEQ ID NO: 18 (hulgG leader), SEQ ID
NO: 20 (huCD8a -1 leader) or SEQ ID NO: 30 (huCD8a -2 leader).
48. A GUCY2C TAC protein comprising an amino acid sequence having at least 80%
sequence identity with the amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686.
49. A GUCY2C TAC protein comprising an amino acid sequence according to the amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686.
50. A nucleic acid sequence encoding the GUCY2C TAC protein of any one of claims 1-49.
51. The nucleic acid sequence of claim 50, wherein the nucleic acid sequence has at least 80% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs:
591-685.
52. The nucleic acid sequence of claim 50, wherein the nucleic acid sequence comprises the nucleic acid sequence of any one of SEQ ID NOs: 591-685.
53. A T cell expressing the GUCY2C-TAC protein of any one of claims 1-49.
54. A T cell comprising the nucleic acid sequence of any one of claims 50-52.
55. A pharmaceutical composition comprising the T cell of claim 53 or 54, and a pharmaceutically acceptable excipient.
56. A method of treating a GUCY2C-expressing cancer in an individual in need thereof, comprising administering to the individual the pharmaceutical composition of claim 55.
57. The method of claim 56, wherein the cancer is a solid cancer.
58. The method of claim 56 or 57, wherein the cancer is a primary colorectal cancer, a primary gastric cancer, a primary gastroesophageal junction cancer, a primary esophageal cancer, or a primary pancreatic cancer.
59. The method of claim 56 or 57, wherein the cancer is a metastatic colorectal cancer, a metastatic gastric cancer, a metastatic gastroesophageal junction cancer, a metastatic esophageal cancer, or a metastatic pancreatic cancer.

CA 03173857 2022- 9- ik63309
CA3173857A 2021-07-08 2022-06-30 Gucy2c t cell-antigen couplers and uses thereof Pending CA3173857A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163203106P 2021-07-08 2021-07-08
US63/203,106 2021-07-08
US202163261930P 2021-09-30 2021-09-30
US63/261,930 2021-09-30
PCT/US2022/035871 WO2023283111A2 (en) 2021-07-08 2022-06-30 Gucy2c t cell-antigen couplers and uses thereof

Publications (1)

Publication Number Publication Date
CA3173857A1 true CA3173857A1 (en) 2023-01-08

Family

ID=84777699

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3173857A Pending CA3173857A1 (en) 2021-07-08 2022-06-30 Gucy2c t cell-antigen couplers and uses thereof

Country Status (2)

Country Link
EP (1) EP4367133A2 (en)
CA (1) CA3173857A1 (en)

Also Published As

Publication number Publication date
EP4367133A2 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
US11111298B2 (en) T cell-antigen coupler with various construct optimizations
CA3016287A1 (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11406667B2 (en) T cell-antigen coupler with various construct optimizations
JP2017506217A (en) Target TGFβ inhibition
US11453723B1 (en) BCMA T cell-antigen couplers and uses thereof
US20230364237A1 (en) Claudin 18.2 t cell-antigen couplers and uses thereof
US11970545B2 (en) T cell-antigen coupler with Y182T mutation and methods of uses thereof
US20240016841A1 (en) Cells comprising t cell-antigen couplers and uses thereof
KR20210021593A (en) T cell-antigen coupler with various structural optimizations
CN113825772A (en) anti-HER 2 affibodies and switchable chimeric antigen receptors using the same as switch molecules
JP2024519335A (en) Dosing regimens for cancer immunotherapy
CA3173857A1 (en) Gucy2c t cell-antigen couplers and uses thereof
WO2023283111A2 (en) Gucy2c t cell-antigen couplers and uses thereof
WO2023283361A1 (en) Gpc3 t cell-antigen couplers and uses thereof
CN117794951A (en) Claudin 18.2T cell antigen conjugate and application thereof
CN118055945A (en) Novel anti-EPHA 2 chimeric antigen receptor and immune cells expressing same